CA2754461A1 - Temperature sensitive mutants of matrix metalloprotease 1 and uses thereof - Google Patents

Abstract

Provided are modified matrix metalloprotease (MMP) enzymes that exhibit temperature-dependent activity and uses thereof. The MMPs can be used, for example, to treat ECM-mediated diseases or disorders characterized by increased deposi-tion or accumulation of one or more ECM components.

Description

DEMANDE OU BREVET VOLUMINEUX

LA PRRSENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS

THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME

NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:

NOTE POUR LE TOME / VOLUME NOTE:

'-1-RELATED APPLICATIONS
Benefit of priority is claimed to U.S. Provisional Application Serial No.
61/209,366, to Louis Bookbinder, Gregory I. Frost, Gilbert Keller, Gerhard Johann Frey, Hwai Wen Chang and Jay Milton Short, entitled "Temperature Sensitive Mutants of Matrix Metalloproteases and Uses Thereof," filed March 06, 2009.
Where permitted, the subject matter of the above-noted applications are incorporated by reference in its entirety.
This application is related to U.S. Patent Application Serial No. 12/660,894, entitled "Temperature Sensitive Mutants of Matrix Metalloproteases and Uses Thereof," which claims priority to U.S. Provisional Application Serial No, 61/209,366, This application is related to International PCT Application Serial No.
PCT/US2009/001486 to Gilbert Keller and Gregory Frost, and to U.S. Application Serial No. 12/381,063 to Gilbert Keller and Gregory Frost, each entitled "In Vivo Temporal Control of Activatable Matrix-Degrading Enzymes," and each which claim priority to U.S. Provisional Application Serial No. 61/068,667 and to U.S.
Provisional Application Serial No. 61/127,725.
Where permitted, the subject matter of the above-noted related application is incorporated by reference in its entirety.
Incorporation by reference of Sequence Listing provided electronically An electronic ,version of the Sequence Listing is filed herewith, the contents of which are incorporated by reference in their entirety. The electronic -Ale is 12.8 mega bytes in size, and titled 3077seq.PC1.txt.
FIELD OF THE INVENTION
Provided are modified matrix metalloprotease (MMP) enzymes that exhibit temperature-dependent activity and uses thereof. MMPs having a controlled duration of action can be used, for example, to treat ECM-mediated diseases or disorders characterized by increased deposition or accumulation of one or more ECM
components.

RECTIFIED SHEET (RULE 91) ISA/EP

BACKGROUND
The extracellular matrix (ECM) provides a critical structural support for cells and tissues. Defects or changes in the extracellular matrix as a result of excessive deposition or accumulation of ECM components can lead to ECM-mediated diseases or conditions. Among these are collagen-mediated diseases or conditions characterized by the presence of abundant fibrous septae of collagen. Often the only approved treatment for such diseases or conditions is surgery, which can be highly invasive. Other treatments, such as needle aponeurotomy for the treatment of Dupuytren's syndrome or liposuction for cellulite, also are highly invasive.
Bacterial collagenase (also called matrix metalloproteinase-1; MMP-1), an enzyme active at neutral pH that degrades collagen, has been used to treat ECM-mediated conditions such as cellulite (see e.g., published U.S. application serial No.
US20070224184); Dupuytren's syndrome (see e.g. U.S. Patent No. USRE39941;
5589171; 6086872); and Peyronie's disease (see e.g., U.S. Patent 6022539).
Collagenase, however, irreversibly cleaves collagens of type I, II and III.
Bacterial collagenase also cleaves type IV collagen, associated with blood vessels, and thus its administration can cause haemorrhage and leaky blood vessels. The prolonged activity of collagenase limits the dosages that can be administered and also risks side effects associated with prolonged activity. Hence, there is a need for alternative treatments of ECM-mediated diseases and conditions. Accordingly, it is among the objects herein to provide alternatives for the treatment of ECM-mediated diseases and conditions.
SUMMARY
Provided are modified matrix metalloprotease (MMP) enzymes and their use, among others, for treating ECM-mediated diseases or conditions. The enzymes include modified MMPs that are modified to exhibit activity at temperatures different from the unmodified enzymes. Hence, provided are temperature-sensitive mutants of MMP. In particular, the mutants are more active at a lower temperature then a higher temperature, and typically are substantially inactive at the higher temperature. For example, the mutants are more active at a temperature that is or is about 25 C then at a higher temperature that is or is about between 34 C to 37 C. The mutants also retain an activity of the unmodified enzyme at the lower temperature.
Hence, provided herein are modified matrix metalloproteases (MMP). The MMPs contain one or more modification(s) in the sequence of amino acid residues of an MMP polypeptide or modifications in an allelic or species variant of the MMP, or modifications in a mature form thereof, or a catalytically active fragment of the MMP.
The modifications, which are in the primary amino acid sequence, include amino acid replacement(s), insertion(s), deletion(s) and combinations thereof. The MMP
can include only one modification, only 2, only 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more replacements. The modification be effected on a wildtype MMP, or on an MMP already modified for some other purpose or activity or already mutated. The modification(s) provided herein, confer to the MMP, allelic or species variant thereof or an active fragment thereof, a ratio of enzymatic activity at a permissive temperature compared to at a nonpermissive temperature of at least 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 20.0, 30, 40, 50, 60, 70, 80, 90, 100 or more. The MMP can include only 1, only 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more replacements to confer a specified ratio of enzymatic activity.
In some embodiments, the modified MMP polypeptide can retain the modified activity of a wildtype MMP at the permissive temperature. For example, it can retain or exhibit at least or about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 140%, 150% or more activity.

The modified MMPs include, but are not limited to, collagenases, gelatinases, stromelysins, matrilysins, metalloelastases, enamelysins and membrane-type MMPs, allelic or species variants thereof and active fragments thereof that include such modification. Exemplary MMPs, include those listed in the Tables herein, such as MMP-1 (collagenase -1), MMP-8 (collagenase-2), MMP-13 (collagenase -3), MMP-18 (collagenase-4), MMP-2 (gelatinase A), MMP-9 (gelatinase B), MMP-3 (stromelysin-1), MMP-10 (stromelysin-2), MMP-11 (atromelysin-3; stromelysin-3), MMP-7 (matrilysin), MMP-26 (matrilysin-2), MMP-12 (metalloelastase), MMP-14 (MT1-MMP), MMP-15 (MT2-MMP), MMP-16 (MT3-MMP), MMP-17 (MT4-MMP), MMP-24 (MT5-MMP), MMP-25 (MT6-MMP), MMP-20 (enamelysin), MMP-19, MMP-21, MMP-23, CA-MMP, MMP-27, CMMP and MMP-28 (epilysin).
These include allelic variants and species variants as well as active fragments thereof.
The allelic and species variants contain the corresponding modification, which readily can be identified, such as by alignment. The active fragment, includes at least one such modification.
The modified MMPs include those that have lower activity at the nonpermissive temperature than the MMP that does not include the modification at the nonpermissive temperature. The permissive temperature can be lower or higher than the nonpermissive temperature. The modified MMPs can have altered activity compared to the unmodified MMP. The activity can be reduced, such as less than %, 90%,80%,70%,60%,50%,40%,30%,25%,20%,15%,10%,5%,3%, 1% or less than the activity of the unmodified MMP. The activity also can be increased, such as by the same percentages. Permissive temperatures include, but are not limited to, 21 C, 22 C, 23 C, 24 C, 25 C, 26 C, 27 C, 28 C, 29 C or 30 C or about C, 21 C, 22 C, 23 C, 24 C, 25 C, 26 C, 27 C, 28 C, 29 C or 30 C, such as at or about 25 C. Nonpermissive temperatures include, but are not limited to, 34 C, 35 C,36 C,37 C,38 Cor39 C orabout34 C,35 C,36 C,37 C, 38 C or 39 C. For example, in one embodiment, the nonpermissive temperature is or is about 20 34 C or 37 C and the permissive temperature is 25 C or about 25 C.
In some embodiments, only a catalytically active fragment is provided or used in any of the methods herein. The catalytically active fragment can be linked, such as fusion protein or chemical conjugate to additional amino acids derived from a different protein, or to another moiety, such as a therapeutic agent. When a catalytically active fragment, such as a catalytic domain is provided, it contains at least one of the amino acid replacements that confer the ratio of enzymatic activity.
Provided herein are modified MMP-1 polypeptides. Exemplary modified MMP-1 polypeptides are any provided herein having a sequence of amino acids set forth in any of SEQ ID NOS:3-705, 779-3458, 3507-3536 or allelic or species variants thereof, zymogen forms, mature forms, or catalytically active fragments thereof.

Among the modified MMPs provided herein that contain a modification that confers a ratio as noted above, are those in which the modification is an amino acid replacement(s), and the replacement(s) is at a position corresponding any one or more positions 84, 85, 95, 98, 99, 100, 103, 104, 105, 106, 109, 110, 111, 112, 118, 123, 124, 126, 147, 150, 151, 152, 153, 155, 156, 158, 159, 170, 171, 176, 178, 179, 180, 1 8 1 , 182, 183, 185, 187, 188, 189, 190, 191, 192, 194, 195, 197, 198, 206, 207, 208, 210, 211, 212, 218, 223, 227, 228, 229, 230, 233, 234, 237, 240, 251, 254, 255, 256, 257 and 258 in an MMP-1 polypeptide comprising the sequence of amino acids set forth in SEQ ID NO:2 or in corresponding residues in an MMP polypeptide. As described herein, corresponding residues can be identified, for example, using standard alignment programs among proteins with substantial homology.
In particular, provided are modified MMP-1 polypeptides, where the unmodified MMP-1 polypeptide contains the sequence of amino acids set forth in SEQ ID NO:2 or is an allelic or species variant thereof or a mature form thereof that contains an amino acid replacement. Such modifications include, but are not limited to, T84F, E85F, L95K, L951, R981), 199Q, E100V, E100R, E100S, E100T, E100F, E1001, E100N, T103Y, P104A, P104M, D105A, D105F, D105G, D1051, D105L, D105N, D105R, D105S, D105T, D105W, D105E, L106C, L106S, A10911, DI IOA, V111R, DI 12S, A118T, S123V, N124D, T126S, G147P, R150P, R150V, R150D, R1501, R150H, D151G, N152A, N152S, S153T, F155L, F155A, D156H, D156L, D156A, D156W, D156V, D156K, D156T, D156R, D156M, P158T, P158G, P158K, P158N, G159V, G159T, G159M, G1591, G159W, G159L, G159C, P1701), P170A, G171P, G171E, G1711), A176F, A176W, F178T, F178L, D179N, D179V, D179C, E180Y, E180R, E180T, E180F, E180G, E180S, E180N, E180D, E181T, D181L, D181K, D181C, D181G, E182T, E182Q, E182M, E182G, E183G, R183S, T185R, T185Y, T185H, T185G, T185V, T185Q, T185A, T185E, T185D, N187R, N187M, N187W, N187F, N187K, N1871, N187A, N187G, N187C, N187H, F188V, R189N, R189T, R189Q, E190G, E190Y, E190D, Y191V, N192H, N192S, N192D, N192C, H194P, R195C, R195W, R195L, R195G, R195Q, R195A, R195D, R195V, A197V, A197C, A198G, A198L, A198M, G206A, G206S, L207R, L207V, L2071, L207G, S208R, S208L, S21OV, S21OA, T211L, D212G, D212H, Y218S, F223C, F223E, F223G, F223A, F223S, F223K, F223M, V227C, V227D, V227E, V227L, V227S, V227W, V227G, V227H, V227Q, V227R, Q228P, L229A, L229T, L291, A230V, D233E, 1234A, 1234T, 1234E, 1234Q, 1237L, 1237W, 1237N, 1240S, 1240A, 1240C, 1251 5,1251 W, Q254S, T255H, P256C, K257P, K257T and A258P, such as L95K, D1051, D105N, D105L, D105A, D105G, R150P, D156R, D156H, D156K, D156T, G159V, G159T, D179N, E180T, E180F, E182T, T185Q, N1871, A198L, V227E, 1234E and 1240S, or L95K, D105N, R1 50P, D156K, D156T, G159V, D179N, El 80T, A198L, V227E, and 1240S.
Other modified MMP polypeptides are those where the modification is an amino acid replacement(s) and the replacement(s) is at a position corresponding any one or more of positions 95, 105, 150, 151, 155, 156, 159, 176, 179, 180, 181, 182, 185, 187, 195, 198, 206, 210, 212, 218, 223, 227, 228, 229, 230, 233, 234, and 240 in an MMP-1 polypeptide having a sequence of amino acids set forth in SEQ ID NO:2 or in corresponding residues in an MMP polypeptide; where the modification(s) confers to the MMP, allelic or species variant thereof or an active fragment thereof, a ratio of enzymatic activity at a permissive temperature compared to at a nonpermissive temperature of at least 1.5. Such modifications, with reference to MMP-1, include, but are not limited to, L95K, D105A, D105F, D105G, D1051, D105L, D105N, D105R, D105S, D105T, D105W, R150P, D151G, F155A, D156K, D156T, D156L, D156A, D156W, D156V, D156H, D156R, G159V, G159T, A176F, D179N, E180Y, E180T, E180F, D181L, D181K, E182T, E182Q, T185R, T185H, T185Q, T185A, T185E, N187R, N187M, N187F, N187K, N1871, R195V, A198L, A198M, G206A, G206S, S21OV, Y218S, F223E, V227C, V227E, V227W, Q228P, L229T, L2291, D233E, 1234A, 1234T, 1234E, 1240S, and 1240C.
Other modified MMP polypeptides are those where the modification is an amino acid replacement(s) and the replacement(s) is at a position corresponding any one or more positions 95, 105, 150, 156, 159, 179, 180, 182, 185, 187, 195, 198, 212, 223, 227, 234, and 240 in an MMP-1 polypeptide having a sequence of amino acids set forth in SEQ ID NO:2 or in corresponding residues in an MMP polypeptide;
and the modified MMP polypeptide retains at least or about 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 140%, 150% or more activity at 25 C compared to wildtype MMP-1 at 25 C. This includes modified MMF polypeptides where a modification is selected from among L95K, D105A, DING, D105I, D105L, D105N, D105S, D105W, D105T, R15OP, D156K, D156T, D156V, D156H, D156R, 0159V, G159T, D179N, E18OY, El SOT, E180F, E182T, T185H, T185Q, T185E, N187M, N187K, N187I, RI95V, A198L, F223E, V227E, I234E and 1240S, Among the modified MMP polypeptides are those in which the activity of the polypeptide is reversible upon exposure to the nonperrnissive temperature, such as, for example, where upon exposure to the nonpermissive temperature and return to the permissive temperature the polypeptide exhibits at or about 120%, 125%,13 0%, 140%,150%,160%,170%,180%, 200% or more or the activity compared to at the nonpermissive temperature. These include modified MMP polypeptides where the modification is an amino acid replacement(s) and the replacement(s) is at a position corresponding to any one or more positions Di 05A, D105F, D105G, DI 05S, MOST, R150P, G159T, El 80Y, El80T, E1801, T185H, T1 B5Q, T1 BSA, TI 85E, N1 87R, N187M, NIS7K, R195V, A198L, A198M, S21OV, Y218S, F223E, V227W, L2291 and 1240C in an MMP polypeptide.
Among the modified MMP polypeptides are those in which the activity of the polypeptide is irreversibly inactive upon exposure to the nonpermissive temperature, such as for example, modified MMP polypeptides, that, upon exposure to the nonpermissive temperature and return to the permissive temperature the polypeptide, exhibit at or about 50%, 60%, 70%, 80%, 90%, 100%, 105%, 110%, 115%, or less than 120% the activity at the non-permissive temperature. These include, but are not limited to, modified. MM? polypeptides with a modification in an MMF
polypeptide selected from. among L95K, D105I, D105L, D105N, D105R, D105W, D151G, F155A, D156K, D156T, D156L, D156A, D1S6W, D156V, D1S6H, D156R, G159V, A176F, D179N, D181L, D181K, E182T, E182Q, T185R, N187F, N187I, 0206A, G206S, V227C, V227E, Q228E, L229T, D233E, I234A, 1234T, I234E and 1240S.
Any of the modified MMP- l polypeptides provided herein above can farther include an activity mutation, whereby the mutation confers increased activity compared to the MMP-1 not containing the modification. For example, such a modified MMP-1 polypeptide can include amino acid replacement(s) at a position RECTIFIED SHEET (RULE 91) ISA/EP

corresponding to any one or more of positions 81, 84, 85, 86, 87, 89, 104, 105, 106, 107, 108, 109, 124, 131, 133, 134, 135, 143, 146, 147, 150, 152, 153, 154, 157, 158, 160, 161, 164, 166, 167, 180, 183, 189, 190, 207, 208, 211, 213, 214, 216, 218, 220, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 235, 236, 238, 239, 244, 249, 254, 256, 257 and 258 in an MMP-1 polypeptide comprising the sequence of amino acids set forth in SEQ ID NO:2. For example, amino acid replacement can be F81L, F81A, F81G, F81Q, F81R, F81H, T84H, T84L, T84D, T84R, T84G, T84A, E85S, E85V, G86S, N87P, N87R, N87G, N87Q, R89A, R89T, R89G, R89K, P104E, P1041), P104Q, D105V, L106V, P107T, P107S, P107A, R108E, R108A, R108K, R108S, A109S, A109R, A109G, A109M, A109V, N124G, T131D, K132R, V133T, V133L, S134E, S134D, E135M, S143I, R146S, G147R, G147F, R150E, R150G, RI 50M, T150T, RI 50A, RI 50N, R150K, RI 50L, RI 50V, RI 50D, N152G, N152F, N152L, N1521, S153T, S153P, S153F, S1531), S153Y, P154S, P1541, G157F, P158V, P1581, G160Q, N161L, N161R, N161Y, N161E, N161T, N1611, N161V, N161F, N161Q, H164S, F166W, Q167R, Q167A, Q167S, Q167F, Q167P, Q167T, Q167V, Q167M, E1801), R183S, R189N, R189T, R189Q, E190D, L207M, S208K, S208R, S208L, T211N, 1213G, G214L, G214E, L2161, Y218W, S220R, S220A, S220Q, S220T, S220G, S220M, S220V, S220N, T222R, T222P, T222S, T222F, T222N, F223Y, F223H, 2224Q, S224K, S2241), G225Q, G225E, G225H, D226S, D226E, D226P, D2261, V227T, Q228A, Q228D, Q228E, Q228G, Q228H, Q228K, Q228L, Q228M, Q228N, Q228R, Q228S, Q228T, Q228W, Q228Y, L229Q, L229P, L229V, A230G, A230W, A230D, A2301, A230S, A230C, A230V, A230T, A230M, A230N, A230H, Q2311, Q231 A, Q231 F, Q2311), Q231 G, Q231 V, Q231 W, Q231 S, Q231H, Q231M, D232H, D232G, D232R, D232P, D232Y, D232S, D232F, D232V, D232K, D232W, D232Q, D232E, D232T, D232L, D235G, D235A, D235L, D235E, D235R, D235Q, D235T, D235N, G236M, G236R, G236S, G236T, G236C, G236K, G236E, G236L, G236N, Q238T, A239S, A239V, A239L, A2391, A239G, A239K, A239H, A239R, S244W, S244Q, Q249W, Q254S, P256S, K257E, K257R, orA258P.
Exemplary modified MMP-1 polypeptides containing at least one temperature sensitive mutant and at least one activity mutant include those having amino acid replacements S208K/G159V; S208K/D179N; S208K/V227E; G214E/G159V;
G214E/D 179N; and 1213 G/D 179N.
Also provided herein are modified MMP-1 polypeptides that are activity mutants, whereby the modified MMP-1 polypeptide exhibits increased activity compared to the MMP-1 not containing the modification. Exemplary activity mutants are any having an amino acid replacement in the above paragraph, and further herein in Section D.2.
MMPs that can be modified include, but are not limited to, MMP-1, MMP-8, MMP-13, MMP-18, MMP-2, MMP-9, MMP-3, MMP-10, MMP-7, MMP-6, MMP-12, and allelic or species variants, mature forms, or catalytically active fragments thereof. Exemplary modified MMPs include any in which the unmodified MMP
polypeptide has a sequence of amino acids set forth in any of SEQ ID NOS:1, 711, 714, 717, 720, 723, 726, 729, 732, 735, 738, 741, 744, 747, 750, 753, 756, 759, 762, 765, 768, 771, 774 or 777, zymogen forms, allelic or species variants thereof or active fragments thereof. Such modified MMPs can have a modification at a corresponding position in the MMP compared to any of the modifications in MMP-1 provided herein. Exemplary of such corresponding positions are set forth in Figures 2 and 3, and exemplary mutations set forth in Section D herein. These include, for example polypeptides containing amino acid replacement(s) at a position corresponding to any two or more positions 95, 105, 151, 156, 159, 176, 179, 180, 181, 182, 185, 195, 198, 206, 210, 212, 218, 223, 228, 229, 233, 234, and 240 in an MMP-l polypeptide having a sequence of amino acids set forth in SEQ ID NO:2 or in corresponding residues in an MMP polypeptide.
Provided are modified MMP polypeptides with two or more modifications, where at least one of the modifications confers the ratio, or where two do so, or more do so. The modified MMP polypeptides can contain 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more modifications. Some or all of these can confer or contribute to a desired ratio of activity between the permissive and non-permissive temperature. Exemplary of modified MMP polypeptides are those that contain two or more amino acid replacement(s) and the replacement(s) are at a position corresponding to any two or more of positions 95, 105, 150, 156, 159, 179, 180, 182, _10-185,187,198,227,234 and 240 in an MMP-1 polypeptide having a sequence of amino acids set forth in SEQ ID NO:2 or in corresponding residues in an MMP
polypeptide, such as, for example, where the two or more modifications in an MMP
polypeptide are selected from among L95K, D105N, R150P, D156K, D156T, G159V, D179N, E180T, A198L, V227E, and 1240S, or any where the two or more modifications in an MMP polypeptide are selected from among any set forth in Table 15.

As noted, the modified MMP polypeptide can be a zymogen, an active enzyme, can contain only a catalytically active fragment, such as the catalytic active domain, or can lack all or a portion of a proline rich linker and/or a hemopexin domain.

The modified MMP polypeptides can contain one or more additional modifications in addition to those that confer the activity ratio, such as, but not limited to, modifications that confer increased stability, increased half-life, altered substrate specificity and/or increased resistance to inhibitors. For example, the modified MMP
polypeptide can be glycosylated as expressed or can be modified to be glycosylated, or can contain other modifications, such as PEGylation. The modified MMP
polypeptide can be a fusion protein with another protein, such as an Fc fusion, or it can be provided as a dimer or a heterodimer or other multimer.
Also provided are nucleic acid molecules and/or vectors that encode any of the modified MMP polypeptides. Vectors include prokaryotic, viral and eukaryotic vectors, including mammalian vector and yeast vectors, such as, for example, adenovirus, an adeno-associated virus, a retrovirus, a herpes virus, a lentivirus, a poxvirus, a cytomegalovirus and Pichia vectors and artificial chromosomes.
Cells, including prokaryotic, such as bacterial and algael cells, and eukaryotic, such as mammalian cells, containing the vectors are provided. The cells can express the modified MMP polypeptide, which can be encoded by nucleic acid that directs its secretion or trafficking to other loci in a cell. Methods for producing the MMPs by expressing the encoded MMP in a cell are provided. The MMPs provided herein can be provided in lyophilized or other dried or non-liquid forms.

Also provided are compositions, including pharmaceutical compositions, containing any or mixtures of the modified MMP polypeptides. The pharmaceutical compositions can be formulated for treatment of any disease amenable to treatment by an MMP, and particularly in the methods provided herein, for treatment of disease or conditions of the extracellular matrix (ECM). The compositions can be formulated for single dosage administration and contain multiple dosages or can require dilution or addition of other agents. Amounts per dosage, include for example, 10 gg to mg, 50 gg to 75 mg, 100 g to 50 mg, 250 g to 25 mg, 500 g to 10 mg, 1 mg to mg, or 2 mg to 4 mg per dosage.
Also provided are uses of the modified MMPs for treating a disease or condition of the ECM or formulation of a medicament therefore, and methods for treating a disease or condition of the extracellular matrix (ECM), and processes for treating a disease or condition of the ECM. In practicing the methods, the MMP
polypeptide or pharmaceutical compositions containing the MMP polypeptide is administered to the ECM with an activator that when administered or provided to the ECM, provides a temperature activating condition for the enzyme such that the MMP
is active. The modified MMP polypeptide is more active at a permissive temperature then at the nonpermissive physiologic temperature, and the activating condition is not present in the ECM prior to administration of the activator.
Also provided herein are methods for treating a disease or condition of the ECM by administering to the ECM a modified MMP-1 polypeptide or composition thereof, or other modified MMP, that exhibits temperature sensitivity, whereby the modified MMP-1 exhibits activity at a permissive temperature that is below the physiologic temperature of the body. In the method, the MMP-1 is administered at or below the permissive temperature. The modified MMP-1 can be mixed with a composition that is at or below the permissive temperature immediately before administration or it can be provided in a composition that is at or below the permissive temperature. In the methods, prior to administration, the ECM can be cooled to below the physiological temperature of the body, for example, by using a cold pack administered at the locus of administration of the MMP. Further, conditional activation of the MMP can be controlled for a predetermined time.
For example, the ECM can be maintained at below the physiological temperature of the body for a predetermined time.
Also provided herein are methods similar to above, whereby the modified MMP is active at a permissive temperature that is above the physiologic temperature a of the body. Hence, the MMP, when administered at or above the permissive temperature, can be mixed with a composition that is at or above the permissive temperature immediately before administration or it can be provided in a composition that is at or above the permissive temperature. Conditional activation can be achieved by exposure of the locus of administration by heat to warm the ECM. This can be for a predetermined time.
In the methods, uses and processes herein, the MMP can be a zymogen that is processed, such by a processing agent, before administration. Processing agents include, but are not limited to, plasmin, plasma kallikrein, trypsin-1, trypsin-2, neutrophil elastase, cathepsin G, tryptase, chymase, proteinase-3, proteinase-3, Turin, urinary plasminogen activator (uPA), an active MMP, 4-aminophenylmercuric acetate (AMPA), HgC12, N-ethylmaleimide, sodium dodeoyl sulfate (SDS), chaotropic agents, oxidized glutathione, reactive oxygen, Au(I) salts, acidic pH and heat. The modified MM? includes any provided herein, including, but are not limited to, modified MMP-1, MMP-2, MMP-3, MMP'-7, MMP-10, MMP-26 and MT1-MMP.
The processing agent is purified away from the modified MMP polypeptide before administration as can any non-active cleavage products of the MMP polypeptide.
The modified MMP polypeptide is administered in an amount to treat the disease or condition under the activating conditions (i.e,, during the period when it is exposed to The permissive temperature). The activator can be administered or provided prior to, simultaneously, subsequently or intermittently from the MME'. Exemplary activator include, a hot pack or a cold pack, a hot or cold liquid, buffer or solution, such as provision of the MMP in chilled buffer, wherein the chilled buffer is the activator.
The buffer can be chilled to 4 C, 5 C, 6 C, 7 C, 8 C, 9 C, 10 C, 11 'C, 12 C, 13 C, 14 C, 15 C, 16 C, 17 C, 18 C, 19 C, 20 C or more or about any of these temperatures.

RECTIFIED SHEET (RULE 91) ISA/EP

Administration can be effected by any suitable route, including but not limited to, subcutaneous, intramuscular, intralesional, intradermal, topical, transdermal, intravenous, oral and rectal administration, such as for example, sub-epidermal administration, including, subcutaneous administration.
The modified MMP polypeptide can be administered simultaneously, intermittently, sequentially or in the same composition with other active agents, such as a pharmacologic agent, including, for example, a small molecule drug compound (i.e., a compound that is not a macromolecule or biomolecule), dispersing agents, anesthetics and vasoconstrictors and combinations thereof. Exemplary of dispersing agents is a hyaluronan-degrading enzyme, such as, for example, a hyaluronidase.
Exemplary of hyaluronidases is PH2O, such as a soluble truncated form thereof, including, a hyaluronidase that contains or has a sequence of amino acids set forth in SEQ ID NO:3475, or an allelic or species variant or other variant thereof, including those having at least 60%, 70%, 80%, 90%, 91%, 92%, 93%, 95% 95%, 96%, 97%, 98%, 99% or more sequence identity to the sequence of amino acids set forth in SEQ
ID NO:3475, such as 91 % or greater sequence identity. The hyaluronidase can be one that is glycosylated. The anesthetics include any suitable anesthetic, such as, for example, lidocaine. The vasoconstrictor can be any suitable vasoconstrictor, such as an alpha adrenergic receptor agonist, such as, for example, levonordefirin, epinephrine or norepinephrine. In the methods, the other agent can be administered prior to administration of the MMP.
The ECM component that is affected by the treatment can include, for example, a collagen, an elastin, a fibronectin or a proteoglycan. The component affected depends upon the MMP selected. Where the ECM component is collagen, the collagen can be selected from among type I, type II, type III or type IV
collagen.
In any embodiment, the MMP is selected to be one that degrades a particular target, such as selection of a collagenase where the target is collagen. Mixtures of MMP can be used to degrade a plurality of ECM components. Diseases and conditions treated include, collagen-mediated diseases or conditions, such as, but not limited to, cellulite, Dupuytren's disease, Peyronie's disease, Ledderhose fibrosis, stiff joints, existing scars, scieroderma, lymphedema and collagenous colitis, herniated discs, stiff joints, such as a frozen shoulder, scars, such as a scar resulting from among surgical adhesions or keloids, hypertrophic scars and depressed scars.
Also provided are combinations of any modified MMP polypeptide provided herein and an activator thereof. Also provided are kits containing the combinations and one or more of a device for administration and, optionally instructions for administration, and other containers and components, such as reducing agents that increase activity, such as for enzyme with free sulfhydryl groups.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1: Figure 1 is an alignment of zymogen MMPs, indicating the propeptide, the catalytic domain, linker region, hemopexin domains 1-4, fibronectin type II
repeats, the basic region, the cysteine switch, the calcium (Ca) binding sites I and II, and the zinc binding site. The alignment includes zymogen MMPs, including MMP-1 (SEQ
ID NO:2), MMP-8 (amino acids 21-467 of SEQ ID NO:711), MMP-13 (amino acids 20-471 of SEQ ID NO:714), MMP-18 (amino acids 18-467 of SEQ ID NO:717), MMP-2 (amino acids 30-660 of SEQ ID NO:720), MMP-9 (amino acids 20-707 of SEQ ID NO:723), MMP-3 (amino acids 18-477 of SEQ ID NO:726), MMP-10 (amino acids 18-476 of SEQ ID NO:729), MMP-11 (amino acids 32-488 of SEQ ID
NO:732), MMP-7 (amino acids 18-267 of SEQ ID NO:735), MMP-26 (amino acids 18-261 of SEQ ID NO:738), MMP-12 (amino acids 17-470 of SEQ ID NO:741), and MMP-19 (amino acids 19-508 of SEQ ID NO:765). A "*" means that the residues or nucleotides in that column are identical in all sequences in the alignment, a means that conserved substitutions have been observed, and a "." means that semi-conserved substitutions are observed.
Figure 2: Figure 2 is an alignment of the catalytic domains of exemplary MMPs, indicating exemplary conserved and conservative amino acid residues. It is understood that other conserved and conservative amino acid residues exist between and among MMPs. Thus, this figure and identification of residues is not intended to limit corresponding residues between and among MMPs. The exemplary MMPs include: MMP-1 (amino acids 81-242 of SEQ ID NO:2), MMP-8 (amino acids 101-242 of SEQ ID NO:711), MMP-13 (amino acids 104-248 of SEQ ID NO:714), MMP-18 (amino acids 100-246 of SEQ ID NO:717), MMP-2 (amino acids 110-417 of SEQ

ID NO:720), MMP-9 (amino acids 94-425 of SEQ ID NO:723), MMP-3 (amino acids 100-247 of SEQ ID NO:726), MMP-10 (amino acids 99-246 of SEQ ID NO:729), MMP-11 (amino acids 98-228 of SEQ ID NO:732), MMP-7 (amino acids 95-242 of SEQ ID NO:735), MMP-26 (amino acids 90-236 of SEQ ID NO:738), MMP-12 (amino acids 106-247 of SEQ ID NO:741), and MMP-19 (amino acids 98-239 of SEQ
ID NO:765). Exemplary conserved and conservative positions between and among MMPs are highlighted.
Figure 3: Figure 3 is an alignment similar to that depicted in Figure 2. In the alignment, exemplary conserved and conservative positions corresponding to MMP-activity mutants are highlighted between and among other MMPs.
DETAILED DESCRIPTION
Outline A. Definitions B. Overview - Temperature Sensitive Matrix Metalloproteases C. Matrix Metalloproteases and the Extracellular Matrix 1. The Extracellular Matrix a. Components of the ECM
i. Collagens ii. Elastin iii. Fibronectin iv. Glycosaminoglycans (GAGs) 1) Proteoglycans 2) Hyaluronic Acid b. Histology of the Skin i. The Epidermis ii. The Dermis iii. The Hypodermis c. Diseases of the ECM
2. Matrix Metalloproteases a. Function b. Structure and Activation 3. Matrix Metalloprotease 1 (MMP-1) D. Modified Matrix Metalloprotease-1 Polypeptides 1. Temperature-Sensitive Matrix Metalloprotease-1 (tsMMP-1 Mutants) Exemplary Temperature Sensitive Modifications 2. Matrix Metalloprotease Activity Mutants 3. Combinations 4. Additional Modifications 5. Other MMPs E. Methods of Producing Nucleic Acids Encoding tsMMPs, and Polypeptides Thereof 1. Vectors and Cells 2. Expression a. Prokaryotic Cells b. Yeast Cells c. Insect Cells d. Mammalian Cells e. Plants 3. Purification Techniques F. Preparation, Formulation and Administration of tsMMPs 1. Injectables, solutions and emulsions Lyophilized Powders 2. Topical Administration 3. Compositions for other routes of administration 4. Activator 5. Combination Therapies Hyaluronidases G. Packaging and Articles of Manufacture of tsMMPs 1. Single Chamber Apparatus 2. Dual Chamber Apparatus 3. Kits H. Methods of Assessing Activity of tsMMPs 1. Methods of Assessing Enzymatic Activity 2. Methods of Assessing ECM Degradation a. In vitro assays b. In vivo assays c. Non-human animal models 1. Exemplary Methods of Treating Diseases or Defects of ECM
1. Collagen-Mediated Diseases or Conditions a. Cellulite b. Dupuytren's Disease c. Peyronie's Disease d. Ledderhose Fibrosis e. Stiff Joints f. Existing Scars i. Surgical Adhesions ii. Keloids iii. Hypertrophic scars iv. Depressed Scars g. Scleroderma It. Lymphedema i. Collagenous colitis 2. Spinal Pathologies J. Examples A. DEFINITIONS
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the invention(s) belong. All patents, patent applications, published applications and publications, Genbank sequences, databases, websites and other published materials referred to throughout the entire disclosure herein, unless noted otherwise, are incorporated by reference in their entirety. In the event that there are a plurality of definitions for terms herein, those in this section prevail. Where reference is made to a URL or other such identifier or address, it understood that such identifiers can change and particular information on the internet can come and go, but equivalent information can be found by searching the internet. Reference thereto evidences the availability and public dissemination of such information.
As used herein, the extracellular matrix (ECM) refers to a complex meshwork structure that surrounds and provides structural support to cells of specialized tissues and organs. The ECM is made up of structural proteins such as collagen and elastin;
specialized proteins such as fibronectin; and proteoglycans. The exact biochemical composition varies from tissue to tissue. In the skin, for example, it is the dermal layer that contains the ECM. Reference to the "interstitium" is used interchangeably herein to refer to the ECM.
As used herein, components of the ECM refers to any material produced by cells of connective tissue and secreted into the interstitium. For purposes herein, reference to ECM components refers to proteins and glycoproteins, and not to other cellular components or other components of the ECM. Exemplary ECM components include, but are not limited to, collagen, fibronectin, elastin and proteoglycans.
As used herein, a matrix degrading enzyme refers to any enzyme that degrades one or more components of the ECM. Matrix-degrading enzymes include proteases, which are enzymes that catalyze the hydrolysis of covalent peptide bonds.
Matrix-degrading enzyme include any known to one of skill in the art. Exemplary matrix-degrading enzymes include matrix metalloproteases, allelic or species variants or other variants thereof As used herein, a matrix metalloprotease (MMP) refers to a type of matrix degrading enzyme that is a zinc-dependent endopeptidase that contain an active site Zn2+ required for activity. MMPs include enzymes that degrade components of the ECM including, but not limited to, collagen, fibronectin, elastin and proteoglycans.
MMPs generally contain a propeptide, a catalytic domain, a proline linker and a hemopexin (also called haemopexin-like C-terminal) domain. Some MMPs contain additional domains. Exemplary MMPs are set forth in Table 5. Reference to an MMP includes all forms, for example, the precursor form (containing the signal sequence), the proenzyme form (containing the propeptide), the processed active form, and forms thereof lacking one or more domains. For example, reference to an MMP refers to MMPs containing only the catalytically active domain. Domains of exemplary MMPs are identified in Figure 1. MMPs also include allelic or species variants or other variants thereof.
As used herein, a modified matrix degrading enzyme or a modified MMP
(also interchangeably referred to as a variant or mutant) refers to an enzyme that has one or more modifications in primary sequence compared to a wildtype enzyme.
The one or more mutations can be one or more amino acids replacements (substitutions), insertions, deletions, and any combination thereof. A modified enzyme includes those with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more modified positions. The modifications can provide altered properties of the enzyme.
Exemplary of modifications include those described herein that confer temperature-sensitive activity of the enzyme. Other modifications include those that confer altered substrate specificity, stability and/or sensitivity to inhibitors (e.g.
TIMPs). A
modified enzyme typically has 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to a corresponding sequence of amino acids of a wildtype enzyme. Typically, a modified enzyme retains an activity or sufficient activity (e.g. degradation of an ECM component) of a wildtype enzyme.
It is understood that modifications conferring temperature sensitivity retain an activity or sufficient activity at the requisite temperature compared to a wildtype enzyme at the physiologic temperature.

As used herein, an activity mutant or mutation or variant or modification refers to a modified enzyme, for example a modified matrix metalloprotease such as a modified MMP-1, that exhibits increased enzymatic activity compared to the enzyme that does not contain the particular modification. For example, the enzyme exhibits 1.2-fold to 100-fold or higher increased enzymatic activity, for example, 1.2-fold, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100-fold or more increased enzymatic activity. It is understood that in determining enzymatic activity, the enzymatic activity of the mutant and the unmodified enzyme (e.g. wildtype) is measured under the same assay conditions.
Reference to an activity mutant herein is not dependent on temperature. For example, an activity mutant provided herein can exhibit increased activity compared to the enzyme that does not contain the modification at both the permissive and nonpermissive temperature.
As used herein, a temperature sensitive (ts) mutant or mutation or variant or modification conferring temperature sensitivity refers to a polypeptide that is modified to exhibit higher enzymatic activity at some temperatures called permissive temperatures compared to other temperatures called nonpermissive temperatures.
Generally, a temperature-sensitive mutant exhibits higher enzymatic activity at lower temperatures then at higher temperatures.
As used herein, permissive temperature is the temperature at which a polypeptide exhibits a higher enzymatic activity then at a second temperature called the nonpermissive temperature. Hence, the modified enzymes provided herein exhibit different activities at different temperatures that is higher at one temperature then at another temperature. The temperature at which it exhibits more activity is the permissive temperature. For example, the permissive temperature is a temperature that is below the physiological temperature of the body, for example, 18 C to 30 C, and in particular 20 C to 25 C . Hence, the enzyme exhibits increased activity at a temperature below the physiological temperature of the body then activity at the physiological temperature of the body, such as exists in the interstitium. For example, the permissive temperature is or is about 18 C 19 C, 20 C, 21 C, 22 C, 23 C, 24 C, 25 C, 26 C, 27 C, 28 C, 29 C or 30 C.

As used herein, a nonpermissive temperature is the temperature where a polypeptide exhibits lower enzymatic activity then at the permissive temperature and exhibits reduced activity compared to the enzyme that is not modified.
Temperature-sensitive mutants provided herein exhibit enzymatic activity at the nonpermissive temperature that is at or about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% up to less then 100% the activity at the permissive temperature. The temperature sensitive mutants provided herein also exhibit 1%, 2%,3%,4%,5%,6%,7%,8%,9%,10%,20%,30%,40%,50%,60%, 70%, 80% or 90% up to less then 100% of the activity at the nonpermissive temperature compared to the enzyme that is not modified (e.g. wildtype enzyme) at the nonpermissive temperature. For example, the nonpermissive temperature is a temperature that is near to, at or above the physiological temperature of the body, for example, 32 C to 39 C, for example, 32 C, 33 C, 34 C, 35 C, 36 C, 37 C, 38 C, or 39 C.
As used herein, the ratio of enzymatic activity at the permissive temperature compared to the nonpermissive temperature refers to the relation of enzymatic activity at the permissive and nonpermissive temperatures. It is expressed by the quotient of the division of the activity at the permissive temperature by the activity at the nonpermissive temperature. It is understood that in determining enzymatic activity and the ratio of enzymatic activity, the enzymatic activity at the permissive and nonpermissive temperatures is measured under the same assay conditions, except for the difference in temperature.
As used herein, physiological temperature refers to temperature conditions maintained in the body, which is approximately 37 C, for example, at or about 34 C, 35 C, 36 C, 37 C, 38 C or 39 T. It is understood that the normal range of a human body temperature varies depending on factors such as the rate of metabolism, the particular organ and other factors. For purposes herein, physiological temperature is the temperature that exists for a non-fasting, comfortably dressed subject that is indoors in a room that is kept at a normal room temperature (e.g. 22.7 to 24.4 C).
As used herein, reversible refers to a modified enzyme whose activity at the permissive temperature is capable of being recovered or partially recovered upon exposure to the nonpermissive temperature and reexposure to the permissive temperature. Hence, the activity of a reversible enzyme once it is exposed to the nonpermissive temperature is the same or substantially retained compared to the activity of the enzyme exposed only to the permissive conditions and is greater then the activity of the enzyme exposed only to the nonpermissive temperature. For example, upon return to permissive conditions from nonpermissive conditions, reversible enzymes exhibit at or about 120%, 125%, 130%, 140%, 150%, 160%, 170%, 180%, 200% or more the activity of the enzyme exposed only to the nonpermissive temperatures and retain the activity of the enzyme exposed only to the permissive temperature.
As used herein, irreversible or nonreversible refers to a modified enzyme whose enzymatic activity at the permissive temperature is not recovered upon exposure to the nonpermissive temperature and reexposure to the permissive temperature. Hence, the activity of an irreversible enzyme once it is exposed to the nonpermissive temperature is less then the activity of the enzyme exposed only to the permissive temperature and also is less then or the same or substantially the same as the activity of the enzyme exposed only to the nonpermissive conditions. For example, upon return to permissive conditions, irreversible enzymes exhibit at or about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%,100%,105%,110%,115%, or 120% the activity at nonpermissive temperatures and less then 100% of the activity at the activity of the enzyme exposed only to the permissive temperature.
As used herein, a domain refers to a portion (a sequence of three or more, generally 5 or 7 or more amino acids) of a polypeptide that is a structurally and/or functionally distinguishable or definable. For example, a domain includes those that can form an independently folded structure within a protein made up of one or more structural motifs (e.g. combinations of alpha helices and/or beta strands connected by loop regions) and/or that is recognized by virtue of a functional activity, such as kinase activity. A protein can have one, or more than one, distinct domain.
For example, a domain can be identified, defined or distinguished by homology of the sequence therein to related family members, such as homology and motifs that define an extracellular domain. In another example, a domain can be distinguished by its function, such as by enzymatic activity, e.g. kinase activity, or an ability to interact with a biomolecule, such as DNA binding, ligand binding, and dimerization. A
domain independently can exhibit a function or activity such that the domain independently or fused to another molecule can perform an activity, such as, for example proteolytic activity or ligand binding. A domain can be a linear sequence of amino acids or a non-linear sequence of amino acids from the polypeptide. Many polypeptides contain a plurality of domains. For example, the domain structure of MMPs is set forth in Figure 1. Those of skill in the art are familiar with domains and can identify them by virtue of structural and/or functional homology with other such domains.
As used herein, a catalytic domain refers to any part of a polypeptide that exhibits a catalytic or enzymatic function. Such domains or regions typically interact with a substrate to result in catalyis thereof. For MMPs, the catalytic domain contains a zinc binding motif, which contains the Zn2+ ion bound by three histidine residues and is represented by the conserved sequence HExxHxxGxxH.
As used herein, a proline rich linker (also called the hinge region) refers to a flexible hinge or linker region that has no determinable function. Such a region is typically is found between domains or regions and contributes to the flexibility of a polypeptide.
As used herein, a hemopexin binding domain or haemopexin-like C-terminal domain refers to the C-terminal region of MMP. It is a four bladed (3-propeller structure, which is involved in protein-protein interactions. For example, the hemopexin binding domain of MMPs interact with various substrates and also interact with inhibitors, for example, tissue inhibitor of metalloproteases (TIMPs).
As used herein, consisting essentially of or recitation that a polypeptide consists essentially of a particular domain, for example the catalytic domain means that the only MMP portion of the polypeptide is the domain or a catalytically active portion thereof. The polypeptide optionally can include additional non-MMP-derived sequences of amino acids, typically at least 3, 4, 5, 6 or more, such as by insertion into another polypeptide or linkage thereto.

As used herein, a "zymogen" refers to an enzyme that is an inactive precursor of and requires some change, such as chemical modification or proteolysis of the polypeptide, to become active. Some zymogens also require the addition of co-factors such as, but not limited to, pH, ionic strength, metal ions, reducing agents, or temperature for activation. Zymogens include the proenzyme form of enzymes.
Hence, zymogens, generally, are inactive and can be converted to a mature polypeptide by chemical modification or catalytic or autocatalytic cleavage of the proregion from the zymogen in the presence or absence of additional cofactors.
As used herein, a prosegment or proregion or propeptide refers to a region or a segment that is cleaved to produce a mature protein. A propeptide is a sequence of amino acids positioned at the amino terminus of a mature polypeptide and can be as little as a few amino acids or can be a multidomain structure. This can include segments that function to suppress the enzymatic activity by masking the catalytic machinery. Propeptides also can act to maintain the stability of an enzyme.
As used herein, a "processing agent" refers to an agent that activates a MMP
by facilitating removal of the propeptide or proregion from the zymogen or inactive form of the enzyme. A processing agent includes chemical agents, proteases and other agents such as acidic pH or heat. Exemplary processing agents include, but are not limited to, trypsin, furin, or 4-aminophenylmercuric acetate (AMPA). Other exemplary processing agents are listed in Table 4.

As used herein, a "catalytically active fragment" refers to a polypeptide fragment that contains the catalytically active domain of the enzyme. It is understood that reference to a catalytically active fragment does not necessarily mean that the fragment exhibits activity, but only that is contains the catalytically active domain or portion thereof that is required for activity. Hence, a catalytically active fragment is the portion that, under appropriate conditions (e.g. permissive temperature), can exhibit catalytic activity. For example, a catalytically active fragment of a tsMMP-1 (containing at least one mutation that confers a temperature sensitive phenotype) exhibits activity when it is provided at the requisite permissive temperature (e.g. 18 C
to 25 C ), but exhibits substantially reduced or no activity at the non-permissive temperature (e.g. physiological temperature of the body).

As used herein, an active enzyme refers to an enzyme that exhibits enzymatic activity. For purposes herein, active enzymes are those that cleave any one or more components of the ECM, such as collagen. Active enzymes include those that are processed from the zymogen form into the mature form..
As used herein, reference to the "mature" form or "processed mature" form of an enzyme refers to enzymes that do not include the prosegment or proregion of the enzyme. It can be produced from the zymogen or pro-enzyme by activation cleavage in which a prosegment or proregion of the proenzyme is processed to produce the mature form. Hence, a processed mature enzyme lacks the sequence of amino acids that correspond to the prosegment or proregion. It is understood that reference to a processed mature form of an enzyme includes synthetic sequences, and thus does not necessarily require that the enzyme actually is processed to remove the prosegment or proregion. It is understood that any MMP enzyme that lacks the prosegment or proregion sequence is a mature enzyme. For example, SEQ ID NO:709 is the mature sequence of MMP-1. The processed mature form of an enzyme can exhibit activity, and is thus an active enzyme, under appropriate conditions. For example, under physiological conditions, the mature form of MMP-1 is an active enzyme. In contrast, tsMMP-1 variants provided herein exhibit enzymatic activity at the permissive temperature of 18 C to 25 C and substantially reduced or no activity at the physiological temperature of the body.
As used herein, an activating condition refers to any physical condition or combination of conditions that is required for an enzyme's activity. For purposes herein, an activating condition for an activatable matrix-degrading enzyme (AMDE), for example, a matrix metalloprotease (MMP) includes those that are not present at the site of administration, for example, not present in the extracellular matrix, in amounts (i.e. quantity, degree, level or other physical measure) required for activation of the enzyme. Exemplary of activating conditions include temperature. For example, in the case of the interstitium, the physiological temperature is at or about 37 C. An activating condition is a temperature that is not at or about 37 C, but that is cooler or warmer. By virtue of the fact that the activating condition is not present at the site of administration of the enzyme, but must be added exogenously, the activating condition will dissipate over time as the temperature adjusts, such that the activating condition is no longer present to activate the enzyme. Hence, the enzyme will be active for a limited or predetermined time upon administration.
As used herein, an activator refers to any composition or other material or item that provides an activating condition for an activatable matrix-degrading enzyme. For purposes herein, an activator refers to any item that is capable of providing a temperature condition at the permissive temperature of the enzyme. Examples of activators include, but are not limited to hot or cold buffers or hot or cold packs.
As used herein, an "activatable matrix-degrading enzyme (AMDE)" refers to a matrix degrading enzyme that requires an activating condition in order to be active.
For purposes herein, for example, an AMDE is substantially inactive in the ECM
unless exposed to activators before, with or subsequent to administration of the AMDE, thereby providing an activating condition for the enzyme. Hence, activation of a activatable enzymes is controlled by exogenous conditions so that the period of time at an in vivo locus or site during which the enzyme is active can be predetermined and/or controlled as a result of the dissipation and/or neutralization of the activation condition (i.e. temporally controllable or time-controlled).
Thus, by virtue of exposure to an activating condition, the enzymes are active for a limited time and/or to a limited extent in the ECM (i.e. are conditionally active). The extent and time of activation can be controlled by selection of activator or activating conditions, and can be for a predetermined time. For example, temperature sensitive enzyme, such as a tsMMP, is activatable in that it can be activated by exposure to the activating condition of temperature, such as provided by a cold buffer or other liquid solution. Upon administration of the activated enzyme with the activator to the physiologic temperature environment of the ECM, the temperature will adjust to and eventually return to the physiologic temperature in a time period that can be predetermined based upon the initial temperature of the activator, the site of administration, the depth of administration and other factors, such that the enzyme will become inactive or less active.

As used herein, a "therapeutically effective amount" or a "therapeutically effective dose" refers to an agent, compound, material, or composition containing a compound that is at least sufficient to produce a therapeutic effect.
As used herein, an enzyme that is active for a limited time or for limited duration refers to an active enzyme having activity that dissipates and/or is neutralized over time. Thus, by virtue of the absence of an activation condition, the enzyme is rendered inactive.
As used herein, predetermined time means a limited time that is known before and can be controlled. The dissipation and/or neutralization of an activation condition required for an enzyme's activity can be titrated or otherwise empirically determined so that the time required for an active enzyme to become inactive is known.
For purposes herein, for example, an enzyme can be active for a predetermined time that is or is about 1 minutes, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, hour, 2 hour, 3 hour, or 4 hour. The predetermined time can be controlled by the subject or the treating physician, for example, where a cold pack or hot pack is used as the activator. Further, it is understood that reversible enzymes can be re-activated by exposure to permissive conditions, and thereby can be active for an additional predetermined time.
As used herein, sub-epidermal administration refers to any administration that results in delivery of the enzyme under the outer-most layer of the skin. Sub-epidermal administration does not include topical application onto the outer layer of the skin. Examples of sub-epidermal administrations include, but are not limited to, subcutaneous, intramuscular intralesional and intradermal routes of administration.
As used herein, substrate refers to a molecule that is cleaved by an enzyme.
Minimally, a target substrate includes a peptide containing the cleavage sequence recognized by the protease, and therefore can be two, three, four, five, six or more residues in length. A substrate also includes a full-length protein, allelic variant, isoform or any portion thereof that is cleaved by an enzyme. Additionally, a substrate includes a peptide or protein containing an additional moiety that does not affect cleavage of the substrate by the enzyme. For example, a substrate can include a four amino acid peptide, or a full-length protein chemically linked to a fluorogenic moiety.
As used herein, cleavage refers to the breaking of peptide bonds or other bonds by an enzyme that results in one or more degradation products.
As used herein, activity refers to a functional activity or activities of a polypeptide or portion thereof associated with a full-length (complete) protein.
Functional activities include, but are not limited to, biological activity, catalytic or enzymatic activity, antigenicity (ability to bind or compete with a polypeptide for binding to an anti-polypeptide antibody), immunogenicity, ability to form multimers, and the ability to specifically bind to a receptor or ligand for the polypeptide.
As used herein, enzymatic activity or catalytic activity or cleavage activity refers to the activity of a protease as assessed in in vitro proteolytic assays that detect proteolysis of a selected substrate.
As used herein, an inactive enzyme refers to an enzyme that exhibits substantially no activity (i.e. catalytic activity or cleavage activity), such as less than 10% of the maximum activity of the enzyme. The enzyme can be inactive by virtue of its conformation, the absence of an activating conditions required for its activity, or the presence of an inhibitor or any other condition or factor or form that renders the enzyme substantially inactive.
As used herein, "retains an activity" refers to the activity exhibited by a modified MMP polypeptide at a particular condition compared to at another condition or to another polypeptide. For example, it is the activity a modified MMP
polypeptide exhibits as compared to an unmodified MMP polypeptide of the same form and under the same conditions. It also can be the activity a modified MMP
polypeptide exhibits as compared to the modified MMP polypeptide under different conditions, for example, different temperature conditions. Generally, a modified MMP polypeptide that retains an activity exhibits increased or decreased activity compared to an unmodified polypeptide under the same conditions or compared to the unmodified polypeptide under different conditions. For example, the modified MMP
polypeptide can retain 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%,150%,160%,170%,180%,190%,200%,300%,400%,500% or more of the enzymatic activity.
As used herein, a human protein is one encoded by a nucleic acid molecule, such as DNA, present in the genome of a human, including all allelic variants and conservative variations thereof. A variant or modification of a protein is a human protein if the modification is based on the wildtype or prominent sequence of a human protein.
As used herein, hyaluronidase refers to an enzyme that degrades hyaluronic acid. Hyaluronidases include bacterial hyaluronidases (EC 4.2.99.1), hyaluronidases from leeches, other parasites, and crustaceans (EC 3.2.1.36), and mammalian-type hyaluronidases (EC 3.2.1.35). Hyaluronidases also include any of non-human origin including, but not limited to, murine, canine, feline, leporine, avian, bovine, ovine, porcine, equine, piscine, ranine, bacterial, and any from leeches, other parasites, and crustaceans. Exemplary non-human hyaluronidases include any set forth in any of SEQ ID NOS: 3482-3505. Exemplary human hyaluronidases include HYALI (SEQ
ID NO:3469), HYAL2 (SEQ ID NO:3470), HYAL3 (SEQ ID NO:3471), HYAL4 (SEQ ID NO:3472), and PH2O (SEQ ID NO:3473). Also included amongst hyaluronidases are soluble human PH2O and soluble rHuPH2O.
Reference to hyaluronidases includes precursor hyaluronidase polypeptides and mature hyaluronidase polypeptides (such as those in which a signal sequence has been removed), truncated forms thereof that have activity, and includes allelic variants and species variants, variants encoded by splice variants, and other variants, including polypeptides that have at least 40%, 45%, 50%, 55%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the precursor polypeptide set forth any of SEQ ID NO: 3473 or the mature form thereof.
Hyaluronidases also include those that contain chemical or posttranslational modifications and those that do not contain chemical or posttranslational modifications. Such modifications include, but are not limited to, PEGylation, albumination, glycosylation, farnesylation, carboxylation, hydroxylation, phosphorylation, and other polypeptide modifications known in the art.

As used herein, soluble human PH2O or sHuPH2O include mature polypeptides lacking all or a portion of the glycosylphospatidylinositol (GPI) attachment site at the C-terminus such that upon expression, the polypeptides are soluble. Exemplary sHuPH20 polypeptides include mature polypeptides having an amino acid sequence set forth in any one of SEQ ID NOS:3476-3481. The precursor polypeptides for such exemplary sHuPH2O polypeptides include an amino acid signal sequence. Exemplary of a precursor is set forth in SEQ ID NO:3473, which contains a 35 amino acid signal sequence at amino acid positions 1-35. Soluble HuPH20 polypeptides can be degraded during or after the production and purification methods described herein.
As used herein, soluble rHuPH2O refers to a soluble form of human PH2O that is recombinantly expressed in Chinese Hamster Ovary (CHO) cells. Soluble rHuPH2O
is encoded by nucleic acid that includes the signal sequence and is set forth in SEQ ID
NO:3475. Also included are DNA molecules that are allelic variants thereof and other soluble variants. The nucleic acid encoding soluble rHuPH2O is expressed in CHO cells which secrete the mature polypeptide. As produced in the culture medium there is heterogeneity at the C-terminus so that the product includes a mixture of species of SEQ ID NOS:3476-3481. Corresponding allelic variants and other variants also are included. Other variants can have 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with any of SEQ
ID NOS:3476-3481 as long they retain a hyaluronidase activity and are soluble.
As used herein, hyaluronidase activity refers to any activity exhibited by a hyaluronidase polypeptide. Such activities can be tested in vitro and/or in vivo and include, but are not limited to, enzymatic activity, such as to effect cleavage of hyaluronic acid, ability to act as a dispersing or spreading agent and antigenicity.
As used herein, the residues of naturally occurring a-amino acids are the residues of those 20 a-amino acids found in nature which are incorporated into protein by the specific recognition of the charged tRNA molecule with its cognate mRNA
codon in humans.
As used herein, nucleic acids include DNA, RNA and analogs thereof, including peptide nucleic acids (PNA) and mixtures thereof. Nucleic acids can be single or double-stranded. When referring to probes or primers, which are optionally labeled, such as with a detectable label, such as a fluorescent or radiolabel, single-stranded molecules are contemplated. Such molecules are typically of a length such that their target is statistically unique or of low copy number (typically less than 5, generally less than 3) for probing or priming a library. Generally a probe or primer contains at least 14, 16 or 30 contiguous nucleotides of sequence complementary to or identical to a gene of interest. Probes and primers can be 10, 20, 30, 50, 100 or more nucleic acids long.
As used herein, a peptide refers to a polypeptide that is from 2 to 40 amino acids in length.
As used herein, the amino acids which occur in the various sequences of amino acids provided herein are identified according to their known, three-letter or one-letter abbreviations (Table 1). The nucleotides which occur in the various nucleic acid fragments are designated with the standard single-letter designations used routinely in the art.
As used herein, an "amino acid" is an organic compound containing an amino group and a carboxylic acid group. A polypeptide contains two or more amino acids.
For purposes herein, amino acids include the twenty naturally-occurring amino acids, non-natural amino acids and amino acid analogs (i.e., amino acids wherein the a-carbon has a side chain).
As used herein, "amino acid residue" refers to an amino acid formed upon chemical digestion (hydrolysis) of a polypeptide at its peptide linkages. The amino acid residues described herein are presumed to be in the "L" isomeric form.
Residues in the "D" isomeric form, which are so designated, can be substituted for any L-amino acid residue as long as the desired functional property is retained by the polypeptide.
NH2 refers to the free amino group present at the amino terminus of a polypeptide.
COOH refers to the free carboxy group present at the carboxyl terminus of a polypeptide. In keeping with standard polypeptide nomenclature described in J.
Biol.
Chem., 243: 3552-3559 (1969), and adopted 37 C.F.R.. 1.821-1.822, abbreviations for amino acid residues are shown in Table 1:

Table 1- Table of Correspondence SYMBOL
1-Letter 3-Letter AMINO ACID
Y Tyr Tyrosine G Gly Glycine F Phe Phenylalanine M Met Methionine A Ala Alanine S Ser Serine I Ile Isoleucine L Leu Leucine T Thr Threonine V Val Valine P Pro proline K Lys Lysine H His Histidine Q Gln Glutamine E Glu lutamic acid Z Glx Glu and/or Gin W Trp Tryptophan R Arg Arginine D Asp aspartic acid N Asn asparagine B Asx Asn and/or Asp C C YS Cysteine X Xaa Unknown or other It should be noted that all amino acid residue sequences represented herein by formulae have a left to right orientation in the conventional direction of amino-terminus to carboxyl-terminus. In addition, the phrase "amino acid residue" is broadly defined to include the amino acids listed in the Table of Correspondence (Table 1) and modified and unusual amino acids, such as those referred to in C.F.R. 1.821-1.822, and incorporated herein by reference. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or more amino acid residues, to an amino-terminal group such as NH2 or to a carboxyl-terminal group such as COOH.
As used herein, "naturally occurring amino acids" refer to the 20 L-amino acids that occur in polypeptides.

As used herein, "non-natural amino acid" refers to an organic compound that has a structure similar to a natural amino acid but has been modified structurally to mimic the structure and reactivity of a natural amino acid. Non-naturally occurring amino acids thus include, for example, amino acids or analogs of amino acids other than the 20 naturally-occurring amino acids and include, but are not limited to, the D-isostereomers of amino acids. Exemplary non-natural amino acids are described herein and are known to those of skill in the art.
As used herein, suitable conservative substitutions of amino acids are known to those of skill in this art and can be made generally without altering the biological activity of the resulting molecule. Those of skill in this art recognize that, in general, single amino acid substitutions in non-essential regions of a polypeptide do not substantially alter biological activity (see, e.g., Watson et al. Molecular Biology of the Gene, 4th Edition, 1987, The Benjamin/Cummings Pub. co., p.224). Such substitutions can be made in accordance with those set forth in TABLE 2 as follows:

Original residue Exemplary conservative substitution Ala (A) Gly; Ser Arg (R) Lys Asn (N) Gln; His Cys (C) Ser Gln (Q) Asn Glu (E) Asp Gly (G) Ala; Pro His (H) Asn; Gin Ile (I) Leu; Val Leu (L) Ile; Val Lys (K) Arg; Gln; Glu Met (M) Leu; Tyr; Ile Phe (F) Met; Leu; Tyr Ser (S) Thr Thr (T) Ser Trp (W) Tyr Tyr (Y) Tip; Phe Val (V) Ile; Leu Other substitutions also are permissible and can be determined empirically or in accord with known conservative substitutions.
As used herein, a DNA construct is a single or double stranded, linear or circular DNA molecule that contains segments of DNA combined and juxtaposed in a manner not found in nature. DNA constructs exist as a result of human manipulation, and include clones and other copies of manipulated molecules.
As used herein, a DNA segment is a portion of a larger DNA molecule having specified attributes. For example, a DNA segment encoding a specified polypeptide is a portion of a longer DNA molecule, such as a plasmid or plasmid fragment, which, when read from the 5' to 3' direction, encodes the sequence of amino acids of the specified polypeptide.
As used herein, the term polynucleotide means a single- or double-stranded polymer of deoxyribonucleotides or ribonucleotide bases read from the 5' to the 3' end. Polynucleotides include RNA and DNA, and can be isolated from natural sources, synthesized in vitro, or prepared from a combination of natural and synthetic molecules. The length of a polynucleotide molecule is given herein in terms of nucleotides (abbreviated "nt") or base pairs (abbreviated "bp"). The term nucleotides is used for single- and double-stranded molecules where the context permits.
When the term is applied to double-stranded molecules it is used to denote overall length and will be understood to be equivalent to the term base pairs. It will be recognized by those skilled in the art that the two strands of a double-stranded polynucleotide can differ slightly in length and that the ends thereof can be staggered; thus all nucleotides within a double-stranded polynucleotide molecule can not be paired. Such unpaired ends will, in general, not exceed 20 nucleotides in length.
As used herein, "similarity" between two proteins or nucleic acids refers to the relatedness between the sequence of amino acids of the proteins or the nucleotide sequences of the nucleic acids. Similarity can be based on the degree of identity and/or homology of sequences of residues and the residues contained therein.
Methods for assessing the degree of similarity between proteins or nucleic acids are known to those of skill in the art. For example, in one method of assessing sequence similarity, two amino acid or nucleotide sequences are aligned in a manner that yields a maximal level of identity between the sequences. "Identity" refers to the extent to which the amino acid or nucleotide sequences are invariant. Alignment of amino acid sequences, and to some extent nucleotide sequences, also can take into account conservative differences and/or frequent substitutions in amino acids (or nucleotides).

Conservative differences are those that preserve the physico-chemical properties of the residues involved. Alignments can be global (alignment of the compared sequences over the entire length of the sequences and including all residues) or local (the alignment of a portion of the sequences that includes only the most similar region or regions).
"Identity" per se has an art-recognized meaning and can be calculated using published techniques. (See, e.g.: Computational Molecular Biology, Lesk, A.M., ed., Oxford University Press, New York, 1988; Biocomputing:= Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M
Stockton Press, New York, 1991). While there exists a number of methods to measure identity between two polynucleotide or polypeptides, the term "identity" is well known to skilled artisans (Carillo, H. & Lipton, D., SIAMJApplied Math 48:1073 (1988)).
As used herein, homologous (with respect to nucleic acid and/or amino acid sequences) means about greater than or equal to 25% sequence homology, typically greater than or equal to 25%, 40%, 50%, 60%, 70%, 80%, 85%, 90% or 95%
sequence homology; the precise percentage can be specified if necessary. For purposes herein the terms "homology" and "identity" are often used interchangeably, unless otherwise indicated. In general, for determination of the percentage homology or identity, sequences are aligned so that the highest order match is obtained (see, e.g.:
Computational Molecular Biology, Lesk, A.M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994;
Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; Carillo et al. (1988) SIAMJApplied Math 48:1073). By sequence homology, the number of conserved amino acids is determined by standard alignment algorithms programs, and can be used with default gap penalties established by each supplier.
Substantially homologous nucleic acid molecules would hybridize typically at moderate stringency or at high stringency all along the length of the nucleic acid of interest. Also contemplated are nucleic acid molecules that contain degenerate codons in place of codons in the hybridizing nucleic acid molecule.
Whether any two molecules have nucleotide sequences or amino acid sequences that are at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%
"identical" or "homologous" can be determined using known computer algorithms such as the "FASTA" program, using for example, the default parameters as in Pearson et al. (1988) Proc. Natl. Acad. Sci. USA 85:2444 (other programs include the GCG program package (Devereux, J., et al., Nucleic Acids Research 12(I):387 (1984)), BLASTP, BLASTN, FASTA (Atschul, S.F., et al., JMolec Biol 215:403 (1990)); Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo et al. (1988) SIAM JApplied Math 48:1073). For example, the BLAST function of the National Center for Biotechnology Information database can be used to determine identity. Other commercially or publicly available programs include, DNAStar "MegAlign" program (Madison, WI) and the University of Wisconsin Genetics Computer Group (UWG) "Gap" program (Madison WI). Percent homology or identity of proteins and/or nucleic acid molecules can be determined, for example, by comparing sequence information using a GAP computer program (e.g., Needleman et al. (1970) J. Mol. Biol. 48:443, as revised by Smith and Waterman ((1981) Adv. Appl. Math. 2:482). Briefly, the GAP program defines similarity as the number of aligned symbols (i.e., nucleotides or amino acids), which are similar, divided by the total number of symbols in the shorter of the two sequences.
Default parameters for the GAP program can include: (1) a unary comparison matrix (containing a value of 1 for identities and 0 for non-identities) and the weighted com-parison matrix of Gribskov et al. (1986) Nucl. Acids Res. 14:6745, as described by Schwartz and Dayhoff, eds., ATLAS OF PROTEIN SEQUENCE AND STRUCTURE, National Biomedical Research Foundation, pp. 353-358 (1979); (2) a penalty of 3.0 for each gap and an additional 0. 10 penalty for each symbol in each gap; and (3) no penalty for end gaps.

Therefore, as used herein, the term "identity" or "homology" represents a comparison between a test and a reference polypeptide or polynucleotide. As used herein, the term at least "90% identical to" refers to percent identities from 90 to 99.99 relative to the reference nucleic acid or amino acid sequence of the polypeptide.
Identity at a level of 90% or more is indicative of the fact that, assuming for exemplification purposes a test and reference polypeptide length of 100 amino acids are compared, no more than 10% (i.e., 10 out of 100) of the amino acids in the test polypeptide differs from that of the reference polypeptide. Similar comparisons can be made between test and reference polynucleotides. Such differences can be represented as point mutations randomly distributed over the entire length of a polypeptide or they can be clustered in one or more locations of varying length up to the maximum allowable, e.g. 10/100 amino acid difference (approximately 90%
identity). Differences are defined as nucleic acid or amino acid substitutions, insertions or deletions. At the level of homologies or identities above about 85-90%, the result should be independent of the program and gap parameters set; such high levels of identity can be assessed readily, often by manual alignment without relying on software.

As used herein, an aligned sequence refers to the use of homology (similarity and/or identity) to align corresponding positions in a sequence of nucleotides or amino acids. Typically, two or more sequences that are related by 50% or more identity are aligned. An aligned set of sequences refers to 2 or more sequences that are aligned at corresponding positions and can include aligning sequences derived from RNAs, such as ESTs and other cDNAs, aligned with genomic DNA sequence.
As used herein, "primer" refers to a nucleic acid molecule that can act as a point of initiation of template-directed DNA synthesis under appropriate conditions (e.g., in the presence of four different nucleoside triphosphates and a polymerization agent, such as DNA polymerase, RNA polymerase or reverse transcriptase) in an appropriate buffer and at a suitable temperature. It will be appreciated that certain nucleic acid molecules can serve as a "probe" and as a "primer." A primer, however, has a 3' hydroxyl group for extension. A primer can be used in a variety of methods, including, for example, polymerase chain reaction (PCR), reverse-transcriptase (RT)-PCR, RNA PCR, LCR, multiplex PCR, panhandle PCR, capture PCR, expression PCR, 3' and 5' RACE, in situ PCR, ligation-mediated PCR and other amplification protocols.
As used herein, "primer pair" refers to a set of primers that includes a 5' (upstream) primer that hybridizes with the 5' end of a sequence to be amplified (e.g.
by PCR) and a 3' (downstream) primer that hybridizes with the complement of the 3' end of the sequence to be amplified.
As used herein, "specifically hybridizes" refers to annealing, by complementary base-pairing, of a nucleic acid molecule (e.g. an oligonucleotide) to a target nucleic acid molecule. Those of skill in the art are familiar with in vitro and in vivo parameters that affect specific hybridization, such as length and composition of the particular molecule. Parameters particularly relevant to in vitro hybridization further include annealing and washing temperature, buffer composition and salt concentration. Exemplary washing conditions for removing non-specifically bound nucleic acid molecules at high stringency are 0.1 x SSPE, 0.1% SDS, 65 C, and at medium stringency are 0.2 x SSPE, 0.1% SDS, 50 C. Equivalent stringency conditions are known in the art. The skilled person can readily adjust these parameters to achieve specific hybridization of a nucleic acid molecule to a target nucleic acid molecule appropriate for a particular application. Complementary, when referring to two nucleotide sequences, means that the two sequences of nucleotides are capable of hybridizing, typically with less than 25%, 15% or 5% mismatches between opposed nucleotides. If necessary, the percentage of complementarity will be specified. Typically the two molecules are selected such that they will hybridize under conditions of high stringency.
As used herein, substantially identical to a product means sufficiently similar so that the property of interest is sufficiently unchanged so that the substantially identical product can be used in place of the product.
As used herein, it also is understood that the terms "substantially identical"
or "similar" varies with the context as understood by those skilled in the relevant art.
As used herein, an allelic variant or allelic variation references any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and can result in phenotypic polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or can encode polypeptides having altered amino acid sequence.
The term "allelic variant" also is used herein to denote a protein encoded by an allelic variant of a gene. Typically the reference form of the gene encodes a wildtype form and/or predominant form of a polypeptide from a population or single reference member of a species. Typically, allelic variants, which include variants between and among species typically have at least 80%, 90% or greater amino acid identity with a wildtype and/or predominant form from the same species; the degree of identity depends upon the gene and whether comparison is interspecies or intraspecies.
Generally, intraspecies allelic variants have at least about 80%, 85%, 90% or 95%
identity or greater with a wildtype and/or predominant form, including 96%, 97%, 98%, 99% or greater identity with a wildtype and/or predominant form of a polypeptide. Reference to an allelic variant herein generally refers to variations n proteins among members of the same species.
As used herein, "allele," which is used interchangeably herein with "allelic variant" refers to alternative forms of a gene or portions thereof. Alleles occupy the same locus or position on homologous chromosomes. When a subject has two identical alleles of a gene, the subject is said to be homozygous for that gene or allele.
When a subject has two different alleles of a gene, the subject is said to be heterozygous for the gene. Alleles of a specific gene can differ from each other in a single nucleotide or several nucleotides, and can include substitutions, deletions and insertions of nucleotides. An allele of a gene also can be a form of a gene containing a mutation.
As used herein, species variants refer to variants in polypeptides among different species, including different mammalian species, such as mouse and human.
As used herein, a splice variant refers to a variant produced by differential processing of a primary transcript of genomic DNA that results in more than one type of mRNA.
As used herein, modification is in reference to modification of a sequence of amino acids of a polypeptide or a sequence of nucleotides in a nucleic acid molecule and includes deletions, insertions, and replacements of amino acids and nucleotides, respectively. Methods of modifying a polypeptide are routine to those of skill in the art, such as by using recombinant DNA methodologies.
As used herein, the term promoter means a portion of a gene containing DNA
sequences that provide for the binding of RNA polymerase and initiation of transcription. Promoter sequences are commonly, but not always, found in the 5' non-coding region of genes.
As used herein, isolated or purified polypeptide or protein or biologically-active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue from which the protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized.
Preparations can be determined to be substantially free if they appear free of readily detectable impurities as determined by standard methods of analysis, such as thin layer chromatography (TLC), gel electrophoresis and high performance liquid chromatography (HPLC), used by those of skill in the art to assess such purity, or sufficiently pure such that further purification would not detectably alter the physical and chemical properties, such as enzymatic and biological activities, of the substance.
Methods for purification of the compounds to produce substantially chemically pure compounds are known to those of skill in the art. A substantially chemically pure compound, however, can be a mixture of stereoisomers. In such instances, further purification might increase the specific activity of the compound.
The term substantially free of cellular material includes preparations of proteins in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly-produced. In one embodiment, the term substantially free of cellular material includes preparations of enzyme proteins having less that about 30% (by dry weight) of non-enzyme proteins (also referred to herein as a contaminating protein), generally less than about 20% of non-enzyme proteins or 10% of non-enzyme proteins or less that about 5% of non-enzyme proteins. When the enzyme protein is recombinantly produced, it also is substantially free of culture medium, i.e., culture medium represents less than about or at 20%, 10% or 5%
of the volume of the enzyme protein preparation.

As used herein, the term substantially free of chemical precursors or other chemicals includes preparations of enzyme proteins in which the protein is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein. The term includes preparations of enzyme proteins having less than about 30% (by dry weight) 20%, 10%, 5% or less of chemical precursors or non-enzyme chemicals or components.
As used herein, synthetic, with reference to, for example, a synthetic nucleic acid molecule or a synthetic gene or a synthetic peptide refers to a nucleic acid molecule or polypeptide molecule that is produced by recombinant methods and/or by chemical synthesis methods.
As used herein, production by recombinant means by using recombinant DNA
methods means the use of the well known methods of molecular biology for expressing proteins encoded by cloned DNA.
As used herein, vector (or plasmid) refers to discrete elements that are used to introduce a heterologous nucleic acid into cells for either expression or replication thereof. The vectors typically remain episomal, but can be designed to effect integration of a gene or portion thereof into a chromosome of the genome. Also contemplated are vectors that are artificial chromosomes, such as yeast artificial chromosomes and mammalian artificial chromosomes. Selection and use of such vehicles are well known to those of skill in the art.
As used herein, an expression vector includes vectors capable of expressing DNA that is operatively linked with regulatory sequences, such as promoter regions, that are capable of effecting expression of such DNA fragments. Such additional segments can include promoter and terminator sequences, and optionally can include one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, and the like. Expression vectors are generally derived from plasmid or viral DNA, or can contain elements of both. Thus, an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, a phage, recombinant virus or other vector that, upon introduction into an appropriate host cell, results in expression of the cloned DNA. Appropriate expression vectors are well known to those of skill in the art and include those that are replicable in eukaryotic cells and/or prokaryotic cells and those that remain episomal or those which integrate into the host cell genome.
As used herein, vector also includes "virus vectors" or "viral vectors." Viral vectors are engineered viruses that are operatively linked to exogenous genes to transfer (as vehicles or shuttles) the exogenous genes into cells.
As used herein, operably or operatively linked when referring to DNA
segments means that the segments are arranged so that they function in concert for their intended purposes, e.g., transcription initiates in the promoter and proceeds through the coding segment to the terminator.
As used herein the term assessing is intended to include quantitative and qualitative determination in the sense of obtaining an absolute value for the activity of a protease, or a domain thereof, present in the sample, and also of obtaining an index, ratio, percentage, visual or other value indicative of the level of the activity.
Assessment can be direct or indirect and the chemical species actually detected need not of course be the proteolysis product itself but can for example be a derivative thereof or some further substance. For example, detection of a cleavage product of a substrate, such as by SDS-PAGE and protein staining with Coomasie blue.
As used herein, biological activity refers to the in vivo activities of a compound or physiological responses that result upon in vivo administration of a compound, composition or other mixture. Biological activity, thus, encompasses therapeutic effects and pharmaceutical activity of such compounds, compositions and mixtures. Biological activities can be observed in in vitro systems designed to test or use such activities. Thus, for purposes herein a biological activity of a protease is its catalytic activity in which a polypeptide is hydrolyzed.
As used herein equivalent, when referring to two sequences of nucleic acids, means that the two sequences in question encode the same sequence of amino acids or equivalent proteins. When equivalent is used in referring to two proteins or peptides, it means that the two proteins or peptides have substantially the same amino acid sequence with only amino acid substitutions that do not substantially alter the activity or function of the protein or peptide. When equivalent refers to a property, the property does not need to be present to the same extent (e.g., two peptides can exhibit different rates of the same type of enzymatic activity), but the activities are usually substantially the same.
As used herein, "modulate" and "modulation" or "alter" refer to a change of an activity of a molecule, such as a protein. Exemplary activities include, but are not limited to, biological activities, such as signal transduction. Modulation can include an increase in the activity (i.e., up-regulation or agonist activity) a decrease in activity (i.e., down-regulation or inhibition) or any other alteration in an activity (such as a change in periodicity, frequency, duration, kinetics or other parameter).
Modulation can be context dependent and typically modulation is compared to a designated state, for example, the wildtype protein, the protein in a constitutive state, or the protein as expressed in a designated cell type or condition.
As used herein, a composition refers to any mixture. It can be a solution, suspension, liquid, powder, paste, aqueous, non-aqueous or any combination thereof.
As used herein, a combination refers to any association between or among two or more items. The combination can be two or more separate items, such as two compositions or two collections, can be a mixture thereof, such as a single mixture of the two or more items, or any variation thereof. The elements of a combination are generally functionally associated or related.
As used herein, a kit is a packaged combination that optionally includes other elements, such as additional reagents and instructions for use of the combination or elements thereof.
As used herein, "disease or disorder" refers to a pathological condition in an organism resulting from cause or condition including, but not limited to, infections, acquired conditions, genetic conditions, and characterized by identifiable symptoms.
Diseases and disorders of interest herein are those involving components of the ECM.
As used herein, an ECM-mediated disease or condition is one where any one or more ECM components is involved in the pathology or etiology. For purposes herein, an ECM-mediated disease or conditions includes those that are caused by an increased deposition or accumulation of one or more ECM component. Such conditions include, but are not limited to, cellulite, Duputyren's syndrome, Peyronie's disease, frozen shoulders, existing scars such as keloids, scleroderma and lymphedema.
As used herein, "treating" a subject with a disease or condition means that the subject's symptoms are partially or totally alleviated, or remain static following treatment. Hence treatment encompasses prophylaxis, therapy and/or cure.
Prophylaxis refers to prevention of a potential disease and/or a prevention of worsening of symptoms or progression of a disease. Treatment also encompasses any pharmaceutical use of a modified interferon and compositions provided herein.
As used herein, a pharmaceutically effective agent, includes any therapeutic agent or bioactive agents, including, but not limited to, for example, anesthetics, vasoconstrictors, dispersing agents, conventional therapeutic drugs, including small molecule drugs and therapeutic proteins.
As used herein, treatment means any manner in which the symptoms of a condition, disorder or disease or other indication thereof is/are ameliorated or otherwise beneficially altered.
As used herein therapeutic effect means an effect resulting from treatment of a subject that alters, typically improves or ameliorates the symptoms of a disease or condition or that cures a disease or condition. A therapeutically effective amount refers to the amount of a composition, molecule or compound which results in a therapeutic effect following administration to a subject. A therapeutically effective amount effects treatment.
As used herein, the term "subject" refers to an animal, including a mammal, such as a human being.
As used herein, a patient refers to a human subject.
As used herein, amelioration of the symptoms of a particular disease or disorder by a treatment, such as by administration of a pharmaceutical composition or other therapeutic, refers to any lessening, whether permanent or temporary, lasting or transient, of the symptoms that can be attributed to or associated with administration of the composition or therapeutic.
As used herein, prevention or prophylaxis refers to methods in which the risk of developing disease or condition is reduced.

As used herein, an effective amount is the quantity of a therapeutic agent necessary for preventing, curing, ameliorating, arresting or partially arresting a symptom of a disease or disorder.
As used herein, unit dose form refers to physically discrete units suitable for human and animal subjects and packaged individually as is known in the art.
As used herein, a single dosage formulation refers to a formulation for direct administration.
As used herein, an "article of manufacture" is a product that is made and sold.
As used throughout this application, the term is intended to encompass activatable matrix degrading enzymes contained in articles of packaging.
As used herein, fluid refers to any composition that can flow. Fluids thus encompass compositions that are in the form of semi-solids, pastes, solutions, aqueous mixtures, gels, lotions, creams and other such compositions.
As used herein, a "kit" refers to a combination of an activatable matrix-degrading enzyme provided herein and another item for a purpose including, but not limited to, activation, administration, diagnosis, and assessment of a biological activity or property. Kits optionally include instructions for use.
As used herein, a cellular extract or lysate refers to a preparation or fraction which is made from a lysed or disrupted cell.
As used herein, animal includes any animal, such as, but are not limited to primates including humans, gorillas and monkeys; rodents, such as mice and rats;
fowl, such as chickens; ruminants, such as goats, cows, deer, sheep; ovine, such as pigs and other animals. Non-human animals exclude humans as the contemplated animal. The enzymes provided herein are from any source, animal, plant, prokaryotic and fungal. Most enzymes are of animal origin, including mammalian origin.
As used herein, a control refers to a sample that is substantially identical to the test sample, except that it is not treated with a test parameter, or, if it is a plasma sample, it can be from a normal volunteer not affected with the condition of interest.
A control also can be an internal control.
As used herein, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a compound, comprising "an extracellular domain"" includes compounds with one or a plurality of extracellular domains.
As used herein, ranges and amounts can be expressed as "about" a particular value or range. About also includes the exact amount. Hence "about 5 bases"
means "about 5 bases" and also "5 bases."
As used herein, "optional" or "optionally" means that the subsequently described event or circumstance does or does not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not. For example, an optionally substituted group means that the group is unsubstituted or is substituted.
As used herein, the abbreviations for any protective groups, amino acids and other compounds, are, unless indicated otherwise, in accord with their common usage, recognized abbreviations, or the IUPAC-IUB Commission on Biochemical Nomenclature (see, (1972) Biochem. 11:1726).
B. OVERVIEW - TEMPERATURE SENSITIVE MATRIX
METALLOPROTEASES AND OTHER MODIFIED METALLOPROTEASES
Provided herein are modified MMP polypeptides, for example temperature sensitive (ts) mutants of matrix metalloproteases (tsMMPs), that degrade one or more components of the extracellular matrix (ECM). The tsMMPs can degrade one or more components of the ECM in a temperature-dependent manner. In particular, mutants provided herein degrade a collagen. In some examples, the mutants display higher activity at lower temperatures (e.g. 25 C) then at higher temperatures, for example, physiologic temperatures (e.g. 37 C ). In other examples, the mutants display higher activity at physiologic temperatures then at lower temperatures. Thus, the activation of the tsMMPs, for example upon administration to the body, can be temporally and conditionally controlled by virtue of changes in temperature.
Uncontrolled MMP activity can be highly disruptive to tissue integrity. By virtue of the conditional activation of activatable tsMMPs, temporary activation is achieved, thereby regulating the duration of enzymatic action on extracellular matrix (ECM) components to reduce deleterious side effects associated with unwanted prolonged activation of enzymes. This is an advantage of the present tsMMPs over existing collagenase treatments. Hence, an advantage of such mutants is that their activity can be regulated, thereby permitting the use of tsMMPs to treat diseases and/or conditions of the ECM.

Modified MMP polypeptides provided herein are modified to exhibit temperature sensitivity via increased activity at a permissive temperature compared to a nonpermissive temperature and/or are modified as activity mutants to exhibit increased activity compared to the MMP polypeptide not containing the modification.
The modified MMP polypeptides provided herein are modified, for example, by amino acid substitution, insertion or replacement. For example, tsMMPs contain one or more amino acid replacements in their primary sequence rendering the protein more active at permissive temperatures then at non-permissive temperatures.
Modified MMP polypeptides provided herein can contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more amino acid modifications. In particular, modified MMP polypeptides, for example tsMMPs, provided herein contain 1, 2, 3, 4, 5 , 6, 7, 8, 9 or 10 amino acids modifications.

tsMMPs provided herein are activatable at a permissive temperature, but are less active or inactive at other non-permissive temperatures. The tsMMPs provided herein have a ratio of activity at a permissive temperature compared to a non-permissive temperature that is or is about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 15, 20, 30, 40, 50 or more. Thus, the activity of the tsMMPs provided herein at the non-permissive temperature is or is about 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1%, 0.5% or less of the activity at a permissive temperature.

For example, MMPs that are normally active at physiological temperature (e.g. 37 C) are modified and enzymes selected that are active at lower temperatures, i.e. temperatures below the physiological temperature of the body (e.g. less than 37 C; e.g. at or about 20 C, 21 C, 22 C, 23 C, 24 C, 25 C, 26 C, 27 C, 28 C, 29 C
or 30 C), but that are less active or inactive at physiologic temperature.
Such modified enzymes can be used as activatable matrix-degrading enzymes (AMDE) where the activation condition is low temperature. The activation of the enzyme is temporally controlled as the in vivo temperature returns to the physiological temperature of 37 C. Thus, for example, tsMMPs provided herein are active at a permissive temperature that is at or about 25 C, but are less active at higher temperatures such as at or about 33 C, 34 C, 35 C, 36 C, 37 C, 38 C or 39 C.
The tsMMPs provided herein have a ratio of activity at the permissive temperature of at or about 25 C compared to a non-permissive temperature of at or about 34 C
or 37 C, for example, 33 C, 34 C, 35 C, 36 C, 37 C, 38 C or 39 C, that is or is about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 15, 20, 30, 40, 50 or more. Thus, the activity of the tsMMPs provided herein at the non-permissive temperature of at or about 34 C or 37 C is or is about 70%,65%,60%,55%,50%,45%,40%,35%,30%,25%,20%,15%, 10%, 5%, 4%, 3%, 2%, 1%, 0.5% or less of the activity at the permissive temperature at or about 25 C.

For example, modified MMPs polypeptides provided herein, in particular modified MMP-1 polypeptides, that exhibit temperature sensitivity are conditionally active and can be used in uses, methods and processes of treating ECM-mediated diseases and disorders. For example, such tsMMP polypeptides are active at a permissive temperature that is below the normal temperature of the ECM. Thus, when administered to the ECM at or below the permissive temperature, the enzymes exhibit activity. In one example, before administration, a tsMMP, for example tsMMP-1, can be reconstituted in a cold buffer and/or can be stored at a cold temperature that that is at or below the permissive temperature. The tsMMP
exhibits activity when exposed to the permissive temperature (e.g. 18 C to 25 C). As the tsMMP is exposed to a steadily warmer temperature approaching or reaching the nonpermissive temperature, for example upon administration to the body due to the physiologic temperature of the body, the activity of the MMP is reduced. Thus, the tsMMP exhibits conditional activity, conditioned upon maintenance of a permissive temperature. For example, the activity of the ECM can be controlled for a predetermined time by maintaining the ECM below the physiological temperature of the body.

Thus, where the activating condition is temperature, an activator can be provided that exposes the tsMMP to the permissive temperature required for activation. The exposure to the activator can be in vitro or in vivo. The activator can be exposed to the tsMMP prior to, simultaneously, subsequently or intermittently upon in vivo administration. The activator can provide the requisite heat or cold required for activation. For example, where the activating condition is low temperature, the activator can be provided as a cold buffer or as an ice pack to be applied to the site of administration. Where the activating condition is heat, the activator can be provided as a warm buffer or as a heat pack to be applied to the site of administration. The activating condition also can be provided by storage of the tsMMP at the permissive temperature immediately and just prior to use. The duration of exposure to the activator can be continuous, can be for a predetermined time, or can be intermittent (for example, if the tsMMP is reversible). Thus, the time period permitting activation is flexible and can be adapted to the particular enzyme that is used, the disease or condition being treated, the site of administration or other factors.
It is within the level of the skilled artisan to determine the duration of exposure to the activator.
In the absence of exposure to the activator providing the activating condition, the tsMMPs present at the non-permissive temperature are inactive or substantially inactive compared to the activity at the permissive temperature. The activating condition of a permissive temperature (e.g. low temperature) not normally present at the site of administration permits the temporal regulation of, and alteration of, the physiological parameters of organs and tissues, such as the interstitium that exhibits a physiologic temperature of approximately 37 C. Under normal physiological conditions, the temperature of the interstitium is approximately 37 C. Thus, for example, tsMMPs active at low temperatures, when present in the interstitium would normally be catalytically inactive because of the physiologic temperature of the interstitium. When the temperature of the interstitium is temporarily rendered cold, for example, by exposure to a cold buffer or to a cold pack administered on the adjacent surface, tsMMPs when administered to the interstitium will become activated. When the temperature increases and returns to physiological levels, then the tsMMPs become inactive or substantially inactive and cease to exert their enzymatic activity. Hence, by taking advantage of the requirement for exogenous activating conditions, tsMMPs are activatable and can be made temporally active for a limited duration during use, such as upon in vivo administration to the body.
The tsMMPs provided herein include those that are irreversibly inactive following exposure to non-permissive temperatures. Such mutants are active when exposed to permissive temperature conditions (e.g. 25 C), but are less active or inactive when the temperature is altered to a non-permissive temperatures (e.g. 37 C, such as can occur upon in vivo administration to the body and removal of an exogenous activator (e.g. cold pack)). Upon return to permissive conditions, irreversible tsMMP polypeptides provided herein exhibit at or about 50%, 60%, 70%, 80%, 90%, 100%, 105%, 110%, 115%, or 120% the activity at non-permissive temperatures. The activity is not reversible.
Also provided herein are tsMMPs that are reversibly inactive following exposure to a non-permissive temperature. Such mutants are active when exposed to a permissive temperature condition, but are less active or inactive when the temperature is altered to a non-permissive temperatures. Upon renewed exposure to an activating condition providing the permissive temperature (e.g. cold pack), the activity of the tsMMP is restored, thereby rendering the enzyme sufficiently active to degrade one or more components of the ECM. For example, upon return to permissive conditions from nonpermissive conditions, reversible tsMMP
polypeptides provided herein exhibit at or about 120%, 125%, 130%, 140%, 150%, 160%, 170%, 180%, 200% or more the activity at non-permissive temperatures.
tsMMPs provided herein retain one or more activities of wildtype MMP, for example, enzymatic activity for cleavage of an ECM component such as collagen.
For example, a tsMMP provided herein retains an activity at the permissive temperature that is or is about 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 140%, 150% or more the activity of wildtype MMP at the permissive temperature. Thus, tsMMPs provided herein include those that are more active than wildtype MMP-1 at the permissive temperature, and also those that are less active than wildtype MMP-1 at the permissive temperature. Generally, tsMMPs provided herein, however, are less active then wildtype MMP-1 at the nonpermissive temperature. For example, tsMMPs provided herein exhibit 95%, 90%, 80%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%,15%,10%, 5%, 4%, 3%, 2%, 1%, 0.5%, generally 40%, 30%, 25%, 20%, 15%, 10%, or 5% residual activity of wildtype MMP-1 at physiologic temperature (e.g. 34 or 37 C).
Typically, modified MMP polypeptides, for example tsMMPs, provided herein are zymogens (containing a propeptide) or processed enzymes (e.g.
mature enzymes, lacking a propeptide), or catalytically active forms thereof. As discussed below, most enzymes, including MMPs, are zymogens and require an initial processing event for activity by removal of a propeptide segment from the N-terminal end of the polypeptide. A processing agent, such as a protease or chemical agent, directly or indirectly initiates one or more cleavage events to generate an active MMP
by virtue of removal of the propeptide segment and/or conformational changes that expose the active site of the MMP. Hence, normally, upon processing of an enzyme to a mature form, the enzyme is active. The activity of a processed enzyme is not reversible, thereby leading to uncontrolled degradation of the ECM upon administration of the processed enzyme to the body. It is contemplated herein that modification of the enzyme to additionally confer temperature sensitivity provides a mechanism to conditionally and temporally control activation of the MMP to avoid continued activation of the processed MMP.
Any MMP, whether synthetic or isolated from natural sources, such as those set forth in Table 5 or elsewhere herein, mature forms thereof lacking the propeptide, and catalytically active forms including polypeptides containing only the catalytically active domain or a portion thereof, and allelic or species variants or other variants thereof, or any known to those of skill in the art can be modified as described herein to be temperature sensitive and/or have increased activity and is intended for use in the compositions, combinations, methods and apparatus provided herein. It is understood that any modified enzyme form provided herein exhibits increased activity and/or temperature sensitivity, i.e. the enzyme is activatable due to the requirement of a temperature activating condition. Exemplary MMPs that can be modified, for example to be temperature sensitive, are set forth in Table 1 and include, for example, any of SEQ ID NOS: 1, 711, 714, 717, 720, 723, 726, 729, 732, 735, 738, 741, 744, 747, 750, 753, 756, 759, 762, 765, 768, 771, 774 or 777, zymogen forms or mature forms thereof, catalytically active forms thereof, and allelic or species variants or other variants thereof, so long as the other forms contain the mutation conferring temperature sensitivity and/or increased activity. For example, SEQ ID NO:2 is the zymogen form of SEQ ID NO:1. Figure 1 exemplifies the zymogen form of other exemplary MMPs. One of skill in the art knows or could identify tsMMPs. For example, one of skill in the art could use routine molecular biology techniques to introduce amino acid mutation(s) herein into an MMP, and test each for enzyme activation under temperature permissive and non-permissive temperatures to assess the requirement of an exogenous activating condition for sustained or reversible activation of any desired enzyme. Exemplary assays for enzyme activation are provided herein and known in the art.
Hence, modified MMP polypeptides, for example tsMMPs, provided herein include zymogen forms (e.g. proenzyme), processed mature forms lacking a propeptide, and polypeptides containing only the catalytically active domains thereof.
For example, tsMMPs include zymogen forms (e.g. proenzyme), processed mature forms lacking a propeptide, and polypeptides containing only the catalytically active domains thereof, so long as the tsMMPs exhibits enzymatic activity at the permissive temperature. Exemplary of such a tsMMP is a tsMMP-1. tsMMP-1 provided herein contains one or more amino acid modifications in its primary sequence corresponding to amino acid replacements in a wildtype MMP-1 set forth in SEQ ID NO:2.
Exemplary modifications are described elsewhere herein in Section D. The modified MMPs, for example tsMMP- 1 mutants or activity mutants, provided herein include those that are zymogens or those that are in a mature form lacking a propeptide. The zymogen or mature polypeptides provided herein include those that are full-length, include all or a portion of the proline rich linker or the hemopexin binding domain, lack all or a portion of the proline rich linker or the hemopexin binding domain, or polypeptides that include only the catalytically active domains thereof (e.g.
corresponding to amino acids 81-242 of the sequence of amino acids set forth in SEQ

ID NO:1) so long as the tsMMP-1 retains enzymatic activity at the permissive temperature and/or exhibits increased activity.
It is understood that when provided in zymogen form, the modified MMP
polypeptides, for example tsMMPs, are inactive and that processing by a processing agent is required for activity. Generally, the processing of the enzyme is effected prior to use, such as prior to administration in vivo. For example, the processing agent can be applied simultaneously, intermittently or subsequently to exposure of the tsMMP to the activating condition (e.g. low temperature) and administration to the body. Generally, the processing agent is chosen that is acceptable for administration to a subject. If desired, the processing agent can be dialyzed or otherwise purified away from the enzyme preparation before administrations. Thus, for zymogen forms of the enzyme, two steps are required for activation: 1) exposure to a processing agent; and 2) exposure to an activating condition. Whether in zymogen or processed form, exposure of the tsMMP to an activator at the permissive temperature temporally controls activity of a tsMMP.
Modified MMP polypeptides, for example tsMMPs, provided herein can be further modified to alter any one or more properties or activities. For example, altered properties or activities include, but are not limited to, modification that render the enzyme more stable, alter the substrate specificity and/or increase resistance to one or more inhibitors. In one example, modified MMP polypeptides, for example tsMMPs, can be modified to alter its substrate specificity. For example, an enzyme can be modified to have increased specificity for a particular substrate. Thus, for example, a modified MMP polypeptide, which exhibits substrate specificity for type I and type IV collagen can be modified so that it has increased substrate specificity for type I
collagen, and not type IV collagen, and vice versa. If desired, enzyme stability also can be increased by PEGylation or glycosylation of the enzyme.
Modifications of polypeptides can be achieved by routine molecular biology techniques, and are within the skill of one in the art. For purposes herein, modified MMP polypeptides, for example tsMMPs, retain one or more activities of the wildtype MMP at the permissive temperature. Retained activity can be 40%, 50%, 60%, 70%, 80%, 90%, 95% or more activity of the wildtype MMP at the permissive temperature. Modified enzymes can be tested for their substrate specificity using routine assays for substrate cleavage such as is described herein, or known in the art.
For example, substrate cleavage can be assessed on fluorogenic peptides or on purified proteins. Cleavage can be assessed using in vitro or in vivo assays.
For example, cleavage can be assessed by incubating the enzyme with the substrate, and then running the mixture on an SDS-PAGE gel. Degradation can be assessed by Western Blot or by using standard protein stains such as Coomasie Blue or Silver Stain reagents.
The modified MMP polypeptides, for example tsMMPs, are provided herein as compositions, combinations and containers. The modified MMPs, for example tsMMP, are provided in a therapeutically effective amount, that when activated, degrade one or more components of the ECM upon administration, such as upon sub-epidermal administration. The resulting modified MMPs, for example tsMMPs, can be used as therapeutics to treat ECM-mediated diseases or conditions. A
description of compositions, combinations, containers and methods of using activatable matrix-degrading proteins is provided in related U.S. Provisional Application Nos.
61/068,667 and 61/127,725, U.S. Patent Application No. 12/81,063 and International PCT Application No. PCT/US2009/001489, each incorporated by reference in their entirety. Such description of the compositions, combinations, containers and methods can be used for the purpose of preparing and providing compositions, combinations and containers of modified MMPs, for example tsMMPs, and use thereof for treating ECM-mediated diseases and conditions.
For example, the tsMMPs are provided in compositions, combinations and/or containers with an activator that provides the activating condition. In some examples, modified MMPs, for example tsMMPs, also are provided in compositions, combinations and/or containers with a processing agent. The activator and/or processing agent can be in the same composition or in separate compositions and in the same container or separate containers with the tsMMP. In addition, the modified MMPs, for example tsMMP, also can be combined or provided in combination, such as in containers, with other agents such as any one or more of an anesthetic, alpha-adrenergic agent, dispersing agent, or therapeutic agent. The modified MMPs, for example tsMMPs, can be provided in the same or separate composition as other agents and/or can be provided in the same or separate containers.
The modified MMPs, for example tsMMPs, can be provided as a liquid or in lyophilized form at a therapeutically effective concentration. Alternatively, the tsMMPs can be provided as a concentrated liquid, such that addition of a sufficient amount of activator results in a therapeutically effective concentration of enzyme.
The enzymes can be provided as a solution or suspension or encapsulated into a suitable delivery vehicle, such as a liposome, glass particle, capillary tube, drug delivery vehicle, gelatin, gel, tablet, capsule, pill, time release coating, as well as transdermal patch preparation and dry powder inhalers or other such vehicle.
The activator typically is provided as a liquid solution or suspension for administration into the interstitium either alone or following reconstitution of and/or exposure to the tsMMP. In some examples, the activator is provided exogenously and applied at the site of administration. For example, an activator can be a hot or cold pack that can be applied to the site of administration, e.g. the skin, prior to, simultaneously, subsequently or intermittently following administration of a tsMMP. As described below, kits containing these combinations and also articles of manufacture, such as containers, also are provided.
Thus, when desired, the tsMMP enzyme is subjected to activating conditions in which the enzyme is exposed to an activator to generate an enzyme that is active.
Exposure to an activator can be achieved in vitro or in vivo. For example, where an activatable enzyme and activator are separately provided, they can be administered together or separately. Where administered separately, the tsMMP can be administered simultaneously, subsequently or intermittently from the activator. In another example, the tsMMP, in a lyophilized or concentrated liquid form, can be reconstituted with the activator just prior to use. In such an example, the mixture of the tsMMP and activator are administered together. Such methods of activation can be empirically determined by one of skill in the art, and may differ depending on the choice of enzyme and activator, and the method of treatment and treatment regime desired.

The tsMMP, can be provided in an article or manufacture alone or in combination with the activator. For example, if the enzyme is provided in combination with the activator, an article of manufacture can contain an enzyme, either lyophilized or in liquid form, in one compartment, and buffer that is cold or can be rendered cold in an adjacent compartment. The compartments can be separated by a dividing member. Articles of manufacture can additionally contain a processing agent. Such articles of manufacture are described elsewhere herein.
The combinations of also can further contain other agents, discussed in detail below. For example, modified MMP polypeptides, for example tsMMP, are provided in combinations containing one or more of a anesthetic, vasoconstrictor, dispersing agent or other therapeutic agent.
The following sections provide a general overview of the extracellular matrix and diseases thereof, and provide exemplary MMPs for preparation as modified MMPs, for example as temperature-sensitive activatable enzymes; methods of making such modified MMPs; exemplary modified MMPs, for example tsMMPs, that are modified MMP-1 polypeptides; compositions and combinations thereof, and methods of using modified MMP, for example modified MMP-1 polypeptides or compositions to treat ECM-mediated diseases and conditions.
C. MATRIX METALLOPROTEASES AND THE EXTRACELLULAR
MATRIX
Provided herein are modified matrix metalloproteases (MMPs). The modified MMPs include those that are activatable by temperature and degrade one or more protein components of the extracellular matrix (ECM) in a temperature controlled manner by virtue of increased activity at a permissive temperature compared to a non-permissive temperature. Hence, the modified MMPs are temperature sensitive. By virtue of such temporal in vivo activation, diseases and/or conditions of the ECM can be treated. In another example, also provided herein are modified MMPs that exhibit increased activity compared to an MMP not containing the modifications.
Mutations that confer increased activity can be combined with at least one mutation that confers temperature sensitivity to generate modified MMP polypeptides that have increased activity at the permissive temperature compared to the tsMMP not containing the activity mutation. The modified MMP polypeptides, for example tsMMPs, can degrade any component of the ECM; enzyme selection can depend upon the targeted component and/or the particular disease or condition to be treated.
1. THE EXTRACELLULAR MATRIX
The ECM makes up the connective tissue or interstitium that surrounds the spaces outside cells and the vascular and lymphatic system, thereby providing mechanical and structural support with and between different tissues. The complex and dynamic microenvironment of the ECM represents a structural and signaling system within connective tissues, such as the skin. Due to the complex nature of the ECM, it can serve diverse functions such as providing support and anchorage for cells, segregating tissues, regulating intercellular communication, and sequestering cellular growth factors. Defects or changes in the organization, or make-up, of the ECM can contribute to a number of diseases or conditions. For example, changes in the synthesis, degradation and organization of collagen fibers contribute to lipodystrophy (e.g., cellulite) and lymphedema.
The ECM is composed of fibrous structural proteins, such as collagens, polysaccharides, such as proteoglycans and hyaluronic acid, and adhesion proteins that link components of the matrix to each other and to cells. Some connective tissues, such as tendon and cartilage, are principally made up of ECM. The ECM
making up the connective tissue of the skin, however, also is distributed with fibroblasts, blood vessels and other components. The ECM also serves as the space where water and its dissolved constituents move from the blood plasma to the lymphatics. The interstitial fluid is nearly isosmotic with the cytoplasm and is bicarbonate buffered providing an extracellular environment that is at neutral pH.
a. Components of the ECM
The ECM (also called the interstitial matrix) is a complex three-dimensional dynamic structure that contains numerous structural macromolecules including fibrous proteins such as collagens, elastin and fibronectin, in which glycosyaminoglycans (GAGs) form a hydrated gel-like substance. The components of the ECM are produced by resident cells, typically fibroblasts or cells of the fibroblast family, and are secreted via exocytosis where they interact with other components of the ECM. It is the variation in the relative amount and the way in which the components organize and form together that give rise to diverse connective tissues such as bone, skin or cornea (Albert et al., "Cell Junctions, Cell Adhesions and the Extracellular Matrix." Molecular Biology of the Cell. New York: Garland Publishers, 1994. Page 972.) L Collagens Collagen is the major structural constituent of connective tissues, such as the skin, and plays a role in the development and maintenance of tissue architecture, tissue strength and cell-cell interactions. Collagens include a family of structurally-related proteins of the ECM that contain one or more domains having the conformation of a collagen triple helix (Van der Rest et al. (1991) FASEB J., 5:2814-2823). Collagens contain a Gly-X-Y repeating structure, which allows collagen chains to twist into a helical structure. Each collagen molecule contains three chains twisted around each other to form a triple helix, designated a1-a3. The triple helix structure provides a high mechanical strength to a collagen molecule. There are at least 27 different types of collagens, which differ in amino acid sequence and chain composition. For example, depending on the type of collagen, the three chains forming the triple helix can be the same or different. Collagens can be homotrimeric (i.e. all three polypeptide chains of the triple helix are made up of the same collagen) or can be heterotypic (i.e. fibrils made of more than one collagen type).
Collagens can be divided into several families depending on the structure they form.
These include fibrillar collagens (also called interstitial collagens; e.g., Type I, II, III, V and XI) and non-fibrillar collagens such as facit (e.g., Type IX, XII, XIV), short chain (e.g., Type VIII, X), basement membrane (e.g., Type IV), and other collagens (e.g., Type VI, VII, and XIII). Table 3 below sets forth common collagen types and their representative location (Van der Rest et al. (1991) FASEB J., 5:2814-2823);
www.collagenlife.com/page-I 167323108078.html;
www.indstate.edu/thcme/mwking/extracellulannatrix.html).
Among the interstitial collagens, collagen molecules associate to form large fibrils, which have a distinctive banding pattern. The banding pattern results from overlap between adjacent molecules. The strength of collagen fibers is based on a multiplicity of intra- and intermolecular linkages of the collagen fibers that form the dense collagen fiber network of connective tissues. The most common of fibrillar collagens include type I, II and III collagens. Type I collagen is found in most connective tissues such as skin, bone, tendon and cornea, and is a made up of two al(I) chains and one a2(I) chain ([al(I)]2 a2(I)). Type II collagen is homotrimeric ([(1l(II)]3) and is predominantly found in the cartilage. Type III collagen also is homotrimeric ([al(III)]3) and is predominantly found in the skin and vessels.
Not all collagens form fibril networks. For example, the basement membrane type IV collagen is non-fibrous and has non-helical interruptions in the helix, which acts as a hinge giving the molecule greater flexibility. Thus, type IV
collagen forms a sheet made by a meshwork of filaments rather than by linear fibrils.
The most abundant protein of the skin is collagen, which is primarily made up of type I (80-85%) and type III (8-11%) collagen. Type I collagen associates with type III collagen to form the major collagen fibers of the dermis. The tensile strength of skin is due predominantly to these fibrillar collagen molecules, which assemble into microfibrils in a head-to-tail and staggered side-to-side lateral arrangement.
Collagen molecules become cross-linked to adjacent collagen molecules, creating additional strength and stability in collagen fibers. For example, type V
collagen also associates with type 1/111 collagen fibers, and regulates the fibril diameter.
Other collagen types in the skin include, for example, type IV, type VI, type VII, type XII, type XIV and type XVII.

Table 3: Types of Collagens Type Molecule Composition Representative tissue Fibrillar Collagens I [al(1)12 [a2(I)] Skin, bone, tendon, dentin, ligaments, interstitial tissues II [al(II)]3 Cartilage, vitreous humor III [al(III)]3 Skin, muscle, blood vessels;
frequently associated with type I

V [al (V)] [a2(v)] [a3(V)] Similar to Type I, also cell cultures, fetal tissues;
associates with Type I
XI [al (XI)] [a2(XI)] [a3(XI)] Cartilage, intervertebral cartilage and bone enamel Non-fibrillar collagens IV [al(IV)]2 [a2 (IV)] Basement membrane VI [al (VI)] [a2(VI)] [a3(VI)] Most interstitial tissues;
associates with type I
VII [al(VII)13 epithelia VIII [al(VIII)]3 Unknown, some endothelial cells IX [al (IX)] [a2(IX)] [a3(IX)] Cartilage; associates with Type II
X [al(X)13 Heterotrophic and mineralizing cartilage XII [al(XII)]3 Ligaments, tendons and tooth enamel; interacts with types I
and III

ii. Elastin A network of elastic fibers in the ECM provides flexibility to tissues that require resilience to recoil after stretching, such as the skin, arteries and lungs. The main component of elastic fibers is the elastin molecule, which creates cross-links to adjacent elastin molecules. These molecules form a core of elastic fibers and are covered by fibrillin, a large glycoprotein that binds to elastin and is important for the integrity of elastic fibers.
W. Fibronectin Fibronectin is a glycoprotein that exists as a pair of two large subunits joined by a pair of disulfide bonds near the carboxyl termini. Each subunit contains functionally distinct domains specific for other matrix macromolecules and receptors on the surface of cells. For example, distinct domains on fibronectin bind collagen (separate domains for types I, II and III), heparin, fibrin and cell surface receptors such as integrins. Fibronectin is present in both plasma and tissue. In tissue, fibronectin functions to link together different types of ECM molecules and cells. It also contains an important cell-binding domain made up of the three amino acids, Arg-Gly-Asp (RGD), which is recognized by integrin receptors in the plasma membranes of cells. The binding of fibronectin molecules to integrin receptors on cells leads to the stimulation of signaling pathways that promote cell attachment, migration and differentiation. These characteristics allow fibronectin to play an important role in cell adhesion and to communicate signals between cells and components of the ECM.
iv. Glycosaminoglycans (GAGs) GAGs are unbranched polysaccharide chains made of repeating disaccharide units that are strongly hydrophilic. GAGs are highly negatively charged and therefore attract osmotically active Na+, causing large amounts of water to be drawn into their structure to keep the ECM hydrated. GAGs, such as dermatan sulfate, typically contain multiple glycosaminoglycan chains of 70-200 sugars long (formed from repeating disaccharide units) that branch from a linear protein core. This results in GAGs occupying a huge volume relative to their mass and forming gels at very low concentrations. The hydrophilic nature of GAGs causes a swelling pressure, or turgor, which allows the ECM to withstand compression forces.
In the ECM, GAGs are attached to ECM proteins to form proteoglycans or, in the case of hyaluronic acid (also called hyaluronan), exist as a non-proteoglycan matrix component. Extracellular proteoglycans are large, highly hydrated molecules that help cushion cells in the ECM. Glycosaminoglycans such as hyaluronan contribute to the "ground substance" by creating a barrier to bulk fluid flow through the interstitial collagenous matrix by way of their viscosity and water of hydration.
Proteoglycans and non-proteoglycan GAGs associate to form large polymeric complexes in the ECM. They associate with each other, and also with fibrous proteins such as collagen.
1) Proteoglycans There are three main types of GAGs that form proteoglycans of the ECM, including dermatan sulfate and chondroitin sulfate, heparin and heparan sulfate, and keratan sulfate. Generally, a proteoglycan is 95% carbohydrate by weight, typically in the form of long unbranched GAG chains. Besides providing hydrated space around cells, proteoglycans also regulate traffic of molecules and cells, bind signaling molecules thereby playing a role in cell activation, and bind other secreted proteins such as proteases and protease inhibitors to regulate the activities of secreted proteins (Albert et al., "Cell Junctions, Cell Adhesions and the Extracellular Matrix"
Molecular Biology of the Cell. New York: Garland Publishers, 1994. pp. 972-978).
For example, the heparin sulfate chains of proteoglycans bind to several different growth factors, including fibroblast growth factors (FGFs), helping them to bind to their specific cell surface receptors.
Aggrecan is a proteoglycan, which principally contains chondroitin sulfate and heparan sulfate GAGs, and is typically found in cartilage forming large aggregates with hyaluronan to provide mechanical support. Decorin is another exemplary GAG
of connective tissues made up primarily of chondroitin sulfate and dermatan sulfate GAGs. It binds to type I collagen fibrils. Perlecan and betaglycan are other exemplary proteoglycans of the ECM. Not all proteoglycans are associated with the ECM: for example, serglycin is associated with secretory vesicles where it helps to package and store secretory molecules, and syndecans are found on the cell surface and act as co-receptors (Albert et al., "Cell Junctions, Cell Adhesions and the Extracellular Matrix" Molecular Biology of the Cell, New York: Garland Publishers, 1994. pp. 972-978).
Heparan sulfate proteoglycans (HSPGs) are ubiquitous macromolecules associated with the cell surface and extracellular matrix (ECM) of a wide range of cells of vertebrate and invertebrate tissues (Wight, T. N., Kinsella, M. G., and Qwarnstromn, E. E. (1992) Curr. Opin. Cell Biol., 4,793-801; Jackson, R. L., Busch, S. J., and Cardin, A. L. (1991) Physiol. Rev., 71,481-539; Wight, T. N. (1989) Arteriosclerosis, 9,1-20; Kjellen, L., and Lindahl, U. (1991) Annu. Rev.
Biochem., 60,443-475; and Ruoslahti, E., and Yamaguchi, Y. (1991) Cell, 64,867-869). The basic HSPG structure has a protein core to which several linear heparan sulfate chains are covalently attached. The polysaccharide chains are typically composed of repeating hexuronic and D-glucosamine disaccharide units that are substituted to a varying extent with N- and O-linked sulfate moieties and N-linked acetyl groups.
Studies on the involvement of ECM molecules in cell attachment, growth and differentiation revealed a central role of HSPGs in embryonic morphogenesis, angiogenesis, metastasis, neurite outgrowth and tissue repair. The heparan sulfate (HS) chains, which are unique in their ability to bind a multitude of proteins, ensure that a wide variety of effector molecules cling to the cell surface. HSPGs are also prominent components of blood vessels. In large vessels they are concentrated mostly in the intima and inner media, whereas in capillaries they are found mainly in the subendothelial basement membrane where they support proliferating and migrating endothelial cells and stabilize the structure of the capillary wall. The ability of HSPGs to interact with ECM macromolecules such as collagen, laminin and fibronectin, and with different attachment sites on plasma membranes suggests a key role for this proteoglycan in the self-assembly and insolubility of ECM components, as well as in cell adhesion and locomotion.
2) Hyaluronic acid Hyaluronic acid (HA; also called hyaluronan) is a large GAG that attracts water, and when bound to water exists in a viscous, gel-like form. Thus, HA
serves as a lubricant, holding together gel-like connective tissues. HA is a polymer of disaccharides (sometimes as many as 25,000 repeats in length) and is composed of repeating units of two modified simple sugars: glucuronic acid and N-acetyl glucosamine. HA is part of the ECM of many connective tissues. HA is found in the greatest amount in the skin with almost 50% of the body's HA found in the skin. The HA provides continuous moisture to the skin by binding up water. Decreased production of HA, such as by age, results in wrinkled and unhealthy skin.
HA, principally through its receptor CD44, also functions to regulate cell behavior during embryonic development and morphogenesis, wound healing, repair and regeneration, inflammation and tumor progression and invasion (Harada et at.
(2006) J. Biol. Chem., 8:5597-5607). HA is degraded by hyaluronidases. The degradation products of HA can be found in increased amounts in damaged or growing tissues, and in a variety of inflammatory conditions. HA fragments promote angiogenesis and can stimulate cytokine production by macrophages and dendritic cells in tissue injury and skin transplant.

b. Histology of the Skin The skin helps to maintain the body's temperature at a physiologic temperature of 37 C. The skin is composed of several distinct layers, principally the epidermis and dermis. The epidermis is a specialized epithelium derived from the ecotoderm, and beneath this is the dermis, which is a derivative of the mesoderm and is a vascular dense connective tissue. These two layers are firmly adherent to one another and form a region which varies in overall thickness form approximately 0.5 to 4 mm in different areas of the body. Beneath the dermis is a layer of loose connective tissue, which varies from areolar to adipose in character. This is referred to as the hypodermis, but is typically considered not to be part of the skin. The dermis is connected to the hypodermis by connect tissue fibers that pass from one layer to the other.

i. The Epidermis The epidermis is the skin layer directly above the dermis, and is the surface layer of the skin. The principle function of the epidermis is to act as a protective barrier against water loss, chemical injury and invading pathogens. The epidermis is a thin layer of approximately fifteen cell layers that is about 0.1 to 1.5 millimeters thick composed primarily of keratinocytes (Inlander, Skin, New York, N.Y.:
People's Medical Society, 1-7 (1998)). The epidermis is itself divided into several layers (e.g., stratum basale, stratum spinosum, stratum granulosum, stratum lucidum, stratum corneum) based on the state of differentiation of the keratinocytes.
Keratinocytes originate in the basal layer from keratinocyte stem cells. As the keratinocytes grow and divide, they undergo gradual differentiation eventually reaching the stratum corneum where they form a layer of enucleated, flattened, highly keratinized cells called squamous cells (also called corneocytes). Besides being made up of corneocytes, the stratum corneum also contains sebum. The sebum is secreted by sebaceous glands, which are usually found in hair-covered areas connected to hair follicles. Sebum is a slightly acid layer that helps to hold the corneocytes together and holds moisture in. This acidity is due to the presence of amphoteric amino acids, lactic acid and fatty acids that make up sebum. Thus, the pH of the skin surface is normally between 5 and 6, typically about 5.5. Sebum acts to waterproof hair and skin, and keep them from becoming dry, brittle and cracked, and it also inhibits the growth of microorganisms on skin. The term "acid mantle" refers to the presence of the water-soluble substances on most regions of the skin.
ii. The Dermis The connective tissue of the skin is called the dermis. The dermis is 1.5 to 4 millimeters thick. In the skin, the dermis contains ECM components; the main protein components are collagen and elastin. The dermis also is home to most of the skin's structures, including sweat and oil glands that secrete substances through openings in the skill called pores, or comedos, hair follicles, nerve endings, and blood and lymph vessels (Inlander, Skin, New York, N.Y.: People's Medical Society, 1-(1998)). In addition, the dermis contains blood vessels that play a role in temperature regulation.
iii. The Hypodermis Below the dermis is the hypodermis, which is a fatty layer and is the deepest layer of the skin. It acts as an insulator for body heat conservation and as a shock absorber for organ protection (Inlander, Skin, New York, N.Y.: People's Medical Society, 1-7 (1998)). In addition, the hypodermis also stores fat for energy reserves.
c. Diseases of the ECM
Certain diseases and conditions result from defects or changes in the architecture of the extracellular matrix due to aberrant expression or production of ECM components. For example, in some inflammatory conditions such as occur upon wound healing, cytokines are secreted, which stimulate fibroblasts to secrete ECM components such as collagen. The ECM components accumulate and become locally deposited, resulting in a wide range of fibrotic conditions. Matrix deposition is a frequent feature in many chronic inflammatory diseases and in other diseases and conditions. Included among these are collagen-mediated disease conditions such as, but not limited to, scars such as keloid and hypertrophic scars, Duputyren's syndrome, Peyronie's disease and lymphedema. Cellulite also is a prominent disease of the ECM that, in addition to increased adipogenicity, is characterized by alterations in the connective tissue matrix resulting in an abnormal fibrous septae network of collagen (Rawlings et al. (2006) Int. J Cos. Science, 28:175-190).

Diseases and conditions of the ECM that are characterized by aberrant expression or overproduction of matrix components, resulting in their accumulation and unwanted deposition, can be treated by the tsMMPs provided herein. By virtue of the temporal activation of such enzymes upon in vivo administration, the treatment of such diseases and conditions is regulated to limit the enzymatic degradation of the matrix components. For example, by limiting the duration of action of matrix degradation, unwanted side effects associated with uncontrolled protein degradation is minimized.

2. MATRIX METALLOPROTEASES
Provided herein are modified MMPs that are temperature sensitive (tsMMPs).
The modified MMPs include those that exhibit increased activity at a lower temperature then a higher temperature and also those that exhibit increased activity at a higher temperature then a lower temperature. The tsMMPs are provided as compositions, combinations and containers, and can be used in methods, processes and uses to treat ECM-mediated diseases or conditions. MMPs are matrix-degrading enzymes that degrade protein components of the extracellular matrix (ECM), including, but not limited to, collagen, elastin, fibronectin and proteoglycans. By virtue of their ability to cleave one or more ECM components, activatable tsMMPs provided herein can be used to modify the matrix of tissues, particularly those exhibiting structural defects or changes due to excess of one or more ECM
protein or unwanted accumulation of fibrous tissue rich in one or more ECM protein, such as collagen. Thus, such enzymes are useful in treating diseases or conditions in which ECM proteins are involved.
a. Function Matrix metalloproteinases (MMPs) are a family of zinc-dependent and calcium-dependent endopeptidases. For example, MMPs contain an active site Zn2+
required for activity. Most MMPs are involved in degradation of the extracellular matrix. For example, many of these enzymes can cleave components of the basement membrane and extracellular matrix. They are involved in tissue remodeling, for example, in processes such as wound healing, pregnancy and angiogenesis. In addition, MMPs also can process a number of cell-surface cytokines, receptors and other soluble proteins. The proteolytic activity of MMPs act as an effector mechanism of tissue remodeling in physiologic and pathologic conditions, and as modulator of inflammation. The excess synthesis and production of MMPs leads to accelerated degradation of the ECM which is associated with a variety of diseases and conditions such as, for example, bone homeostasis, arthritis, cancer, multiple sclerosis and rheumatoid arthritis. In the context of neuroinflammatory diseases, MMPs have been implicated in processes such as (a) blood-brain barrier (BBB) and blood-nerve barrier opening, (b) invasion of neural tissue by blood-derived immune cells, (c) shedding of cytokines and cytokine receptors, and (d) direct cellular damage in diseases of the peripheral and central nervous system (Leppert et al. Brain Res. Rev.
36(2-3): 249-57 (2001); Borkakoti et al. Prog. Biophys. Mol. Biol. 70(1): 73-(1998)). The enzymes are specifically regulated by endogenous inhibitors called tissue inhibitors of matrix metalloproteases (TIMPs).
b. Structure and Activation Generally, MMPs contain three common domains: the pro-peptide, the catalytic domain and the hemopexin-like C-terminal domain. MMPs are synthesized as zymogens. Zymogen activation prevents unwanted protein degradation that could occur if proteases were always present in active form. Generally, zymogens contain N-terminal portions (or prosegments or proregions or propeptide) that sterically block the active site of the protease and prevent access of substrates to the active site of the protease. The propeptide also acts to stabilize the polypeptide. The propeptide of zymogen forms of MMPs range in size from about 80-100 residues in length. The propeptide of MMPs contains a cysteine residue generally contained in the conserved sequence PRCxxPD (with the exception of MMP-23, which contains the critical cysteine and different surrounding amino acids). The cysteine residue interacts with the zinc in the active site and prevents binding and cleavage of the substrate, thereby keeping the enzyme in an inactive form. Thus, upon secretion from a preproenzyme form, the proenzyme (containing the propeptide) is inactive. For example, in the propeptide cysteine residue corresponds to amino acid residue 73 in the sequence of amino acids set forth in SEQ ID NO:2.

MMPs require processing for activation. Generally, processing involves removal of the propeptide and/or conformational changes of the enzyme to generate a processed mature form. Processing of the enzyme by removal of the propeptide is required for activity of MMPs. For normal MMPs (e.g. wildtype) that are not conditionally active as provided herein, the processed mature form is an active enzyme. Thus, it is understood that wildtype MMPs in their processed mature form are enzymatically active, and thus for these enzymes this is the active form.
tsMMPs provided herein, however, also additionally require the permissive temperature condition to be fully active.

Processing (and thereby activation) can be induced by processing agents such as proteases, including other previously activated MMPs; by chemical activation, such as thiol-modifying agents (4-aminophenylmercuric acetate, HgC12 and N-ethylmaleimide), oxidized glutathione, SDS, chaotropic agents and reactive oxygens;
and by low pH or heat treatment. For example, Table 4 below lists exemplary processing agents (see also Visse et al. (2003) Circ. Res., 92:827-839; Khan et al.
(1998) Protein Science, 7:815-836; Okada et al. (1988) Biochem J., 254:731-741;
Okada & Nakanashi (1989) FEBS Lett., 249:353-356; Nagase et al. (1990) Biochemistry, 29:5783-5789; Koklitis et al. (1991) Biochem J., 276:217-221;
Springman et al. (1990) PNAS, 87:364-8; Murphy et al. (1997) Matrix Biol., 15:511-8).

Table 4. Z mo en Activators (i.e. processing agents) Proteolytic Compounds Proteases Plasmin Plasma kallikrein Trypsin-1 (Trypsin I) Trypsin-2 (Trypsin II) Neutrophil elastase Cathepsin G
Tryptase Chymase Proteinase-3 Furin uPA
MMPs, including MMP-1, MMP-2, MMP-3, MMP-7, MMP-10, MMP-26, and MT1-MMP

Non-Proteol tic Compounds Thiol-modifying Agents 4-aminophenylmercuric acetate (AMPA) HgC12 N-ethylmaleimide Conformational Perturbants Sodium dodecyl sulfate (SDS) Chaotropic agents Other Chemical Agents Oxidized glutathione (GSSG) Reactive oxygen Au(I) salts Other Activating Conditions Acidic pH
Heat MMP activation occurs in a stepwise manner. For example, activation by proteases involves a first proteolytic attack of a bait region (corresponding to amino acids 32-3 8 of proMMP-1 (SEQ ID NO:2)), an exposed loop region found between the first and second helices of the pro-peptide. The sequence of the bait region confers cleavage specificity. Following initial cleavage, the remaining propeptide is destabilized allowing for intermolecular processing by other partially active MMP
intermediates or active MMPs. For example, the protease plasmin activates both proMMP-1 and proMMP-3. Once activated, MMP-3 effects the final activation of proMMP-1. Alternatively, activation by chemicals, for example APMA, initially causes the modification of the propeptide cysteine residue, which in turn causes partial activation and intramolecular cleavage of the propeptide. The remaining segment of propeptide is then processed by other proteases or MMPs.
Metalloproteinases contain a Zn2+ ion at the active center of the enzyme required for catalytic activity. Generally, these enzymes have a common zinc binding motif (HExxHxxGxxH) in their active site, and a conserved methionine turn following the active site. The zinc binding motif at the active site of a metalloproteinase includes two histidine residues whose imidazole side-chains are ligands to the Zn2+. During catalysis, the Zn2+ promotes nucleophilic attack on the carbonyl carbon by the oxygen atom of a water molecule at the active site. An active site base (a glutamate residue in carboxypeptidases) facilitates this reaction by extracting a proton from the attacking water molecule. Thus, the glutamate (E) residue activates a zinc-bound H2O molecule, thereby providing the nucleophile that cleaves peptide bonds. Mutation of any one of the histidines ablates catalytic activity.
The catalytic domain also contains two calcium binding sites on either side of the zinc binding motif. The Ca2+ binding sites are characterized as being a highly conserved Glu- and Asp- rich region.
Many MMPs also contain a flexible proline-rich hinge region, which is up to about 75 amino acids long, but has no known structure. MMPs also contain a hemopexin-like C-terminal domain that functions in substrate recognition and also interacts with inhibitors, in particular tissue inhibitor of metalloproteinases (TIMPs).
MMP-7, MMP-23 and MMP-26 do not contain a hemopexin domain. MMP-2 and MMP-9 also contain an insert in the catalytic domain made up of three tandem repeats of fibronectin type II modules that confer gelatin-binding properties to these enzymes.
There are over 25 MMPs known and they are grouped into different families depending on function, substrate specificity and/or sequence similarity. The families of MMPs include collagenases, gelatinases, stromelysins and matrilysins. Among the various families, some MMPs contain additional domains. For example, membrane-type MMPs contain a transmembrane or a GPI-anchoring domain. Exemplary MMPs are set forth in Table 5. The sequence identifiers (SEQ ID NO) for the nucleotide sequence and encoded amino acid sequence of the precursor polypeptide for each of the exemplary proteases is depicted in the Table. The sequence identifiers (SEQ ID
NO) for the amino acid sequence of the preproprotein and the zymogen-activated processed mature form of the protein (lacking the propeptide) also are depicted in the Table. The location of domains also is indicated. Those of skill in the art are familiar with such domains and can identify them by virtue of structural and/or functional homology with other such domains. It is understood that polypeptides and the description of domains thereof are theoretically derived based on homology analysis and alignments with similar polypeptides. Thus, the exact locus can vary, and is not necessarily the same for each polypeptide. Variations of MMPs also exist among allelic and species variants and other variants known in the art, and such variants also are contemplated for modification as activatable tsMMPs as described herein below.
The Table also sets forth exemplary ECM target substrates for each enzyme.

Reference to such substrates is for reference and exemplification, and are not intended to represent an exhaustive list of all target substrates. One of skill in the art knows or can empirically determine ECM target substrates for a desired enzyme using routine assays, such as any described herein.

TABLE 5: Metalloprotease Protease Substrate Enzyme Genbank SEQ ID NO
databank No.
access Precursor Mature code (processed form) (EC) nt Aa as www.exp asy.ch/sp rot/enzy me.html Collagenases:

MMP-1 collagen I, II, 3.4.24.7 P03956, 708 1 709 (collagenase III, VII, VIII, NM_00242 (ss as 1-19;
-1) X, XI, gelatin, 1 pp as 20-99) proteoglycan, fibronectin, glycoprotein MMP-8 collagen I, II, 3.4.24.34 P22894 710 711 712 (collagenase- III, aggrecan NM_00242 (ss as 1-20;
2) 4 pp as 21-100) MMP-13 collagen 1, II, 3.4.24.- P45452 713 714 715 (collagenase III, IV, VI, NM_00242 (ss as 1-19;
-3) IX, X, XIV, 7 pp as 20-103) gelatin, proteoglycan, fibronectin, glycoprotein MMP-18 collagen 1 3.4.24.- Xenopus 716 717 718 (collagenase- laevis (ss as 1-17;
4) 013065 pp as 18-99) Gelatinases:

MMP-2 gelatins, 3.4.24.24 P08253 719 720 721 (gelatinase collagen I, II, NM_00453 (ss as 1-29;
A) III, IV, V, 0 pp 30-109) VII, X, XI, elastin, fibronectin, laminin, proteoglycan, TABLE 5: Metalloprotease Protease Substrate Enzyme Genbank SEQ ID NO
databank No.
access Precursor Mature code (processed form) (EC) nt Aa as www.exp asy.ch/sp rot/enzy me.html glycoprotein MMP-9 gelatin, 3.4.24.35 P14780 722 723 724 (gelatinase collagen IV, NM_00499 (ss as 1-19;
B) V, VI, XIV, 4 pp as 20-93) elastin, laminin, proteoglycan, glycoprotein Stromelysins:

MMP-3 fibronectin, 3.4.24.17 P08254 725 726 727 (stromelysin- elastin, NM_00242 (ss as 1-17;
1) laminin, 2 pp as 18-99) gelatin, proteoglycan, glycoprotein, collagen III, IV, V, VII, IX, X, XI
MMP-10 collagen III, 3.4.24.22 P09238 728 729 730 (stromelysin- IV, V, elastin, NM_00242 (ss as 1-17;
2) gelatin, 5 pp as 18-98) fibronectin, aggrecan MMP-11 Gelatin, 3.4.24.- P24347 731 732 733 (stromelysin- fibronectin, X57766 (ss as 1-31;
3) laminin, pp as 32-97) collagen IV
Matrilysins:
MMP-7 fibronectin, 3.4.24.23 P09237 734 735 736 (matrilysin) laminin, NM 00242 (ss as 1-17;
elastin, 3 pp as 18-94) gelatin, collagen I, IV, proteoglycan, glycoprotein MMP-26 collagen IV, 3.4.24.- Q9NRE1 737 738 739 (matrilysin-2) fibronectin, NM 02180 (ss as 1-17;

TABLE 5: Metalloprotease Protease Substrate Enzyme Genbank SEQ ID NO
databank No.
access Precursor Mature code (processed (EC) form) nt Aa as www.exp asy.ch/sp rot/enzy me.html gelatin, 1 pp as 18-89) proteoglycan Metalloelastase:

MMP-12 elastin, 3.4.24.65 P39900 740 741 742 (metalloelast fibronectin, NM_00242 (ss as 1-16;
ase) laminin, 6 pp as 17-105) collagen I, IV, V, gelatin, proteoglycan, glycoprotein Membrane-type MMPs:

MMP-14 Collagen I, II, 3.4.24.80 P50281 743 744 745 (MT1-MMP) III, gelatin, NM_00499 (ss as 1-20;
Transmembra aggrecan, 5 pp as 21-111) ne fibronectin, laminin, proteoglycan, glycoprotein MMP-15 aggrecan, EC P51511 746 747 748 (ss as 1-41;
(MT2-MMP) fibronectin, 3.4.24.- NM 00242 Transmembra laminin, 8 pp as 42-131) ne glycoprotein MMP-16 Collagen III, EC P51512 749 750 751 (MT3-MMP) fibronectin, 3.4.24.- NM_00594 (ss as 1-31;
Transmembra laminin, 1 pp as 32-119) ne gelatin, proteoglycan MMP-17 gelatin EC Q9ULZ9 752 753 754 (MT4-MMP) 3.4.24.- AB021225 (ss as 1-38;
GPI anchor pp as 39-128) MMP-24 fibronectin, EC Q9Y5R2 755 756 757 (MT5-MMP) gelatin, 3.4.24.- NM_00669 (ss as 1-52;
Transmembra proteoglycan 0 pp as 53-155) ne MMP-25 collagen IV, EC Q9NPA2 758 759 760 (MT6-MMP) gelatin, 3.4.24.- NM 0224 (ss as 1-21;
GPI anchor fibronectin, 68 pp as 22-107) TABLE 5: Metalloprotease Protease Substrate Enzyme Genbank SEQ ID NO
databank No.
access Precursor Mature code (processed form) (EC) nt Aa as www.exp asy.ch/sp rot/enzy me.html proteoglycan Enamelysin:
MMP-20 aggrecan EC 060882 761 762 763 (enamelysin) 3.4.24.- Y12779 (ss as 1-22;
pp as 23-107) Other:

MMP-19 collagen IV, EC Q99542 764 765 766 gelatin, 3.4.24.- NM_00242 (ss as 1-18;
laminin, 9 pp as 19-97) aggrecan, fibronectin, gl co rotein MMP-21 gelatin EC Q8N119 767 768 769 3.4.24.- NM_14719 (ss as 1-24;
1 pp as 25-144) MMP-23 gelatin EC 075900 770 771 772 CA-MMP 3.4.24.- AJO05256 MMP-27 gelatin EC Q9H306 773 774 775 CMMP 3.4.24.- NM_02212 (ss as 1-17;
2 pp as 18-98) (epilysin) 3.4.24.- NM_02430 (ss as 1-22;
2 pp as 23-122) 3. Matrix Metalloprotease -1 (MMP-1) MMP-1 (also called collagenase) is encoded by a nucleic acid molecule set forth in SEQ ID N0:708 resulting in a pre-procollagenase (SEQ ID NO:1), which is co-translationally processed to generate a procollagenase zymogen form (SEQ ID
N0:2). Procollagenase contains a propeptide of 80 amino acids (corresponding to amino acid residues 1-80 of the sequence of amino acids set forth in SEQ ID
N0:2), a catalytic domain of 162 amino acids (corresponding to amino acid residues 81-242 of the sequence of amino acids set forth in SEQ ID N0:2), a 16-residue linker (corresponding to amino acid residues 243-258 of the sequence of amino acids set forth in SEQ ID NO:2) and a hemopexin (Hpx) domain of 189 amino acid residues (corresponding to amino acid residues 259-450 of the sequence of amino acids set forth in SEQ ID NO:2). Upon processing, the propeptide is removed, resulting in a processed mature form having a sequence of amino acids set forth in SEQ ID NO:
709.
As noted above, MMP-1 cleaves collagen type I and collagen type III, which are the most abundant protein of the skin. These collagen types are associated with many of the conditions of the ECM as described herein in Section I. In contrast, other collagens, for example collagen type IV, is a major component of the basal lamina of blood vessels. Hence, targeting of type IV collagen, for example, can lead to leaky blood vessels, which can be a side effect of treatments that are meant to target the extracellular matrix as described herein. For example, bacterial collagenase, a known treatment for cellulite, can induce haemorrhages (see e.g. Vargaftig et al.
(2005) Inflammation Research, 6:627-635). Thus, an advantage of the use of MMP-1, and in particular tsMMP-1 that can be conditionally or temporally controlled, as a therapeutic agent to treat conditions of the ECM is that it does not cleave type IV
collagen.
D. MODIFIED MATRIX METALLOPROTEASE- 1 POLYPEPTIDES
Provided herein are modified MMP-1 polypeptides. In one example, modified MMP-1 polypeptides provided herein exhibit temperature sensitivity, whereby the modified polypeptide exhibits higher activity at a permissive temperature than a non-permissive temperature. Also provided herein are modified MMP-1 polypeptides that exhibit increased activity compared to the unmodified MMP-1 not containing the modification (e.g. wildtype) at both permissive and non-permissive temperatures. In an additional example, provided herein are modified MMP-1 polypeptides that exhibit modifications that both increase temperature sensitivity and activity.
Modifications provided herein of a starting, unmodified reference polypeptide include amino acid replacements or substitutions, additions or deletions of amino acids, or any combination thereof. For example, modified MMP-1 polypeptides include those with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more modified positions. Also provided herein are modified MMP-1 polypeptides with two or more modifications compared to a starting reference MMP-1 polypeptide.
Modified MMP-1 polypeptides include those with 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more modified positions. In some examples, modified MMP-1 polypeptide provided herein contain only a single modification. In other examples, modified MMP-1 polypeptides provided herein contain two, three, four, five or six modifications. In additional examples, any modification(s) provided herein can be combined with any other modification known to one of skill in the art so long as the resulting modified MMP-1 polypeptide retains enzymatic activity when it is in its processed mature form. Where the modified MMP-1 contains a mutation conferring temperature sensitivity, the enzymatic activity of such combination mutant is greater at the permissive temperature compared to the non-permissive temperature.
Modified MMP-1 polypeptides provided herein can be assayed for enzymatic activity under various conditions (e.g. permissive and non-permissive temperatures) to identify those that retain enzymatic activity.
Modifications in an MMP-1 polypeptide can be made to any form of an MMP-1 polypeptide, including inactive (e.g. zymogen) or processed mature forms (activated form), allelic and species variants, splice variants, variants known in the art, or hybrid or chimeric MMP-1 polypeptides. For example, modifications provided herein can be made in a precursor MMP-1 polypeptide set forth in SEQ ID NO:1, an inactive pro-enzyme MMP-1 containing the propeptide set forth in SEQ ID NO:2, a mature MMP-1 polypeptide lacking the propeptide set forth in SEQ ID NO:709, or any species, allelic or modified variant and active fragments thereof that has 40%, 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any of the MMP-1 polypeptides set forth in SEQ ID NOS:1, 2 or 709.
Modifications also can be in an MMP-1 polypeptide lacking one or more domains, so long as the MMP-1 polypeptide retains enzymatic activity. For example, modifications can be in an MMP-1 polypeptide that includes only the catalytic domain (corresponding to amino acids 81-242) of the proenzyme MMP-1 polypeptide set forth in SEQ ID NO:2). Modifications also can be made in an MMP-1 polypeptide lacking all or a portion of the proline rich linker (corresponding to amino acids 243-258 of the proenzyme MMP-1 polypeptide set forth in SEQ ID NO:2) and/or lacking all or a portion of the hemopexin binding domain (corresponding to amino acids 259-450 of the proenzyme MMP-1 polypeptide set forth in SEQ ID
NO:2). Allelic variants and other variants of MMP-1 polypeptides include, but are not limited to, any of MMP-1 polypeptide containing any one or more amino acid variant set forth in SEQ ID NO:3506 and 3549. Exemplary species variants for modification herein include, but are not limited to, pig, rabbit, bovine, horse, rat, and mouse, for example, set forth in any of SEQ ID NOS:3459-3464.
Modifications in an MMP-1 polypeptide provided herein, for example in an MMP-1 containing a modification to confer temperature sensitivity and/or increased activity, can be made to an MMP-1 polypeptide that also contains other modifications, such as those described in the art, including modification of the primary sequence and modifications not in the primary sequence of the polypeptide. It is understood that modifications in an allelic or species variant or other variant include modification in any form thereof such as an active or inactive form, a form including only the catalytic domain, or a form lacking all or a portion of the proline rich linker or the hemopexin binding domain. As discussed herein below, corresponding MMP-I
modifications can be made to similar forms of other MMP polypeptides.
Hence, the resulting modified MMP-1 polypeptides include those that are inactive zymogen proenzymes and those that are processed mature polypeptides.
For example, any modified polypeptide provided herein that is a zymogen proenzyme can be activated by a processing agent to generate a processed mature MMP-1 polypeptide. Activity of MMP-1 polypeptides are typically exhibited in its processed mature form following cleavage of the propeptide and/or intermolecular and intramolecular processing of the enzyme to remove the propeptide(see e.g.
Visse et al.
(2003) Cir. Res., 92:827-839). As noted elsewhere herein, tsMMP's require permissive temperature to be fully active.
The modifications provided herein can be made by standard recombinant DNA techniques such as are routine to one of skill in the art. Any method known in the art to effect mutation of any one or more amino acids in a target protein can be employed. Methods include standard site-directed mutagenesis (using e.g. a kit, such as QuikChange available from Stratagene) of encoding nucleic acid molecules, or by solid phase polypeptide synthesis methods.
Other modifications that are or are not in the primary sequence of the polypeptide also can be included in a modified MMP-1 polypeptide, or conjugate thereof, including, but not limited to, the addition of a carbohydrate moiety, the addition of a polyethylene glycol (PEG) moiety, the addition of an Fe domain, etc.
For example, such additional modifications can be made to increase the stability or half-life of the protein.
Exemplary of such modified MMP-1 polypeptides are set forth in any of SEQ
ID NOS:3-705, 779-3458 and 3532 and processed mature forms and other forms thereof, and allelic and species variants thereof.
1. TEMPERATURE-SENSITIVE MATRIX
METALLOPROTEASE- 1 (tsMMP-1) MUTANTS
Provided herein are tsMMP-1 polypeptides that are temperature sensitive by virtue of modifications in the primary sequence of the polypeptide compared to an unmodified MMP-1 polypeptide. The tsMMP-1 polypeptides exhibit increased enzymatic activity at a permissive temperature compared with activity of the tsMMP-1 polypeptide at a non-permissive temperature. For example, tsMMP-1 polypeptides provided herein exhibit increased enzymatic activity at a low temperature that is less then 37 C, for example, that is at or about 18 C, 19 C, 20 C, 21 C, 22 C, 23 C, 24 C, 25 C, 26 C, 27 C, 28 C, 29 C or 30 C, in particular at or about 18 C
to 25 C, for example at or about 25 C compared to a non-permissive high temperature that is at or about 34 C, 35 C, 36 C, 37 C, 38 C or 39 C, in particular at or about 34 C
or 37 C. Due to the temperature-dependent activity of tsMMP-1 polypeptides, the activity of MMP-1 can be conditionally controlled, thereby temporally regulating activation to prevent prolonged and unwanted degradation of the ECM. In particular, such tsMMP-1 polypeptides can be used in uses, processes or methods to treat diseases or conditions of the ECM, for example, to treat collagen-mediated diseases or conditions such as cellulite.
The tsMMP-1 polypeptides provided herein have a ratio of activity at a permissive temperature compared to a non-permissive temperature that is or is about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more. Thus, the activity of tsMMP-1 polypeptides provided herein at the non-permissive temperature is or is about 70%,65%,60%,55%,50%,45%,40%,35%,30%,25%,20%,15%,10%,5%, 4%, 3%, 2%, 1%, 0.5% or less of the activity at a permissive temperature.
tsMMPs-1 polypeptides provided herein retain one or more activities of wildtype MMP-1 polypeptide at the permissive temperature, for example, enzymatic activity for cleavage of an ECM component such as collagen. Typically, such activity is substantially unchanged (less than 1%, 5%, 10%, 20% or 30% changed) compared to a wildtype or starting protein. In other examples, the activity of a modified polypeptide is increased or is decreased as compared to a wildtype or starting polypeptide. Activity is assessed at the permissive temperature and is compared to the activity of a starting, unmodified MMP-1 polypeptide (i.e. polypeptide not containing the modification) at the permissive temperature or a non-permissive temperature. For example, a tsMMP-1 polypeptide provided herein retains an activity at the permissive temperature that is or is about 10%, 20%, 30%, 40%, 50%, 60%,70%, 80%, 90%, 100%, 110%, 120%, 140%, 150% or more the activity of wildtype MMP-1 at the permissive temperature or non-permissive temperature.
Activity can be assessed in vitro, ex vivo or in vivo and can be compared to that of the unmodified MMP-1 polypeptide, such as for example, an inactive MMP-1 polypeptide set forth in SEQ ID NO:2 activated by a processing agent, or any other MMP-1 polypeptide known to one of skill in the art that is used as the starting material. As discussed elsewhere herein, it is understood that the zymogen inactive form of an MMP-1 or a modified MMP-1 must be processed to a processed mature form required for activity before use or measurement of an activity.
Exemplary Temperature Sensitive Modifications Provided herein are modified tsMMP-1 polypeptides containing one or more amino acid modifications in a starting, unmodified MMP-1 polypeptide.
Typically, the modification is an amino acid replacement. The amino acid replacement or replacements can be at any one or more positions corresponding to any of the following positions: 84, 85, 95, 98, 99, 100, 103, 104, 105, 106, 109, 110, 111, 112, 118, 123, 124, 126, 147, 150, 151, 152, 153, 155, 156, 158, 159, 170, 171, 176, 178, 179, 180, 181, 182, 183, 185, 187, 188, 189, 190, 191, 192, 194, 195, 197, 198, 206, 207, 208, 210, 211, 212, 218, 223, 227, 228, 229, 230, 233, 234, 237, 240, 251, 254, 255, 256, 257, 258, 259 of an unmodified MMP-1 polypeptide having a sequence of amino acids set forth in SEQ ID NO:2, or at a corresponding position in an allelic or species variant or other variant of an MMP-1 polypeptide that has at least or at least about 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to an MMP-1 polypeptide set forth in SEQ ID
NO:2. Amino acid replacements include replacement of amino acids to an acidic (D
or E); basic (H, K or R); neutral (C, N, Q, T, Y, S, G) or hydrophobic (F, M, W, I V, L A, P) amino acid residue. For example, amino acid replacements at the noted positions include replacement by amino acid residues E, H, R, C, Q, T, S, G, M, W, I, V, L, A, P, N, F, D, Y or K.
Such modified MMP-1 polypeptides include MMP-1 polypeptides that are temperature sensitive by virtue of increased activity at the permissive temperature of C compared to the non-permissive temperatures of 34 C or 37 T. For example, modified MMP-1 polypeptides provided herein can include polypeptides having an amino acid modification corresponding to any one or more modifications of T84F
(i.e.
replacement of T by F at a position corresponding to position 84 of an MMP-1 20 polypeptide set forth in SEQ ID NO:2), E85F, L95K, L951, R98D, 199Q, E100V, E100R, E100S, E100T, E100F, ElOOl, E100N, T103Y, P104A, P104M, D105A, D105F, D105G, D1051, D105L, D105N, D105R, D105S, D105T, D105W, D105E, L106C, L106S, A109H, D11OA, V111R, DI 12S, A118T, S123V, N124D, T126S, G147P, R150P, R150V, R1501), R1501, R150H, D151G, N152A, N152S, S153T, 25 F155L, F155A, D156H, D156L, D156A, D156W, D156V, D156K, D156T, D156R, D156M, P158T, P158G, P158K, P158N, G159V, G159T, G159M, G1591, G159W, G159L, G159C, P170D, P170A, G171P, G171E, G1711), A176F, A176W, F178T, F178L, D179N, D179V, D179C, E180Y, E180R, E180T, E180F, E180G, E180S, E180N, E180D, D181T, D181L, D181K, D181C, D181G, E182T, E182Q, E182M, E182G, R183G, R183S, T185R, T185Y, T185H, T185G, T185V, T185Q, T185A, T185E, T185D, N187R, N187M, NI 87W, N187F, NI 87K, N1871, N187A, N187G, NI 87C, N187H, F188V, R189N, R189T, R189Q, El 90G, El 90Y, El 90D, Y191V, N192H, N192S, N192D, N192C, H194P, R195C, R195W, R195L, R195G, R195Q, R195A, R1951), R195V, A197C, A197V, A198G, A198L, A198M, G206A, G206S, L207R, L207V, L2071, L207G, S208R, S208L, S21OV, S21OA, T211L, D212G, D212H, Y218S, F223C, F223E, F223G, F223A, F223S, F223K, F223M, V227C, V2271), V227E, V227L, V227S, V227W, V227G, V227H, V227Q, V227R, Q228P, L229A, L229T, L229I, A230V, D233E, 1234A, 1234T, 1234E, 1234Q, 1237L, I237W, 1237N, 1240S, 1240A, 1240C, 1251 S, I251 W, Q254S, T255H, P256C, K257P, K257T, A258P and C259Q. Exemplary modified MMP-1 polypeptides have a sequence of amino acids set forth in any of SEQ ID NOS:6, 18, 22, 25, 27, 29, 31-33, 35-36, 38-39, 41, 43, 55-56, 59, 70, 95-96, 99-101, 105, 110-111, 113-115,122,125,129-133, 148,150,159-160,170,174,177,179,181-185,195,197,200, 203, 209, 218-219, 222, 224, 231-233, 235, 238-239, 241, 246, 248, 252-255, 260-264, 267, 269, 273, 275, 279, 282, 284-286, 299, 301, 305, 317, 324, 341, 343, 354, 365, 367, 369, 376, 381, 383-385, 387-388, 390, 393-394, 397, 399, 420, 429, 436, 438, 440, 460, 466-467, 476, 483, 488, 495, 500, 502, 504, 506, 508, 511-512, 524, 543, 554-555, 572-573, 581, 583, 607, 611, 613, 616, 620, 648, 653, 660, 664-665, 669, 678, 703, 847, 866, 1083, 1109, 1172, 1177, 1183, 1188, 1237, 1271, 1277, 1301, 1414, 1516, 1520, 1567, 1975, 2023, 2031, 2075, 2078, 2080, 2083, 2281, 2299, 2403, 2411, 2423-2424, 2486, 2495-2497, 2552, 2563, 2703, 2715, 2753, 3066, 3074, 3076, 3317, 3321, 3373, 3385, 3407, 3439, 3428, 3458, 3532 and processed mature forms and other forms thereof, and allelic and species variants thereof.
In some examples, such modified MMP-1 polypeptides include polypeptides having an amino acid replacement or replacements at any one or more positions corresponding to any of the following positions: 95, 100, 103, 105, 150, 151, 153, 155, 156, 159, 171, 176, 179, 180, 181, 182, 185, 187, 190, 191, 192, 194, 195, 198, 206, 207, 210, 212, 218, 223, 227, 228, 229, 230, 233, 234, 237, 240 and 259 of an unmodified MMP-1 polypeptide having a sequence of amino acids set forth in SEQ
ID NO:2, or at a corresponding position in an allelic or species variant or other variant of an MMP-1 polypeptide that has at least or at least about 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to an MMP-l polypeptide set forth in SEQ ID NO:2. For example, modified MMP-l polypeptides provided herein include polypeptides having an amino acid modification corresponding to any one or more modifications of L95K, EI OOV, T103Y, D105A, D105F, D105G, D1051, D105L, D105N, D105R, D105S, D105T, D105W, R150P, D151G, S153T, F155L, F155A, D156H, D156L, D156A, D156W, D156V, D156K, D156T, D156R, G159V, G159T, G171P, A176F, D179N, E180Y, E180R, E180T, E180F, D181T, D181L, D181K, E182T, E182Q, T185R, T185Y, T185H, T185G, T185V, T185Q, T185A, T185E, N187R, N187M, N187W, N187F, N187K, N1871, N187A, E190G, Y191V, N192H, N192S, N1921), N192C, H194P, R195C, R195W, R195L, R195G, R195Q, R195A, R195D, R195V, A198G, A198L, A198M, G206A, G206S, L207R, L207V, S210V, D212G, Y218S, F223C, F223E, F223G, F223A, F223S, V227C, V2271), V227E, V227L, V227S, V227W, Q228P, L229A, L229T, L2291, A230V, D233E, 1234A, 1234T, 1234E, 1234Q, 1237L, 1240S, 1240A, 1240C, and C259Q. Such modified MMP-1 polypeptides exhibit at least 1.2 times or more activity at the permissive temperature of 25 C compared to the non-permissive temperatures of 34 C or 37 C, for example, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8,1.9,2.0,2.5, 3.0, 3.5,4.0,4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5,10,15, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more times the activity. Exemplary of such modified MMP-1 polypeptides have a sequence of amino acids set forth in any of SEQ ID
NOS:6, 25, 27, 29, 31-33, 35-36, 38-39, 59, 70, 95-96, 99-101, 105, 111, 113-115, 125,132,148,160,177,181-182,185,195,200,209,218-219,232-233, 235, 238-239, 241, 246, 248, 253-254, 261-264, 267, 269, 273, 275, 279, 282, 284-286, 299, 301, 305, 317, 324, 341, 354, 365, 369, 374-375, 381, 383-384, 388, 393, 397, 399, 420, 429, 436, 438, 440, 460, 466-467, 476, 483, 488, 495, 512, 524, 543, 572, 583, 607, 611, 613, 616, 620, 648, 653, 665, 678, 703, 3076 and 3532 and processed mature forms and other forms thereof, and allelic and species variants thereof.
In other examples, such modified MMP-1 polypeptides include polypeptides having an amino acid replacement or replacements at any one or more positions corresponding to any of the following positions: 95, 105, 150, 151, 155, 156, 159, 176, 179, 180, 181, 182, 185, 187, 195, 198, 206, 210, 212, 218, 223, 227, 228, 229, 230, 233, 234, 240, 259 of an unmodified MMP-1 polypeptide having a sequence of amino acids set forth in SEQ ID NO:2, or at a corresponding position in an allelic or species variant or other variant of an MMP-1 polypeptide that has at least or at least about 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to an MMP-1 polypeptide set forth in SEQ ID
NO:2. For example, modified MMP-1 polypeptides provided herein include polypeptides having an amino acid modification corresponding to any one or more modifications of L95K, D105A, D105F, D105G, D1051, D105L, D105N, D105R, D105S, D105T, D105W, R150P, D151G, F155A, D156K, D156T, D156L, D156A, D156W, D156V, D156H, D156R, G159V, G159T, A176F, D179N, E180Y, E180T, E180F, D181L, D181K, E182T, E182Q, T185R, T185H, T185Q, T185A, T185E, N187R, N187M, N187F, N187K, N1871, R195V, A198L, A198M, G206A, G206S, S21OV, Y218S, F223E, V227C, V227E, V227W, Q228P, L229T, L2291, D233E, 1234A, 1234T, 1234E, 1240S, 1240C and C259Q. Such modified MMP-1 polypeptides exhibit at least 1.5 times or more activity at the permissive temperature of compared to the non-permissive temperatures of 34 C or 37 C, for example, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more times the activity. Exemplary of such modified MMP-1 polypeptides have a sequence of amino acids set forth in any of SEQ ID NOS:6, 25, 27, 29, 31-33, 35-36, 38-39, 59, 70, 96, 99-101, 105, 111, 115,125,132,148,160,181-182,185,195,209,218-219, 232-233, 235, 238, 248, 253-254, 261-262, 264, 284, 301, 305, 317, 324, 341, 354, 365, 384, 388, 397, 420, 429, 436, 440, 460, 467, 476, 483, 488, 3532 and processed mature forms and other forms thereof, and allelic and species variants thereof.
In additional examples, modified MMP-1 polypeptides provided herein include modified MMP-1 polypeptides that are temperature sensitive at the permissive temperature of 25 C and exhibit at least 30%, for example, 30%, 40%, 50%, 60%, 70%, 80%, 90%,100%,110%,120%,140%,150% or more activity at 25 C
compared to wildtype MMP-1 at 25 C. For example, tsMMP-1 polypeptides that exhibit increased activity compared to wildtype MMP-1 include polypeptides having an amino acid replacement or replacements at any one or more positions corresponding to any of the following positions: 95, 105, 150, 156, 159, 179, 180, 182, 185, 187, 195, 198, 212, 223, 227, 234, and 240 of an unmodified MMP-1 polypeptide having a sequence of amino acids set forth in SEQ ID NO:2, or at a corresponding position in an allelic or species variant or other variant of an polypeptide that has at least or at least about 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to an MMP-1 polypeptide set forth in SEQ ID NO:2. For example, modified tsMMP-1 polypeptides provided herein that have increased activity at the permissive temperature of compared to wildtype MMP-1 include polypeptides having an amino acid modification corresponding to any one or more modifications L95K, D105A, D105G, D1051, D105L, D105N, D105S, D105W, D105T, R150P, D156K, D156T, D156V, D156H, D156R, G159V, G159T, D179N, E180Y, E180T, E180F, E182T, T185H, T185Q, T185E, N187M, NI 87K, NI 871, R195V, A198L, F223E, V227E, 1234E and 1240S. Exemplary of such modified MMP-1 polypeptides have a sequence of amino acids set forth in any of SEQ ID NOS:6, 27, 29, 31-32, 35-36, 38-39, 59, 99-101, 105, 113, 125, 132, 160, 181-182, 185, 219, 232-233, 238, 253, 262, 264, 284, 305, 365, 384, 460, 488 or processed mature forms and other forms thereof, and allelic and species variants thereof.
In particular, modified MMP-1 polypeptides provided herein that are temperature sensitive have an amino acid replacement or replacements at any one or more positions corresponding to any of the following positions: 95, 105, 150, 156, 159, 179, 180, 182, 185, 187, 198, 227, 234 and 240 of an unmodified MMP-1 polypeptide having a sequence of amino acids set forth in SEQ ID NO:2, or at a corresponding position in an allelic or species variant or other variant of an polypeptide that has at least or at least about 60%, 70%, 75%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to an MMP-1 polypeptide set forth in SEQ ID NO:2. Such modified MMP-1 polypeptides provided herein include polypeptides having an amino acid modification corresponding to any one or more modifications L95K, DI 051, D105N, DI 05L, D105A, D105G, RI 50P, D156R, D156H, D156K, D156T, G159V, G159T, D179N, E180T, E18017, E182T, T185Q, N187I, A198L, V227E, 1234E and 1240S. More particularly, modified MMP-1 polypeptides provided herein include polypeptides having an amino acid modification corresponding to any one or more modifications L95K, D105N, RI
50P, D156K, D156T, G159V, D179N, E180T, A198L, V227E, and 1240S.
Modified MMP-1 polypeptides provided herein include those that exhibit reversible or irreversible (also called non-reversible) temperature-dependent activity.
In all cases, modified MMP-1 polypeptides provided herein above exhibit increased activity at a permissive temperature (e.g. 25 C) compared to a non-permissive temperatures (e.g. 34 C or 37 C.) For non-reversible polypeptides, exposure to the non-permissive temperature prior to, subsequently or intermittently from exposure to the permissive temperature renders the polypeptide irreversibly inactive.
Thus, a modified MMP-1 polypeptide that is returned to temperature permissive conditions, for example 25 C, exhibits the same or similar activity of the MMP-1 polypeptide at non-permissive temperatures, for example, 34 C or 37 C. For example, upon return to permissive conditions, irreversible modified MMP-1 polypeptides provided herein exhibit at or about 50%, 60%, 70%, 80%, 90%,100%,105%,110%,115%, or 120%
the activity at non-permissive temperatures. Exemplary non-reversible modified MMP-1 polypeptides provided herein include polypeptides having an amino acid modification corresponding to any one or more modifications L95K, D1051, D105L, D105N, D105R, D105W, D151G, F155A, D156K, D156T, D156L, D156A, D156W, D156V, D156H, D156R, G159V, A176F, D179N, D181L, D181K, E182T, E182Q, T185R, N18717, N1871, G206A, G206S, V227C, V227E, Q228E, L229T, D233E, 1234A, 1234T, 1234E, 1240S, for example, any set forth in any of SEQ ID NOS:6, 25, 27, 35-36, 38, 70, 96, 99-101, 105, 111, 113-115, 132, 148, 160, 195, 209, 218-219, 235, 261, 264, 317, 324, 384, 388, 403, 429, 440, 460, 467, 476, 488, or processed mature forms and other forms thereof, and allelic and species variants thereof.
For reversible polypeptides, exposure to the non-permissive temperature prior to, subsequently or intermittently from exposure to the permissive temperature renders the polypeptide reversibly active. Thus, a modified MMP-1 polypeptide that is returned to temperature permissive conditions recovers activity, and thereby exhibits increased activity at the permissive temperature compared to the non-permissive temperature. In such examples, the recovered activity can be complete or partial. Thus, a modified MMP-1 polypeptide that is returned to temperature permissive conditions, for example 25 C, exhibits an increased activity compared to activity at non-permissive temperatures, for example, 34 C or 37 C. For example, upon return to permissive conditions, reversible modified MMP-1 polypeptides provided herein exhibit at or about 120%, 125%, 130%,140%,150%, 160%, 170%, 180%, 200% or more of the activity at non-permissive temperatures. Exemplary reversible modified MMP-1 polypeptides provided herein include polypeptides having an amino acid modification corresponding to any one or more modifications D105A, D105F, D105G, D105S, D105T, R150P, G159T, E180Y, E180T, E1SOF, T185H, T185Q, T185A, T185E, N187R, N187M, N187K, R195V, A198L, A198M, S21OV, Y218S, F223E, V227W, L2291 and 1240C, for example, any set forth in any of SEQ ID NOS: 29,31-33,39,59,125,181-182,185,232-233,238,248,253-254, 262, 284, 301, 305, 341, 354, 365, 397, 436, 483, or processed mature forms and other forms thereof, and allelic and species variants thereof.
2. MATRIX METALLOPROTEASE-1 ACTIVITY MUTANTS
Also provided herein are modified MMP-1 polypeptides that exhibit increased activity compared to wild-type MMP-1 at the permissive and non-permissive temperature. Unlike tsMMP-1 polypeptides provided herein, such activity mutants exhibit increased activity at both the permissive and non-permissive temperature compared to the MMP-1 not containing the modification (e.g. wildtype), For example, modified MMP-1 Is that are provided herein have increased activity compared to wildtype at a low temperature that is less then 37 C, for example, that is at or about 18 C, 19 C, 20 C, 21 C, 22 C, 23 C, 24 C, 25 C, 26 C, 27 C, 28 C, 29 C or 30 C, in particular at or about 18 C to 25 C, for example at or about 25 C.
Modified MMP-1 s that are provided herein that have increased activity also exhibit increased activity compared to wild-type at higher temperature that is at or about 34 C, 35 C, 36 C, 37 C, 38 C or 39 C, in particular at or about 34 C or 37 C. The modified MM.P-1s provided herein exhibit 1.1-fold, 1.2, 13, 1.4, 1.5, 1.6, 1.7, 1.8, 1,9, 2Ø 3Ø 4Ø 5,0, 6.0 , 7.0, 8Ø9.0, 10.0, 20.0 or more increased activity than an MMP-1 not containing the modification (e.g. wildtype) at the same temperature (permissive or non-permissive). For example, the modified MMP-ls provided herein exhibit 110%, 120%,130 /a, 140%,150%,160%,170%,180%,190%,200%,250%, RECTIFIED SHEET (RULE 91) ISA/EP

300%,400%,500%,600%, 700%,800%,900%, 1000% or more increased activity than an MMP-1 not containing the modification (e.g. wildtype) at the same temperature (permissive or non-permissive).
Typically, the modification is an amino acid replacement. The amino acid replacement or replacements can be at any one or more positions corresponding to any of the following positions: 81, 84, 85, 86, 87, 89, 104, 105, 106, 107, 108, 109, 124, 131, 133, 134, 135, 143, 146, 147, 150, 152, 153, 154, 157, 158, 160, 161, 164, 166, 167, 180, 183, 189, 190, 207, 208, 211, 213, 214, 216, 218, 220, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 235, 236, 238, 239, 244, 249, 254, 256, 257, 258 of an unmodified MMP-1 polypeptide having a sequence of amino acids set forth in SEQ ID NO:2, or at a corresponding position in an allelic or species variant or other variant of an MMP-1 polypeptide that has at least or at least about 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to an MMP-1 polypeptide set forth in SEQ ID NO:2. Amino acid replacements include replacement of amino acids to an acidic (D or E); basic (H, K or R); neutral (C, N, Q, T, Y, S, G) or hydrophobic (F, M, W, I V, L A, P) amino acid residue. For example, amino acid replacements at the noted positions include replacement by amino acid residues E, H, R, C, Q, T, S, G, M, W, I, V, L, A, P, N, F, D, Y or K.
For example, modified MMP-1 polypeptides provided herein can include polypeptides having an amino acid modification corresponding to any one or more modifications of F81L (i.e. replacement of F by L at a position corresponding to position 81 of an MMP-1 polypeptide set forth in SEQ ID NO:2), F81A, F81G, F81Q, F81R, F81H, T84H, T84L, T84D, T84R, T84G, T84A, E85S, E85V, G86S, N87P, N87R, N87G, N87Q, R89A, R89T, R89G, R89K, P104E, P104D, P104Q, D105V, L106V, P107T, P107S, P107A, R108E, R108A, R108K, R108S, A109S, A109R, A109G, A109M, A109V, N124G, T131D, K132R, V133T, V133L, S134E, S134D, E135M, S1431, R146S, G147R, G147F, R150E, R150G, R150M, T150T, R150A, RI 50N, RI 50K, RI 50L, RI 50V, RI 50D, N152G, N152F, N152L, N1521, S153T, S153P, S153F, S153D, S153Y, P154S, P1541, G157F, P158V, P1581, G160Q, N161L, N161R, N161Y, N161E, N161T, N1611, N161V, N161F, N161Q, H164S, F166W, Q167R, Q167A, Q167S, Q167F, Q167P, Q167T, Q167V, Q167M, E1801), R183S, R189N, R189T, R189Q, E1901), L207M, S208K, S208R, S208L, T211N, I213G, G214L, G214E, L2161, Y218W, S220R, S220A, S220Q, S220T, S220G, S220M, S220V, S220N, T222R, T222P, T222S, T222F, T222N, F223Y, F223H, 2224Q, S224K, S2241), G225Q, G225E, G225H, D226S, D226E, D226P, D226I, V227T, Q228A, Q228D, Q228E, Q228G, Q228H, Q228K, Q228L, Q228M, Q228N, Q228R, Q228S, Q228T, Q228W, Q228Y, L229Q, L229P, L229V, A230G, A230W, A2301), A230I, A230S, A230C, A230V, A230T, A230M, A230N, A230H, Q2311, Q231 A, Q231 F, Q2311), Q231 G, Q231 V, Q231 W, Q231 S, Q231 H, Q231 M, D232H, D232G, D232R, D232P, D232Y, D232S, D232F, D232V, D232K, D232W, D232Q, D232E, D232T, D232L, D235G, D235A, D235L, D235E, D235R, D235Q, D235T, D235N, G236M, G236R, G236S, G236T, G236C, G236K, G236E, G236L, G236N, Q238T, A239S, A239V, A239L, A239I, A239G, A239K, A239H, A239R, S244W, S244Q, Q249W, Q254S, P256S, K257E, K257R, or A258P.
In particular, modified MMP-1 polypeptides provided herein having increased activity have an amino acid modification corresponding to any one or more modifications of N161I, S208K, 1213G, G214E, Q228A, Q228D, Q228E, Q228G, Q228H, Q228K, Q228L, Q228M, Q228N, Q228R, Q228S, Q228W, Q228Y, L229V, A230G, A2301), A230S, A230C, A230T, A230M, A230N, A230H, Q231A, Q2311), Q231 G, Q231 V, Q231 S, D232H, D232G, D232P, D232V, D232K, D232W, D232Q, D232E, or D232T. In one example, activity mutants of MMP-1 provided herein including modified MMP-1 polypeptides having one of more modifications of S208K, 1213G, or G214E.
Exemplary modified MMP-1 polypeptides have a sequence of amino acids set forth in any of SEQ ID NOS: 37, 41, 42, 44, 46, 48, 51, 53, 56, 57, 58, 174, 358, 366, 373, 391, 402, 403, 404, 405, 406, 408, 409, 410, 411, 412, 414, 415,418, 419, 428, 437, 439, 535, 543, 544, 546, 553, 573, 662, 687, 689, 692, 693, 695, 697, 698, 700, 701, 702, 703, 781, 783, 786, 795, 796, 790, 838, 836, 840, 852, 846, 853, 864, 870, 884, 911, 897, 903, 899, 938, 941, 948, 934, 1160, 1159, 1166, 1194, 1205, 1207, 1215, 1217, 1219, 1225, 1233, 1239, 1245, 1246, 1248, 1251, 1530, 1653, 1675, 1699, 1707, 1710, 1711, 1741, 1895, 1947, 1961, 1968, 2024, 2025, 2028, 2030, 2043, 2048, 2087, 2088, 2098, 2111, 2114, 2116, 2117, 2118, 2124, 2125, 2121, 2126, 2176, 2218, 2228, 2241, 2231, 2233, 2235, 2236, 2239, 2242, 2423, 2495, 2496, 2497, 2702, 2703, 2715, 2743 2767, 2776, 2791, 2828, 2874, 2887, 2876, 2877, 2878, 2880, 2882, 2885, 2912, 2914, 2917, 2919, 2926, 2927, 2930, 2934, 2947, 2948, 2953, 2965, 2974, 2979, 2983, 2984, 2986, 2993, 2994, 2995, 2996, 2997, 2998, 2999, 3001, 3003, 3004, 3005, 3006, 3009, 3010, 3011, 3012, 3013, 3014, 3016, 3018, 3019, 3021, 3022, 3025, 3027, 3028, 3029, 3032, 3038, 3039, 3042, 3044, 3046, 3047, 3049, 3051, 3057, 3086, 3100, 3101, 3102, 3108, 3109, 3113, 3114, 3115, 3181, 3187, 3282, 3373, 3412, 3422, 3424, or 3458 and processed mature forms and other forms thereof, and allelic and species variants thereof.
3. Combinations Provided herein are modified MMP-1 polypeptides that contain 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more modifications compared to a starting or reference MMP-1 polypeptide. Modified MMP-1 polypeptides provided herein can contain any two or more modifications provided above. The two or more modifications can include two or more temperature-sensitive modifications, two or more activity modifications, or at least one temperature sensitive modification and at least one activity modification.
For example, modified MMP-1 polypeptides provided herein contain amino acid replacements at any two or more positions corresponding to any of the following positions: 84, 85, 95, 98, 99, 100, 103, 104, 105, 106, 109, 110, 111, 112, 118, 123, 124, 126, 147, 150, 151, 152, 153, 155, 156, 158, 159, 170, 171, 176, 178, 179, 180, 181, 182, 183, 185, 187, 188, 189, 190, 191, 192, 194, 195, 197, 198, 206, 207, 208, 210, 211, 212, 218, 223, 227, 228, 229, 230, 233, 234, 237, 240, 251, 254, 255, 256, 257, 258 or 259 of an unmodified MMP-1 polypeptide having a sequence of amino acids set forth in SEQ ID NO:2, or at a corresponding position in an allelic or species variant or other variant of an MMP-1 polypeptide that has at least or at least about 60%,70%,75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%,96%,97%, 98%, 99%
or more sequence identity to an MMP-1 polypeptide set forth in SEQ ID NO:2 Generally, such combination mutants are temperature sensitive and exhibit increased enzymatic activity at a permissive temperature compared with activity of the tsMMP-1 polypeptide at a non-permissive temperature. Typically, combination mutants also retain activity at the permissive temperature compared to the single mutant polypeptides alone or compared to an unmodified MMP-1 polypeptide not containing the amino acid changes (e.g. a wildtype MMP-1 polypeptide set forth in SEQ ID
NO:2 or active forms or other forms thereof) at the permissive or non-permissive temperature.
Exemplary MMP-1 combination mutants provided herein contain amino acid replacements at any two or more positions corresponding any of the following positions: 95, 105, 150, 156, 159, 179, 180, 182, 185, 187, 198, 227, 234 and 240 of an unmodified MMP-1 polypeptide having a sequence of amino acids set forth in SEQ ID NO:2, or at a corresponding position in an allelic or species variant or other variant of an MMP-1 polypeptide that has at least or at least about 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to an MMP-1 polypeptide set forth in SEQ ID NO:2. For example, modified MMP-1 polypeptides provided herein include polypeptides having amino acid modification corresponding to any two or more modifications L95K, D1051, D105N, D105L, D105A, D105G, R150P, D156R, D156H, D156K, D156T, G159V, G159T, D179N, E180T, E180F, E182T, T185Q, N1871, A198L, V227E, 1234E and I240S. More particularly, modified MMP-1 polypeptides provided herein include polypeptides having amino acid modification corresponding to any two or more modifications L95K, D105N, R150P, D156K, D156T, G159V, D179N, E180T, Al 98L, V227E, and I240S. It is understood that at least two different positions are modified in the combination mutants provided herein. Exemplary MMP-1 combination mutant polypeptides provided herein are set forth in Table 15 in Example 3. For example, combination mutants provided herein that exhibit temperature sensitivity include DI56K/G159V/D179N; R150P/V227E; D156T/V227E;
G159V/A198L; D105N/A198L; D179N/V227E; A198L/V227E; E180T/V227E;
D179N/A198L; D156K/D179N; D105N/R150P/D1561QG159V/D179N/E180T;
D105N/R150P/E180T; G159V/1240S; D156T/D179N/1240S; D156T/G159V;
R150P/E180T; D156T/D179N; D179N/1240S; L95K/D156T/D179N; G159V/D179N;
L95K/D105N/EI80T; R150P/D156T/A198L;

L95K/D105N/R150P/D156T/G159V/A198L/V227E/I240S; L95K/R150P; or D105N/E180T. Exemplary modified MMP-1 polypeptides have a sequence of amino acids set forth in any of SEQ ID NOS: 3507-3531 and processed mature forms and other forms thereof, and allelic and species variants thereof.
Combination mutants provided herein also can include amino acid modification C259Q and at least one other modification. The other modification can be another temperature sensitive modification, for example, any of modifications L95K, D1051, D105N, D105L, D105A, D105G, R150P, D156R, D156H, D156K, D156T, G159V, G159T, D179N, E180T, E180F, E182T, T185Q, N1871, A198L, V227E, 1234E and 1240S. Exemplary of such combination mutants include C259Q/D105N; C259Q/R150P; C259Q/G159V; C259Q/D179N/ or C259Q/E180T, for example, as set forth in SEQ ID NOS: 3533-3537.
Also included among the combination mutants provided herein are MMP-1 polypeptides that contain at least one temperature sensitive modification and at least one activity modification, and retain temperature sensitivity. For example, such combination mutants exhibit increased activity at a permissive temperature compared to a non-permissive temperature as described herein above. Any one or more of the temperature sensitive mutants provided in Section D.1 above can be combined with any one or more of the activity mutants provided in Section D.2 above. For example, a combination mutant provided herein contains at least one modification of L95K, D1051, D105N, D105L, D105A, D105G, R150P, D156R, D156H, D156K, D156T, G159V, G159T, D179N, El 80T, El 80F, E182T, T185Q, N1871, A198L, V227E, 1234E and 1240S and at least one modification of N161I, S208K, 1213 G, G214E, Q228A, Q228D, Q228E, Q228G, Q228H, Q228K, Q228L, Q228M, Q228N, Q228R, Q228S, Q228W, Q228Y, L229V, A230G, A2301), A230S, A230C, A230T, A230M, A230N, A230H, Q231A, Q2311), Q231G, Q231V, Q231S, D232H, D232G, D232P, D232V, D232K, D232W, D232Q, D232E, or D232T. For example, a combination mutant provided herein contains at least one modification of L95K, D105N, R150P, D156K, D156T, G159V, D179N, E180T, A198L, V227E, or 1240S and at least one modification of S208K, 1213G, or G214E. Exemplary combination mutants provided herein include S208K/G159V; S208K/D179N; S208K/V227E; G214E/G159V;

G214E/D179N; or 1213G/DI79N, for example, as set forth in any of SEQ ID NOS:
3541-3546.
4. Additional Modifications Any modified MMP-I polypeptide provided herein also can contain one or more other modifications described in the art. The additional modifications can include, for example, any amino acid substitution, deletion or insertion known in the art. In addition to containing one or more modification(s) described above in Sections D.1 and D.2, any modified MMP-1 polypeptide provided herein can contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more additional modifications. Typically, MMP-1 polypeptides retain enzymatic activity of wildtype MMP'-1 at the permissive or non-permissive temperature, or exhibit increased enzymatic activity of wildtype MMP-1. Generally, where at least one modification is a temperature sensitive mutation, the MMP-1 polypeptide also exhibits increased activity at the permissive temperature (e,g, 25 C) compared to the non-permissive temperature (e.g. 34 C or 37 C). The additional modifications can confer additional properties to the enzyme, for example, increased stability, increased half-life and/or increased resistance to inhibitors, for example, TIMP. The additional modifications include modifications to the primary sequence of the polypeptide, as well as other modification such as PEGylation and glycosylation of the polypeptide.
Generally, such polypcptides include one or more modifications provided herein and exhibit increased activity at the lower temperature then at the higher temperature.
For example, any of the amino acid replacements, including allelic variants and other variants known in the art, as sot forth in SEQ ID NO. 3506 or 3549, can be included herein, Exemplary modifications that can be included in a polypeptide provided herein include, but are not limited to, modifications T4P, QlOF, R3 OM, R30S, T96R, A114V, F166C, I172V, D131H, R189T, H199A; E200A, G214E, D232N, D233G, R243S, Q254P, 1271A, R272A, T286A, 1298T, E3140, F315S, V374M, R386Q, S387T, 0391 S, and T432A of a polypeptide set forth in SEQ ID NO-.2, 5. Other MMPs Matrix metalloproteases are highly homologous polypeptides and exhibit similar specificities for extracellular matrix components. Exemplary sequences of RECTIFIED SHEET (RULE 91) ISA/EP

MMPs are set forth in Table 5, for example, any set forth in SEQ ID NOS:1, 711, 714, 717, 720, 723, 726, 729, 732, 735, 738, 741, 744, 747, 750, 753, 756, 759, 762, 765, 768, 771, 774 or 777 or zymogen forms, processed mature forms or other forms thereof, or allelic or species variants thereof. Figure 1 provides an alignment of the zymogen form of exemplary MMP polypeptides. Thus, any of the modifications provided herein in an MMP-1 can be made in any other MMP polypeptide. Hence, based on the description herein, any MMP, species, allelic variant or other variant, can be made temporally active (reversible or irreversible) by virtue of activity at a permissive temperature (generally a lower temperature) compared to a nonpermissive temperature (generally a higher temperature). Such tsMMP mutants can be used by one of skill in the art and used in compositions, processes or methods for the treatment of ECM-mediated diseases or conditions.
It is within the level of one of skill in the art to align various MMPs to MMP-(for example set forth in SEQ ID NO:2) and identify corresponding residues.
Any of the modifications provided herein can be made in any other MMP at the corresponding residue. One of skill in the art can test the activity of the resulting modified polypeptide for enzymatic activity and/or temperature sensitivity at a permissive temperature compared to a non-permissive temperature. In particular, it is understood that conservative amino acid differences at a corresponding position in an MMP are functionally invariant. Thus, where a residue in MMP-1 aligns with a conservative residue thereto in another MMP, it is understood that such a residue is contemplated for modification herein. For example, position 95 in an MMP-1 set forth in SEQ ID NO:2 is a leucine (L). Alignment of SEQ ID NO:2 with other MMPS
shows that position 95 in other MMPs is a leucine, isoleucine (I) or valine (V) residue (see Figure 1). Each of L, I and V are conservative residues.
In particular, provided herein are modified MMP polypeptides that are modified by one or more amino acid replacement to confer temperature sensitivity and/or increased activity by effecting a corresponding MMP-1 modification at a corresponding residue Exemplary modifications provided herein include modification of any MMP, for example, an MMP-8, MMP-13, MMP-18, MMP-2, MMP-9, MMP-3, MMP-10, MMP-11, MMP-7, MMP-26 and MMP-12, at any one or more positions corresponding to any of the following positions: 95, 105, 151, 156, 159, 176, 179, 180, 181, 182, 185, 195, 198, 206, 210, 212, 218, 223, 228, 229, 233, 234, and 240 of an unmodified MMP-1 polypeptide having a sequence of amino acids set forth in SEQ ID NO:2. In other example, exemplary modifications provided herein include modification of any MMP, for example, an MMP-8, MMP-13, MMP-18, MMP-2, MMP-9, MMP-3, MMP-10, MMP-11, MMP-7, MMP-26 and MMP-12, at any one or more positions corresponding to any of the following positions: 81, 89, 109, 131, 133, 154, 157, 158, 160, 164, 166, 180, 207, 216, 218, 223, 228, 229, 231, 232, 236, 238, 256. The modification includes any one or more of the modifications provided herein in sections D.1 and D.2 at the corresponding position to the recited position in MMP-1. For example, residue 95 in an MMP-1 polypeptide set forth in SEQ ID NO:2 corresponds to residue 113 in an MMP-8 polypeptide set forth in SEQ ID NO:
711.
Thus, provided herein are modified MMP-8 polypeptides having an amino acid modification L1 13K of an unmodified MMP-8 polypeptide having a sequence of amino acids set forth in SEQ ID NO:711. Similar modifications are provided herein based on this description.

Any modified MMP polypeptide provided herein also can contain one or more other modifications described in the art. The additional modifications can include, for example, any amino acid substitution, deletion or insertion known in the art.
In addition to containing one or modification described above in Sections D. 1 and D.2, any modified MMP polypeptide provided herein can contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more additional modifications, so long as the resulting MMP polypeptides exhibits increased activity at the permissive temperature (e.g. 25 C) compared to the non-permissive temperature (e.g. 34 C or 37 C) and retains activity of wildtype MMP at the permissive or non-permissive temperature. The additional modifications can confer additional properties to the enzyme, for example, increased stability, increased half-life and/or increased resistance to inhibitors, for example, TIMP. The additional modifications include modifications to the primary sequence of the polypeptide, as well as other modification such as PEGylation and glycosylation of the polypeptide.
Generally, such polypeptides include one or more modifications provided herein and exhibit increased activity at the lower temperature then a higher temperature.
Exemplary modifications that can be included in a polypeptide provided herein include, but are not limited to, any modifications set forth in Table 6, below.

Table 6. Exem lary modifications in MMPs MMP SEQ ID NO Amino Acid Modifications MMP-8 711 S3C; T321; K87E; E153G; D193V; S229T;
N246Y; L249V; Q251A;Q251D; Q251G;
Q251 V; Q251 S; D25211; D252G; D252P;
D252V; D252K; D252W; D252Q; D252E;
D252T; K460T
MMP-13 714 H2L; A8V; F75S; D89H; L254V; D257H;
D257G; D257P; D257V; D257K; D257W;
D257Q; D257E; D257T;D390G; I427T
MMP-2 720 A27S; R101H; D210Y; A228T; F239L; E404K;
L433V; Q435A;Q435D; Q435G; Q435V;
Q435S; D436H; D436G; D436P; D436V;
D436K; D436W; D436Q; D436E;
D436T;A447V; T498M; V620I; V621L; S644I
MMP-9 723 A20V; N38S; E82K; N127K; L187F; R239H;
T258I; Q279R; L431V; D43411; D434G; D434P;
D434V; D434K; D434W; D434Q; D434E;
D434T; F571 V; P574R; R668Q
MMP-3 726 K45E; H113P; R248W; L251V; Q253A;Q253D;
Q253G; Q253V; Q253S; D254H; D254G;
D254P; D254V; D254K; D254W; D254Q;
D254E; D254T
MMP-10 729 L4V; V8G; R53K; G65R; E142Q; L250V;
Q252A;Q252D; Q252G; Q252V; Q252S;
D253H; D253G; D253P; D253V; D253K;
D253W; D253Q; D253E; D253T; F2261,;
G282E; L440F; H475L
MMP-11 732 V38A; E44K; P61L; S86P; D166N; F182S;
L245V; D248H; D248G; D248P; D248V;
D248K; D248W; D248Q; D248E; D248T;

MMP-7 735 C7W; R77R; S115T; G137D; P241L; L246V;
Q248A;Q248D; Q248G; Q248V; Q248S;
D249H; D249G; D249P; D249V; D249K;
D249W; D249Q; D249E; D249T
MMP-26 738 K43E; S461,; Q239A; Q239D; Q239E; Q239G;
Q239H; Q239K; Q239L; Q239M; Q239N;
Q239R; Q239S; Q239W; Q239Y; Q239V;

L240V; D243H; D243G; D243P; D243V;
D243K; D243W; D243Q; D243E; D243T;

MMP-12 741 L250V; D253H; D253G; D253P; D253V;
D253K; D253W; D253Q; D253E; D253T;
N357S; F468L; G469R
MMP-19 765 R103C; L243V; D246H; D246G; D246P;
D246V; D246K; D246W; D246Q; D246E;
D246T; P245S; P488T; T491M

E. METHODS OF PRODUCING NUCLEIC ACIDS ENCODING tsMMPS
AND POLYPEPTIDES THEREOF
Modified MMP polypeptides, for example tsMMPs set forth herein, can be obtained by methods well known in the art for protein purification and recombinant protein expression. Any method known to those of skill in the art for identification of nucleic acids that encode desired genes can be used. Any method available in the art can be used to obtain a full length (i.e., encompassing the entire coding region) cDNA
or genomic DNA clone encoding a desired MMP, such as from a cell or tissue source.
Modified or variant tsMMPs, can be engineered from a wildtype polypeptide, such as by site-directed mutagenesis.

Polypeptides can be cloned or isolated using any available methods known in the art for cloning and isolating nucleic acid molecules. Such methods include PCR
amplification of nucleic acids and screening of libraries, including nucleic acid hybridization screening, antibody-based screening and activity-based screening.
Methods for amplification of nucleic acids can be used to isolate nucleic acid molecules encoding a desired polypeptide, including for example, polymerase chain reaction (PCR) methods. A nucleic acid containing material can be used as a starting material from which a desired polypeptide-encoding nucleic acid molecule can be isolated. For example, DNA and mRNA preparations, cell extracts, tissue extracts, fluid samples (e.g. blood, serum, saliva), samples from healthy and/or diseased subjects can be used in amplification methods. Nucleic acid libraries also can be used as a source of starting material. Primers can be designed to amplify a desired polypeptide. For example, primers can be designed based on expressed sequences from which a desired polypeptide is generated. Primers can be designed based on back-translation of a polypeptide amino acid sequence. Nucleic acid molecules generated by amplification can be sequenced and confirmed to encode a desired polypeptide.
Additional nucleotide sequences can be joined to a polypeptide-encoding nucleic acid molecule, including linker sequences containing restriction endonuclease sites for the purpose of cloning the synthetic gene into a vector, for example, a protein expression vector or a vector designed for the amplification of the core protein coding DNA sequences. Furthermore, additional nucleotide sequences specifying functional DNA elements can be operatively linked to a polypeptide-encoding nucleic acid molecule. Examples of such sequences include, but are not limited to, promoter sequences designed to facilitate intracellular protein expression, and secretion sequences, for example heterologous signal sequences, designed to facilitate protein secretion. Such sequences are known to those of skill in the art. For example, exemplary heterologous signal sequences include, but are not limited to, human kappa IgG heterologous signal sequence set forth in SEQ ID NO:3468. For bacterial expression, and exemplary heterologous signal sequence is the pelB leader sequence, for example, as set forth in SEQ ID NO: 3547. Additional nucleotide residues sequences such as sequences of bases specifying protein binding regions also can be linked to enzyme-encoding nucleic acid molecules. Such regions include, but are not limited to, sequences of residues that facilitate or encode proteins that facilitate uptake of an enzyme into specific target cells, or otherwise alter pharmacokinetics of a product of a synthetic gene. For example, enzymes can be linked to PEG
moieties.
In addition, tags or other moieties can be added, for example, to aid in detection or affinity purification of the polypeptide. For example, additional nucleotide residues sequences such as sequences of bases specifying an epitope tag or other detectable marker also can be linked to enzyme-encoding nucleic acid molecules. Exemplary of such sequences include nucleic acid sequences encoding a His tag (e.g., 6xHis, HHHHHH; SEQ ID NO:3465) or Flag Tag (DYKDDDDK; SEQ
ID NO:3467).
The identified and isolated nucleic acids can then be inserted into an appropriate cloning vector. A large number of vector-host systems known in the art can be used. Possible vectors include, but are not limited to, plasmids or modified viruses, but the vector system must be compatible with the host cell used.
Such vectors include, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as pCMV4, pBR322 or pUC plasmid derivatives or the Bluescript vector (Stratagene, La Jolla, CA). Other expression vectors include the pET303CTHis (SEQ ID NO:3466; Invitrogen, CA) or pET-26B vector (SEQ ID NO:3548) expression vector exemplified herein. The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. Insertion can be effected using TOPO
cloning vectors (INVITROGEN, Carlsbad, CA). If the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA
molecules can be enzymatically modified. Alternatively, any site desired can be produced by ligating nucleotide sequences (linkers) onto the DNA termini;
these ligated linkers can contain specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. In an alternative method, the cleaved vector and protein gene can be modified by homopolymeric tailing. Recombinant molecules can be introduced into host cells via, for example, transformation, transfection, infection, electroporation and sonoporation, so that many copies of the gene sequence are generated.
In specific embodiments, transformation of host cells with recombinant DNA
molecules that incorporate the isolated protein gene, cDNA, or synthesized DNA
sequence enables generation of multiple copies of the gene. Thus, the gene can be obtained in large quantities by growing transformants, isolating the recombinant DNA
molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA.
1. Vectors and cells For recombinant expression of one or more of the desired proteins, such as any described herein, the nucleic acid containing all or a portion of the nucleotide sequence encoding the protein can be inserted into an appropriate expression vector, i.e., a vector that contains the necessary elements for the transcription and translation of the inserted protein coding sequence. The necessary transcriptional and translational signals also can be supplied by the native promoter for enzyme genes, and/or their flanking regions.

Also provided are vectors that contain a nucleic acid encoding the enzyme.
Cells containing the vectors also are provided. The cells include eukaryotic and prokaryotic cells, and the vectors are any suitable for use therein.
Prokaryotic and eukaryotic cells, including endothelial cells, containing the vectors are provided. Such cells include bacterial cells, yeast cells, fungal cells, Archea, plant cells, insect cells and animal cells. The cells are used to produce a protein thereof by growing the above-described cells under conditions whereby the encoded protein is expressed by the cell, and recovering the expressed protein. For purposes herein, for example, the enzyme can be secreted into the medium.
Provided are vectors that contain a sequence of nucleotides that encodes the proenzyme polypeptide coupled to the native or heterologous signal sequence, as well as multiple copies thereof. The vectors can be selected for expression of the enzyme protein in the cell or such that the enzyme protein is expressed as a secreted protein.
The proenzyme (i.e. zymogen) form of the enzyme can be purified for use as an activatable, i.e. conditional active, enzyme herein. Alternatively, upon secretion the prosegment can be cleaved by chemical agents or catalytically or autocatalytically to generate a mature enzyme by the use of a processing agent. This processing step can be performed during the purification step and/or immediately before use of the enzyme. If desired, the processing agent can be dialyzed away or otherwise purified away from the purified protein before use. Alternative or additionally, if necessary, the enzyme can be purified such that the prosegment is removed from the preparation.
A variety of host-vector systems can be used to express the protein coding sequence. These include but are not limited to mammalian cell systems transfected with plasmid DNA or infected with virus (e.g. vaccinia virus, adenovirus and other viruses); insect cell systems infected with virus (e.g. baculovirus);
microorganisms such as yeast containing yeast vectors; or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system used, any one of a number of suitable transcription and translation elements can be used.

Any methods known to those of skill in the art for the insertion of DNA
fragments into a vector can be used to construct expression vectors containing a chimeric gene containing appropriate transcriptional/translational control signals and protein coding sequences. These methods can include in vitro recombinant DNA
and synthetic techniques and in vivo recombinants (genetic recombination).
Expression of nucleic acid sequences encoding protein, or domains, derivatives, fragments or homologs thereof, can be regulated by a second nucleic acid sequence so that the genes or fragments thereof are expressed in a host transformed with the recombinant DNA molecule(s). For example, expression of the proteins can be controlled by any promoter/enhancer known in the art. In a specific embodiment, the promoter is not native to the genes for a desired protein. Promoters which can be used include but are not limited to the SV40 early promoter (Bernoist and Chambon, Nature 290:304-(1981)), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al. Cell 22:787-797 (1980)), the herpes thymidine kinase promoter (Wagner et al., Proc. Natl. Acad. Sci. USA 78:1441-1445 (1981)), the regulatory sequences of the metallothionein gene (Brinster et al., Nature 296:39-42 (1982));
prokaryotic expression vectors such as the (3-lactamase promoter (Jay et al., (1981) Proc. Natl. Acad. Sci. USA 78:5543) or the tac promoter (DeBoer et al., Proc.
Natl.
Acad. Sci. USA 80:21-25 (1983)); see also "Useful Proteins from Recombinant Bacteria": in Scientific American 242:79-94 (1980)); plant expression vectors containing the nopaline synthase promoter (Herrara-Estrella et al., Nature 303:209-213 (1984)) or the cauliflower mosaic virus 35S RNA promoter (Gardner et al., Nucleic Acids Res. 9:2871 (1981)), and the promoter of the photosynthetic enzyme ribulose bisphosphate carboxylase (Herrera-Estrella et al., Nature 310:115-120 (1984)); promoter elements from yeast and other fungi such as the Ga14 promoter, the alcohol dehydrogenase promoter, the phosphoglycerol kinase promoter, the alkaline phosphatase promoter, and the following animal transcriptional control regions that exhibit tissue specificity and have been used in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., Cell 38:639-646 (1984); Ornitz et al., Cold Spring Harbor Symp. Quant. Biol. 50:399-409 (1986);
MacDonald, Hepatology 7:425-515 (1987)); insulin gene control region which is _100-active in pancreatic beta cells (Hanahan et al., Nature 315:115-122 (1985)), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., Cell 38:647-658 (1984); Adams et al., Nature 318:533-538 (1985);
Alexander et al., Mol. Cell Biol. 7:1436-1444 (1987)), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., Cell 45:485-495 (1986)), albumin gene control region which is active in liver (Pinckert et al., Genes and Devel. 1:268-276 (1987)), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., Mol. Cell. Biol. 5:1639-1648 (1985);
Hammer et al., Science 235:53-58 1987)), alpha-1 antitrypsin gene control region which is active in liver (Kelsey et al., Genes and Devel. 1:161-171 (1987)), beta globin gene control region which is active in myeloid cells (Magram et al., Nature 315:338-340 (1985);
Kollias et al., Cell 46:89-94 (1986)), myelin basic protein gene control region which is active in oligodendrocyte cells of the brain (Readhead et al., Cell 48:703-(1987)), myosin light chain-2 gene control region which is active in skeletal muscle (Shani, Nature 314:283-286 (1985)), and gonadotrophic releasing hormone gene control region which is active in gonadotrophs of the hypothalamus (Mason et al., Science 234:1372-1378 (1986)).
In a specific embodiment, a vector is used that contains a promoter operably linked to nucleic acids encoding a desired protein, or a domain, fragment, derivative or homolog, thereof, one or more origins of replication, and optionally, one or more selectable markers (e.g., an antibiotic resistance gene). Exemplary plasmid vectors for transformation of E. coli cells, include, for example, the pQE expression vectors (available from Qiagen, Valencia, CA; see also literature published by Qiagen describing the system). pQE vectors have a phage T5 promoter (recognized by E.
coli RNA polymerase) and a double lac operator repression module to provide tightly regulated, high-level expression of recombinant proteins in E. coli, a synthetic ribosomal binding site (RBS II) for efficient translation, a 6XHis tag coding sequence, to and Ti transcriptional terminators, ColEl origin of replication, and a beta-lactamase gene for conferring ampicillin resistance. The pQE, vectors enable placement of a 6xHis tag at either the N- or C-terminus of the recombinant protein.
Such plasmids include pQE 32, pQE 30, and pQE 31 which provide multiple cloning sites for all three reading frames and provide for the expression of N-terminally 6xHis-tagged proteins. Other exemplary plasmid vectors for transformation of E. coli cells, include, for example, the pET expression vectors (see, U.S. patent 4,952,496;
available from NOVAGEN, Madison, WI; see, also literature published by Novagen describing the system). Such plasmids include pET 11 a, which contains the T71ac promoter, T7 terminator, the inducible E. coli lac operator, and the lac repressor gene;
pET 12a-c, which contains the T7 promoter, T7 terminator, and the E. coli ompT
secretion signal; and pET 15b and pET19b (NOVAGEN, Madison, WI), which contain a His-TagTM leader sequence for use in purification with a His column and a thrombin cleavage site that permits cleavage following purification over the column, the T7-lac promoter region and the T7 terminator, and pET-26B (SEQ ID
NO:3548).
An additional pET vector is pET303CTHis (set forth in SEQ ID NO: 3466;
Invitrogen, CA), which contains a T71ac promoter, T7 terminator, the inducible E.coli lac operator, a beta-lactamase gene for conferring ampicillin resistance, and also a His-Tag sequence for use in purification.
Exemplary of a vector for mammalian cell expression is the HZ24 expression vector. The HZ24 expression vector was derived from the pCI vector backbone (Promega). It contains DNA encoding the Beta-lactamase resistance gene (AmpR), an F1 origin of replication, a Cytomegalovirus immediate-early enhancer/promoter region (CMV), and an SV40 late polyadenylation signal (SV40). The expression vector also has an internal ribosome entry site (IRES) from the ECMV virus (Clontech) and the mouse dihydrofolate reductase (DHFR) gene.
2. Expression Modified MMP polypeptides, for example tsMMPs , can be produced by any method known to those of skill in the art including in vivo and in vitro methods.
Desired proteins can be expressed in any organism suitable to produce the required amounts and forms of the proteins, such as for example, needed for administration and treatment. Expression hosts include prokaryotic and eukaryotic organisms such as E.coli, yeast, plants, insect cells, mammalian cells, including human cell lines and transgenic animals. Expression hosts can differ in their protein production levels as well as the types of post-translational modifications that are present on the expressed proteins. The choice of expression host can be made based on these and other factors, such as regulatory and safety considerations, production costs and the need and methods for purification.
Many expression vectors are available and known to those of skill in the art and can be used for expression of proteins. The choice of expression vector will be influenced by the choice of host expression system. In general, expression vectors can include transcriptional promoters and optionally enhancers, translational signals, and transcriptional and translational termination signals. Expression vectors that are used for stable transformation typically have a selectable marker which allows selection and maintenance of the transformed cells. In some cases, an origin of replication can be used to amplify the copy number of the vector.
Modified MMP polypeptides, for example tsMMPs, also can be utilized or expressed as protein fusions. For example, an enzyme fusion can be generated to add additional functionality to an enzyme. Examples of enzyme fusion proteins include, but are not limited to, fusions of a signal sequence, a tag such as for localization, e.g.
a his6 tag or a myc tag, or a tag for purification, for example, a GST fusion, and a sequence for directing protein secretion and/or membrane association.
Generally, modified MMP polypeptides, for example tsMMPs, are expressed in an inactive zymogen form. Zymogen conversion can be achieved by exposure to chemical agents, to other proteases or to autocatalysis to generate a mature enzyme as described elsewhere herein. Any form of an enzyme is contemplated herein. It is understood that, if provided and expressed in a zymogen form, that it is activated prior to use by a processing agent.
a. Prokaryotic Cells Prokaryotes, especially E. coli, provide a system for producing large amounts of proteins. Transformation of E.coli is simple and rapid technique well known to those of skill in the art. Expression vectors for E. coli can contain inducible promoters, such promoters are useful for inducing high levels of protein expression and for expressing proteins that exhibit some toxicity to the host cells.
Examples of inducible promoters include the lac promoter, the tip promoter, the hybrid tac promoter, the T7 and SP6 RNA promoters and the temperature regulated X PL
promoter.

Proteins, such as any provided herein, can be expressed in the cytoplasmic environment of E. coli. The cytoplasm is a reducing environment and for some molecules, this can result in the formation of insoluble inclusion bodies.
Reducing agents such as dithiothreotol and (3-mercaptoethanol and denaturants, such as guanidine-HC1 and urea can be used to resolubilize the proteins. An alternative approach is the expression of proteins in the periplasmic space of bacteria which provides an oxidizing environment and chaperonin-like and disulfide isomerases and can lead to the production of soluble protein. Typically, a leader sequence is fused to the protein to be expressed which directs the protein to the periplasm. The leader is then removed by signal peptidases inside the periplasm. Examples of periplasmic-targeting leader sequences include the pelB leader (SEQ ID NO: 3547) from the pectate lyase gene and the leader derived from the alkaline phosphatase gene.
In some cases, periplasmic expression allows leakage of the expressed protein into the culture medium. The secretion of proteins allows quick and simple purification from the culture supernatant. Proteins that are not secreted can be obtained from the periplasm by osmotic lysis. Similar to cytoplasmic expression, in some cases proteins can become insoluble and denaturants and reducing agents can be used to facilitate solubilization and refolding. Temperature of induction and growth also can influence expression levels and solubility, typically temperatures between 25 C and 37 C are used. Typically, bacteria produce aglycosylated proteins. Thus, if proteins require glycosylation for function, glycosylation can be added in vitro after purification from host cells.

b. Yeast Cells Yeasts such as Saccharomyces cerevisae, Schizosaccharomyces pombe, Yarrowia lipolytica, Kluyveromyces lactis and Pichia pastoris are well known yeast expression hosts that can be used for production of proteins, such as any described herein. Yeast can be transformed with episomal replicating vectors or by stable chromosomal integration by homologous recombination. Typically, inducible promoters are used to regulate gene expression. Examples of such promoters include GAL I, GAL7 and GAL5 and metallothionein promoters, such as CUP I, AOXI or other Pichia or other yeast promoter. Expression vectors often include a selectable marker such as LEU2, TRP1, HIS3 and URA3 for selection and maintenance of the transformed DNA. Proteins expressed in yeast are often soluble. Co-expression with chaperonins such as Bip and protein disulfide isomerase can improve expression levels and solubility. Additionally, proteins expressed in yeast can be directed for secretion using secretion signal peptide fusions such as the yeast mating type alpha-factor secretion signal from Saccharomyces cerevisae and fusions with yeast cell surface proteins such as the Aga2p mating adhesion receptor or the Arxula adeninivorans glucoamylase. A protease cleavage site such as for the Kex-2 protease, can be engineered to remove the fused sequences from the expressed polypeptides as they exit the secretion pathway. Yeast also is capable of glycosylation at Asn-X-Ser/Thr motifs.
c. Insect Cells Insect cells, particularly using baculovirus expression, are useful for expressing polypeptides such as matrix-degrading enzymes. Insect cells express high levels of protein and are capable of most of the post-translational modifications used by higher eukaryotes. Baculovirus have a restrictive host range which improves the safety and reduces regulatory concerns of eukaryotic expression. Typical expression vectors use a promoter for high level expression such as the polyhedrin promoter of baculovirus. Commonly used baculovirus systems include the baculoviruses such as Autographa californica nuclear polyhedrosis virus (AcNPV), and the bombyx mori nuclear polyhedrosis virus (BmNPV) and an insect cell line such as Sf9 derived from Spodoptera frugiperda, Pseudaletia unipuncta (A7 S) and Danaus plexippus (DpN
1).
For high-level expression, the nucleotide sequence of the molecule to be expressed is fused immediately downstream of the polyhedrin initiation codon of the virus.
Mammalian secretion signals are accurately processed in insect cells and can be used to secrete the expressed protein into the culture medium. In addition, the cell lines Pseudaletia unipuncta (A7S) and Danaus plexippus (DpN1) produce proteins with glycosylation patterns similar to mammalian cell systems.

An alternative expression system in insect cells is the use of stably transformed cells. Cell lines such as the Schnieder 2 (S2) and Kc cells (Drosophila melanogaster) and C7 cells (Aedes albopictus) can be used for expression. The Drosophila metallothionein promoter can be used to induce high levels of expression in the presence of heavy metal induction with cadmium or copper. Expression vectors are typically maintained by the use of selectable markers such as neomycin and hygromycin.
d. Mammalian Cells Mammalian expression systems can be used to express proteins including tsMMPs. Expression constructs can be transferred to mammalian cells by viral infection such as adenovirus or by direct DNA transfer such as liposomes, calcium phosphate, DEAE-dextran and by physical means such as electroporation and microinjection. Expression vectors for mammalian cells typically include an mRNA
cap site, a TATA box, a translational initiation sequence (Kozak consensus sequence) and polyadenylation elements. IRES elements also can be added to permit bicistronic expression with another gene, such as a selectable marker. Such vectors often include transcriptional promoter-enhancers for high-level expression, for example the promoter-enhancer, the human cytomegalovirus (CMV) promoter and the long terminal repeat of Rous sarcoma virus (RSV). These promoter-enhancers are active in many cell types. Tissue and cell-type promoters and enhancer regions also can be used for expression. Exemplary promoter/enhancer regions include, but are not limited to, those from genes such as elastase I, insulin, immunoglobulin, mouse mammary tumor virus, albumin, alpha fetoprotein, alpha 1 antitrypsin, beta globin, myelin basic protein, myosin light chain 2, and gonadotropic releasing hormone gene control. Selectable markers can be used to select for and maintain cells with the expression construct. Examples of selectable marker genes include, but are not limited to, hygromycin B phosphotransferase, adenosine deaminase, xanthine-guanine phosphoribosyl transferase, aminoglycoside phosphotransferase, dihydrofolate reductase (DHFR) and thymidine kinase. For example, expression can be performed in the presence of methotrexate to select for only those cells expressing the DHFR

gene. Fusion with cell surface signaling molecules such as TCR-c and Fc,RI-y can direct expression of the proteins in an active state on the cell surface.
Many cell lines are available for mammalian expression including mouse, rat human, monkey, chicken and hamster cells. Exemplary cell lines include but are not limited to CHO, Balb/3T3, HeLa, MT2, mouse NSO (nonsecreting) and other myeloma cell lines, hybridoma and heterohybridoma cell lines, lymphocytes, fibroblasts, Sp2/0, COS, NIH3T3, HEK293, 293S, 2B8, and HKB cells. Cell lines also are available adapted to serum-free media which facilitates purification of secreted proteins from the cell culture media. Examples include CHO-S cells (Invitrogen, Carlsbad, CA, cat # 11619-012) and the serum free EBNA-1 cell line (Pham et al., (2003) Biotechnol. Bioeng. 84:332-42.). Cell lines also are available that are adapted to grow in special mediums optimized for maximal expression.
For example, DG44 CHO cells are adapted to grow in suspension culture in a chemically defined, animal product-free medium.
e. Plants Transgenic plant cells and plants can be used to express proteins such as any described herein. Expression constructs are typically transferred to plants using direct DNA transfer such as microprojectile bombardment and PEG-mediated transfer into protoplasts, and with agrobacterium-mediated transformation. Expression vectors can include promoter and enhancer sequences, transcriptional termination elements and translational control elements. Expression vectors and transformation techniques are usually divided between dicot hosts, such as Arabidopsis and tobacco, and monocot hosts, such as corn and rice. Examples of plant promoters used for expression include the cauliflower mosaic virus promoter, the nopaline synthase promoter, the ribose bisphosphate carboxylase promoter and the ubiquitin and UBQ3 promoters.
Selectable markers such as hygromycin, phosphomannose isomerase and neomycin phosphotransferase are often used to facilitate selection and maintenance of transformed cells. Transformed plant cells can be maintained in culture as cells, aggregates (callus tissue) or regenerated into whole plants. Transgenic plant cells also can include algae engineered to produce matrix-degrading enzymes. Because plants have different glycosylation patterns than mammalian cells, this can influence the choice of protein produced in these hosts.
3. Purification Techniques Method for purification of polypeptides, including modified MMP
polypeptides such as tsMMPs or other proteins, from host cells will depend on the chosen host cells and expression systems. For secreted molecules, proteins are generally purified from the culture media after removing the cells. For intracellular expression, cells can be lysed and the proteins purified from the extract.
When transgenic organisms such as transgenic plants and animals are used for expression, tissues or organs can be used as starting material to make a lysed cell extract.
Additionally, transgenic animal production can include the production of polypeptides in milk or eggs, which can be collected, and if necessary, the proteins can be extracted and further purified using standard methods in the art. If there are free cysteines, these can be replaced with other amino acids, such as serine. Replacement of free cysteines can prevent unwanted aggregation.
Generally, modified MMP polypeptides, such as tsMMPs, are expressed and purified to be in an inactive form (zymogen form) for subsequent activation as described in the systems and methods provided herein. Hence, following expression, mature forms can be generated by the use of a processing agent and chemical modification, catalysis and/or autocatalysis to remove the prosegment.
Generally, a processing agent is chosen that is acceptable for administration to a subject.
If necessary, additional purification steps can be performed to remove the processing agent from the purified preparation. In addition, if necessary, additional purification steps can be performed to remove the prosegment from the purified preparation.
Activation can be monitored by SDS-PAGE (e.g., a 3 kilodalton shift) and by enzyme activity (cleavage of a fluorogenic substrate). Where an active enzyme is desired, typically, an enzyme is allowed to achieve >75% activation before purification.
Typically, MMPs are rendered active by activation cleavage removing the propeptide or prosegment to generate a mature enzyme from a zymogen form. In some applications under nonpermissive temperatures, however, tsMMPs are inactive in their mature form until exposure to the requisite permissive temperature as described herein. For example, many MMPs provided herein are not active or substantially inactive at the non-permissive temperature.
Proteins, such as modified MMP polypeptides, for example, tsMMPs, can be purified using standard protein purification techniques known in the art including but not limited to, SDS-PAGE, size fraction and size exclusion chromatography, ammonium sulfate precipitation and ionic exchange chromatography, such as anion exchange. Affinity purification techniques also can be utilized to improve the efficiency and purity of the preparations. For example, antibodies, receptors and other molecules that bind MMPs can be used in affinity purification.
Expression constructs also can be engineered to add an affinity tag to a protein such as a myc epitope, GST fusion or His6 and affinity purified with myc antibody, glutathione resin and Ni-resin, respectively. Purity can be assessed by any method known in the art including gel electrophoresis and staining and spectrophotometric techniques.
F. PREPARATION, FORMULATION AND ADMINISTRATION OF
tsMMPS
The pharmaceutical compositions provided herein contain modified MMP
polypeptides as described herein, for example tsMMPs and/or activity mutants .
The compounds can be formulated into suitable pharmaceutical preparations such as solutions, suspensions, tablets, dispersible tablets, pills, capsules, powders, sustained release formulations or elixirs, for oral administrate, as well as transdermal patch preparation and dry powder inhalers. Typically, the compounds are formulated into pharmaceutical compositions using techniques and procedures well known in the art (see e.g., Ansel Introduction to Pharmaceutical Dosage Forms, Fourth Edition, 1985, 126). The pharmaceutical compositions are administered prior to, simultaneously, subsequently or intermittently with an activator that provides the requisite temperature for activation.
A selected modified MMP polypeptide, for example tsMMP, is included in an amount sufficient that, when activated to a mature form and, if necessary, exposed to the permissive temperature, exerts a therapeutically useful effect in the absence of undesirable side effects on the patient treated. The composition containing the modified MMP polypeptide, for example tsMMP, can include a pharmaceutically acceptable carrier. Therapeutically effective concentration can be determined empirically by testing the compounds in known in vitro and in vivo systems, such as the assays provided herein. The concentration of a selected modified MMP
polypeptide, for example tsMMP, in the composition depends on absorption, inactivation and excretion rates of the complex, the physicochemical characteristics of the complex, the dosage schedule, and, amount administered as well as other factors known to those of skill in the art. For example, it is understood that the precise dosage and duration of treatment is a function of the tissue being treated and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data. It is to be noted that concentrations and dosage values may also vary with the age of the individual treated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the formulations, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope thereof.
The amount of a selected modified MMP polypeptide, for example tsMMP, to be administered for the treatment of a disease or condition, for example an ECM-mediated disease or condition such as cellulite or lymphedema, can be determined by standard clinical techniques. In addition, in vitro assays and animal models can be employed to help identify optimal dosage ranges. The precise dosage, which can be determined empirically, can depend on the particular enzyme, the route of administration, the type of disease to be treated and the seriousness of the disease.
Exemplary dosages range from or about 10 g to 100 mg, particularly 50 g to mg, 100 g to 50 mg, 250 g to 25 mg, 500 g to 10 mg, 1 mg to 5 mg, or 2 mg to 4 mg. The particular dosage and formulation thereof depends upon the indication and individual. If necessary dosage can be empirically determined. Typically the dosage is administered for indications described herein in a volume of 1 -100 ml, particularly, 1 -50 ml, 10- 50 ml, 10-30 ml, 1-20 ml, or 1-10 ml volumes following reconstitution, such as by addition of an activator (e.g. a cold buffer). Typically, such dosages are from at or about 100 g to 50 mg, generally I mg to 5 mg, in a 10 - 50 ml final volume.

A modified MMP polypeptide, for example tsMMP, can be administered at once, or can be divided into a number of smaller doses to be administered at intervals of time. Selected modified MMP polypeptides, for example tsMMPs, can be administered in one or more doses over the course of a treatment time for example over several hours, days, weeks, or months. In some cases, continuous administration is useful. It is understood that the precise dosage and course of administration depends on the methods and system of activation contemplated.
Also, it is understood that the precise dosage and duration of treatment is a function of the disease being treated and can be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data. It is to be noted that concentrations and dosage values also can vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or use of compositions and combinations containing them. The compositions can be administered hourly, daily, weekly, monthly, yearly or once. Generally, dosage regimens are chosen to limit toxicity. It should be noted that the attending physician would know how to and when to terminate, interrupt or adjust therapy to lower dosage due to toxicity, or bone marrow, liver or kidney or other tissue dysfunctions. Conversely, the attending physician would also know how to and when to adjust treatment to higher levels if the clinical response is not adequate (precluding toxic side effects).
Pharmaceutically acceptable compositions are prepared in view of approvals for a regulatory agency or other agency prepared in accordance with generally recognized pharmacopeia for use in animals and in humans. Compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, and sustained release formulations. A composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and other such agents. The formulation should suit the mode of administration.
Pharmaceutical compositions can include carriers such as a diluent, adjuvant, excipient, or vehicle with which an enzyme is administered. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences"
by E.
W. Martin. Such compositions will contain a therapeutically effective amount of the compound, generally in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, and sesame oil. Water is a typical carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions also can be employed as liquid carriers, particularly for injectable solutions.
Compositions can contain along with an active ingredient: a diluent such as lactose, sucrose, dicalcium phosphate, or carboxymethylcellulose; a lubricant, such as magnesium stearate, calcium stearate and talc; and a binder such as starch, natural gums, such as gum acaciagelatin, glucose, molasses, polyvinylpyrrolidine, celluloses and derivatives thereof, povidone, crospovidones and other such binders known to those of skill in the art. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, and ethanol. A composition, if desired, also can contain minor amounts of wetting or emulsifying agents, or pH buffering agents, for example, acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, and other such agents.
Formulations are provided for administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders, granules, sterile parenteral solutions or suspensions, and oral solutions or suspensions, and oil water emulsions containing suitable quantities of the compounds or pharmaceutically acceptable derivatives thereof. Pharmaceutically therapeutically active compounds and derivatives thereof are typically formulated and administered in unit dosage forms or multiple dosage forms. Each unit dose contains a predetermined quantity of therapeutically active compound sufficient to produce the desired therapeutic effect, in association with the required pharmaceutical carrier, vehicle or diluent.
Examples of unit dose forms include ampoules and syringes and individually packaged tablets or capsules. Unit dose forms can be administered in fractions or multiples thereof. A
multiple dose form is a plurality of identical unit dosage forms packaged in a single container to be administered in segregated unit dose form. Examples of multiple dose forms include vials, bottles of tablets or capsules or bottles of pints or gallons. Hence, multiple dose form is a multiple of unit doses that are not segregated in packaging.
Generally, dosage forms or compositions containing active ingredient in the range of 0.005% to 100% with the balance made up from non-toxic carrier can be prepared.
Compositions can be formulated for administration by any route known to those of skill in the art including intramuscular, intravenous, intradermal, intralesional, intraperitoneal injection, subcutaneous, epidural, nasal, oral, vaginal, rectal, topical, local, otic, inhalational, buccal (e.g., sublingual), and transdermal administration or any route. Administration can be local, topical or systemic depending upon the locus of treatment. Local administration to an area in need of treatment can be achieved by, for example, but not limited to, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant. Compositions also can be administered with other biologically active agents, either sequentially, intermittently or in the same composition. Administration also can include controlled release systems including controlled release formulations and device controlled release, such as by means of a pump.
The most suitable route in any given case depends on a variety of factors, such as the nature of the disease, the progress of the disease, the severity of the disease the particular composition which is used. For purposes herein, it is desired that modified MMP polypeptides, for example tsMMPs, are administered so that they reach the interstitium of skin or tissues. Thus, direct administration under the skin, such as by sub-epidermal administration methods, is contemplated. These include, for example, subcutaneous, intradermal and intramuscular routes of administration. Thus, in one example, local administration can be achieved by injection, such as from a syringe or other article of manufacture containing a injection device such as a needle.
Other modes of administration also are contemplated. Pharmaceutical compositions can be formulated in dosage forms appropriate for each route of administration.
In one example, pharmaceutical preparation can be in liquid form, for example, solutions, syrups or suspensions. If provided in liquid form, the pharmaceutical preparation of tsMMP, for example, can be provided as a concentrated preparation to be diluted to a therapeutically effective concentration upon exposure to the permissive temperature, for example, addition of the activator (e.g. a cold buffer).
The activator can be added to the preparation prior to administration, or the activator can be added simultaneously, intermittently or sequentially with the tsMMP
preparation. Further, if provided in liquid form, the temperature of the preparation can be regulated prior to use in order to achieve a desired temperature for activation.
For example, the liquid preparation can be chilled in an ice bucket or in a cold fridge or cold room prior to use and administration. Such liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid).
In another example, pharmaceutical preparations can be presented in lyophilized form for reconstitution with water or other suitable vehicle before use.
For example, the pharmaceutical preparations of tsMMP can be reconstituted with a solution containing an activator at the requisite temperature, generally a cold buffer or liquid solution or a room temperature buffer or liquid solution.
Alternatively, once reconstituted, the preparation can be regulated prior to use in order to achieve a desired temperature for activation. For example, the reconstituted liquid preparation can be stored at temperatures that are below the physiological temperature of the body, e.g. at 4 C to 25 C.
Typically, modified MMP polypeptides provided herein are prepared in compositions containing requisite metals required for activity. For example, MMPs are Zn-dependent and Ca-dependent polypeptides. It is within the level of one of skill in the art to empirically determine the optimal concentration of zinc and calcium required for activity. Where the modified MMP polypeptide is a tsMMP, the optimal concentration of zinc and calcium is a concentration that maintains the temperature-sensitive phenotype. For example, as described herein (e.g. Examples 13 and 14) the presence of zinc can affect the temperature sensitive phenotype of MMP
polypeptides.
For example, the optimal concentration of ZnC12 in MMP compositions provided herein is typically less than 0.01 mM, for example, 0.0005 mM to 0.009 mM, and in particular 0.0005 mM to 0.005 mM, for example 0.001 mM. The optimal concentration of CaC12 is typically greater than about 1 mM, for example, 2 mM
to 50 mM, in particular 5 mM to 20 mM, for example 10 mM to 15 mM, such as 10 mM.
Other metals also can be included in the compositions as required for activity.
Administration methods can be employed to decrease the exposure of modified MMP polypeptides to degradative processes, such as proteolytic degradation and immunological intervention via antigenic and immunogenic responses.
Examples of such methods include local administration at the site of treatment.
PEGylation of therapeutics has been reported to increase resistance to proteolysis, increase plasma half-life, and decrease antigenicity and immunogenicity. Examples of PEGylation methodologies are known in the art (see for example, Lu and Felix, Int. J.
Peptide Protein Res., 43: 127-138, 1994; Lu and Felix, Peptide Res., 6: 142-6, 1993;
Felix et at., Int. J. Peptide Res., 46: 253-64, 1995; Benhar et al., J. Biol. Chem., 269: 13398-404, 1994; Brumeanu et al., Jlmmunol., 154: 3088-95, 1995; see also, Caliceti et at.
(2003) Adv. Drug Deliv. Rev. 55(10):1261-77 and Molineux (2003) Pharmacotherapy 23 (8 Pt 2):3S-8S). PEGylation also can be used in the delivery of nucleic acid molecules in vivo. For example, PEGylation of adenovirus can increase stability and.
gene transfer (see, e.g., Cheng et al. (2003) Pharm. Res. 20(9): 1444-5 1).
1. Injectables, solutions and emulsions Parenteral administration, generally characterized by injection, either subcutaneously, intramuscularly or intraderinally is contemplated herein.
Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.

Suitable excipients are, for example, water, saline, dextrose, glycerol or ethanol. The pharmaceutical compositons also may contain other minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, and other such agents, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate and cyclodextrins.
Implantation of a slow-release or sustained-release system, such that a constant level of dosage is maintained (see, e. g., U. S. Patent No. 3,710,795) is also contemplated herein. The percentage of active compound contained in such parenteral compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the subject.
Parenteral administration of the compositions generally includes sub-epidermal routes of administration such as intradermal, subcutaneous and intramuscular administrations. If desired, intravenous administration also is contemplated. Injectables are designed for local and systemic administration.
For purposes herein, local administration is desired for direct administration to the affected interstitium. Preparations for parenteral administration include sterile solutions ready for injection, sterile dry soluble products, such as lyophilized powders, ready to be combined with a solvent just prior to use, including hypodermic tablets, sterile suspensions ready for injection, sterile dry insoluble products ready to be combined with a vehicle just prior to use and sterile emulsions. The solutions may be either aqueous or nonaqueous. If administered intravenously, suitable carriers include physiological saline or phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, and polypropylene glycol and mixtures thereof.
Pharmaceutically acceptable carriers used in parenteral preparations include aqueous vehicles, nonaqueous vehicles, antimicrobial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifying agents, sequestering or chelating agents and other pharmaceutically acceptable substances.
Examples of aqueous vehicles include Sodium Chloride Injection, Ringers Injection, Isotonic Dextrose Injection, Sterile Water Injection, Dextrose and Lactated Ringers Injection. Nonaqueous parenteral vehicles include fixed oils of vegetable origin, _116-cottonseed oil, corn oil, sesame oil and peanut oil. Antimicrobial agents in bacteriostatic or fungistatic concentrations can be added to parenteral preparations packaged in multiple-dose containers, which include phenols or cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoic acid esters, thimerosal, benzalkonium chloride and benzethonium chloride. Isotonic agents include sodium chloride and dextrose. Buffers include phosphate and citrate.
Antioxidants include sodium bisulfate. Local anesthetics include procaine hydrochloride. Suspending and dispersing agents include sodium carboxymethylcelluose, hydroxypropyl methylcellulose and polyvinylpyrrolidone.
Emulsifying agents include Polysorbate 80 (TWEENs 80). A sequestering or chelating agent of metal ions include EDTA. Pharmaceutical carriers also include ethyl alcohol, polyethylene glycol and propylene glycol for water miscible vehicles and sodium hydroxide, hydrochloric acid, citric acid or lactic acid for pH
adjustment.
The concentration of the pharmaceutically active compound is adjusted so that an injection provides an effective amount to produce the desired pharmacological effect. The exact dose depends on the age, weight and condition of the patient or animal as is known in the art. The unit-dose parenteral preparations are packaged in an ampoule, a vial or a syringe with a needle. The volume of liquid solution or reconstituted powder preparation, containing the pharmaceutically active compound, is a function of the disease to be treated and the particular article of manufacture chosen for package. For example, for the treatment of cellulite, it is contemplated that for parenteral injection the injected volume is or is about 10 to 50 milliliters. All preparations for parenteral administration must be sterile, as is known and practiced in the art.
Lyophilized powders Of interest herein are lyophilized powders, which can be reconstituted for administration as solutions, emulsions and other mixtures. They may also be reconstituted and formulated as solids or gels.
The sterile, lyophilized powder is prepared by dissolving a compound of inactive enzyme in a buffer solution. The buffer solution may contain an excipient which improves the stability or other pharmacological component of the powder or reconstituted solution, prepared from the powder. Subsequent sterile filtration of the solution followed by lyophilization under standard conditions known to those of skill in the art provides the desired formulation. Briefly, the lyophilized powder is prepared by dissolving an excipient, such as dextrose, sorbital, fructose, corn syrup, xylitol, glycerin, glucose, sucrose or other suitable agent, in a suitable buffer, such as citrate, sodium or potassium phosphate or other such buffer known to those of skill in the art.
Then, a selected enzyme is added to the resulting mixture, and stirred until it dissolves. The resulting mixture is sterile filtered or treated to remove particulates and to insure sterility, and apportioned into vials for lyophilization. Each vial will contain a single dosage (1 mg -1 g, generally 1-100 mg, such as 1-5 mg) or multiple dosages of the compound. The lyophilized powder can be stored under appropriate conditions, such as at about 4 C to room temperature.
Reconstitution of this lyophilized powder with a buffer solution provides a formulation for use in parenteral administration. The solution chosen for reconstitution can be any buffer. For reconstitution about 1 gg -20 mg, preferably 10 g- 1 mg, more preferably about 100 g is added per mL of buffer or other suitable carrier. The precise amount depends upon the indication treated and selected compound. Such amount can be empirically determined.
2. Topical administration Topical mixtures are prepared as described for the local and systemic administration. The resulting mixture may be a solution, suspension, emulsions or the like and are formulated as creams, gels, ointments, emulsions, solutions, elixirs, lotions, suspensions, tinctures, pastes, foams, aerosols, irrigations, sprays, suppositories, bandages, dermal patches or any other formulations suitable for topical administration.
The compounds or pharmaceutically acceptable derivatives thereof may be formulated as aerosols for topical application, such as by inhalation (see, e.
q., U. S.
Patent Nos. 4,044,126,4,414,209, and 4,364,923, which describe aerosols for delivery of a steroid useful for treatment inflammatory diseases, particularly asthma).
These formulations for administration to the respiratory tract can be in the form of an aerosol or solution for a nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose. In such a case, the particles of the formulation will typically diameters of less than 50 microns, preferably less than 10 microns.

The compounds may be formulated for local or topical application, such as for topical application to the skin and mucous membranes, such as in the eye, in the form of gels, creams, and lotions and for application to the eye or for intracisternal or intraspinal application. Topical administration is contemplated for transdermal delivery and also for administration to the eyes or mucosa, or for inhalation therapies.
Nasal solutions of the active compound alone or in combination with other pharmaceutically acceptable excipients also can be administered.
Formulations suitable for transdermal administration are provided. They can be provided in any suitable format, such as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time.
Such patches contain the active compound in optionally buffered aqueous solution of, for example, 0.1 to 0.2M concentration with respect to the active compound.
Formulations suitable for transdermal administration also can be delivered by iontophoresis (see, e.g., Pharmaceutical Research 3(6), 318 (1986)) and typically take the form of an optionally buffered aqueous solution of the active compound.
3. Compositions for other routes of administration Depending upon the condition treated other routes of administration, such as topical application, transdermal patches, oral and rectal administration are also contemplated herein. For example, pharmaceutical dosage forms for rectal administration are rectal suppositories, capsules and tablets for systemic effect. Rectal suppositories include solid bodies for insertion into the rectum which melt or soften at body temperature releasing one or more pharmacologically or therapeutically active ingredients. Pharmaceutically acceptable substances utilized in rectal suppositories are bases or vehicles and agents to raise the melting point. Examples of bases include cocoa butter (theobroma oil), glycerin-gelatin, carbowax (polyoxyethylene glycol) and appropriate mixtures of mono-, di-and triglycerides of fatty acids.
Combinations of the various bases may be used. Agents to raise the melting point of suppositories include spermaceti and wax. Rectal suppositories may be prepared either by the _119-compressed method or by molding. The typical weight of a rectal suppository is about 2 to 3 gm. Tablets and capsules for rectal administration are manufactured using the same pharmaceutically acceptable substance and by the same methods as for formulations for oral administration.
Formulations suitable for rectal administration can be provided as unit dose suppositories. These can be prepared by admixing the active compound with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.
For oral administration, pharmaceutical compositions can take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch, polyvinyl pyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate). The tablets can be coated by methods well-known in the art.
Formulations suitable for buccal (sublingual) administration include, for example, lozenges containing the active compound in a flavored base, usually sucrose and acacia or tragacanth; and pastilles containing the compound in an inert base such as gelatin and glycerin or sucrose and acacia.
Pharmaceutical compositions also can be administered by controlled release formulations and/or delivery devices (see, e.g., in U.S. Patent Nos.
3,536,809;
3,598,123; 3,630,200;3,845,770; 3,847,770; 3,916,899; 4,008,719; 4,687,610;
4,769,027; 5,059,595; 5,073,543; 5,120,548; 5,354,566; 5,591,767; 5,639,476;
5,674,533 and 5,733,566).
Various delivery systems are known and can be used to administer selected tsMMPs, such as but not limited to, encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor mediated endocytosis, and delivery of nucleic acid molecules encoding selected matrix-degrading enzymes such as retrovirus delivery systems.

Hence, in certain embodiments, liposomes and/or nanoparticles also can be employed with administration of matrix-degrading enzymes. Liposomes are formed from phospholipids that are dispersed in an aqueous medium and spontaneously form multilamellar concentric bilayer vesicles (also termed multilamellar vesicles (MLVs)). MLVs generally have diameters of from 25 nm to 4 gm. Sonication of MLVs results in the formation of small unilamellar vesicles (SUVs) with diameters in the range of 200 to 500 angstroms containing an aqueous solution in the core.
Phospholipids can form a variety of structures other than liposomes when dispersed in water, depending on the molar ratio of lipid to water. At low ratios, the liposomes form. Physical characteristics of liposomes depend on pH, ionic strength and the presence of divalent cations. Liposomes can show low permeability to ionic and polar substances, but at elevated temperatures undergo a phase transition which markedly alters their permeability. The phase transition involves a change from a closely packed, ordered structure, known as the gel state, to a loosely packed, less-ordered structure, known as the fluid state. This occurs at a characteristic phase-transition temperature and results in an increase in permeability to ions, sugars and drugs.
Liposomes interact with cells via different mechanisms: endocytosis by phagocytic cells of the reticuloendothelial system such as macrophages and neutrophils; adsorption to the cell surface, either by nonspecific weak hydrophobic or electrostatic forces, or by specific interactions with cell-surface components; fusion with the plasma cell membrane by insertion of the lipid bilayer of the liposome into the plasma membrane, with simultaneous release of liposomal contents into the cytoplasm; and by transfer of liposomal lipids to cellular or subcellular membranes, or vice versa, without any association of the liposome contents. Varying the liposome formulation can alter which mechanism is operative, although more than one can operate at the same time. Nanocapsules can generally entrap compounds in a stable and reproducible way. To avoid side effects due to intracellular polymeric overloading, such ultrafine particles (sized around 0.1 m) should be designed using polymers able to be degraded in vivo. Biodegradable polyalkyl-cyanoacrylate nanoparticles that meet these requirements are contemplated for use herein, and such particles can be easily made.
4. Activator Generally, a tsMMP is administered in the presence of an activator that provides the requisite permissive temperature for activation of the enzyme. In other words, tsMMP provided herein are provided for administration at the requisite permissive temperature. Thus, activators provided herein include any that are capable of providing a temperature condition, hot or cold, and that do not exist at the site of administration unless provided exogenously. Thus, tsMMPs can be regulated by controlling the timing and duration of exposure to the temperature condition.
An activator is chosen such that it provides a warm or cold temperature depending on the particular enzyme and the permissive temperature requirements provided for activation.
For example where the permissive temperature is 25 C an activator includes a buffer or other liquid diluent that is at or about 25 C, 24 C, 23 C, 22 C, 21 C, 20 C, 19 C, 18 C, 17 C, 16 C, 15 C, 14 C, 13 C, 12 C, 11 C, 10 C, 9 C, 8 C, 7 C, 6 C, 5 C or less. In other words, the tsMMP is provided and/or exposed to a buffer or other liquid diluent that is at or about 25 C, 24 C, 23 C, 22 C, 21 C, 20 C, 19 C, 18 C, 17 C, 16 C, 15 C, 14 C, 13 C, 12 C, 11 C, 10 C, 9 C, 8 C, 7 C, 6 C, 5 C or less. The buffer or liquid can be provided in the same composition as the tsMMP or in a separate composition. When provided separately, it can be administered prior to, simultaneously, subsequently or intermittently from the tsMMP.
Upon administration in vivo where the physiologic temperature is at or about 37 C, the temperature of the buffer will warm up to a temperature providing the permissive temperature for activation of the tsMMP (which could occur immediately or almost immediately depending on the temperature of the liquid). Due to the physiologic temperature conditions in vivo, the temperature will warm to non-permissive conditions, thereby resulting in inactivation of the enzyme and temporal control thereof.
In another example, the activator can be a cold pack or a hot pack, depending on the particular enzyme and the permissive temperature provided. Such activators include, but are not limited to ice wraps, gel ice packs, cold therapy, ice packs, cold compress, ice blankets, or other similar items. In other words, the site of locus of administration of the tsMMP can be exposed to the cold pack or hot pack in order to cool or warm the site of administration below or above the physiological temperature of the body, respectively, prior to, concurrently or subsequently with administration of the tsMMP to the same locus. For example, the cold pack can be frozen (e.g.
ice pack), or can be a liquid cold pack maintained at a temperature that is 4 C, 5 C, 6 C, 7 C, 8 C, 9 C, 10 C, 11 C, 12 C, 13 C, 14 C, 15 C or more. A cold or hot pack can be applied directly to the locus of treatment, and generally is applied locally to the skin at the site of administration of the tsMMP. One of skill in the art can empirically determine the length of time required for application depending of the particular target depth of the tissue that is being treated, the particular enzyme that is being used, and other factors based on known testing protocols or extrapolation from in vivo or in vitro test data. The hot pack or cold pack can be applied prior to, subsequently, simultaneously or intermittently from the tsMMP. For example, if the particular enzyme is reversibly active, the cold pack can be applied intermittently over a course of hours or days. It is understood that it is customary for a subject to feel cold, aching and burning and numbness upon administration of a cold pack, and such symptoms can be monitored by the subject or a treating physician.
In particular embodiments, the tsMMP is exposed to a temperature that is at or below the permissive temperature of the body immediately before administration. For example, the tsMMP is stored at a cold temperature and/or is reconstituted in a cold buffer. In some examples, the locus of administration of the tsMMP also is exposed cold by exposure to a cold pack to cool the site of administration below the physiologic temperature of the body. Upon administration of the tsMMP, the tsMMP
is exposed to the permissive temperature, which will steadily warm to the nonpermissive physiologic temperature of the body (e.g. about 37 C). Where the temperature reaches the nonpermissive temperature, the tsMMP is rendered inactive or substantially inactive. Hence, activation of the tsMMP is conditionally controlled.
The duration of time of exposure to a permissive temperature below the physiological temperature of the body can be controlled by continued exposure to a cold pack at the site of administration for a predetermined length of time.
In another embodiment, the tsMMP is exposed to a temperature that is at or above the permissive temperature of the body immediately before administration. For example, the tsMMP is stored at a warm temperature and/or is reconstituted in a warm buffer that is above the physiological temperature of the body. In some examples, the locus of administration of the tsMMP also is warmed by exposure to a hot pack to warm the site of administration above the physiologic temperature of the body.
Upon administration of the tsMMP, the tsMMP is exposed to the permissive temperature, which will steadily cool to the nonpermissive physiologic temperature of the body (e.g. about 37 C). Where the temperature reaches the nonpermissive temperature, the tsMMP is rendered inactive or substantially inactive. Hence, activation of the tsMMP
is conditionally controlled. The duration of time of exposure to a permissive temperature above the physiological temperature of the body can be controlled by continued exposure to a hot pack at the site of administration for a predetermined length of time.

5. Combination Therapies Any of the modified MMP polypeptides, for example tsMMPs, described herein can be further co-formulated or co-administered together with, prior to, intermittently with, or subsequent to, other therapeutic or pharmacologic agents or procedures. Such agents include, but are not limited to, other biologics, small molecule compounds, dispersing agents, anesthetics, vasoconstrictors and surgery, and combinations thereof. For example, for any disease or condition, including all those exemplified above, for which other agents and treatments are available, selected modified MMPs, for example tsMMPs, for such diseases and conditions can be used in combination therewith. In another example, a local anesthetic, for example, lidocaine can be administered to provide pain relief. In some examples, the anesthetic can be provided in combination with a vasoconstrictor to increase the duration of the anesthetic effects. Any of the pharmacological agents provided herein can be combined with a dispersion agent that facilitates access into the tissue of pharmacologic agents, for example, following subcutaneous administration. Such substances are known in the art and include, for example, soluble glycosaminoglycanase enzymes such as members of the hyaluronidase glycoprotein family (US20050260186, US20060104968).
Compositions of modified MMPs, for example tsMMPs, provided herein can be co-formulated or co-administered with a local anesthesia. Anesthesias include short-acting and long-lasting local anesthetic drug formulations. Short-acting local anesthetic drug formulations contain lidocaine or a related local anesthetic drug dissolved in saline or other suitable injection vehicle. Typically, local anesthesia with short-acting local anesthetics last approximately 20-30 minutes. Exemplary anesthetics include, for example, non-inhalation local anesthetics such as ambucaines;
amoxecaines; amylocaines; aptocaines; articaines; benoxinates; benzyl alcohols;
benzocaines; betoxycaines; biphenamines; bucricaines; bumecaines;
bupivacaines;
butacaines; butambens; butanilicaines; carbizocaines; chloroprocaine;
clibucaines;
clodacaines; cocaines; dexivacaines; diamocaines; dibucaines; dyclonines;
elucaines;
etidocaines; euprocins; fexicaines; fomocaines; heptacaines; hexylcaines;
hydroxyprocaines; hydroxytetracaines; isobutambens; ketocaines; leucinocaines;
lidocaines; mepivacaines; meprylcaines; octocaines; orthocaines; oxethacaines;
oxybuprocaines; phenacaines; pinolcaines; piperocaines; piridocaines;
polidocanols;
pramocaines; prilocaines; procaines; propanocaines; propipocaines;
propoxycaines;
proxymetacaines; pyrrocaines; quatacaines; quinisocaines; risocaines;
rodocaines;
ropivacaines; salicyl alcohols; suicaines; tetracaines; trapencaines; and trimecaines; as well as various other non-inhalation anesthetics such as alfaxalones;
amolanones;
etoxadrols; fentanyls; ketamines; levoxadrols; methiturals; methohexitals;
midazolams; minaxolones; propanidids; propoxates; pramoxines; propofols;
remifentanyls; sufentanyls; tiletamines; and zolamine. The effective amount in the formulation will vary depending on the particular patient, disease to be treated, route of administration and other considerations. Such dosages can be determined empirically.
Due to the short half-life of local anesthetics, it is often desirable to co-administer or co-formulate such anesthetics with a vasoconstrictor. Examples of vasoconstrictors include alpha adrenergic receptor agonists including catecholamines and catecholamine derivatives. Particular examples include, but are not limited to, levonordefrin, epinephrine and norepinephrine. For example, a local anesthetic formulation, such as lidocaine, can be formulated to contain low concentrations of epinephrine or another adrenergic receptor agonist such as levonordef mn.
Combining local anesthetics with adrenergic receptor agonists is common in pharmaceutical preparations (see e.g., U.S. Patent No. 7,261,889 and 5,976,556). The vasoconstrictor is necessary to increase the half-life of anesthetics. The vasoconstrictor, such as epinephrine, stimulates alpha-adrenergic receptors on the blood vessels in the injected tissue. This has the effect of constriction the blood vessels in the tissue.
The blood vessel constriction causes the local anesthetic to stay in the tissue much longer, resulting in a large increase in the duration of the anesthetic effect.
Generally, a vasoconstrictor is used herein in combination with an anesthetic.
The anesthetic agent and vasoconstrictor can be administered together as part of a single pharmaceutical composition or as part of separate pharmaceutical compositions acting together to prolong the effect of the anesthesia, so long as the vasoconstrictor acts to constrict the blood vessels in the vicinity of the administered anesthetic agent.
In one example, the anesthetic agent and vasoconstrictor are administered together in solution. In addition, the anesthetic agent and vasoconstrictor can be formulated together or separate from the activatable matrix-degrading enzyme and activator.
Single formulations are preferred. The anesthetic agent and vasoconstrictor can be administered by injection, by infiltration or by topical administration, e.g., as part of a gel or paste. Typically, the anesthetic agent and vasoconstrictor are administered by injection directly into the site to be anesthetized, for example, by subcutaneous administration. The effective amount in the formulation will vary depending on the particular patient, disease to be treated, route of administration and other considerations. Such dosages can be determined empirically. For example, exemplary amounts of lidocaine are or are about 10 mg to 1000 mg, 100 mg to mg, 200 mg to 400 mg, 20 mg to 60 mg, or 30 mg to 50 mg. The dosage of lidocaine administered will vary depending on the individual and the route of administration.
Epinephrine can be administered in amounts such as, for example, 10 g to 5 mg, 50 g to 1 mg, 50 g to 500 g, 50 g to 250 g, 100 g to 500 g, 200 g to 400 g, 1 mg to 5 mg or 2 mg to 4 mg. Typically, epinephrine can be combined with lidocaine in a 1:100,000 to 1:200,000 dilution, which means that 100 ml of anesthetic contains 0.5 to 1 mg of epinephrine. Volumes administered can be adjusted depending on the disease to be treated and the route of administration. It is contemplated herein that 1 -100 ml, 1 -50 ml, 10- 50 ml, 10-30 ml, 1-20 ml, or 1-10 ml, typically 10-50 ml of an anesthetic/vasoconstrictor formulation can be administered subcutanously for the treatment of an ECM-mediated disease or condition, such as cellulite. The administration can be subsequent, simultaneous or intermittent with administration of an activatable matrix-degrading enzyme and activator.
Compositions of modified MMP polypeptides, for example tsMMPs, provided herein also can be co-formulated or co-administered with a dispersion agent.
The dispersion agent also can be co-formulated or co-administered with other pharmacological agents, such as anesthetics, vasoconstrictors, or other biologic agents. Exemplary of dispersion agents are glycosaminoglycanases that open channels in the interstitial space through degradation of glycosaminoglycans.
These channels can remain relatively open for a period of 24-48 hours depending on dose and formulation. Such channels can be used to facilitate the diffusion of exogenously added molecules such as fluids, small molecules, proteins (such as matrix degrading enzymes), nucleic acids and gene therapy vectors and other molecules less than about 500 nm in size. In addition, it is thought that the formation of such channels can facilitate bulk fluid flow within an interstitial space, which can in turn promote the dispersion or movement of a solute (such as a detectable molecule or other diagnostic agent, an anesthetic or other tissue-modifying agent, a pharmacologic or pharmaceutically effective agent, or a cosmetic or other esthetic agent) that is effectively carried by the fluid in a process sometimes referred to as "convective transport" or simply convection. Such convective transport can substantially exceed the rate and cumulative effects of molecular diffusion and can thus cause the therapeutic or other administered molecule to more rapidly and effectively perfuse a tissue. Furthermore, when an agent, such as a modified MMP, for example a tsMMP, anesthetic or other agent, is co-formulated or co-administered with a glycosaminoglycanase and both are injected into a relatively confined local site, such as a site of non-intravenous parenteral administration (e.g., intradermal, subcutaneous, intramuscular, or into or around other internal tissues, organs or other relatively confined spaces within the body), then the fluid associated with the administered dose can both provide a local driving force (i.e. hydrostatic pressure) as well as lower impedance to flow (by opening channels within the interstitial matrix), both of which could increase fluid flow, and with it convective transport of the therapeutic agent or other molecule contained within the fluid. As a result, the use of glycosaminoglycanases can have substantial utility for improving the bioavailability as well as manipulating other pharmacokinetic and/or pharmacodynamic characteristics of co-formulated or co-administered agents, such as matrix degrading enzymes.
Hyaluronidases Exemplary of glycosaminoglycanases are hyaluronidases. Hyaluronidases are a family of enzymes that degrade hyaluronic acid. By catalyzing the hydrolysis of hyaluronic acid, a major constituent of the interstitial barrier, hyaluronidase lowers the viscosity of hyaluronic acid, thereby increasing tissue permeability.
There are three general classes of hyaluronidases: Mammalian-type hyaluronidases, (EC
3.2.1.35) which are endo-beta-N-acetylhexosaminidases with tetrasaccharides and hexasaccharides as the major end products. They have both hydrolytic and transglycosidase activities, and can degrade hyaluronan and chondroitin sulfates (CS), generally C4-S and C6-S; Bacterial hyaluronidases (EC 4.2.99.1), which degrade hyaluronan and to various extents, CS and DS. They are endo-beta-N-acetylhexosaminidases that operate by a beta elimination reaction that yields primarily disaccharide end products; and Hyaluronidases (EC 3.2.1.36) from leeches, other parasites, and crustaceans that are endo-beta-glucuronidases that generate tetrasaccharide and hexasaccharide end products through hydrolysis of the beta linkage.
There are six hyaluronidase-like genes in the human genome, HYALI (SEQ
ID NO:3469), HYAL2 (SEQ ID NO: 3470), HYAL3 (SEQ ID NO:3471), HYAL4 (SEQ ID NO:3472), PH2O/SPAM1 (SEQ ID NO:3473) and one expressed pseudogene, HYALP 1. Among hyaluronidases, PH2O is the prototypical neutral active enzyme, while the others exhibit no catalytic activity towards hyaluronan or any known substrates, or are active only under acidic pH conditions. The hyaluronidase-like enzymes can also be characterized by those which are generally locked to the plasma membrane via a glycosylphosphatidyl inositol anchor such as human HYAL2 and human PH20 (Danilkovitch-Miagkova, et al. (2003) Proc Natl Acad Sci USA. 100(8):4580-5), and those which are generally soluble such as human HYAL1 (Frost et al., (1997) Biochem Biophys Res Commun. 236(1):10-5). N-linked glycosylation of some hyaluronidases can be very important for their catalytic activity and stability. While altering the type of glycan modifying a glycoprotein can have dramatic affects on a protein's antigenicity, structural folding, solubility, and stability, many enzymes are not thought to require glycosylation for optimal enzyme activity.
Hyaluronidases are, therefore, unique in this regard, in that removal of N-linked glycosylation can result in near complete inactivation of the hyaluronidase activity.
For such hyaluronidases, the presence of N-linked glycans is critical for generating an active enzyme.
Human PH2O (also known as sperm surface protein PH2O) is naturally involved in sperm-egg adhesion and aids penetration by sperm of the layer of cumulus cells by digesting hyaluronic acid. The PH2O mRNA transcript (corresponding to nucleotides 1058-2503 of the sequence set forth in SEQ ID NO:3474) is normally translated to generate a 509 amino acid precursor protein containing a 35 amino acid signal sequence at the N-terminus (amino acid residue positions 1-35) and a 19 amino acid GPI anchor at the C-terminus (corresponding to amino acid residues 491-509).
The precursor sequence is set forth in SEQ ID NO:3473. An mRNA transcript containing a mutation of C to T at nucleotide position 2188 of the sequence of nucleic acids set forth in SEQ ID NO:3474 also exists and is a silent mutation resulting in the translated product set forth in SEQ ID NO: 3473. The mature PH2O is, therefore, a 474 amino acid polypeptide corresponding to amino acids 36-509 of the sequence of amino acids set forth in SEQ ID NO:3473. There are potential N-linked glycosylation sites required for hyaluronidases activity at N82, N166, N235, N254, N368, N393, N490 of human PH2O exemplified in SEQ ID NO: 3473. Disulfide bonds form between the cysteine residues C60 and C3 51 and between C224 and C238 (corresponding to amino acids set forth in SEQ ID NO:3473) to form the core hyaluronidase domain. Additional cysteines are required in the carboxy terminus for neutral enzyme catalytic activity such that amino acids 36 to 464 of SEQ ID
NO:3473 contain the minimally active human PH2O hyaluronidase domain.
Soluble forms of recombinant human PH2O have been produced and can be used in the methods described herein for co-administration or co-formulation with tsMMPs, activators, anesthetics, vasoconstrictors, other pharmacologic or therapeutic agents, or combinations thereof, to permit the diffusion into tissues. The production of such soluble forms of PH2O is described in related Application Nos. 11/065,716 and 11/238,171. Soluble forms include, but are not limited to, any having C-terminal truncations to generate polypeptides containing amino acid 1 to amino acid 442, 443, 444, 445, 446 and 447 of the sequence of amino acids set forth in SEQ ID
NOS:3476-3481. Exemplary of such a polypeptides are those generated from a nucleic acid molecule encoding amino acids 1-482 set forth in SEQ ID NO:3475. Resulting purified rHuPH2O can be heterogenous due to peptidases present in the culture medium upon production and purification. Generally soluble forms of PH2O are produced using protein expression systems that facilitate correct N-glycosylation to ensure the polypeptide retains activity, since glycosylation is important for the catalytic activity and stability of hyaluronidases. Such cells include, for example Chinese Hamster Ovary (CHO) cells (e.g. DG44 CHO cells).
The soluble PH2O can be administered by any suitable route as described elsewhere herein. Typically, administration is by parenteral administration, such as by intradermal, intramuscular, subcutaneous or intravascular administration.
The compounds provided herein can be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection can be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions can be suspensions, solutions or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient can be in powder form for reconstitution with a suitable vehicle, e.g., sterile pyrogen-free water or other solvents, before use. For example, provided herein are parenteral formulations containing an effective amount of soluble PH2O, such as 10 Units to 500,000 Units, 100 Units to 100,000 Units, 500 Units to 50,000 Units, 1000 Units to 10,000 Units, 5000 Units to 7500 Units, 5000 Units to 50,000 Units, or 1,000 Units to 10,000 Units, generally 10,000 to 50,000 Units, in a stabilized solution or suspension or a lyophilized from. The formulations can be provided in unit-dose forms such as, but not limited to, ampoules, syringes and individually packaged tablets or capsules.
The dispersing agent can be administered alone, or with other pharmacologically effective agents in a total volume of 1 -100 ml, 1 -50 ml, 10- 50 ml, 10-30 ml, 1-20 ml, or 1-10 ml, typically 10-50 ml.
In one example of a combination therapy, it is contemplated herein that an anesthetic, vasoconstrictor and dispersion agent are co-administered or co-formulated with a tsMMP to be administered subsequently, simultaneously or intermittently therewith. An exemplary formulation is one containing lidocaine, epinephrine and a soluble PH2O, for example, a soluble PH2O set forth in SEQ ID NO:3476. Soluble PH2O can be mixed directly with lidocaine (Xylocaine), and optionally with epinephrine. The formulation can be prepared in a unit dosage form, such as in a syringe. For example, the lidocaine/epinephrine/soluble PH2O formulation can be provided in a volume, such as 1 -100 ml, 1 -50 ml, 10- 50 ml, 10-30 ml, 1-20 ml, or 1-10 ml, typically 10-50 ml, prepackaged in a syringe for use.
In the combination therapies, the other pharmacologic agents, such as a lidocaine/epinephrine/soluble PH2O formulation, can be co-administered together with or in close temporal proximity to the administration of an activatable matrix-degrading enzyme (and activator). Typically it is preferred that an anesthetic and/or dispersion agent be administered shortly before (e.g. 5 to 60 minutes before) or, for maximal convenience, together with the pharmacologic agent. As will be appreciated by those of skill in the art, the desired proximity of co-administration depends in significant part on the effective half lives of the agents in the particular tissue setting, and the particular disease being treated, and can be readily optimized by testing the effects of administering the agents at varying times in suitable models, such as in suitable animal models.

G. PACKAGING AND ARTICLES OF MANUFACTURE OF tsMMPS
Pharmaceutical compounds of modified MMPs, for example tsMMPs, or nucleic acids encoding modified MMPs, or a derivative or variant thereof can be packaged as articles of manufacture containing packaging material, a pharmaceutical composition which is effective for treating the disease or disorder, and a label that indicates that selected modified MMP or nucleic acid molecule is to be used for treating the disease or disorder. Instructions for use can be provided. For example, instructions can be provided that specify that the tsMMP is to be reconstituted with the accompanying liquid buffer or solution, kept cold, immediately before administration. Instructions also can be provided for administration of a cold pack at the site of administration of the tsMMP. Combinations of a modified MMP, for example tsMMP, or derivative or variant thereof and an activator (e.g. cold pack or liquid buffer) also can be packaged in an article of manufacture. In some examples, combinations also can include a processing agent.
The articles of manufacture provided herein contain packaging materials.
Packaging materials for use in packaging pharmaceutical products are well known to those of skill in the art. See, for example, U.S. Patent Nos. 5,323,907, 5,052,558 and 5,033,252, each of which is incorporated herein in its entirety. Examples of pharmaceutical packaging materials include, but are not limited to, blister packs, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, bottles, and any packaging material suitable for a selected formulation and intended mode of administration and treatment. The articles of manufacture can include a needle or other injection device so as to facilitate administration (e.g. sub-epidermal administration) for local injection purposes. A wide array of formulations of the compounds and compositions provided herein are contemplated as are a variety of treatments for any ECM-mediated disease or disorder.
The choice of package depends on the tsMMP and activator (if included therewith), and whether such compositions will be packaged together or separately.
In general, the packaging is non-reactive with the compositions contained therein such that activation of the tsMMP does not occur prior to addition of the activator. In one example, the modified MMP can be packaged in lyophilized form with a buffer or diluent for reconstitution. The buffer or diluent can be stored separately at a temperature providing the activated condition, or can be provided in a form capable of providing the activating condition when desired. For example, instructions can be provided to chill or cool and or warm the buffer or diluent before use.
Alternatively, instructions can be provided to activate the enzyme by use of a cold pack or heat pack at the locus of administration, for example, following reconstitution of the enzyme and administration thereof.
Exposure to the activator can occur at any time preceding administration of the tsMMP by exposure of the tsMMP to the requisite permissive temperature. For example, the container can have a single compartment containing the tsMMP and being amenable to addition of the activator (e.g. cold or room temperature liquid buffer or solution) by the user, for example through an opening in the compartment.
Any container or other article of manufacture that is amenable to having a defining space for containment of the tsMMP and that is amenable to simple manipulation to permit addition of the final components necessary for activation is contemplated. The activator is added prior to use. Exposure to the activator also can occur following administration to the interstitium. For example, if heat is the activator, a tsMMP can be administered and the local injection site subjected to heat. If colder temperatures are the activator, a tsMMP can be administered and the local injection site subjected to cold, e.g. by a cold pack.
In other examples, the tsMMP is packaged in a container with the activator such that activation of the matrix-degrading enzyme is amenable to activation by the user at will in the container. Generally, examples of such containers include those that have an enclosed, defined space that contains the matrix-degrading enzyme, and a separate enclosed, defined space containing the activator such that the two spaces are separated by a readily removable membrane which, upon removal, permits the components to mix and thereby react, resulting in activation of the protease.
The container can be stored under conditions such that the activator is at or near the requisite permissive temperature for activation of the MMP. Alternatively, only the side of the container containing the activator can be cooled or warmed to the desired temperature (e.g. by exposing it to an ice wrap or other temperature condition) just prior to use and reconstitution of the enzyme. Any container or other article of manufacture is contemplated, so long as the tsMMP is separated from the activator.
Exposure of the activator to the tsMMP is prior to use. For example, the physical separation means are those that are readily removed by the user, to permit mixing, resulting in activation of the enzyme. For example, an article of manufacture can contain a tsMMP in one compartment and an activator (e.g. cold or room temperature liquid buffer or solution) in an adjacent compartment. The compartments are separated by a dividing member, such as a membrane, that, upon compression of the article or manufacture ruptures permitting separated components to mix. For suitable embodiments see e.g., containers described in U.S. Patent Nos. 3,539,794 and 5,171,081.
Following are some examples of the packaging requirements of various end uses of activatable matrix-degrading enzymes. These are offered as examples only and in no way are intended as limiting.
1. Single Chamber Apparatus Among the simplest embodiments herein, are those in which the apparatus contains a single chamber or container and, if needed, ejection means. Single chamber housings or containers include any item in which a tsMMP is included in the container. The tsMMP is housed in the vessel in liquid phase or as a powder or other paste or other convenient composition. The vessel or liquid can be stored at a temperature that is at or below the permissive temperature and/or cooled to at or below the permissive temperature prior to administration. Alternatively, a tsMMP is reconstituted with an appropriate liquid diluent or buffer and the activator is applied locally to the site of administration (e.g. cold pack) or is administered separately at the site of administration. Kits containing the item and the activator also are provided.
2. Dual Chamber Apparatus An example of an apparatus contemplated for use herein is a dual chamber container. In general, this apparatus has two chambers or compartments thereby maintaining the tsMMP from an activator capable of providing the activating condition until activation is desired. The apparatus can include a mixing chamber to permit mixing of the components prior to dispensing from the apparatus.

Alternatively, mixing can occur by ejection of the activator from one chamber into a second chamber containing the tsMMP. For example, the activatable tsMMP can be provided in lyophilized form, and reconstitution can be achieved by ejection of the activator (e.g. e.g. cold or room temperature buffer or liquid solution) from a first chamber into the second chamber containing the lyophilized enzyme. It is understood that the temperature of the entire apparatus can be controlled together and/or the chamber containing the activator can be brought to the desired temperature prior to use and reconstitution of the enzyme.
In one embodiment, a dual chamber apparatus employs a mechanical pump mechanism in its operation. In such an example, the dispensing apparatus maintains the components in separate chambers. A pump mechanism is operated to withdraw the contents from each chamber and into a mixing chamber, or from one chamber into the second chamber. Upon mixing, the mixed composition is activated by reaction of the components in the chambers. The pump mechanism can be manually operated, for example, by a plunger. Exemplary of such dual chamber apparatus include dual chamber syringes (see e.g., U.S. Patent Nos. 6972005, 6692468, 5971953, .4529403, 4202314, 4214584, 4983164, 5788670, 5395326; and Intl. Patent Appl. Nos.
W02007006030, W02001047584).
Another embodiment of a dual chamber fluid dispensing apparatus contemplated for use herein takes the form of a compressible bottle or tube or other similar device. The device has two compartments within it that keep the components separated. The cap of the device can serve as a mixing chamber, a mixing chamber can be positioned between the two chambers and the cap, or mixing can be achieved within one of the chambers. The components are forced by compression from the separate compartments into the mixing chamber. They are then dispensed from the mixing chamber. For example, the mixed contents can be removed from the device by attaching a plunger/syringe apparatus to the dispensing end and withdrawing the contents therethrough. Such devices are known in the art (see e.g., Intl.
Patent Appln.
No. W01994015848).

3. Kits Selected modified MMP polypeptides, for example tsMMPs, and/or articles of manufacture thereof also can be provided as kits. The kits optionally can include an activator and/or processing agent. Kits can include a pharmaceutical composition described herein and an item for administration provided as an article of manufacture.
For example a selected tsMMP can be supplied with a device for administration, such as a syringe, an inhaler, a dosage cup, a dropper, or an applicator. The compositions can be contained in the item for administration or can be provided separately to be added later. Generally, kits contain an item with a tsMMP, and optionally a processing agent and/or an activator capable of providing the activating condition.
The kit can, optionally, include instructions for application including dosages, dosing regimens, instructions for using the activator (e.g. warming or cooling the buffer or applying a cold or hot pack), and instructions for modes of administration.
Kits also can include a pharmaceutical composition described herein and an item for diagnosis.
For example, such kits can include an item for measuring the concentration, amount or activity of the selected protease in a subject.
H. METHODS OF ASSESSING ACTIVITY OF tsMMPS
1. Methods of Assessing Enzymatic Activity Modified MMPs, including tsMMPs, can be tested for their enzymatic activity against known substrates. Activity assessment can be performed in the presence or absence of an activator and at varying temperatures. Activity assessments can be performed on conditioned medium or other supernatants or on purified protein.
Enzymatic activity can be assessed by assaying for substrate cleavage using known substrates of the enzyme. The substrates can be in the form of a purified protein or provided as peptide substrates. For example, enzymatic activity of MMP
can be assessed by cleavage of collagen. Cleavage of a purified protein by an enzyme can be assessed using any method of protein detection, including, but not limited to, HPLC, SDS-PAGE analysis, ELISA, Western blotting, immunohistochemistry, immunoprecipitation, N1-12-terminal sequencing, protein labeling and fluorometric methods. For example, Example 5 describes an assay to assess enzymatic activity for cleavage of a collagen that is FITC-labeled. Fluorescence of the supernatant is an indication of the enzymatic activity of the protein and can be normalized to protein concentration and a standard curve for specific activity assessment.
In addition, enzymatic activity can be assessed on tetrapeptide substrates.
The use of fluorogenic groups on the substrates facilitates detection of cleavage.
For example, substrates can be provided as fluorogenically tagged tetrapeptides of the peptide substrate, such as an ACC- or 7-amino-4-methyl courmarin (AMC)-tetrapeptide. Other fluorogenic groups are known and can be used and coupled to protein or peptide substrates. These include, for example, 7-amino-4-methyl-2-quinolinone (AMeq), 2-naphthylamine (NHNap) and 7 amino-4-methylcoumarin (NHMec) (Sarath et al. "Protease Assay Methods," in Proteolytic Enzymes: A
Practical Approach. Ed. Robert J. Beynon and Judith S. Bond. Oxford University Press, 2001. pp. 45-76). Peptide substrates are known to one of skill in the art, as are exemplary fluorogenic peptide substrates. For example, exemplary substrates for MMP include, peptide IX, designated as Mca-K-P-L-G-L-Dpa-A-R-NH2 (SEQ ID
NO:707; Mca=(7-Methoxycoumarin-4-yl)acetyl; Dpa=N-3-(2,4,-Dinitrophenyl)-L-2,3-diaminopropionyl; R&D Systems, Minneapolis, MN, Cat# ES010) and variations thereof such as with different fluorogenic groups. Enzyme assays to measure enzymatic activity by fluorescence intensity are standard and are typically performed as a function of incubation time of the enzyme and substrate (see e.g., Dehrmann et al. (1995) Arch. Biochem. Biophys., 324:93-98; Barrett et al. (1981) Methods Enzymol., 80:536-561). Exemplary assays using fluorescence substrates are described in Example 2 herein.
While detection of fluorogenic compounds can be accomplished using a fluorometer, detection can be accomplished by a variety of other methods well known to those of skill in the art. Thus, for example, when the fluorophores emit in the visible wavelengths, detection can be simply by visual inspection of fluorescence in response to excitation by a light source. Detection also can be by means of an image analysis system utilizing a video camera interfaced to a digitizer or other image acquisition system. Detection also can be by visualization through a filter, as under a fluorescence microscope. The microscope can provide a signal that is simply visualized by the operator. Alternatively, the signal can be recorded on photographic film or using a video analysis system. The signal also can simply be quantified in real time using either an image analysis system or a photometer.
Thus, for example, a basic assay for enzyme activity of a sample involves suspending or dissolving the sample in a buffer (at the pH optima of the particular protease being assayed) adding to the buffer a fluorogenic enzyme peptide indicator, and monitoring the resulting change in fluorescence using a spectrofluorometer as shown in e.g., Harris et al., (1998) JBiol Chem 273:27364. The spectrofluorometer is set to excite the fluorophore at the excitation wavelength of the fluorophore.
The fluorogenic enzyme indicator is a substrate sequence of an enzyme (e.g. of a protease) that changes in fluorescence due to a protease cleaving the indicator.
2. Methods of Assessing ECM Degradation The degradation of extracellular matrix proteins by modified MMPs, for example tsMMPs, including, but not limited to, those described above, such as tsMMP-1, can be assessed in vitro or in vivo. Assays for such assessment are known to those of skill in the art, and can be used to test the activities of a variety of modified MMPs, for example tsMMPs, on a variety of extracellular matrix proteins, including, but not limited to collagen (I, II, III and IV), fibronectin, vitronectin and proteoglycans. Assays can be performed at permissive and non-permissive temperatures. Experiments also can be performed in the presence of an MMP that is not modified to be temperature sensitive. It is understood that assays for enzymatic activity are performed subsequent to activation of the enzyme by a processing agent.
As a further control, activity of the zymogen enzyme also can be assessed.
a. In vitro assays Exemplary in vitro assays include assays to assess the degradation products of extracellular matrix proteins following incubation with a modified MMP, for example tsMMP. In some examples, the assays detect a single, specific degradation product.
In other examples, the assays detect multiple degradation products, the identity of which may or may not be known. Assessment of degradation products can be performed using methods well known in the art including, but not limited to, HPLC, CE, Mass spectrometry, SDS-PAGE analysis, ELISA, Western blotting, immunohistochemistry, immunoprecipitation, NI2-terminal sequencing, and protein labeling. Extracellular matrix degradation products can be visualized, for example, by SDS-PAGE analysis following incubation with MMPs, such as tsMMPs, for an appropriate amount of time at an appropriate temperature. For example, collagen can be incubated with mature modified MMP, for example tsMMP, and subjected to SDS-PAGE using, for example, a 4-20% Tris/glycine gel to separate the products.
Coomassie staining of the gel facilitates visualization of smaller degradation products, or disappearance of collagen bands, compared to intact collagen.
Immunoblotting using, for example, a polyclonal Ig specific to the extracellular matrix protein also can be used to visualize the degradation products following separation with SDS-PAGE.
Assays that specifically detect a single product following degradation of an extracellular matrix protein also are known in the art and can be used to assess the ability of a tsMMP to degrade an extracellular matrix protein. For example, the hydroxyproline (HP) assay can be used to measure degradation of collagen. 4-hydroxyproline is a modified imino acid that makes up approximately 12% of the weight of collagen. HP assays measure the amount of solubilized collagen by determining the amount of HP in the supernatant following incubation with a matrix-degrading enzyme (see e.g., Reddy and Enwemeka (1996) Clinical Biochemistry 29:225-229). Measurement of HP can be effected by, for example, colorimetric methods, high performance liquid chromatography, mass spectrometry and enzymatic methods (see e.g., Edwards et al., (1980) Clin. Chim. Acta 104:161-167; Green (1992) Anal. Biochem. 201:265-269; Tredget et al., (1990) Anal. Biochem. 190:259-265;
Ito et al., (1985) Anal. Biochem. 151:510-514; Garnero et al. (1998) J. Biol. Chem 273:32347-32352).
The collagen source used in such in vitro assays can include, but is not limited to, commercially available purified collagen, bone particles, skin, cartilage and rat tail tendon. Collagenolytic activity of a modified MMP, such as tsMMP such as tsMMP-1, can be assessed by incubating the activated enzyme with an insoluble collagen suspension, followed by hydrolysis, such as with HCI. The amount of hydroxyproline derived from the solubilized (degraded) collagen can be determined by spectrophotometric methods, such as measuring the absorbance at 550 nm following incubation with Ehrlich's reagent. In some examples, the collagen source is rat or pig skin explant that is surgically removed from anesthetized animals and then perfused with the tsMMP, for example, tsMMP-1, prior to, subsequently, simultaneously or intermittently with a temperature activator. HP levels in the perfusates can then be assessed. In a modification of this method, the effect on the fibrous septae in the explants can also be assessed. Briefly, following perfusion with the enzyme, the explants are cut into small pieces and embedded in paraffin and analyzed by microscopy following Masson's Trichrome staining for visualization of collagen. The number of collagen fibrous septae can be visualized and compared to tissue that has not been treated with a enzyme.
Assays to detect degradation of specific collagens also are known in the art.
Such assays can employ immunological methods to detect a degradation product unique to the specific collagen. For example, the degradation of collagen I by some MMPs releases telopeptides with different epitopes that can be detected using immunoassays. Such assays detect the cross-linked N-telopeptides (NTx) and the cross-linked C-telopeptides (CTx and ICTP), each of which contain unique epitopes.
Typically, CTx assays utilize the CrossLaps (Nordic Biosciences) antibodies that recognize the 8 amino acid sequence EKAHD-(3-GGR octapeptide, where the aspartic acid is in 0-isomerized configuration, in the C-terminal telopeptide region of the al chain (Eastell (2001) Bone Markers: Biochemical and Clinical Perspectives, pg 40).
Immunoassays to detect ICTP also are known in the art and can be used to detect degradation of collagen I (US Patent No. 5,538,853). In other examples, immunoassays, such as, for example, ELISAs, can be used to detect NTx following incubation of collagen type I with proteases such as an MMP (Atley et al., (2000) Bone, 26:241-247). Other antibodies and assays specific for degraded collagens are known in the art and can be used to detect degradation by matrix-degrading enzymes.
These include antibodies and assays specific for degraded collagen I (Hartmann et al (1990) Clin. Chem. 36:421-426), collagen II (Hollander et al (1994) J. Clin.
Invest.
93:1722-1732), collagen III (U.S. Patent No. 5,34,2756), and collagen IV
(Wilkinson et al (1990) Anal. Biochem. 185:294-6).
b. In vivo assays Assays to detect the in vivo degradation of ECM also are known in the art.
Such assays can utilize the methods described above to detect, for example, hydroxyproline and N- and C-telopeptides and degraded collagens or other ECM
in biological samples such as urine, blood, serum and tissue. Detection of degraded ECM can be performed following administration to the patient of one or more enzymes. Detection of pyridinoline (PYD) and deoxypyridinoline (DPYD), also can be used to assess degradation of collagen. Also known as hydroxylysylpyridinoline and lysylpyridinoline, respectively, PYD and DPYD are the two nonreducible trivalent cross-links that stabilize type I collagen chains and are released during the degradation of mature collagen fibrils. Pyridinoline is abundant in bone and cartilage, whereas deoxypyridinoline is largely confined to bone. Type III collagen also contains pyridinoline cross-links at the amino terminus. Total PYD and DPYD
can be measured, for example, in hydrolyzed urine samples or serum by fluorometric detection after reversed-phase HPLC (Hata et al (1995) Clin.Chimica. Acta.
235:221-227).
c. Non-human animal models Non-human animal models can be used to assess the activity of matrix-degrading enzymes. For example, non-human animals can be used as models for a disease or condition. Non-human animals can be injected with disease and/or phenotype-inducing substances prior to administration of enzymes. Genetic models also are useful. Animals, such as mice, can be generated which mimic a disease or condition by the overexpression, underexpression or knock-out of one or more genes.
For example, animal models are known in the art for conditions including, but not limited to, Peyronie's Disease (Davila et al. (2004) Biol. Reprod., 71:1568-1577), tendinosis (Warden et al., (2006) Br. J. Sports Med. 41:232-240) and scleroderma (Yamamoto (2005) Cur. Rheum. Rev. 1:105-109).
Non-human animals also can be used to test the activity of enzymes in vivo in a non-diseased animal. For example, enzymes can be administered to, non-human animals, such as, a mouse, rat or pig, and the level of ECM degradation can be determined. In some examples, the animals are used to obtain explants for ex vivo assessment of ECM degradation. In other examples, ECM degradation is assessed in vivo. For example, collagen degradation of the skin of anesthetized animals can be assessed. Briefly, an MMP, such as a tsMMP-1, is perfused prior to, simultaneously, subsequently or intermittently with a temperature activator via insertion of a needle into the dermal layer of the skin of the tail. Perfusate fractions are collected from the tail skin and analyzed for collagen degradation by hydroxyproline analysis.
Other methods can be used to detect degradation including, but not limited to, any of the assays described above, such as immunoassays to detect specific degradation products.

1. Exemplary Methods of Treating Diseases or Defects of ECM
The modified MMPs, for example tsMMPs, provided herein can be used for treatment of any condition mediated by any one or more ECM components. This section provides exemplary uses of, and administration methods for, modified MMPs, such as tsMMPs. These described therapies are exemplary and do not limit the applications of enzymes. Such methods include, but are not limited to, methods of treatment of any ECM condition or disease that is caused by excess, aberrant or accumulated expression of any one or more ECM component. Exemplary of diseases or conditions to be treated are any mediated by collagen, elastin, fibronectin, or a glycosaminoglycan such as a proteoglycan. For example, exemplary of collagen-mediated diseases or disorders include, but are not limited to, cellulite, Dupuytren's disease (also called Dupuytren's contracture), Peyronie's disease, frozen shoulder, chronic tendinosis or scar tissue of the tendons, localized scleroderma and lymphedema. It is within the skill of a treating physician to identify such diseases or conditions.
The particular disease or condition to be treated dictates the enzyme that is selected. For example, treatment of a collagen-mediated disease or disorder can be effected by administration of a modified MMP, for example tsMMP, that cleaves collagen. For example, a modified MMP-1, for example tsMMP-1, can be selected for cleaving collagen. Such MMPs include modified forms on any MMP listed above in Table 5, and/or known to one of skill in the art. tsMMPs, and systems and methods for activation can be chosen accordingly to treat a particular disease or condition.

Treatment of diseases and conditions with modified MMPs, for example tsMMPs, can be effected by any suitable route of administration using suitable formulations as described herein including, but not limited to, subcutaneous injection, intramuscular, intradermal, oral, and topical and transdermal administration.
As described above, a route of administration of modified MMPs, for example tsMMPs, typically is chosen that results in administration under the skin directly to the affected site. Exemplary of such routes of administration include, but are not limited to, subcutaneous, intramuscular, or intradermal.
If necessary, a particular dosage and duration and treatment protocol can be empirically determined or extrapolated. For example, exemplary doses of recombinant and native active MMPs or modified MMPs, for example tsMMPs, can be used as a starting point to determine appropriate dosages. Dosage levels can be determined based on a variety of factors, such as body weight of the individual, general health, age, the activity of the specific compound employed, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease, and the patient's disposition to the disease and the judgment of the treating physician. The amount of active ingredient that can be combined with the carrier materials to produce a single dosage form will vary depending upon the particular matrix-degrading enzyme, the host treated, the particular mode of administration, and the activating condition required for activation, and/or the predetermined or length of time in which activation is desired. The pharmaceutical compositions typically should provide a dosage of from about 1 g/ml to about 20 mg/ml. Generally, dosages are from or about 10 g/ml to I mg/ml, typically about 100 g/ml, per single dosage administration. It is understood that the amount to administer will be a function of the tsMMP and the activating condition chosen, the indication treated, and possibly side effects that will be tolerated. Dosages can be empirically determined using recognized models for each disorder. Also, as described elsewhere herein, modified MMPs, for example tsMMPs, can be administered in combination with other agents sequentially, simultaneously or intermittently. Exemplary of such agents include, but are not limited to, lidocaine, epinephrine, a dispersing agent such as hyaluronidase and combinations thereof Upon improvement of a patient's condition, a maintenance dose of a compound or compositions can be administered, if necessary; and the dosage, the dosage form, or frequency of administration, or a combination thereof can be modified. In some cases, a subject can require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
Descriptions of the involvement of collagen to collagen-mediated diseases or conditions is provided below as an example of the role of ECM components in diverse disease and conditions. Such descriptions are meant to be exemplary only and are not limited to a particular modified MMP or tsMMP or to a particular ECM-mediated diseases or conditions. One of skill in the art can select a modified MMP, for example, tsMMP and activating condition for activation thereof, to be used in the treatment of any desired ECM-mediated disease, based on the ability of a particular enzyme to cleave or degrade an ECM component involved in the particular disease or condition. For example, as described herein, MMP-1 cleaves type I and type III
collagens, such as those abundant in the skin. Hence, a modified MMP-1 can be used for treatments, uses and processes for treating a collagen-mediated disease or condition. The particular treatment and dosage can be determined by one of skill in the art. Considerations in assessing treatment include, for example, the disease to be treated, the ECM component involved in the disease, the severity and course of the disease, whether the modified MMP, for example tsMMP, is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to therapy, and the discretion of the attending physician.
Collagen-mediated Diseases or Conditions Collagen is a major structural constituent of mammalian organisms and makes up a large portion of the total protein content of the skin and other parts of the animal body. Numerous diseases and conditions are associated with excess collagen deposition, for example, due to erratic accumulation of fibrous tissue rich in collagen or other causes. Collagen-mediated diseases or conditions (also referred to as fibrotic tissue disorders) are known to one of skill in the art (see e.g., published U.S.
Application No. 20070224183; U.S. Patent Nos. 6,353,028; 6,060,474; 6,566,331;
6,294,350). Excess collagen has been associated with diseases and conditions, such as, but not limited to, fibrotic diseases or conditions resulting in scar formation, cellulite, Dupuytren's syndrome, Peyronie's disease, frozen shoulder, localized scleroderma, lymphedema, Interstitial cystitis (IC), Telangrectase, Barrett's metaplasia, Pneumatosis cytoides intestinalis, collagenous colitis. For example, disfiguring conditions of the skin, such as wrinkling, cellulite formation and neoplastic fibrosis result from excessive collagen deposition, which produces unwanted binding and distortion of normal tissue architecture.
Modified MMP polypeptides, for example tsMMPs described herein, including but not limited to modified MMP-1 and tsMMP- 1, can be used to treat collagen-mediated diseases or conditions. Exemplary of tsMMPs for treatment of diseases and conditions described herein is a tsMMP-1 that is more active at a non-permissive temperature that is below the physiological temperature of the body such as at or about 25 C compared to the nonpermissive physiologic temperature at the site of administration. For example, temporary cooling of the extracellular matrix, such as the skin interstitium, can be achieved by infusing a cold buffered solution or other liquid directly at the affected site and/or applying a cold pack directly to the locus of administration. In one example, a cold buffer can be administered via sub-epidermal administration, i.e. under the skin, such that administration is effected directly at the site where ECM components are present and accumulated. Other methods of activation can be employed, and are known to one of skill in the art in view of the descriptions herein.

a. Cellulite Modified MMP polypeptides, for example, tsMMPs, such as those described herein, including a modified MMP-1 polypeptide or tsMMP-1, can be used to treat cellulite. In normal adipose tissues, a fine mesh of blood vessels and lymph vessels supplies the tissue with necessary nutrients and oxygen, and takes care of the removal of metabolized products. For example, triglycerides are stored in individual adipocytes that are grouped into capillary rich lobules. Each fat lobule is composed of adipocytes. Vertical strands of collagen fibers named fibrous septae separate the fat lobules and tether the overlying superficial fascia to the underlying muscle.

Cellulite is typically characterized by dermal deterioration due to a breakdown in blood vessel integrity and a loss of capillary networks in the dermal and subdermal levels of the skin. The vascular deterioration tends to decrease the dermal metabolism. This decreased metabolism hinders protein synthesis and repair processes, which results in dermal thinning. The condition is further characterized by fat cells becoming engorged with lipids, swelling and clumping together, as well as excess fluid retention in the dermal and subdermal regions of the skin. The accumulation of fat globules or adipose cells creates a need for a bigger blood supply to provide extra nourishment. To provide the blood to tissues, new capillaries are formed, which release more filtrate resulting in a saturation of tissues with interstitial fluid causing edema in the adipose tissues. Abundant reticular fibers in the interstitial tissues accumulate and thicken around the aggregated adipose cells; they form capsules or septa, which gradually transform into collagen fibers and are felt as nodules. The formation of these septa further occludes fat cells. Collagen fibers are also laid down in the interstitial tissue spaces, rendering the connective tissue sclerotic (hard).
Hence, as the condition further progresses, hard nodules of fat cells and clumps of fats surrounded by septa form in the dermal region. This leads to the surface of the skin displaying considerable heterogeneity and being characterized as having a "cottage cheese" or "orange peel" appearance. The dimpling occurs when the fibrous septae that connect the skin to the dermis and deeper tissue layers tighten and pull in the skin. Thus, the "orange peel" appearance of cellulite is due to the deformation of the fat lobules as a result of outward forces on the adipose tissue. The fat lobules can be large, for example up to 1 cm wide, and easily protrude into the overlying dermis, causing a visible deformation on the surface of the skin.
The net result is the undulating appearance of the outer skin as the fat pushes upwards. As the connective septae run in the same direction as these outward forces, they can offer no counter force to keep the adipose from protruding into the dermis.
Cellulite is more prevalent among females than males. The prevalence of cellulite is estimated between 60% and 80% of the female population and its severity tends to worsen with obesity. Recently, a published study showed by in vivo magnetic resonance imaging that women with cellulite have a higher percentage of perpendicular fibrous septae than women without cellulite or men (Querleux et al., (2002) Skin Research and Technology, 8:118-124). Cellulite occurs most often on the hips, thighs and upper arms. For example, premenopausal females tend to accumulate fat subcutaneously, primarily in the gluteal/thigh areas where cellulite is most common. Clinically, cellulite is accompanied by symptoms that include thinning of the epidermis, reduction and breakdown of the microvasculature leading to subdermal accumulations of fluids, and subdermal agglomerations of fatty tissues.
b. Dupuytren's Disease Modified MMP polypeptides, for example tsMMPs, such as a modified MMP-1 or a tsMMP-1 such as those described herein, can be used to treat Dupuytren's syndrome (also called Dupuytren's contracture). Dupuytren's contracture (also known as Morbus Dupuytren) is a fixed flexion contracture of the hand where the fingers bend towards the palm and cannot be fully extended. A similar lesion sometimes occurs in the foot. The connective tissue within the hand becomes abnormally thick and is accompanied by the presence of nodules containing fibroblasts and collagen, particularly type III collagen. The fibrous cord of collagen is often interspersed with a septa-like arrangement of adipose tissue. These present clinically as mattress-type "lumps" of varying sized and in Dupuytren's disease are termed nodules. This can cause the fingers to curl, and can result in impaired function of the fingers, especially the small and ring fingers. Dupuytren's disease occurs predominantly in men. It is generally found in middle aged and elderly persons, those of Northern European ancestry, and in those with certain chronic illnesses such as diabetes, alcoholism and smoking.
Dupuytren's disease is a slowly progressive disease that occurs over many years causing fixed flexion deformities in the metacarpophalangeal (MP) and proximal interphalangeal (PIP) joints of the fingers. The small and ring fingers are the most often affected. The disease progresses through three stages (Luck et al.
(1959) J. Bone Joint Surg., 41A:635-664). The initial proliferative stage is characterized by nodule formation in the palmar fascia in which a cell known as the myofibroblast appears and begins to proliferate. The involutional or mid-disease stage involves myofibroblast proliferation and active type III collagen formation. In the last or residual phase, the nodule disappears leaving acellular tissue and thick bands of collagen. The ratio of type III collagen to type I collagen increases.
Treatment of Dupuytren's disease with an activatable-matrix degrading enzyme is typically in the mid-disease and residual disease stages.
c. Peyronie's Disease Modified MMP-1, for example tsMMPs, such as a modified MMP-1 or a tsMMP-1 such as those described herein, can be used to treat Peyronie's disease.
Peyronie's disease is a connective tissue disorder involving the growth of fibrous plaques in the soft tissue of the penis affecting as many as 1-4% of men.
Collagen is the major component of the plaque in Peyronie's disease. Specifically, the fibrosing process occurs in the tunica albuginea, a fibrous envelope surrounding the penile corpora cavemosa. The pain and disfigurement associated with Peyronie's disease relate to the physical structure of the penis in which is found two erectile rods, called the corpora cavernosa, a conduit (the urethra) through which urine flows from the bladder, and the tunica which separates the cavernosa from the outer layers of skin of the penis. A person exhibiting Peyronie's disease will have formation(s) of plaque or scar tissue between the tunica and these outer layers of the skin (referred to as "sub-dermal" in this application). The scarring or plaque accumulation of the tunica reduces its elasticity causes such that, in the affected area, it will not stretch to the same degree (if at all) as the surrounding, unaffected tissues. Thus, the erect penis bends in the direction of the scar or plaque accumulation, often with associated pain of some degree. In all but minor manifestations of Peyronie's disease, the patient has some degree of sexual dysfunction. In more severe cases, sexual intercourse is either impossible, or is so painful as to be effectively prohibitive.
Empirical evidence indicates an incidence of Peyronie's disease in approximately one percent of the male population. Although the disease occurs mostly in middle-aged men, younger and older men can acquire it. About 30 percent of men with Peyronie's disease also develop fibrosis (hardened cells) in other elastic tissues of the body, such as on the hand or foot. Common examples of such other conditions include Dupuytren's contracture of the hand and Ledderhose Fibrosis of the foot.
d. Ledderhose Fibrosis Modified MMP polypeptides, for example tsMMPs, for example, a modified MMP-1 or tsMMP-1 such as those described herein, can be used to treat Ledderhose fibrosis. Ledderhose fibrosis is similar to Dupuytren's disease and Peyronie's disease, except that the fibrosis due to fibroblast proliferation and collagen deposition occurs in the foot. Ledderhose disease is characterized by plantar fibrosis over the medial sole of the foot, and is sometimes referred to as plantar fibrosis.
e. Stiff joints Modified MMP polypeptides, for example tsMMPs, such as a modified MMP-1 or a tsMMP-1 such as those described herein, can be used to treat stiff joints, for example, frozen shoulder. Frozen shoulder (adhesive capsulitis) is a chronic fibrozing condition of the capsule of the joint characterized by pain and loss of motion or stiffness in the shoulder. It affects about 2% of the general population.
Frozen shoulder results from increased fibroblast matrix synthesis. The synthesis is caused by an excessive inflammatory response resulting in the overproduction of cytokines and growth factors. Fibroblasts and myofibroblasts lay down a dense matrix of collagen in particular, type-I and type-III collagen within the capsule of the shoulder.
This results in a scarred contracted shoulder capsule and causes joint stiffness.
Other examples of stiff joints include, but are not limited to, those caused by capsular contractures, adhesive capsulitis and arthrofibrosis, which result from musculoskeletal surgery. Such stiff joints can occur in joints, including, for example, joints of the knees, shoulders, elbows, ankles and hips. Like frozen shoulder, such joint diseases are caused by increased matrix synthesis and scar formation.
The stiff joints inevitably can cause abnormally high forces to be transmitted to the articular cartilage of the affected area. Over time, these forces result in the development of degenerative joint disease and arthritis. For example, in arthrofibrosis and capsular contracture, fibroblasts form excessive amounts of matrix in response to local trauma, such as joint dislocation.
f. Existing Scars Modified MMP-1, for example tsMMPs, such as a modified MMP-1 or tsMMP-1 such as those described herein, can be used to treat existing scars.
Collagen is particularly important in the wound healing process and in the process of natural aging, where it is produced by fibroblast cells. In some cases, however, an exaggerated healing response can result in the production of copious amounts of healing tissue (ground substance), also termed scar tissue. For example, various skin traumas such as burns, surgery, infection, wounds and accident are often characterized by the erratic accumulation of fibrous tissue rich in collagen. There also is often an increased proteoglycan content. In addition to the replacement of the normal tissue that has been damaged or destroyed, excessive and disfiguring deposits of new tissue sometimes form during the healing process. The excess collagen deposition has been attributed to a disturbance in the balance between collagen synthesis and collagen degradation. Including among scars are, for example, chronic tendinosis or scar tissue of the tendons, surgical adhesions, keloids, hypertrophic scars, and depressed scars.
i. Surgical adhesions Surgical adhesions are attachments of organs or tissues to each other through scar formation, which can cause severe clinical problems. The formation of some scar tissue after surgery or tissue injury is normal. In some cases, however, the scar tissue overgrows the region of injury and creates surgical adhesions, which tend to restrict the normal mobility and function of affected body parts. In particular, fibroblast proliferation and matrix synthesis is increased locally following such soft tissue injury. Adhesions then form when the body attempts to repair tissue by inducing a healing response. For example, this healing process can occur between two or more otherwise healthy separate structures (such as between loops of bowel following abdominal surgery). Alternately, following local trauma to a peripheral nerve, fibrous adhesions can form, resulting in severe pain during normal movement.
ii. Keloids Keloids are scars of connective tissue containing hyperplastic masses that occur in the dermis and adjacent subcutaneous tissue, most commonly following trauma. Keloids generally are fibrous nodules that can vary in color from pink or red to dark brown. Keloids form in scar tissue as a result of overgrowth of collagen, which participates in wound repair. Keloid lesions are formed when local skin fibroblasts undergo vigorous hyperplasia and proliferation in response to local stimuli.
The resulting lesion can result in a lump many times larger than the original scar. In addition to occur as a result of wound or other trauma, keloids also can form from piercing, pimples, a scratch, severe acne, chickenpox scarring, infection at a wound site, repeated trauma to an area, or excessive skin tension during wound closure.
iii. Hypertrophic scars Hypertrophic scars are raised scars that form at the site of wounds. They generally do not grow beyond the boundaries of the original wound. Like keloid scars, hypertrophic scars are a result of the body overproducing collagen.
iv. Depressed scars Depressed scars generally result from an inflammatory episode and are characterized by contractions of the skin, and leave a cosmetically displeasing and permanent scar. The most common example is scarring that occurs following inflammatory acne. The depression occurs as a normal consequence of wound healing, and the scar tissue causing the depression is predominantly made up of collagen resulting from fibroblast proliferation and metabolism.
g. Scleroderma Modified MMP polypeptides, for example tsMMPs, for example, a modified MMP-1 or a tsMMP-1 such as those described herein, can be used to treat scleroderma. Scleroderma is characterized by a thickening of the collagen. The more common form of the disease, localized scleroderma, affects only the skin, usually in just a few places, and sometimes the face. It is sometimes referred to as CREST
syndrome. Symptoms include hardening of the skin and associated scarring. The skin also appears reddish or scaly, and blood vessels can be more visible. In more serious cases, scleroderma can affect the blood vessels and internal organs.
Diffuse scleroderma can be fatal as a result of heart, kidney lung or intestinal damage, due to musculoskeletal, pulmonary, gastrointestinal, renal and other complications.
The condition is characterized by collagen buildup leading to loss of elasticity.
The overproduction of collagen has been attributed to autoimmune dysfunction, resulting in accumulation of T cells and production of cytokines and other proteins that stimulate collagen deposition from fibroblasts.
h. Lymphedema Modified MMP polypeptides, for example tsMMPs, for example, a modified MMP-1 or tsMMP-1 such as those described herein, can be used to treat lymphedema.
Lymphedema is an accumulation of lymphatic fluid that causes swelling in the arms and legs. Lymphedema can progress to include skin changes such as, for example, lymphostatic fibrosis, sclerosis and papillomas (benign skin tumors) and swelling.
Tissue changes associated with lymphedema include proliferation of connective tissue cells, such as fibroblasts, production of collagen fibers, an increase in fatty deposits and fibrotic changes. These changes occur first at the lower extremities, i.e.
the fingers and toes. Lymphedema can be identified based on the degree of enlargement of the extremities. For example, one method to assess lymphedema is based on identification of 2-cm or 3-cm difference between four comparative points of the involved and uninvolved extremities.
i. Collagenous colitis Modified MMP polypeptides, for example tsMMPs, such as a modified MMP-1 or a tsMMP-1 such as those described herein, can be used to treat collagenous colitis. Collagenous colitis was first described as chronic watery diarrhea (Lindstrom et al. (1976) Pathol. Eur., 11:87-89). Collagenous colitis is characterized by collagen deposition, likely resulting from an imbalance between collagen production by mucosal fibroblasts and collagen degradation. It results in secretory diarrhea. The incidence of collagenous colitis is similar to primary biliary cirrhosis. The disease has an annual incidence of 1.8 per 100,000 and a prevalence of 15.7 per 100,000, which is similar to primary biliary cirrhosis (12.8 per 100,000) and lower than ulcerative colitis (234 per 100,000), Crohn's disease (146 per 100,000) or celiac disease (5 per 100,000). In patients with chronic diarrhea, about 0.3 to 5% have collagenous colitis.
Collagenous colitis is an inflammatory disease resulting in increased production of cytokines and other agents that stimulate the proliferation of fibroblasts, resulting in increased collagen accumulation.

2. Spinal Pathologies As described herein, the modified MMPs provided herein can be used to treat diseases and conditions of the ECM or involving the ECM. These include spinal pathologies, typically referred to as herniated disc or bulging discs, that can be treated by administering an MMP provided herein and activating as described herein.
Herniated discs that can be treated include protruded and extruded discs. A
protruded disc is one that is intact but bulging. In an extruded disk, the fibrous wrapper has torn and nucleus pulposus (NP) has oozed out, but is still connected to the disk.
While the NP is not the cause of the herniation, the NP contributes to pressure on the nerves causing pain. The NP contains hyaluronic acid, chondrocytes, collagen fibrils, and proteoglycan aggrecans that have hyaluronic long chains which attract water.
Attached to each hyaluronic chain are side chains of chondroitin sulfate and keratan sulfate.
Herniated discs have been treated with chemonucleolytic drugs, such as chymopapain and a collagenase, typically by local introduction of the drug into the disc. A chemonucleolytic drug degrades one or more components of the NP, thereby relieving pressure. Chemonucleolysis is effective on protruded and extruded disks.
Chemonucleolysis has been used treat lumbar (lower) spine and cervical (upper spine) hernias. Hence, the MMPs provided herein can be used as chemonucleolytic drugs and administered, such as by injection, to the affected disc, under conditions that activate the MMP.
J. EXAMPLES
The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.
Example 1 Cloning and Expression of hMMP-1 A. Cloning and High-Throughput Expression of hMMP-1 Library In this example, a human matrix metalloprotease 1 (hMMP-1) library was created by cloning DNA encoding human MMP-1 into a plasmid followed by transformation and protein expression/isolation. The library was created by introducing mutations in a parent human MMP-1 DNA sequence having the sequence of nucleotides set forth in SEQ ID NO:706, which encodes the inactive zymogen proMMP-1 (set forth in SEQ ID NO:2), to generate single amino acid variants of MMP-1 across the catalytic domain and proline rich linker domain of the polypeptide.
The hMMP-1 library was designed to contain at least 15 amino acid variants at each of 178 amino acids positions within the catalytic domain (amino acids 81-242 of SEQ
ID NO:2) and the linker region (amino acids 243-258 of SEQ ID NO:2) of human MMP-1 (See Table 7, below).

Table 7: hMMP-1 Library Amino Amino Acid Substitutions SEQ ID NOS
Acid E; H; R; C; Q; T; S; G; M; W; I; V; L; 780-781, 783-784, 786, 787, F81 A; P 789-797 R; C; N; Q; T; Y; S; G; F; M; W; I; L;
V82 A; P 802-816 D; E; H; R; C; Q; T; Y; S; G; M; W; I; 817-819, 821-822, 824-825, A; P 826, 827-828, 830-832, 834-D; E; H; R; C; Q; Y; S; G; F; I; V; L; A; 836-838, 840-841, 843-847, K; R; C; N; Q; T; Y; S; G; F; M; V; L;
E85 A; P 857-867, 870-873 D; H; K; C; N; T; Y; S; F; M; W; I; V; 874, 876-877, 879-880, 882-G86 L; P 890, 892 E; H; R; C; Q; Y; S; G; F; M; I; V; L; 894-895, 897-899, 901-905, N87 A; P 907-911 D; E; H; K; R; C; Q; T; Y; G; W; I; V; 912-917, 919-921, 923, 926-P88 L; A 930 E; H; K; N; T; Y; S; G; F; M; W; V; L; 932-934, 936, 938-944, 946-R89 A; P 949 E; H; R; N; Q; T; S; G; F; M; I; V; L; A; 951-952, 954, 956-958, 960-D; H; R; C; N; T; Y; S; G; F; W; I; V; 969-970, 972-974, 976-980, E91 L; A 982-986 E; K; R; N; T; Y; S; G; F; W; I; V; L; 989, 991-992, 994-999, 1001-Q92 A; P 1006 D; E; K; R; N; S; G; F; M; W; I; V; L; 1007-1008, 1010-1011, 1013, T93 A; P 1016-1025 D; E; R; N; T; S; G; F; M; W; I; V; L; 1026-1027, 1029, 1031, 1033, H94 A; P 1035-1044 D; E; H; K; R; C; T; Y; S; G; W; I; V;
L95 A; P 3-8,11-14,17-21 Table 7: hMMP-1 Librar Amino Amino Acid Substitutions SEQ ID NOS
Acid E; H; R; C; N; Q; S; G; F; W; I; V; L; 1046-1047, 1049-1052, 1054-T96 A; P 1056, 1058-1063 D; E; H; K; R; N; Q; T; S; G; W; V; L; 1064-1068, 1070-1074, 1077, Y97 A; P 1079-1082 D; E; H; K; C; Y; S; G; F; M; W; V; L; 1083-1087,1091-1096,1098-R98 A; P 1101 E; H; R; C; N; Q; T; Y; S; G; F; W; V; 1103-1104,1106-1114,1116-199 L; A; P 1120 D; H; R; N; T; Y; S; G; F; M; W; I; V; 497-498, 500, 502, 504-513, E100 L; P 515 D; H; K; R; C; T; Y; S; F; M; W; V; L; 1121,1123-1126,1128-1130, N101 A; P 1132-1134, 1136-1139 D; E; K; R; C; N; Q; S; G; F; M; V; L; 1140-1141,1143-1147,1149-Y102 A; P 1152, 1155-1158 D; E; K; R; C; N; Q; Y; S; G; W; V; L; 516-517, 519-526, 529, 531-T103 A; P 534 D; E; H; R; C; Q; T; Y; S; G; F; M; V; 1159-1161, 1163-1164, 1166-P104 L; A 1172, 1175-1177 E; R; C; N; T; S; G; F; M; W; I; V; L;
D105 A; P 22, 25-27, 29, 31-40 D; H; R; C; N; T; Y; S; G; F; M; I; V; 1178,1180,1182-1184,1186-L106 A; P 1191, 1193-1196 D; K; R; C; T; Y; S; G; F; M; W; I; V;
P107 L; A 1197, 1200-1202, 1205-1215 E; K; C; N; T; Y; S; G; F; W; I; V; L; 1217,1219-1221,1223-1227, R108 A; P 1229-1234 D; E; H; R; N; Q; T; Y; S; G; M; W; I; 1235-1237, 1239, 1241-1246, A109 V; L; 1248-1252 H; R; C; Q; T; Y; S; G; F; M; I; V; L; 1255, 1257-1258, 1260-1266, D110 A; P 1268-1272 D; E; K; R; C; Q; T; Y; S; G; W; I; L; 1273-1274, 1276-1278, 1280-Vill A; P 1284, 1287-1291 H; K; R; C; Q; T; Y; S; G; F; M; W; I;
D112 V; L; A; P 1293-1296, 1298-1310 D; E; R; N; T; Y; S; G; F; M; W; V; L; 1311-1312,1314,1316,1318-H113 A; P 1324, 1326-1329 E; R; C; N; Q; T; S; G; F; M; W; I; V;
A114 L; P 1331,1334-1338,1340-1348 D; E; H; K; R; C; Q; T; S; G; F; W; V; 1349-1354, 1356-1357, 1359-1115 L; P 1361, 1363-1365, 1367 D; H; K; R; C; N; Q; S; G; F; M; I; L; 1368-1374,1377-1380,1382, E116 A; P 1384-1386 Table 7: hMMP-1 Library Amino Amino Acid Substitutions SEQ ID NOS
Acid D; E; H; R; N; Q; T; Y; S; G; F; W; L; 1387-1390, 1392-1398, 1400, K117 A; P 1403-1405 D; E; H; K; R; Q; T; S; G; F; W; I; V; 1406-1410,1413-1414,1416-A118 L; P 1418, 1420-1424 E; H; K; R; C; N; T; Y; S; G; W; V; L; 1426-1431, 1433-1436, 1438, F119 A; P 1440-1443 D; E; H; K; R; C; N; T; Y; G; M; W; V; 1444-1452, 1454, 1456-1457, Q120 A; P 1459, 1461-1462 E; H; K; R; C; N; Q; T; S; G; F; I; V; A; 1464-1471, 1473-1475, 1478-E; H; K; R; N; Q; T; Y; S; G; F; V; L; 1483-1486,1488-1494,1497-W122 A; P 1500 D; H; K; R; C; N; Q; T; Y; G; F; M; W;
S123 I; V; L; A; P 1501,1503-1519 D; K; R; C; T; S; G; F; M; W; I; V; L; 1520, 1523-1525, 1527, 1529-N124 A; P 1538 D; E; H; R; C; Q; T; Y; S; G; F; M; W; 1539-1541, 1543-1544, 1546-V125 A; P 1553, 1556-1557 E; H; K; R; N; Q; S; G; F; M; W; V; L; 1559-1562, 1564-1565, 1567-T126 A; P 1571, 1573-1576 E; H; K; R; C; Q; T; S; F; M; W; I; V; 1578-1582,1584-1585,1587, P127 L; A 1589-1595 D; K; R; C; Q; T; S; G; F; M; W; I; V; 1596, 1599-1601, 1603-1604, L128 A; P 1606-1614 E; H; K; R; C; Y; S; G; F; M; I; V; L; 1616-1620, 1623-1627, 1629-T129 A; P 1633 E; H; K; R; C; N; T; Y; S; G; I; V; L; A; 1635-1640, 1642-1645, 1648-D; E; H; R; C; Q; Y; S; G; F; M; I; L; 1653-1655, 1657-1658, 1660-T131 A; P 1665, 1667, 1669-1671 D; E; H; R; T; Y; S; G; F; M; I; V; L; A; 1672-1675, 1679-1684, 1686-D; E; H; K; R; C; N; T; S; G; M; W; L; 1691-1697, 1699, 1701-1702, V133 A; P 1704-1705, 1707-1709 D; E; H; K; R; C; N; Q; T; Y; G; V; L;
S134 A; P 1710-1720, 1725-1728 D; H; R; N; Q; T; S; F; M; W; I; V; L; 1729-1730, 1732, 1734-1736, E135 A; P 1738, 1740-1747 D; E; H; R; C; N; T; S; M; W; I; V; L; 1748-1750, 1752-1754, 1756, G136 A; P 1758, 1760-1766 E; H; K; R; C; N; T; Y; S; G; F; W; L;
Q137 A; P 1768-1778,1780,1783-1785 Table 7: hMMP-1 Library Amino Amino Acid Substitutions SEQ ID NOS
Acid D; E; H; R; C; Q; T; S; G; M; W; I; V; 1786-1788,1790-1791,1793-A138 L; P 1794, 1796-1797, 1799-1804 E; H; R; C; N; Y; S; G; F; M; W; I; V; 1805-1806,1808-1810,1813-D139 L;A;P 1823 D; E; H; K; R; C; T; Y; G; F; M; W; V; 1824-1829,1832-1833,1835-1140 L; A 1841 D; E; H; R; C; N; T; Y; S; G; W; I; L; 1843-1845,1847-1849,1851-M141 A; P 1854,1856-1857,1859-1861 K; R; N; Q; T; Y; S; G; F; M; W; V; L;
1142 A; P 1865-1866, 1868-1880 E; H; R; C; N; Q; T; Y; G; M; W; I; L; 1882-1883,1885-1891,1893-S143 A; P 1895, 1897-1899 E; H; K; R; C; N; Q; T; S; G; M; W; V; 1901-1908,1910-1913,1915-F144 L; P 1916, 1918 D; E; H; K; R; C; N; Q; T; S; G; W; L; 1919-1927, 1929-1930, 1933, V145 A; P 1935-1937 D; E; H; K; C; N; Q; T; Y; S; F; V; L;
R146 A; P 1938-1947, 1949, 1953-1956 E; H; R; C; Q; T; S; F; M; W; I; V; L; 1958-1959, 1961-1962, 1964-G147 A; P 1965, 1967-1975 E; K; R; C; N; T; S; G; M; W; I; V; L; 1976,1978-1981,1983,1985-D148 A; P 1986, 1988-1994 E; R; C; N; Q; T; Y; S; G; W; I; V; L;
H149 A; P 1996, 1998-2005, 2008-2013 D; E; H; K; N; T; S; G; M; W; I; V; L;
R150 A; P 41-44, 46, 48, 50-51, 53-59 K; R; N; Q; T; Y; S; G; F; M; W; V; L;
D151 A; P 62-63, 65-73, 75-78 D; H; K; R; C; T; Y; S; G; F; W; I; L; 2014, 2016-2019, 2021-2025, N152 A; P 2027-2028, 2030-2032 D; H; K; R; C; Q; T; Y; G; F; I; V; L; 535, 537-540, 542-546, 549-S153 A;P 553 H; K; R; C; N; Q; T; Y; S; F; W; I; V;
P154 L; A 2035-2043, 2045, 2047-2051 E; H; R; N; Q; T; Y; S; G; M; W; V; L;
F155 A; P 80-81, 83,85-92,94-97 E; H; K; R; C; T; Y; S; G; M; W; V; L; 98-102, 105-108, 110-111, D156 A; P 113-116 D; H; K; R; N; Q; T; Y; S; F; M; V; L; 2052, 2054-2056, 2059-2065, G157 A; P 2068-2071 D; K; R; C; N; Q; T; Y; S; G; F; W; I;
P158 V; L; A 2072, 2075-2084, 2086-2090 Table 7: hMMP-1 Library Amino Amino Acid Substitutions SEQ ID NOS
Acid E; K; R; C; Q; T; Y; S; M; W; I; V; L; 118,120-122,124-127,129-G159 A; P 135 E; H; R; C; N; Q; T; S; M; W; I; V; L; 2092-2093, 2095-2099, 2101, G160 A; P 2103-2109 E; H; R; C; Q; T; Y; S; G; F; W; I; V; L; 2111-2112, 2114-2121, 2123-N161 P 2126, 2128 D; E; R; C; Q; T; Y; S; G; F; M; W; I; 2129-2130, 2133-2134, 2136-L162 A; P 2144, 2146-2147 E; K; R; C; N; Q; T; Y; S; G; F; I; V; L;
A163 P 2149, 2151-2160, 2163-2166 E; K; R; C; N; Q; Y; S; G; F; M; V; L; 2168-2173, 2175-2179, 2182-H164 A; P 2185 D; H; K; R; N; Q; T; S; G; F; M; W; V; 2186, 2188-2190, 2192-2194, A165 L; P 2196-2200, 2202-2204 E; H; K; R; C; N; S; G; M; W; I; V; L;
F166 A; P 2206-2211, 2215-2223 D; E; K; R; N; T; Y; S; G; F; M; V; L; 2224-2225, 2227-2228, 2230-Q167 A; P 2236, 2239-2242 D; H; R; C; N; T; S; G; F; M; W; I; V; 2243, 2245, 2247-2249, 2251, P168 L; A 2253-2261 D; E; H; R; C; Q; T; S; M; W; I; V; L; 2262-2264, 2266-2267, 2269-G169 A; P 2270, 2272, 2274-2280 D; H; K; R; C; Q; T; S; G; F; M; W; I; 2281, 2283-2286, 2288-2289, P170 L; A 2291-2296, 2298-2299 D; E; H; K; R; C; N; Q; Y; S; M; W; L; 554-561, 563-564, 566-567, G171 A; P 570-572 D; E; R; C; N; Q; T; Y; G; M; W; V; L; 2300-2301, 2304-2309, 2311, 1172 A;P 2313-2318 D; K; R; C; N; T; Y; S; F; M; W; V; L; 2319, 2322-2325, 2327-2332, G173 A; P 2334-2337 D; E; H; R; N; T; Y; S; F; M; W; V; L; 2338-2340, 2342, 2344, 2346-G174 A; P 2351, 2353-2356 E; H; R; C; N; Q; T; Y; S; G; F; I; V; L; 2357-2358, 2360-2368, 2371-D175 A; P 2375 D; E; K; R; C; N; Q; T; S; G; F; W; V; 136-137,139-144,146-148, A176 L; P 150, 152-154 D; R; C; N; Q; T; Y; S; G; W; I; V; L;
H177 A; P 2376, 2379-2386, 2389-2394 E; H; K; R; C; Q; T; Y; S; G; W; I; V; 2396-2400, 2402-2406, 2408-F178 L;A;P 2413 E; K; R; C; N; Q; T; S; G; W; I; V; L; 155,157-162,164-165,168-D179 A; P 173 Table 7: hMMP-1 Library Amino Amino Acid Substitutions SEQ ID NOS
Acid D; K; R; C; N; Q; T; Y; S; G; F; M; I;
E180 A; P 174,176-186,188,191-192 E; K; R; C; Q; T; Y; S; G; F; M; V; L; 193, 195-197, 199-205, 208-D181 A; P 211 D; R; C; Q; T; Y; S; G; F; M; W; I; L; 212,215-216,218-226,228-E182 A; P 230 E; H; K; C; N; T; S; G; M; W; I; V; L; 2415-2419, 2421, 2423-2424, R183 A; P 2426-2432 E; H; R; N; Q; T; S; G; F; M; I; V; L; A; 2434-2435, 2437, 2439-2441, D; E; H; R; C; N; Q; Y; S; G; W; V; L; 231-233, 235-241, 244, 246-T185 A; P 249 D; E; H; R; C; Q; T; Y; S; G; F; V; L; 2452-2454, 2456-2463, 2467-N186 A; P 2470 D; H; K; R; C; T; S; G; F; M; W; I; L; 250, 252-255, 257, 259-264, N187 A; P 266-268 D; E; H; K; R; N; Q; S; G; W; I; V; L; 2471-2475, 2477-2478, 2481-F188 A; P 2482, 2484-2489 D; E; H; K; C; N; Q; T; Y; G; W; V; L; 2490-2498, 2500, 2503, 2505-R189 A; P 2508 D; H; K; R; C; T; Y; S; G; M; I; V; L; 573-577, 580-583, 585, 587-E190 A; P 591 D; E; H; K; R; C; Q; T; S; G; W; V; L; 592-597, 599-602, 605, 607-Y191 A; P 610 D; H; K; R; C; Q; T; S; G; M; W; V; L; 611, 613-618, 620-621, 623-N192 A; P 624, 626-629 D; E; K; R; N; Q; T; Y; S; G; F; W; I; 2509-2510, 2512-2513, 2515-L193 A; P 2521, 2523-2524, 2526-2527 E; K; Q; T; Y; S; G; F; M; W; I; V; L;
H194 A; P 631-632, 636-648 D; E; K; C; Q; T; Y; S; G; F; W; V; L; 269-270, 272-273, 275-280, R195 A; P 282, 284-287 D; E; H; K; R; Q; T; Y; S; G; M; I; L; 2528-2532, 2535-2539, 2541, V196 A; P 2543-2546 E; H; R; C; N; Q; T; Y; S; G; W; I; V; 2548-2549, 2551-2558, 2561-A197 L; P 2565 D; E; H; K; R; T; Y; S; G; F; M; W; V;
A198 L; P 288-292, 296-302, 304-306 E; K; R; C; N; T; S; G; M; W; I; V; L; 2567-2571, 2573, 2575-2576, H199 A; P 2578-2584 D; R; C; N; T; Y; S; G; F; M; W; I; V; 2585, 2588-2590, 2592-2600, E200 A; P 2602-2603 Table 7: hMMP-1 Library Amino Amino Acid Substitutions SEQ ID NOS
Acid D; E; K; R; N; Q; T; S; G; M; W; I; V; 2604-2605, 2607-2608, 2610-L201 A; P 2612, 2614-2615, 2617-2622 D; E; H; K; R; C; T; Y; S; M; I; V; L; 2623-2628, 2631-2633, 2635, G202 A; P 2637-2641 D; E; R; C; N; Q; T; Y; S; G; I; V; L; A; 2642-2643, 2645-2652, 2656-D; H; K; R; N; Q; T; Y; G; W; I; V; L; 2661, 2663-2665, 2667-2671, S204 A; P 2674-2679 D; E; R; C; N; Q; T; S; G; M; W; I; V; 2680-2681-2684-2688, 2690-L205 A; P 2691, 2693-2698 D; E; H; R; C; Q; T; S; M; W; I; V; L; 307-309, 311-312, 314-315, G206 A; P 317, 319-325 D; H; K; R; N; Q; Y; S; G; M; W; I; V; 649, 651-653, 655-656, 658-L207 A; P 660, 662-667 D; E; K; R; C; N; Q; T; G; F; W; V; L; 2669-2700, 2702-2707, 2709-S208 A; P 2710, 2712, 2714-2717 D; R; C; N; Q; T; Y; S; G; F; W; V; L; 2718, 2721-2729, 2731, 2733-H209 A; P 2736 H; K; R; C; N; Q; T; G; F; W; I; V; L;
S210 A; P 328-334, 336-337, 339-344 D; H; K; R; N; Q; S; G; F; M; W; V; L; 2737, 2739-2741, 2743-2744, T211 A; P 2746-2750, 2752-2755 E; H; K; R; N; Q; T; Y; S; G; F; V; L;
D212 A; P 668-671, 673-679, 683-686 D; E; H; K; R; C; N; Q; T; S; G; F; M; 2756-2764, 2766-2769, 2771-I213 V; L; A; P 2774 D; E; R; C; Q; T; Y; S; F; M; I; V; L; A; 2775-2776, 2779-2780, 2782-G214 P 2787, 2789-2793 D; H; K; R; C; N; Q; T; S; G; M; W; I; 2794, 2796-2802, 2804-2805, A215 V; L; P 2807-2812 D; E; K; R; C; Q; T; S; G; M; W; I; V; 2813-2814, 2816-2818, 2820-L216 A; P 2821, 2823-2824, 2826-2831 D; H; K; R; C; N; Q; T; Y; S; G; I; L; 2832, 2834-2843, 2846, 2848-M217 A; P 2850 D; E; R; C; N; Q; S; G; F; W; I; V; L; 345-346, 349-352, 354-356, Y218 A; P 358-363 D; E; H; K; R; C; Q; T; S; G; F; W; V; 2851-2856, 2858-2859, 2861-P219 L; A 2863, 2865, 2867-2869 E; H; K; R; N; Q; T; G; F; M; I; V; L; 2871-2874, 2876-2878, 2880-S220 A; P 2882, 2884-2888 E; K; R; C; N; Q; T; S; G; M; W; V; L; 2890, 2892-2899, 2901-2902, Y221 A; P 2904-2907 Table 7: hMMP-1 Library Amino Amino Acid Substitutions SEQ ID NOS
Acid D; H; R; C; N; Y; S; G; F; M; W; I; V; 2908,2910,2912-2914,2916-T222 L; A; P 2926 E; H; K; R; C; N; Q; T; Y; S; G; M; L;
F223 A; P 365-376, 380-382 D; H; K; R; C; Q; T; G; M; W; I; V; L; 2927,2929-2932,2934-2935, S224 A; P 2937, 2939-2945 D; E; H; K; R; C; N; Q; T; S; M; W; V; 2946-2954, 2956, 2958-2959, G225 A; P 2961, 2963-2964 E; H; R; C; N; T; S; G; M; W; I; V; L; 2965-2966, 2968-2970, 2972, D226 A; P 2974-2975, 2977-2983 D; E; H; K; R; C; Q; T; Y; S; G; W; L; 383-388, 390-394, 397, 399-V227 A; P 401 D; E; H; K; R; N; T; Y; S; G; M; W; L; 402-406, 408-412, 414-415, Q228 A; P 418-420 D; E; H; R; C; Q; T; Y; G; M; W; I; V; 421-423, 425-426, 428-430, L229 A; P 432, 434-439 D; H; R; C; N; T; Y; S; G; M; W; I; V; 687, 689, 691-693, 695-698, A230 L; P 700-705 D; H; R; C; Y; S; G; F; M; W; I; V; L; 2984, 2986, 2988-2989, 2992-Q231 A; P 3002 E; H; K; R; N; Q; T; Y; S; G; F; W; V; 3003-3006, 3008-3014, 3016, D232 L; P 3018-3019, 3021 E; K; R; N; Q; T; S; G; M; W; I; V; L; 440, 442-443, 445-447, 449-D233 A; P 450, 452-458 D; E; H; C; N; Q; T; Y; G; M; W; V; L; 459-461, 464-468, 470, 472-1234 A; P 477 E; H; R; C; N; Q; T; Y; S; G; I; V; L; A; 3022-3023, 3025-3032, 3036-D; E; K; R; C; N; T; Y; S; F; M; I; V; L; 3041-3042, 3044-3047, 3049-G236 P 3053, 3055-3057, 3059 D; E; K; R; C; N; Q; T; Y; S; G; W; L; 3060-3061, 3063-3071, 3074, 1237 A; P 3076-3078 E; H; K; R; C; N; T; Y; S; G; F; W; I; L; 3080-3090, 3092-3093, 3095, D; H; K; R; C; Q; T; Y; S; G; F; W; I; 3099, 3100-3103, 3105-3110, A239 V; L; P 3112-3116 D; K; R; C; Q; T; Y; S; G; F; M; V; L; 478, 481-483, 485-491, 493-1240 A; P 496 D; H; R; N; Q; T; S; G; M; W; I; V; L; 3117, 3119, 3121, 3123-3127, Y241 A; P 3129-3135 E; H; K; R; N; T; Y; S; F; W; I; V; L; 3137-3140, 3142, 3144-3147, G242 A; P 3149-3154 Table 7: hMMP-1 Library Amino Amino Acid Substitutions SEQ ID NOS
Acid D; H; K; C; N; Q; T; Y; S; G; I; V; L;
R243 A; P 3155, 3157-3165, 3169-3173 D; E; H; R; Q; T; Y; G; F; M; W; V; L; 3174-3176, 3178, 3181-3187, S244 A; P 3189-3192 E; H; K; R; C; T; S; G; F; M; W; I; V; 3194-3198, 3200, 3202-3209, Q245 L; P 3211 D; K; R; C; Q; T; Y; S; G; F; W; I; V;
N246 L; A; P 3212, 3215-3223, 3225-3230 D; E; H; K; R; N; Q; T; S; G; F; I; V; L; 3231-3235, 3237-3239, 3241-P247 A 3243, 3246-3249 E; H; K; R; C; Q; T; Y; S; G; F; M; W;
V248 I; L; A 3251-3255, 3257-3267 E; H; K; R; C; N; T; Y; G; W; I; V; L;
Q249 A; P 3270-3277, 3279, 3282-3287 D; K; R; N; Q; T; Y; S; G; F; M; W; V; 3288, 3291-3292, 3294-3302, P250 L; A 3304-3306 D; E; K; R; C; Q; T; Y; S; G; W; V; L; 3307-3308, 3310-3312, 3314-1251 A; P 3318, 3321-3325 D; E; H; K; R; C; T; S; F; M; W; I; V;
G252 L; A; P 3326-3331, 3334, 3336-3344 E; K; R; C; N; Q; T; Y; G; M; W; I; V; 3346, 3348-3354, 3356, 3358-P253 L; A 3363 D; E; R; C; T; Y; S; G; F; W; I; V; L; A; 3364-3365, 3368-3369, 3371-Q254 P 3375, 3377-3382 E; H; K; R; C; N; Q; S; G; F; I; V; L; A; 3384-3390, 3392-3394, 3397-E; K; R; C; N; Q; Y; S; G; F; M; I; V; 3403, 3405-3409, 3411-3415, P256 L; A 3417-3420 E; R; C; N; T; S; G; F; M; W; I; V; L; 3422, 3424-3426, 3428, 3430-K257 A; P 3439 D; E; R; N; Q; T; Y; G; F; M; W; I; V; 3440-3441, 3444, 3446-3449, A258 L; P 3451-3458 The cDNA encoding each individual hMMP-1 mutant was generated by changing the wildtype codon, encoding each of the 178 amino acids positions identified in Table 8 below, to a codon encoding the desired amino acid substitution.
The wildtype codons are set forth in SEQ ID NO:706. SEQ ID NO:706 also depicts the encoded amino acids. The amino acids substitutions and corresponding mutated codons are listed in Table 8, below.

Table 8. Codons encoding each amino acid substitution Mutation Codon Mutation Codon Mutation Codon Mutation Codon Table 8. Codons encoding each amino acid substitution Mutation Codon Mutation Codon Mutation Codon Mutation Codon Table 8. Codons encoding each amino acid substitution Mutation Codon Mutation Codon Mutation Codon Mutation Codon Table 8. Codons encoding each amino acid substitution Mutation Codon Mutation Codon Mutation Codon Mutation Codon R108F TTT Vi11I ATT A114W TGG A118R CGT

Table 8. Codons encoding each amino acid substitution Mutation Codon Mutation Codon Mutation Codon Mutation Codon Table 8. Codons encoding each amino acid substitution Mutation Codon Mutation Codon Mutation Codon Mutation Codon Table 8. Codons encoding each amino acid substitution Mutation Codon Mutation Codon Mutation Codon Mutation Codon Table 8. Codons encoding each amino acid substitution Mutation Codon Mutation Codon Mutation Codon Mutation Codon Table 8. Codons encoding each amino acid substitution Mutation Codon Mutation Codon Mutation Codon Mutation Codon Table 8. Codons encoding each amino acid substitution Mutation Codon Mutation Codon Mutation Codon Mutation Codon Table 8. Codons encoding each amino acid substitution Mutation Codon Mutation Codon Mutation Codon Mutation Codon Table 8. Codons encoding each amino acid substitution Mutation Codon Mutation Codon Mutation Codon Mutation Codon Table 8. Codons encoding each amino acid substitution Mutation Codon Mutation Codon Mutation Codon Mutation Codon Table 8. Codons encoding each amino acid substitution Mutation Codon Mutation Codon Mutation Codon Mutation Codon Table 8. Codons encoding each amino acid substitution Mutation Codon Mutation Codon Mutation Codon Mutation Codon Table 8. Codons encoding each amino acid substitution Mutation Codon Mutation Codon Mutation Codon Mutation Codon Table 8. Codons encoding each amino acid substitution Mutation Codon Mutation Codon Mutation Codon Mutation Codon 1. Expression The DNA encoding each individual library member was generated according to standard DNA synthesis protocols and protein was expressed using routine molecular biology techniques. Briefly, the DNA was ligated into vector pET303CTHis (Invitrogen, SEQ ID NO:3466) using routine molecular biology techniques. Plasmid containing one individual hMMP-1 mutant was transformed into BL21 (DE3) E.coli cells (Tigen, Beiging, China) using manufacturers recommendations. The process was repeated for all library members. The transformation culture was used to inoculate 1 mL LB medium containing ampicillin additives. The culture was grown at 37 C with shaking for 16 hours. Protein expression was induced by the addition of 1 mM isopropyl-P-D-thiogalactoside (IPTG) and the culture was incubated at 25 C with shaking. After 6 hours, the cells were pelleted by centrifugation at 6,000g for 10 minutes and the supernatant was removed. The periplasmic protein was enriched by incubating the cells in 50 gl OS
buffer (200 mM Tris-HC1, pH 7.5, 20% sucrose, 1 mM EDTA) with 4 l DNAse (10 g/ml), 4 l RNAse (10 gg/ml), and 4 gl lysozyme (10 g/ml) for 10 minutes at C. 50 l of water was added to each well followed by centrifugation at 6000 g for 10 minutes to remove cell debris. The supernatant, containing the hMMP-1 protein, was stored at -20 C. Activity of supernatants were screened as described in the following examples.

B. Cloning and Expression of wildtype hMMP-1 In this example, wildtype hMMP-1 was individually expressed in both E. coli and CHO-S cells.
1. Expression in E. coli Wildtype hMMP-1 (clone BAP006_10, having a sequence of nucleotides set forth as nucleotides in SEQ ID NO:706 and containing a pel B signal sequence set forth in SEQ ID NO:3547) was cloned into vector pET303CTHis (Invitrogen, SEQ
ID

NO:3466) and grown in BL21(DE3) E. coli. The pET303CTHis vector contained a C-terminal His tag (SEQ ID NO:3465). Protein expression was induced upon the addition of 1 mM isopropyl-(3-D-thiogalactoside (IPTG) as described above.
Following expression, the protein was enriched as described in Example IA, and subsequently purified using a HiTrap Ni2+ column (GE Healthcare) according to standard molecular biology protocols. Expression and purification were monitored by SDS/PAGE and Western blot analysis.
2. Expression in CHO-S cells Wildtype hMMP-1 (clone BAP006_2, having a sequence of nucleotides set forth as nucleotides 72-1478 in SEQ ID NO:708 and a sequence encoding a C-terminal His tag) was expressed in CHO-S cells and secreted into the medium.
Transfected cells were cultured at 37 C in CD-CHO serum free media (Invitrogen).
The wildtype hMMP-1 protein was purified using a HiTrap Ni2+ column (GE
Healthcare) according to standard molecular biology protocols Example 2 Determination of Enzymatic Activity of the hMMP-1 Mutants using a fluorogenic peptide substrate In this example, the hMMP-1 mutant library, generated in Example 1, was screened using a high throughput fluorescence activity assay to identify temperature sensitive hMMP-1 mutants. To screen for temporally sensitive hMMP-1 mutants, the enzymatic activity of each individual mutant was determined at 25 C and 37 C
and/or 34 C, using a commercially available fluorogenic substrate, peptide IX, designated as Mca-K-P-L-G-L-Dpa-A-R-NH2 (SEQ ID NO:707; Mca=(7-Methoxycoumarin-4-yl)acetyl; Dpa=N-3-(2,4,-Dinitrophenyl)-L-2,3-diaminopropionyl; R&D Systems, Minneapolis, MN, Cat# ESO10). The peptide substrate contains a highly fluorescent 7-methoxycoumarin group that is quenched by resonance energy transfer to the 2,4-dinitrophenyl group. Activated hMMP-1 cleaves the amide bond between glycine and leucine resulting in an increase in released fluorescence. Reactions were initially performed in a 96-well assay and confirmed using a 14 ml tube format.

A. 96-well assay Prior to assessing activity of the supernatants, supernatants were treated with a processing agent to activate the inactive zymogen form into an active enzyme.
Briefly, 4p1 of each hMMP-1 mutant supernatant generated in Example 1 was added to 100 gl of TCNB (50 nM Tris, 10 mM CaC12, 150 mM NaCl, 0.05% Brij 35, pH
7.5) with 1 mM of the processing agent p-aminophenylmercuric acetate (APMA) in a 96-well plate. The solution was incubated at the reaction temperature (either 25 C or 37 C) for 2 hours. This activation step cleaves the pro-peptide and generates mature hMMP-1.
Following activation, 1.6 l of TCNB containing 620gM Mca-K-P-L-G-L-Dpa-A-R-NH2 fluorescent substrate was added to each well to a final concentration of 10 M, at the indicated reaction temperature (either 25 C or 37 C) for 1 hour.
Fluorescence was detected by measuring fluorescence in a fluorescent plate reader at 320 nm exitation/405 nm emission. Relative fluorescence units (RFU) were determined. Supernatant from wildtype hMMP-1 and plasmid/vector transformed cells were used as positive and negative controls. Duplicate reactions were performed for each sample, reaction temperature, and positive and negative control.
The results of the initial screen of 2687 hMMP-1 mutants are shown in Table 9. The initial screen resulted in the identification of 199 putative primary hits (see Table 10) with reduced activity at 37 C as compared to the activity at 25 C.

Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
C 37 C 37 C Mut/wt Mut/wt Down F81C 784 1740.62 3123.63 0.56 0.35 0.46 Down F81E 780 871.51 1243.66 0.70 0.18 0.18 Down F811 793 4100.22 5376.62 0.76 0.83 0.79 Neutral F81 L 795 8890.68 7913.44 1.12 1.57 1.51 Neutral F81P 797 1102.23 1043.87 1.06 0.19 0.20 Neutral F81S 789 2527.30 2312.47 1.09 0.45 0.44 Neutral F81A 796 8780.53 7784.51 1.13 1.55 1.48 Neutral F81M 791 2545.25 3095.21 0.82 0.45 0.59 Neutral F81 G 790 8979.05 7773.71 1.16 1.59 1.48 Neutral F81T 787 1564.49 1373.60 1.14 0.28 0.26 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral F81 Q 786 9225.28 7923.69 1.16 1.63 1.51 Neutral F81R 783 8514.40 7454.74 1.14 1.50 1.42 Neutral F81W 792 6078.70 5909.04 1.03 1.07 1.12 Neutral F81H 781 8126.15 7360.21 1.10 1.44 1.40 Neutral F81 V 794 7263.15 6614.17 1.10 1.28 1.26 Neutral V821 813 535.78 548.02 0.98 0.06 0.06 Down V82C 803 4177.57 6476.29 0.65 0.50 0.72 Neutral V82A 815 9540.61 9240.92 1.03 1.14 1.03 Neutral V82P 816 599.23 634.69 0.94 0.07 0.07 Down V82Y 807 3295.59 6173.45 0.53 0.39 0.69 Down V82M 811 6824.39 8606.64 0.79 0.82 0.96 Neutral V82Q 805 581.51 652.74 0.89 0.07 0.07 Neutral V82F 810 7233.54 8739.45 0.83 0.87 0.98 Down V82W 812 6194.12 8397.19 0.74 0.74 0.94 Neutral V82N 804 9421.72 8759.51 1.08 1.13 0.98 Down V82R 802 603.22 781.77 0.77 0.07 0.09 Neutral V82G 809 8298.42 8911.04 0.93 0.99 0.99 Neutral V82S 808 8293.03 9022.13 0.92 0.99 1.01 Down V82L 814 6951.75 8694.05 0.80 0.83 0.97 Neutral V82T 806 7993.81 8975.05 0.89 0.96 1.00 Neutral L83A 834 8629.03 9023.51 0.96 1.03 1.01 Neutral L83C 822 554.26 567.87 0.98 0.07 0.06 Neutral L83D 817 8705.34 8957.38 0.97 1.04 1.00 Neutral L83E 818 9212.48 9265.02 0.99 1.10 1.03 Neutral L83G 828 7713.92 9073.74 0.85 0.92 1.01 Neutral L83H 819 6449.24 7800.76 0.83 0.77 0.87 Down L831 832 4575.76 6963.24 0.66 0.55 0.78 Down L83M 830 5921.65 8064.61 0.73 0.71 0.90 Neutral L83P 835 7794.15 8608.36 0.91 0.93 0.96 Neutral L83Q 824 7291.24 8673.39 0.84 0.87 0.97 Neutral L83R 821 8509.58 8988.62 0.95 1.02 1.00 Neutral L83 S 827 9261.79 9205.93 1.01 1.11 1.03 Neutral L83T 825 7549.73 8580.54 0.88 0.90 0.96 Down L83W 831 4193.18 6044.52 0.69 0.50 0.67 Neutral L83Y 826 7968.79 9051.39 0.88 0.95 1.01 Down T84V 851 3169.35 4931.29 0.64 0.64 0.72 Down T84E 837 498.18 627.84 0.79 0.10 0.09 Neutral T84H 838 7046.83 6974.20 1.01 1.24 1.33 Neutral T84L 852 7687.84 6946.59 1.11 1.36 1.32 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral T84D 836 7972.32 7331.43 1.09 1.41 1.39 Neutral T84R 840 7298.49 6880.17 1.06 1.29 1.31 Neutral T841 850 6508.69 5860.75 1.11 1.15 1.11 Neutral T84S 845 6073.28 5981.85 1.02 1.07 1.14 Neutral T84G 846 8087.79 7200.99 1.12 1.43 1.37 Neutral T84Q 843 6275.12 6690.38 0.94 1.11 1.27 Neutral T84P 854 3528.37 3832.34 0.92 0.62 0.73 Neutral T84A 853 8718.27 7840.72 1.11 1.54 1.49 Neutral T84C 841 5177.89 5107.57 1.01 0.91 0.97 Neutral T84Y 844 4768.51 4818.30 0.99 0.84 0.92 Neutral T84F 847 6312.72 6453.46 0.98 1.10 1.27 Down E85L 871 1633.29 2148.43 0.76 0.33 0.31 Down E85Q 861 2834.50 4068.60 0.70 0.57 0.59 Neutral E85P 873 2855.52 3389.51 0.84 0.58 0.50 Neutral E85T 862 401.26 382.58 1.05 0.08 0.06 Down E85K 857 2293.84 3049.87 0.75 0.46 0.45 Down E85M 867 2158.30 2821.39 0.76 0.44 0.41 Neutral E85G 865 1767.69 1734.31 1.02 0.31 0.33 Down E85R 858 912.46 7286.41 0.13 0.16 1.39 Neutral E85S 864 7811.54 7488.09 1.04 1.38 1.42 Neutral E85C 859 6027.10 5938.05 1.01 1.06 1.13 Neutral E85Y 863 4449.33 3909.71 1.14 0.79 0.74 Neutral E85A 872 5552.19 5461.08 1.02 0.98 1.04 Down E85N 860 522.81 7634.45 0.07 0.09 1.45 Neutral E85V 870 7152.74 7011.60 1.02 1.26 1.33 Neutral E85F 866 6092.47 6362.37 0.96 1.06 1.26 Down G86L 890 2452.10 3232.22 0.76 0.50 0.47 Down G86P 892 2117.46 5219.90 0.41 0.43 0.76 Neutral G861 888 1888.26 2293.71 0.82 0.38 0.34 Neutral G86T 882 363.85 380.61 0.96 0.07 0.06 Neutral G86H 876 389.15 372.78 1.04 0.08 0.05 Neutral G86D 874 415.45 406.81 1.02 0.08 0.06 Down G86N 880 2612.85 3755.02 0.70 0.53 0.55 Neutral G86S 884 8500.13 7717.19 1.10 1.50 1.47 Neutral G86K 877 1660.95 2002.39 0.83 0.29 0.38 Neutral G86W 887 1570.85 1690.05 0.93 0.28 0.32 Neutral G86Y 883 1829.24 2126.68 0.86 0.32 0.40 Neutral G86V 889 1830.80 2092.69 0.87 0.32 0.40 Neutral G86C 879 1784.05 2091.03 0.85 0.32 0.40 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral G86M 886 1687.28 2025.99 0.83 0.30 0.39 Up G86F 885 1897.87 1483.82 1.28 0.34 0.28 Neutral N87M 905 418.35 412.23 1.01 0.08 0.06 Down N87L 909 3385.42 4941.20 0.69 0.69 0.72 Neutral N87P 911 8762.48 8941.20 0.98 1.55 1.70 Neutral N87V 908 6199.21 7269.38 0.85 1.09 1.38 Neutral N87R 897 7761.00 8810.25 0.88 1.37 1.68 Up N87F 904 6882.19 4428.08 1.55 1.22 0.84 Down N87S 902 2083.05 3304.46 0.63 0.37 0.63 Neutral N871 907 7572.66 8090.13 0.94 1.34 1.54 Neutral N87C 898 3291.22 3945.40 0.83 0.58 0.75 Down N87A 910 5482.33 6869.11 0.80 0.97 1.31 Neutral N87G 903 8060.01 8916.11 0.90 1.42 1.70 Down N87Y 901 4397.56 5611.87 0.78 0.78 1.07 Up N87E 894 5876.33 4763.86 1.23 1.04 0.91 Down N87H 895 5013.05 7306.33 0.69 0.89 1.39 Neutral N87Q 899 8559.37 9021.72 0.95 1.51 1.72 Down P88C 917 1255.12 2197.65 0.57 0.15 0.25 Neutral P88K 915 6857.61 8492.90 0.81 0.82 0.95 Down P88W 926 664.95 845.70 0.79 0.08 0.09 Down P88G 923 1694.96 3159.20 0.54 0.20 0.35 Down P88L 929 2562.59 3576.95 0.72 0.31 0.40 Down P88Q 919 4499.52 7270.91 0.62 0.54 0.81 Neutral P88A 930 6549.92 8130.83 0.81 0.78 0.91 Neutral P88T 920 6576.99 8126.45 0.81 0.79 0.91 Down P88Y 921 5515.19 7868.29 0.70 0.66 0.88 Down P88R 916 4209.25 6681.38 0.63 0.50 0.75 Down P88H 914 2580.97 4465.31 0.58 0.31 0.50 Down P881 927 841.81 1249.17 0.67 0.10 0.14 Neutral P88V 928 1666.69 1915.49 0.87 0.20 0.21 Down P88E 913 971.61 1460.63 0.67 0.12 0.16 Down P88D 912 1300.22 1911.83 0.68 0.16 0.21 Down R89V 946 1163.86 2620.05 0.44 0.24 0.38 Down R89W 944 1252.89 1744.18 0.72 0.25 0.25 Neutral R89M 943 402.00 386.98 1.04 0.08 0.06 Neutral R89A 948 7883.15 8954.83 0.88 1.39 1.70 Neutral R89T 938 6791.27 6752.46 1.01 1.20 1.28 Neutral R89G 941 8957.06 8693.72 1.03 1.58 1.65 Up R89S 940 7342.24 4138.54 1.77 1.30 0.79 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral R89K 934 7679.02 8254.00 0.93 1.36 1.57 Neutral R89F 942 4764.35 5589.97 0.85 0.84 1.06 Neutral R89Y 939 5614.23 5949.31 0.94 0.99 1.13 Up R89N 936 3502.08 1995.86 1.75 0.62 0.38 Neutral R89H 933 3611.69 4222.47 0.86 0.64 0.80 Neutral R89L 947 3123.66 3332.30 0.94 0.55 0.63 Neutral R89E 932 1490.93 1265.89 1.18 0.26 0.24 Down R89P 949 2659.02 3342.56 0.80 0.47 0.64 Neutral W90L 966 394.24 411.82 0.96 0.08 0.06 Neutral W90G 961 448.08 427.28 1.05 0.09 0.06 Neutral W90P 968 444.72 442.65 1.00 0.09 0.06 Neutral W90T 958 397.42 365.04 1.09 0.08 0.05 Neutral W90S 960 443.43 442.72 1.00 0.09 0.06 Neutral W90V 965 384.57 385.18 1.00 0.08 0.06 Neutral W901 964 443.81 432.28 1.03 0.09 0.06 Neutral W90A 967 497.94 554.07 0.90 0.10 0.08 Neutral W90F 962 730.98 656.84 1.11 0.15 0.10 Neutral W90H 952 498.51 493.15 1.01 0.10 0.07 Neutral W90M 963 512.18 508.03 1.01 0.10 0.07 Neutral W90R 954 1974.98 1695.11 1.17 0.23 0.19 Up W90E 951 1537.84 1076.32 1.43 0.18 0.12 Up W90N 956 1308.11 1001.91 1.31 0.15 0.11 Up W90Q 957 1392.58 1015.03 1.37 0.16 0.12 Down E91N 974 4746.43 6166.37 0.77 0.96 0.90 Down E91R 972 2760.48 3810.12 0.72 0.56 0.56 Down E91W 982 2595.35 5651.48 0.46 0.53 0.83 Down E91G 979 4826.02 6684.79 0.72 0.98 0.98 Neutral E91 V 984 454.87 459.17 0.99 0.09 0.07 Neutral E91Y 977 4885.18 5469.16 0.89 0.99 0.80 Down E91C 973 3525.68 5567.75 0.63 0.71 0.81 Down E91H 970 5114.86 6610.88 0.77 1.04 0.97 Neutral E91T 976 442.21 427.42 1.03 0.09 0.06 Neutral E91 S 978 8147.93 7696.77 1.06 0.94 0.87 Neutral E91A 986 1140.60 1252.34 0.91 0.13 0.14 Neutral E911 983 8414.79 8744.30 0.96 0.97 0.99 Neutral E91D 969 8482.61 8681.73 0.98 0.98 0.98 Neutral E91F 980 1159.80 1117.15 1.04 0.13 0.13 Neutral E91 L 985 2012.22 1956.07 1.03 0.23 0.22 Down Q92V 1003 3748.94 5787.25 0.65 0.76 0.85 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 0 Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Down Q92Y 996 2141.40 5383.55 0.40 0.43 0.79 Down Q92L 1004 2422.01 3765.30 0.64 0.49 0.55 Neutral Q92N 994 8685.91 8183.03 1.06 1.00 0.93 Neutral Q92E 989 8489.89 8972.33 0.95 0.98 1.02 Neutral Q921 1002 7791.35 8518.64 0.91 0.90 0.97 Neutral Q92T 995 8289.96 8916.74 0.93 0.96 1.01 Neutral Q92G 998 7218.56 8372.74 0.86 0.83 0.95 Neutral Q92P 1006 3678.59 4021.57 0.91 0.43 0.46 Neutral Q92W 1001 7277.76 8042.96 0.90 0.84 0.91 Neutral Q92F 999 8216.00 8989.59 0.91 0.95 1.02 Neutral Q92S 997 8760.81 9254.16 0.95 1.01 1.05 Neutral Q92R 992 8566.65 8894.65 0.96 0.99 1.01 Neutral Q92K 991 8790.93 9239.36 0.95 1.02 1.05 Neutral Q92A 1005 8138.84 9037.58 0.90 0.94 1.02 Down T93A 1024 2321.71 5447.47 0.43 0.47 0.80 Neutral T93L 1023 541.85 545.89 0.99 0.11 0.08 Down T93M 1019 5256.54 7088.24 0.74 1.07 1.04 Neutral T93N 1013 5852.91 7141.52 0.82 1.19 1.04 Neutral T93V 1022 7976.61 8668.81 0.92 0.92 0.98 Neutral T931 1021 9015.76 9426.26 0.96 1.04 1.07 Neutral T93D 1007 8742.88 9032.61 0.97 1.01 1.02 Neutral T93S 1016 8832.30 8978.09 0.98 1.02 1.02 Neutral T93R 1011 8802.98 8782.70 1.00 1.02 1.00 Neutral T93W 1020 7872.73 8474.20 0.93 0.91 0.96 Down T93F 1018 4307.35 5656.46 0.76 0.50 0.64 Neutral T93P 1025 8315.28 8629.67 0.96 0.96 0.98 Down T93G 1017 4926.38 6453.11 0.76 0.57 0.73 Neutral T93K 1010 8581.02 8663.14 0.99 0.99 0.98 Neutral T93E 1008 8081.66 8373.46 0.97 0.93 0.95 Neutral H94L 1042 509.44 507.83 1.00 0.10 0.07 Down H94S 1035 3442.98 5184.16 0.66 0.70 0.76 Neutral H94M 1038 7388.19 8302.74 0.89 0.85 0.94 Neutral H94R 1029 7237.77 7718.22 0.94 0.84 0.87 Neutral H94E 1027 8375.45 8466.04 0.99 0.97 0.96 Neutral H941 1040 6326.35 7655.54 0.83 0.73 0.87 Neutral H94D 1026 7358.29 8057.05 0.91 0.85 0.91 Neutral H94P 1044 2892.06 3183.37 0.91 0.33 0.36 Neutral H94A 1043 8285.72 8772.41 0.94 0.96 0.99 Neutral H94N 1031 8497.48 8732.16 0.97 0.98 0.99 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 0 Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Down H94F 1037 6046.02 7839.76 0.77 0.70 0.89 Neutral H94G 1036 7671.85 7912.46 0.97 0.89 0.90 Neutral H94T 1033 7121.14 8100.48 0.88 0.82 0.92 Neutral H94V 1041 7941.67 8381.81 0.95 0.92 0.95 Neutral H94W 1039 6520.52 7583.08 0.86 0.75 0.86 Down L95E 4 4165.44 5381.52 0.77 0.48 0.61 Neutral L95Y 12 1044.63 1118.92 0.93 0.12 0.13 Neutral L95R 7 1328.79 1312.13 1.01 0.15 0.15 Neutral L95A 20 1262.99 1297.06 0.97 0.15 0.15 Neutral L95G 14 1090.24 1183.93 0.92 0.13 0.13 Up L95K 6 1333.28 1191.46 1.12 0.15 0.14 Neutral L95S 13 1077.02 1117.02 0.96 0.12 0.13 Neutral L95T 11 1407.58 1310.18 1.07 0.16 0.15 Neutral L95H 5 1270.21 1086.69 1.17 0.15 0.12 Neutral L95W 17 1133.63 1041.65 1.09 0.13 0.12 Neutral L95V 19 8390.57 8371.68 1.00 0.97 0.95 Neutral L95C 8 2189.50 2519.34 0.87 0.25 0:29 Neutral L95P 21 1084.88 1147.69 0.95 0.13 0.13 Neutral L95D 3 909.41 933.49 0.97 0.11 0.11 Down L951 18 1707.98 2294.02 0.74 0.30 0.45 Neutral T96E 1046 415.05 397.38 1.04 0.07 0.06 Neutral T96R 1049 478.81 441.86 1.08 0.08 0.07 Neutral T96P 1063 589.64 692.90 0.85 0.09 0.11 Down T96S 1054 3055.53 4011.47 0.76 0.49 0.64 Neutral T96A 1062 1873.45 2254.28 0.83 0.30 0.36 Down T96L 1061 2337.67 3156.45 0.74 0.37 0.51 Down T96W 1058 1194.79 1631.19 0.73 0.19 0.26 Down T96N 1051 2674.35 3874.07 0.69 0.43 0.62 Neutral T96G 1055 415.04 387.45 1.07 0.07 0.06 Down T96F 1056 2640.74 3897.10 0.68 0.42 0.62 Down T96Q 1052 1865.64 2509.48 0.74 0.30 0.40 Down T96H 1047 1294.29 1620.22 0.80 0.21 0.26 Down T96V 1060 1904.14 2730.27 0.70 0.30 0.44 Down T961 1059 1814.91 2921.26 0.62 0.29 0.47 Neutral T96C 1050 701.03 774.48 0.91 0.11 0.12 Neutral Y97R 1068 447.48 449.81 0.99 0.14 0.09 Neutral Y97V 1079 637.70 789.90 0.81 0.20 0.16 Neutral Y97A 1081 507.18 504.63 1.01 0.16 0.10 Neutral Y97P 1082 488.40 452.67 1.08 0.15 0.09 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral Y97L 1080 510.25 549.53 0.93 0.16 0.11 Neutral Y97T 1072 538.83 600.97 0.90 0.17 0.12 Up Y97K 1067 469.55 390.08 1.20 0.15 0.08 Down Y97W 1077 3115.45 4974.99 0.63 0.98 1.01 Down Y97H 1066 685.71 879.64 0.78 0.22 0.18 Neutral Y97S 1073 482.94 471.85 1.02 0.15 0.10 Neutral Y97E 1065 435.12 432.07 1.01 0.14 0.09 Neutral Y97D 1064 466.89 455.39 1.03 0.15 0.09 Neutral Y97N 1070 486.98 490.84 0.99 0.15 0.10 Neutral Y97G 1074 521.34 516.64 1.01 0.11 0.08 Neutral Y97Q 1071 567.66 575.73 0.99 0.12 0.08 Down R98H 1085 1456.51 3257.97 0.45 0.46 0.66 Down R98K 1086 2994.82 4670.17 0.64 0.95 0.95 Neutral R98C 1087 761.34 938.43 0.81 0.24 0.19 Down R98L 1099 3592.72 5087.24 0.71 1.14 1.03 Down R98M 1095 3551.60 5834.31 0.61 1.12 1.18 Down R98F 1094 2925.55 4988.31 0.59 0.92 1.01 Down R98W 1096 833.68 1098.48 0.76 0.26 0.22 Neutral R98Y 1091 505.91 479.02 1.06 0.16 0.10 Down R98P 1101 2306.44 3388.72 0.68 0.73 0.69 Down R98E 1084 1812.72 2769.07 0.65 0.57 0.56 Down R98A 1100 3006.35 4371.72 0.69 0.95 0.89 Down R98G 1093 1525.20 2367.66 0.64 0.48 0.48 Down R98V 1098 1298.78 3330.10 0.39 0.26 0.49 Down R98S 1092 4646.88 6142.58 0.76 0.94 0.90 Down R98D 1083 2905.96 3867.31 0.75 0.33 0.47 Neutral I99C 1107 514.61 514.66 1.00 0.16 0.10 Neutral 199E 1103 550.80 548.33 1.00 0.17 0.11 Neutral I99G 1113 588.17 598.60 0.98 0.19 0.12 Neutral 199H 1104 749.01 834.15 0.90 0.24 0.17 Neutral 199N 1108 691.55 805.73 0.86 0.22 0.16 Neutral 199P 1120 567.03 526.02 1.08 0.18 0.11 Down I99T 1110 1087.94 1583.58 0.69 0.34 0.32 Down 199V 1117 2373.86 3390.37 0.70 0.75 0.69 Neutral 199A 1119 654.22 809.57 0.81 0.13 0.12 Down 199F 1114 2098.09 2958.45 0.71 0.43 0.43 Down 199L 1118 2592.09 4336.89 0.60 0.53 0.63 Neutral I99R 1106 561.16 555.21 1.01 0.11 0.08 Neutral I99S 1112 616.13 673.46 0.91 0.12 0.10 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Down 199Q 1109 3318.21 4623.91 0.72 0.37 0.56 Neutral 199W 1116 509.03 492.00 1.04 0.06 0.06 Neutral 199Y 1111 690.55 700.48 0.99 0.08 0.09 Down E100V 512 3980.72 5009.20 0.79 1.26 1.01 Neutral E100P 515 727.82 785.14 0.93 0.23 0.16 Down E100L 513 3370.21 4726.28 0.71 1.06 0.96 Down E100H 498 1484.00 2354.50 0.63 0.47 0.48 Down E100D 497 1886.86 3049.67 0.62 0.60 0.62 Down E100M 509 3046.42 4566.62 0.67 0.96 0.92 Neutral E100G 507 541.78 567.31 0.95 0.11 0.08 Down E100W 510 1544.77 3766.06 0.41 0.31 0.55 Down E100Y 505 2885.60 4167.75 0.69 0.58 0.61 Neutral E100R 500 7410.11 7964.52 0.93 0.83 0.96 Neutral E100S 506 3768.09 4664.58 0.81 0.42 0.56 Neutral E100T 504 6985.28 7478.12 0.93 0.79 0.90 Neutral E100F 508 6709.27 7436.60 0.90 0.75 0.90 Neutral E1001 511 8824.19 8458.79 1.04 0.99 1.02 Neutral E100N 502 8809.68 8215.63 1.07 0.99 0.99 Neutral N101M 1133 7907.75 7930.91 1.00 0.89 0.96 Neutral N101F 1132 5045.54 5244.47 0.96 0.57 0.63 Neutral N101L 1137 6427.09 6656.60 0.97 0.72 0.80 Neutral N101V 1136 8153.10 7605.57 1.07 0.92 0.92 Neutral N101H 1123 8863.48 8197.03 1.08 1.00 0.99 Neutral NIOIR 1125 8050.92 7576.48 1.06 0.91 0.91 Down N101C 1126 2651.70 3359.06 0.79 0.30 0.41 Neutral N101T 1128 9660.15 8437.52 1.14 1.09 1.02 Neutral N101P 1139 8232.08 7996.53 1.03 0.93 0.96 Neutral N101W 1134 3302.54 3773.04 0.88 0.37 0.46 Neutral N101K 1124 7396.60 7283.35 1.02 0.83 0.88 Neutral N101S 1130 8913.81 8187.44 1.09 1.00 0.99 Neutral N101D 1121 5424.50 5676.43 0.96 0.61 0.68 Neutral N101A 1138 6371.04 6423.71 0.99 0.72 0.78 Neutral N101Y 1129 3878.66 3898.52 0.99 0.44 0.47 Neutral Y102R 1144 9027.37 8170.55 1.10 1.02 0.99 Neutral Y102K 1143 5806.60 5157.24 1.13 0.65 0.62 Neutral Y102V 1155 6412.64 6500.28 0.99 0.72 0.78 Neutral Y102M 1152 6668.55 6964.91 0.96 0.75 0.84 Neutral Y102P 1158 4670.45 4431.46 1.05 0.53 0.53 Neutral Y102N 1146 4618.85 4579.81 1.01 0.52 0.55 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral Y102G 1150 7272.09 6976.34 1.04 0.82 0.84 Neutral Y102L 1156 3323.14 3802.15 0.87 0.37 0.46 Neutral Y102D 1140 5174.42 4862.10 1.06 0.58 0.59 Neutral Y102S 1149 8744.32 8244.11 1.06 0.98 0.99 Neutral Y102F 1151 7629.25 8362.12 0.91 0.86 1.01 Neutral Y102A 1157 7177.10 7304.92 0.98 0.81 0.88 Neutral Y102E 1141 3375.30 3325.21 1.02 0.38 0.40 Neutral Y102Q 1147 5644.96 5711.44 0.99 0.64 0.69 Neutral Y102C 1145 1544.43 1842.83 0.84 0.17 0.22 Neutral T103E 517 619.06 617.97 1.00 0.20 0.13 Neutral T103D 516 848.44 877.46 0.97 0.27 0.18 Neutral T103S 525 761.49 855.80 0.89 0.24 0.17 Up T103L 532 855.65 650.61 1.32 0.27 0.13 Neutral T103V 531 822.60 1017.88 0.81 0.26 0.21 Neutral T103R 520 674.37 652.99 1.03 0.21 0.13 Neutral T103Y 524 1181.09 1423.76 0.83 0.37 0.29 Down T103N 522 3131.62 4822.91 0.65 0.99 0.98 Neutral T103C 521 628.62 604.98 1.04 0.20 0.12 Up T103Q 523 791.61 624.86 1.27 0.25 0.13 Neutral T103W 529 513.42 548.41 0.94 0.10 0.08 Neutral TI 03P 534 513.57 526.91 0.97 0.10 0.08 Neutral T103A 533 1058.92 950.05 1.11 0.21 0.14 Neutral T103G 526 749.67 656.69 1.14 0.15 0.10 Neutral T103K 519 884.09 777.94 1.14 0.18 0.11 Neutral P104G 1170 602.57 620.78 0.97 0.19 0.13 Down P104E 1160 4330.78 6029.01 0.72 1.37 1.22 Down P104T 1167 3213.10 4681.67 0.69 1.02 0.95 Neutral P104F 1171 2191.45 1923.19 1.14 0.69 0.39 Down P104R 1163 591.46 5625.37 0.11 0.19 1.14 Down P104D 1159 4022.87 5896.28 0.68 1.27 1.19 Neutral P104C 1164 779.25 879.87 0.89 0.25 0.18 Down P 104Q 1166 4140.44 5971.62 0.69 1.31 1.21 Down P104V 1175 2675.96 4161.77 0.64 0.85 0.84 Down P104Y 1168 1907.52 2912.52 0.65 0.60 0.59 Down P104H 1161 3404.74 5009.27 0.68 1.08 1.01 Down P104L 1176 2981.52 4000.85 0.75 0.60 0.58 Down P104S 1169 1205.11 2392.05 0.50 0.24 0.35 Neutral P104A 1177 8861.30 8360.82 1.06 1.00 1.01 Up P104M 1172 6709.44 7118.65 0.94 0.88 0.75 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 0 Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Up D105A 39 2674.16 1227.06 2.18 0.65 0.24 Neutral D105C 26 871.16 737.92 1.18 0.21 0.15 Up D105F 33 2009.56 1221.58 1.65 0.49 0.24 Up D105G 32 2407.89 1686.68 1.43 0.58 0.34 Up D1051 36 1732.38 1105.99 1.57 0.42 0.22 Up D105L 38 1563.61 859.56 1.82 0.38 0.17 Neutral D105M 34 2703.51 2920.93 0.93 0.65 0.58 Up D105N 27 3766.72 1475.08 2.55 0.91 0.29 Up D105P 40 856.02 604.56 1.42 0.21 0.12 Up D105R 25 3892.02 2016.90 1.93 0.94 0.40 Up D105S 31 3646.49 2727.22 1.34 0.88 0.54 Up D105T 29 2513.64 1729.46 1.45 0.61 0.34 Neutral D105V 37 5824.43 6784.65 0.86 1.41 1.35 Up D105W 35 2565.93 1855.05 1.38 0.62 0.37 Neutral D105E 22 4000.92 3366.64 1.19 0.59 0.45 Up L106P 1196 793.18 480.45 1.65 0.16 0.10 Neutral L106D 1178 455.97 436.46 1.04 0.09 0.09 Neutral L106N 1184 579.84 499.77 1.16 0.12 0.10 Up L106G 1189 778.24 578.12 1.35 0.16 0.12 Down L106M 1191 2299.74 3704.96 0.62 0.48 0.74 Down L1 06A 1195 3604.47 5633.39 0.64 0.75 1.12 Neutral L106R 1182 658.60 552.82 1.19 0.14 0.11 Neutral L106Y 1187 4761.33 5769.09 0.83 0.99 1.15 Neutral L106T 1186 1604.22 1508.31 1.06 0.33 0.30 Neutral L1 06V 1194 8561.50 8230.68 1.04 1.77 1..64 Neutral L1 06H 1180 644.13 641.84 1.00 0.13 0.13 Down L106F 1190 1776.88 2525.65 0.70 0.36 0.37 Down L1061 1193 2787.16 4408.75 0.63 0.56 0.64 Neutral L106C 1183 2995.56 3678.33 0.81 0.34 0.44 Neutral L106S 1188 2730.64 2899.36 0.94 0.31 0.35 Neutral P107L 1214 3183.54 3874.49 0.82 0.77 0.75 Neutral P107W 1211 1255.79 1303.70 0.96 0.30 0.25 Neutral P107T 1205 5673.07 6084.28 0.93 1.37 1.18 Neutral P107S 1207 5865.31 6191.65 0.95 1.42 1.20 Neutral P107R 1201 2981.87 3300.34 0.90 0.72 0.64 Neutral P107Y 1206 2005.11 2383.15 0.84 0.48 0.46 Neutral P107M 1210 3551.42 4031.55 0.88 0.86 0.78 Neutral P 107V 1213 3499.60 4142.87 0.84 0.85 0.80 Neutral P107D 1197 3531.02 4095.17 0.86 0.85 0.80 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt 'Mut/wt Neutral P107A 1215 5661.84 6316.88 0.90 1.37 1.23 Neutral P 107C 1202 786.68 776.20 1.01 0.19 0.15 Neutral P107K 1200 3176.89 3653.27 0.87 0.77 0.71 Neutral P107F 1209 1603.40 1832.50 0.87 0.39 0.36 Neutral P1071 1212 2003.91 2369.36 0.85 0.48 0.46 Neutral P107G 1208 2694.02 3272.63 0.82 0.65 0.64 Up R108P 1234 4652.14 3388.90 1.37 0.96 0.67 Down R108G 1226 4168.56 6204.10 0.67 0.86 1.24 Neutral R108T 1223 1360.40 1652.92 0.82 0.28 0.33 Down R108E 1217 5311.31 6829.34 0.78 1.10 1.36 Down R108A 1233 5676.42 7183.19 0.79 1.18 1.43 Down R108Y 1224 1527.69 2690.78 0.57 0.32 0.54 Down R108K 1219 7212.78 9049.80 0.80 1.49 1.80 Down R108C 1220 2092.15 2852.47 0.73 0.43 0.57 Neutral R108S 1225 8515.31 8202.68 1.04 1.76 1.63 Neutral R108F 1227 4264.07 5199.96 0.82 0.88 1.04 Down R108W 1229 1522.39 2152.20 0.71 0.31 0.31 Down R1081 1230 2968.84 4628.28 0.64 0.60 0.68 Down R108L 1232 2200.90 3462.10 0.64 0.45 0.51 Down R108N 1221 2820.25 4415.19 0.64 0.57 0.65 Neutral R108V 1231 571.77 618.30 0.92 0.12 0.09 Neutral A109S 1245 6193.70 7627.42 0.81 1.28 1.52 Down A109R 1239 4933.84 9751.06 0.51 1.02 1.94 Down A109T 1243 4678.95 6089.37 0.77 0.97 1.21 Down A109W 1249 5152.58 6447.41 0.80 1.07 1.28 Down A1091 1250 2587.03 4255.55 0.61 0.54 0.85 Down A109Q 1242 3475.21 4698.87 0.74 0.72 0.94 Up A109N 1241 6266.66 4399.73 1.42 1.30 0.88 Up A109Y 1244 1880.37 1444.85 1.30 0.39 0.29 Down A109G 1246 5864.62 12111.28 0.48 1.21 2.41 Neutral A109M 1248 7784.21 8628.31 0.90 1.61 1.72 Down A109D 1235 4410.30 6431.60 0.69 0.91 1.28 Neutral A109V 1251 8073.90 8388.34 0.96 1.67 1.67 Down A109E 1236 2859.74 7453.25 0.38 0.58 1.09 Down A109L 1252 3649.92 5241.27 0.70 0.74 0.77 Neutral A109H 1237 7206.01 7536.96 0.96 0.81 0.91 Down D 110P 1272 691.78 937.18 0.74 0.14 0.19 Down D110F 1265 2469.89 3158.71 0.78 0.51 0.63 Down D110Q 1260 3028.40 4201.99 0.72 0.63 0.84 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Down D11OR 1257 756.25 1109.97 0.68 0.16 0.22 Neutral D 110M 1266 1094.79 917.81 1.19 0.23 0.18 Down D110H 1255 3327.99 6569.83 0.51 0.69 1.31 Down D1101 1268 1457.92 2219.69 0.66 0.30 0.44 Down D 110L 1270 1494.01 1991.44 0.75 0.31 0.40 Down D110V 1269 2494.40 3413.88 0.73 0.52 0.68 Down D 110T 1261 2731.23 4170.98 0.65 0.57 0.83 Down D110S 1263 1262.77 1714.94 0.74 0.26 0.34 Down D110Y 1262 2764.78 5378.21 0.51 0.57 1.07 Neutral D11OG 1264 510.14 537.48 0.95 0.10 0.08 Neutral D110C 1258 827.23 996.83 0.83 0.17 0.15 Neutral D110A 1271 4179.59 5112.44 0.82 0.47 0.62 Down V111E 1274 779.81 1134.36 0.69 0.16 0.23 Down V111A 1290 1964.87 2890.23 0.68 0.41 0.58 Down V111S 1283 2947.29 4188.33 0.70 0.61 0.83 Neutral V111W 1287 601.19 580.46 1.04 0.12 0.12 Neutral V111G 1284 833.15 974.76 0.85 0.17 0.19 Neutral V111Y 1282 813.12 942.64 0.86 0.17 0.19 Up V111P 1291 923.36 696.55 1.33 0.19 0.14 Down V1.11L 1289 1070.50 1565.39 0.68 0.22 0.31 Neutral V111D 1273 591.79 576.36 1.03 0.12 0.11 Down V111K 1276 1017.96 1328.59 0.77 0.21 0.26 Down V111T 1281 3551.97 4859.95 0.73 0.74 0.97 Down V 111 Q 1280 1546.82 2061.98 0.75 0.32 0.41 Down V1111 1288 4959.51 6699.66 0.74 1.03 1.33 Neutral V 111 C 1278 843.17 943.89 0.89 0.17 0.14 Neutral V 111 R 1277 2401.69 2925.16 0.82 0.27 0.35 Down D112A 1309 1419.86 2167.48 0.66 0.29 0.43 Down D112M 1304 1668.58 2249.91 0.74 0.35 0.45 Down D112V 1307 2683.45 3699.41 0.73 0.56 0.74 Down D112R 1295 1072.27 1395.54 0.77 0.22 0.28 Down D112K 1294 967.53 1261.79 0.77 0.20 0.25 Neutral D112P 1310 565.23 589.06 0.96 0.12 0.12 Down D112Q 1298 4681.31 8975.21 0.52 0.97 1.79 Down D112F 1303 1148.89 1477.74 0.78 0.24 0.29 Down D112G 1302 1824.01 2601.95 0.70 0.38 0.52 Neutral D112C 1296 866.83 1034.64 0.84 0.18 0.21 Down D112W 1305 937.80 1277.50 0.73 0.19 0.25 Neutral D112T 1299 2538.82 2941.38 0.86 0.53 0.59 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 0 Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral D 112H 1293 480.11 467.40 1.03 0.10 0.07 Neutral D112S 1301 7203.69 7600.93 0.95 0.81 0.92 Down D1 121 1306 4020.53 5498.90 0.73 0.44 0.72 Down D112Y 1300 2132.97 2869.86 0.74 0.23 0.38 Down D112L 1308 2626.71 4159.92 0.63 0.29 0.55 Neutral H113T 1318 9107.72 8278.01 1.10 1.03 1.00 Neutral H113L 1327 9479.59 8454.16 1.12 1.07 1.02 Neutral H113M 1323 9463.40 8759.43 1.08 1.07 1.06 Neutral H113S 1320 9278.22 9159.47 1.01 1.04 1.11 Neutral H113N 1316 8609.35 8502.46 1.01 0.97 1.03 Neutral H113R 1314 7702.30 7852.46 0.98 0.87 0.95 Neutral H113A 1328 8505.43 8090.18 1.05 0.96 0.98 Neutral H113E 1312 9118.02 8443.69 1.08 1.03 1.02 Neutral H113V 1326 9183.53 8450.30 1.09 1.03 1.02 Neutral H113Y 1319 9688.60 8548.83 1.13 1.09 1.03 Neutral H113F 1322 9472.51 8729.41 1.09 1.07 1.05 Up H113D 1311 9304.42 4925.78 1.89 1.05 0.59 Up H113W 1324 8683.10 5775.24 1.50 0.98 0.70 Neutral H113G 1321 8953.60 8320.09 1.08 1.01 1.00 Neutral H113P 1329 2987.12 3102.32 0.96 0.34 0.37 Neutral A114E 1331 7136.25 7924.97 0.90. 0.80 0.96 Neutral A114S 1340 9211.05 8794.50 1.05 1.04 1.06 Neutral A1141 1345 7073.18 7475.79 0.95 0.80 0.90 Up A114P 1348 1691.05 1357.51 1.25 0.19 0.16 Neutral A114N 1336 9250.51 8746.70 1.06 1.04 1.06 Neutral A114L 1347 7749.61 8007.88 0.97 0.87 0.97 Neutral A114T 1338 6242.22 6974.59 0.89 0.70 0.84 Neutral A114F 1342 605.35 675.10 0.90 0.07 0.08 Neutral A114V 1346 5527.85 6054.48 0.91 0.62 0.73 Neutral A114G 1341 7663.26 7892.13 0.97 0.86 0.95 Neutral A114C 1335 2412.52 3005.83 0.80 0.27 0.36 Neutral A114M 1343 5287.05 5931.99 0.89 0.60 0.72 Neutral Al 14R 1334 4454.65 3915.86 1.14 0.50 0.47 Neutral A114W 1344 4654.58 5477.95 0.85 0.52 0.66 Neutral A114Q 1337 8094.57 8337.94 0.97 0.91 1.01 Neutral 1115F 1361 9634.62 9011.34 1.07 1.08 1.09 Neutral 1115T 1357 1935.83 2379.92 0.81 0.22 0.29 Neutral 1115H 1351 805.66 825.35 0.98 0.09 0.10 Neutral 11 15G 1360 725.85 626.12 1.16 0.08 0.08 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Down 11 15K 1352 642.87 920.32 0.70 0.07 0.11 Neutral 11 15E 1350 1276.09 1211.16 1.05 0.14 0.15 Neutral 1115S 1359 796.93 780.25 1.02 0.09 0.09 Neutral 11 15P 1367 626.77 597.01 1.05 0.07 0.07 Neutral 11 15C 1354 1021.21 982.43 1.04 0.11 0.12 Neutral 1115L 1365 8869.57 8467.55 1.05 1.00 1.02 Neutral 11 15Q 1356 732.25 652.35 1.12 0.08 0.08 Up 11 15R 1353 750.11 575.36 1.30 0.08 0.07 Neutral 11 15W 1363 2203.68 2304.27 0.96 0.25 0.28 Neutral 11 15V 1364 9365.90 8785.30 1.07 1.05 1.06 Neutral 11 15D 1349 694.17 641.97 1.08 0.08 0.08 Neutral E116A 1385 9273.62 9051.39 1.02 1.04 1.09 Neutral E116C 1372 5022.73 5732.42 0.88 0.57 0.69 Neutral E116D 1368 9114.14 8594.45 1.06 1.03 1.04 Neutral E116F 1379 8569.56 8473.84 1.01 0.96 1.02 Neutral E116G 1378 8305.07 8358.04 0.99 0.94 1.01 Neutral E116H 1369 8630.15 8386.63 1.03 0.97 1.01 Neutral E1161 1382 9386.17 8740.84 1.07 1.06 1.05 Neutral E116K 1370 9320.21 8760.44 1.06 1.05 1.06 Neutral E116L 1384 8997.58 8736.18 1.03 1.01 1.05 Neutral E116M 1380 9046.33 8478.98 1.07 1.02 1.02 Neutral E116N 1373 8629.15 8503.39 1.01 0.97 1.03 Neutral E116P 1386 852.91 806.00 1.06 0.10 0.10 Neutral E116Q 1374 9480.67 8716.72 1.09 1.07 1.05 Neutral E116R 1371 8871.32 8479.40 1.05 1.00 1.02 Neutral E116S 1377 9714.89 8843.17 1.10 1.09 1.07 Neutral K117H 1389 4516.51 4612.42 0.98 0.52 0.55 Neutral K117T 1394 6149.94 6317.74 0.97 0.71 0.75 Neutral K1 17Q 1393 6602.62 6024.00 1.10 0.77 0.72 Neutral KI17E 1388 668.03 667.32 1.00 0.08 0.08 Neutral K117A 1404 7727.36 7375.30 1.05 0.90 0.88 Neutral K117F 1398 4020.90 4038.83 1.00 0.47 0.48 Neutral K117D 1387 5330.37 5924.02 0.90 0.62 0.70 Down K117N 1392 4666.40 7745.69 0.60 0.54 0.92 Neutral K117G 1397 7619.16 7218.94 1.06 0.88 0.86 Neutral K117W 1400 5440.86 4780.56 1.14 0.63 0.57 Neutral K117Y 1395 5047.23 4760.05 1.06 0.59 0.57 Neutral K117L 1403 5277.39 5328.70 0.99 0.61 0.63 Neutral K117S 1396 7278.89 6995.65 1.04 0.85 0.83 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 0 Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Down K117P 1405 737.96 1153.03 0.64 0.09 0.14 Neutral K117R 1390 8236.16 7677.40 1.07 0.96 0.91 Down A118G 1417 2782.31 6427.69 0.43 0.32 0.76 Neutral A118R 1410 4889.61 5639.79 0.87 0.57 0.67 Up A118W 1420 652.55 465.07 1.40 0.08 0.06 Neutral A118K 1409 584.59 543.84 1.07 0.07 0.06 Neutral A118P 1424 883.04 810.72 1.09 0.10 0.10 Neutral A118V 1422 869.06 754.10 1.15 0.10 0.09 Neutral A118L 1423 543.99 523.84 1.04 0.06 0.06 Up A118D 1406 617.40 468.39 1.32 0.07 0.06 Down A118S 1416 5502.11 8251.39 0.67 0.64 0.98 Neutral A118F 1418 7092.17 7315.30 0.97 0.82 0.87 Up Al 181 1421 556.24 456.62 1.22 0.06 0.05 Neutral A118H 1408 482.33 466.40 1.03 0.06 0.06 Up A118E 1407 560.55 406.52 1.38 0.07 0.05 Neutral A118Q .1413 517.05 477.18 1.08 0.06 0.06 Neutral A118T 1414 745.83 665.63 1.12 0.13 0.13 Down F119G 1436 2058.01 3284.43 0.63 0.24 0.39 Down F119T 1433 4492.83 8234.56 0.55 0.52 0.98 Neutral F119R 1429 648.01 665.21 0.97 0.08 0.08 Neutral F119L 1441 8529.66 7666.52 1.11 0.99 0.91 Neutral F119N 1431 1298.98 1614.30 0.80 0.15 0.19 Down F119S 1435 3021.31 4383.36 0.69 0.35 0.52 Neutral F119C 1430 2921.13 3375.91 0.87 0.34 0.40 Neutral F119P 1443 567.10 665.80 0.85 0.07 0.08 Neutral F119W 1438 4474.41 4610.60 0.97 0.52 0.55 Neutral F119K 1428 679.32 762.81 0.89 0.08 0.09 Down F119H 1427 2479.46 3939.67 0.63 0.29 0.47 Neutral F119A 1442 7345.58 7881.39 0.93 0.85 0.94 Neutral F119V 1440 7388.01 7712.75 0.96 0.86 0.92 Neutral F119Y 1434 5832.62 6222.88 0.94 0.68 0.74 Down F119E 1426 1044.34 1357.80 0.77 0.12 0.16 Neutral Q120K 1447 8732.08 8385.78 1.04 1.01 1.00 Neutral Q120N 1450 9186.34 8785.94 1.05 1.07 1.05 Down Q120A 1461 613.72 979.68 0.63 0.07 0.12 Neutral Q120V 1459 8711.16 8484.49 1.03 1.01 1.01 Down Q120D 1444 5912.84 8887.98 0.67 0.69 1.06 Neutral Q120R 1448 8845.48 8351.59 1.06 1.03 0.99 Neutral Q120P 1462 1083.78 1186.17 0.91 0.13 0.14 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral Q120W 1457 9339.94 7899.14 1.18 1.08 0.94 Down Q120Y 1452 4891.24 8236.87 0.59 0.57 0.98 Neutral Q120C 1449 5241.83 5502.66 0.95 0.61 0.65 Neutral Q120H 1446 9155.83 8431.63 1.09 1.06 1.00 Neutral Q120T 1451 9413.75 8645.01 1.09 1.09 1.03 Down Q120M 1456 5740.33 8861.16 0.65 0.67 1.05 Neutral Q120E 1445 8896.83 8424.76 1.06 1.03 1.00 Neutral Q120G 1454 9176.97 8435.97 1.09 1.07 1.00 Up L121E 1464 3183.74 2155.16 1.48 0.37 0.26 Down L121Q 1470 2122.18 3128.11 0.68 0.25 0.37 Neutral L121P 1481 1446.80 1342.92 1.08 0.17 0.16 Up L121R 1467 1129.37 875.68 1.29 0.13 0.10 Up L121C 1468 1592.13 1145.83 1.39 0.18 0.14 Down L121G 1474 2613.21 4720.78 0.55 0.30 0.56 Neutral L121K 1466 4678.64 4882.50 0.96 0.54 0.58 Up L121F 1475 1227.52 957.08 1.28 0.14 0.11 Neutral L1211 1478 7406.57 6937.72 1.07 0.86 0.83 Down L121S 1473 2463.24 3614.68 0.68 0.29 0.43 Neutral L121 V 1479 7973.31 7244.01 1.10 0.93 0.86 Up L121H 1465 3156.18 2605.48 1.21 0.37 0.31 Neutral L121T 1471 7283.06 7372.13 0.99 0.85 0.88 Down L121A 1480 3311.41 4989.77 0.66 0.38 0.59 Neutral L121N 1469 6619.84 6504.79 1.02 0.77 0.77 Neutral W122R 1486 651.20 598.41 1.09 0.08 0.07 Neutral W 122A 1499 699.90 617.84 1.13 0.08 0.07 Neutral W122N 1488 484.17 598.30 0.81 0.06 0.07 Neutral W122P 1500 619.39 605.42 1.02 0.07 0.07 Neutral W 122T 1490 621.86 570.65 1.09 0.07 0.07 Neutral W122L 1498 580.35 563.09 1.03 0.07 0.07 Neutral W122G 1493 602.75 646.94 0.93 0.07 0.08 Neutral W122S 1492 602.28 564.94 1.07 0.07 0.07 Neutral W122V 1497 607.75 532.36 1.14 0.07 0.06 Neutral W122H 1484 596.81 545.92 1.09 0.07 0.06 Down W122F 1494 2018.83 3056.56 0.66 0.23 0.36 Neutral W122Y 1491 667.50 661.98 1.01 0.08 0.08 Neutral W122K 1485 2724.60 2334.11 1.17 0.32 0.28 Neutral W122Q 1489 576.75 528.48 1.09 0.07 0.06 Neutral W122E 1483 564.38 580.16 0.97 0.07 0.07 Neutral S123D 1501 9453.37 8830.71 1.07 0.92 0.94 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral S123L 1517 9912.51 9431.98 1.05 0.97 1.01 Neutral S 123A '1518 9881.07 9237.14 1.07 0.97 0.99 Neutral S123C 1506 10654.40 8973.60 1.19 1.04 0.96 Neutral S1231 1515 9679.91 8521.19 1.14 0.95 0.91 Neutral S123K 1504 10567.78 9024.26 1.17 1.03 0.96 Neutral S123N 1507 6481.00 5911.32 1.10 0.63 0.63 Neutral S123F 1512 7485.79 8458.67 0.88 0.73 0.90 Neutral S123Y 1510 7667.20 8806.19 0.87 0.75 0.94 Neutral S123M 1513 9800.43 9159.15 1.07 0.96 0.98 Neutral S123H 1503 10038.71 9099.05 1.10 0.98 0.97 Down S123R 1505 5290.53 9248.50 0.57 0.52 0.99 Down S123W 1514 2039.75 5970.03 0.34 0.20 0.64 Down S123T 1509 5042.33 9146.80 0.55 0.49 0.98 Neutral S123P 1519 884.66 799.56 1.11 0.09 0.09 Neutral S123G 1511 10847.89 9512.32 1.14 1.06 1.02 Neutral S123Q 1508 10841.56 9551.30 1.14 1.06 1.02 Down S123V 1516 3220.29 4504.25 0.71 0.41 0.60 Neutral N124G 1530 5601.70 6396.41 0.88 1.35 1.27 Neutral N124C 1525 2241.39 2691.13 0.83 0.54 0.53 Neutral N124V 1535 2966.25 3399.34 0.87 0.72 0.68 Neutral N124L 1536 2342.72 2849.98 0.82 0.57 0.57 Neutral N124T 1527 3872.37 4747.39 0.82 0.94 0.94 Neutral N124R 1524 3795.95 4479.74 0.85 0.92 0.89 Neutral N124M 1532 2818.81 3511.81 0.80 0.68 0.70 Neutral N124S 1529 4245.94 5151.63 0.82 1.03 1.02 Down N124P 1538 3825.40 5084.71 0.75 0.92 1.01 Neutral N124A 1537 4174.53 4857.21 0.86 1.01 0.96 Neutral N124K 1523 5006.93 5514.55 0.91 1.21 1.10 Neutral N124F 1531 3681.53 4406.27 0.84 0.89 0.88 Neutral N124W 1533 1506.21 1714.90 0.88 0.36 0.34 Neutral N1241 1534 1663.57 1830.11 0.91 0.40 0.36 Neutral N124D 1520 6218.73 6620.92 0.94 0.92 0.88 Neutral V125G 1550 532.18 540.26 0.99 0.09 0.07 Down V125Q 1546 1480.08 1883.56 0.79 0.26 0.25 Down V125S 1549 2153.87 2966.73 0.73 0.38 0.39 Down V125P 1557 1410.46 1873.09 0.75 0.25 0.24 Neutral V125M 1552 1056.84 1118.42 0.94 0.19 0.15 Down V 125Y 1548 1484.83 2214.89 0.67 0.26 0.29 Down V125T 1547 1444.16 1850.94 0.78 0.25 0.24 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Down V125A 1556 3246.01 5558.20 0.58 0.57 0.73 Up V125C 1544 892.38 690.11 1.29 0.16 0.09 Neutral V 125D 1539 727.50 723.91 1.00 0.13 0.09 Neutral V125W 1553 1537.82 1638.09 0.94 0.27 0.21 Neutral V 125R 1543 1087.69 1057.82 1.03 0.19 0.14 Neutral V125E 1540 1324.10 1545.82 0.86 0.23 0.20 Down V125F 1551 1360.07 2068.15 0.66 0.24 0.27 Neutral V125H 1541 2227.75 2720.50 0.82 0.39 0.36 Neutral T126K 1561 646.69 546.31 1.18 0.16 0.11 Down T126V 1573 3034.58 4559.28 0.67 0.73 0.91 Neutral T126G 1568 970.67 820.16 1.18 0.23 0.16 Neutral T126R 1562 692.68 612.62 1.13 0.17 0.12 Neutral T126L 1574 1084.98 970.83 1.12 0.26 0.19 Neutral T126H 1560 648.90 592.08 1.10 0.16 0.12 Neutral T126M 1570 1168.66 1078.26 1.08 0.28 0.21 Neutral T126P 1576 684.23 614.07 1.11 0.17 0.12 Neutral T126A 1575 2433.37 2923.43 0.83 0.59 0.58 Neutral T126N 1564 1449.19 1384.47 1.05 0.35 0.28 Up T126E 1559 697.86 580.78 1.20 0.17 0.12 Neutral T126F 1569 642.61 550.97 1.17 0.16 0.11 Neutral T126W 1571 632.89 564.16 1.12 0.15 0.11 Neutral T126Q 1565 664.00 591.91 1.12 0.16 0.12 Neutral T126S 1567 7114.42 6856.69 1.04 1.06 0.91 Neutral P127C 1582 1713.51 1846.56 0.93 0.41 0.37 Neutral P127F 1589 1444.31 1603.37 0.90 0.35 0.32 Neutral P127T 1585 2193.26 2519.16 0.87 0.53 0.50 Down P127E 1578 2480.57 3177.56 0.78 0.60 0.63 Neutral P127W 1591 1399.71 1476.35 0.95 0.34 0.29 Neutral P127A 1595 1751.82 1662.47 1.05 0.42 0.33 Neutral P127S 1587 2842.19 3070.41 0.93 0.69 0.61 Up P 127H 1579 2151.26 1693.77 1.27 0.52 0.34 Neutral P127Q 1584 1729.40 1882.54 0.92 0.42 0.37 Neutral P127K 1580 729.23 657.19 1.11 0.18 0.13 Neutral P127R 1581 1590.44 1491.10 1.07 0.38 0.30 Neutral P1271 1592 1432.03 1464.78 0.98 0.35 0.29 Neutral P127V 1593 1214.79 1401.27 0.87 0.29 0.28 Neutral P127L 1594 1536.18 1604.60 0.96 0.37 0.32 Neutral P127M 1590 2950.98 3052.79 0.97 0.71 0.61 Neutral L128F 1608 1165.63 1269.01 0.92 0.28 0.25 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 0 Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral L128M 1609 1898.38 2135.63 0.89 0.46 0.42 Neutral L128T 1604 756.63 698.21 1.08 0.18 0.14 Neutral L128R 1600 919.42 960.28 0.96 0.22 0.19 Neutral L128S 1606 764.28 672.98 1.14 0.18 0.13 Neutral L128G 1607 738.26 694.65 1.06 0.18 0.14 Neutral L1281 1611 1482.67 1715.03 0.86 0.36 0.34 Neutral L128Q 1603 1042.55 936.43 1.11 0.25 0.19 Neutral L128P 1614 792.57 760.45 1.04 0.19 0.15 Neutral L128A 1613 769.15 712.50 1.08 0.19 0.14 Neutral L128D 1596 682.02 642.58 1.06 0.16 0.13 Down L128V 1612 1285.36 1696.88 0.76 0.31 0.34 Neutral L128W 1610 776.89 664.61 1.17 0.19 0.13 Neutral L128C 1601 856.43 770.10 1.11 0.21 0.15 Neutral L128K 1599 858.27 846.02 1.01 0.21 0.17 Neutral T129G 1625 4435.98 5356.41 0.83 1.07 1.06 Down T129A 1632 2021.18 2774.35 0.73 0.49 0.55 Neutral T129C 1620 1057.55 1033.96 1.02 0.26 0.21 Neutral T129K 1618 3686.95 4446.15 0.83 0.89 0.88 Down T129F 1626 2980.80 3803.12 0.78 0.72 0.76 Neutral T129Y 1623 2527.88 2885.14 0.88 0.61 0.57 Neutral T129S 1624 1649.34 1529.13 1.08 0.40 0.30 Neutral T129R 1619 3334.95 3827.40 0.87 0.81 0.76 Neutral T129V 1630 4967.86 5698.42 0.87 1.20 1.13 Neutral T129L 1631 1649.57 1692.51 0.97 0.40 0.34 Down T129H 1617 3019.81 3803.29 0.79 0.73 0.76 Neutral T129P 1633 647.52 619.28 1.05 0.16 0.12 Neutral T129E 1616 3205.16 3919.94 0.82 0.77 0.78 Neutral T1291 1629 3967.14 4452.39 0.89 0.96 0.88 Down T129M 1627 4118.98 5214.21 0.79 1.00 1.04 Neutral F130L 1650 1452.17 1651.58 0.88 0.25 0.23 Neutral F130P 1652 703.36 797.39 0.88 0.12 0.11 Neutral F130C 1639 803.88 939.50 0.86 0.14 0.13 Neutral F130R 1638 613.42 687.58 0.89 0.10 0.09 Down F130Y 1643 2355.45 3604.50 0.65 0.40 0.49 Down F130H 1636 1209.72 1960.40 0.62 0.21 0.27 Down F1301 1648 4480.99 5648.72 0.79 0.76 0.77 Down F130V 1649 3403.91 4744.33 0.72 0.58 0.65 Neutral F130K 1637 581.97 670.87 0.87 0.10 0.09 Down F130T 1642 1529.21 2157.46 0.71 0.26 0.30 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral F130E 1635 571.41 648.15 0.88 0.10 0.09 Down F130A 1651 1414.89 1990.16 0.71 0.24 0.27 Neutral F130N 1640 616.91 710.45 0.87 0.10 0.10 Neutral F130G 1645 1553.35 1726.90 0.90 0.26 0.24 Down F130S 1644 793.40 1055.93 0.75 0.13 0.14 Down T131F 1664 2738.64 4500.49 0.61 0.48 0.59 Neutral T131P 1671 540.49 640.19 0.84 0.10 0.08 Down T131A 1670 3622.28 6028.39 0.60 0.64 0.79 Down T131S 1662 3644.14 5779.25 0.63 0.64 0.75 Down T131G 1663 3345.71 5523.72 0.61 0.59 0.72 Down T1311 1667 2987.26 4570.78 0.65 0.53 0.60 Down T131L 1669 3081.92 4518.80 0.68 0.54 0.59 Down T131H 1655 4201.01 5298.03 0.79 0.74 0.69 Down T131Q 1660 6169.43 8400.64 0.73 1.08 1.10 Neutral T131D 1653 8629.30 9616.48 0.90 1.52 1.26 Down T131E 1654 4396.59 6846.70 0.64 0.77 0.89 Down T131C 1658 2232.15 3514.32 0.64 0.39 0.46 Down T131R 1657 4325.73 6209.92 0.70 0.76 0.81 Down T131Y 1661 2684.82 3916.43 0.69 0.47 0.51 Down T131M 1665 3101.25 4674.29 0.66 0.55 0.61 Down K132G 1682 3779.04 5835.32 0.65 0.64 0.80 Down K132V 1687 3181.94 4834.70 0.66 0.54 0.66 Down K132L 1688 2407.98 3744.64 0.64 0.41 0.51 Down K132A 1689 5397.96 7468.39 0.72 0.92 1.02 Down K132P 1690 4062.71 5742.05 0.71 0.69 0.79 Down K132F 1683 2012.87 2934.12 0.69 0.34 0.40 Neutral K132R 1675 7317.48 8467.31 0.86 1.24 1.16 Down K1321 1686 1811.13 2747.29 0.66 0.31 0.38 Down K132H 1674 3291.99 4588.07 0.72 0.56 0.63 Neutral K132S 1681 4947.26 4913.96 1.01 0.84 0.67 Down K132M 1684 4521.82 6773.06 0.67 0.77 0.93 Down K132D 1672 2079.75 3166.80 0.66 0.35 0.43 Down K132T 1679 2515.58 4096.35 0.61 0.43 0.56 Down K132Y 1680 2363.32 3794.19 0.62 0.40 0.52 Down K132E 1673 3617.16 5597.32 0.65 0.61 0.77 Down V133G 1702 3203.88 5198.66 0.62 0.54 0.71 Down V133E 1692 3621.55 5211.22 0.69 0.62 0.71 Neutral V133T 1699 7931.49 8920.49 0.89 1.35 1.22 Down V133N 1697 4321.90 6145.40 0.70 0.73 0.84 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 0 Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Down V133A 1708 4764.29 6847.44 0.70 0.81 0.94 Down V133H 1693 3351.37 4739.59 0.71 0.57 0.65 Down V133P 1709 1405.33 2047.83 0.69 0.24 0.28 Down V133K 1694 5737.27 7514.38 0.76 0.97 1.03 Down V133R 1695 5773.82 7252.24 0.80 0.98 0.99 Neutral V133L 1707 7039.08 8445.43 0.83 1.20 1.16 Down V133W 1705 2475.35 3564.76 0.69 0.42 0.49 Down V133C 1696 1863.63 2666.24 0.70 0.32 0.37 Down V133D 1691 1792.46 2630.40 0.68 0.30 0.36 Down V133M 1704 4618.45 6302.34 0.73 0.78 0.86 Down V133S 1701 3077.53 4401.10 0.70 0.52 0.60 Down S 134V 1725 4041.51 5701.67 0.71 0.69 0.78 Neutral S 134H 1712 6079.44 7343.68 0.83 1.03 1.01 Down S134P 1728 4779.98 6326.78 0.76 0.81 0.87 Down S134G 1720 5540.33 7442.86 0.74 0.94 1.02 Neutral S134N 1716 6292.89 7595.95 0.83 1.07 1.04 Down S 134R 1714 5129.73 6824.16 0.75 0.87 0.94 Down S134L 1726 6015.18 8101.31 0.74 1.02 1.11 Down S 134Q 1717 4325.14 6159.02 0.70 0.73 0.84 Neutral S 134E 1711 7105.19 8577.53 0.83 1.21 1.18 Down S 134Y 1719 5061.86 6645.94 0.76 0.86 0.91 Down S134A 1727 5179.47 6920.72 0.75 0.88 0.95 Down S134K 1713 5768.02 7876.85 0.73 0.98 1.08 Neutral S134D 1710 6958.26 8316.41 0.84 1.18 1.14 Down S134T 1718 5585.98 7301.80 0.77 0.95 1.00 Down S134C 1715 1950.58 2625.09 0.74 0.33 0.36 Down E135V 1744 4036.77 5545.23 0.73 0.69 0.76 Neutral E135M 1741 8700.42 9297.63 0.94 1.48 1.27 Down E135S 1738 3895.80 5128.41 0.76 0.66 0.70 Down E135D 1729 4858.77 6640.34 0.73 0.83 0.91 Down E135T 1736 4870.41 6518.41 0.75 0.83 0.89 Down E135L 1745 3276.24 4342.02 0.75 0.56 0.59 Down E135A 1746 5143.68 7429.20 0.69 0.87 1.02 Down E135W 1742 3407.93 4761.19 0.72 0.58 0.65 Down E135F 1740 3206.26 4561.41 0.70 0.54 0.63 Down E135P 1747 1077.62 1567.43 0.69 0.18 0.21 Neutral E135R 1732 815.91 921.41 0.89 0.14 0.13 Down E135N 1734 4626.44 6661.57 0.69 0.79 0.91 Neutral E135H 1730 6074.22 7339.12 0.83 1.03 1.01 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 0 Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Down E135Q 1735 5656.70 7144.49 0.79 0.96 0.98 Down E1351 1743 2140.04 5232.08 0.41 0.36 0.72 Down G136V 1763 1813.26 2616.78 0.69 0.31 0.36 Down G136W 1761 993.10 1243.43 0.80 0.17 0.17 Down G136D 1748 3591.52 5274.69 0.68 0.61 0.72 Down G136M 1760 3515.40 5367.37 0.65 0.60 0.74 Down G136N 1754 3503.65 5155.57 0.68 0.60 0.71 Down G136A 1765 3559.58 5813.34 0.61 0.60 0.80 Down G136L 1764 2187.68 3866.01 0.57 0.37 0.53 Down G136C 1753 905.15 1515.22 0.60 0.15 0.21 Down G136P 1766 3234.60 4934.89 0.66 0.55 0.68 Down G136T 1756 2555.79 3746.36 0.68 0.43 0.51 Down G136R 1752 2716.62 4398.06 0.62 0.46 0.60 Down G136S 1758 3375.11 4670.21 0.72 0.57 0.64 Down G1361 1762 2006.39 3604.58 0.56 0.34 0.49 Down G136H 1750 3564.72 4804.54 0.74 0.61 0.66 Down G136E 1749 5583.49 7289.45 0.77 0.95 1.00 Down Q137A 1784 3966.25 6312.83 0.63 0.75 0.85 Down Q137R 1771 3671.71 6256.44 0.59 0.69 0.84 Down Q137G 1777 4573.46 6739.55 0.68 0.86 0.91 Down Q137K 1770 6317.49 8133.50 0.78 1.19 1.09 Down Q137H 1769 5645.75 7063.96 0.80 1.06 0.95 Down Q137P 1785 5676.99 7744.50 0.73 1.07 1.04 Down Q137S 1776 5384.46 7395.46 0.73 1.01 1.00 Down Q137L 1783 5870.03 8003.53 0.73 1.10 1.08 Down Q137W 1780 3200.77 5519.86 0.58 0.60 0.74 Down Q137F 1778 3505.51 5883.52 0.60 0.66 0.79 Down Q137T 1774 6636.95 8394.25 0.79 1.25 1.13 Down Q137C 1772 1924.03 2898.49 0.66 0.36 0.39 Down Q137Y 1775 5307.87 7091.79 0.75 1.00 0.95 Down Q137N 1773 5369.70 7661.25 0.70 1.01 1.03 Down Q137E 1768 5683.74 7333.42 0.78 1.07 0.99 Down A138V 1802 1926.65 3043.75 0.63 0.36 0.41 Neutral A138L 1803 594.07 675.23 0.88 0.11 0.09 Down A138P 1804 1481.25 2478.85 0.60 0.28 0.33 Down A138C 1791 1603.91 2981.97 0.54 0.30 0.40 Down A138T 1794 1740.56 2785.40 0.62 0.33 0.37 Down A138S 1796 2042.67 2909.34 0.70 0.38 0.39 Down A138R 1790 759.61 962.30 0.79 0.14 0.13 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Down A138G 1797 3108.95 4692.85 0.66 0.58 0.63 Down A138E 1787 1450.57 2644.44 0.55 0.27 0.36 Down A138H 1788 667.58 839.37 0.80 0.13 0.11 Neutral A138M 1799 626.50 749.79 0.84 0.12 0.10 Down A138Q 1793 1747.09 2754.75 0.63 0.33 0.37 Down A138I 1801 1984.57 3124.09 0.64 0.37 0.42 Neutral A138D 1786 601.71 673.39 0.89 0.11 0.09 Neutral A138W 1800 595.15 681.04 0.87 0.11 0.09 Neutral D139R 1808 639.90 725.74 0.88 0.12 0.10 Neutral D139V 1820 733.94 879.96 0.83 0.14 0.12 Down D139M 1817 820.44 1093.19 0.75 0.15 0.15 Neutral D139C 1809 763.17 886.67 0.86 0.14 0.12 Down D139P 1823 794.89 1048.41 0.76 0.15 0.14 Down D139S 1814 1060.53 1350.12 0.79 0.20 0.18 Neutral D139L 1821 802.45 923.25 0.87 0.15 0.12 Neutral D139I 1819 759.45 884.92 0.86 0.14 0.12 Down D139H 1806 1442.05 1944.83 0.74 0.27 0.26 Down D139A 1822 899.50 1179.38 0.76 0.17 0.16 Neutral D139G 1815 667.47 801.55 0.83 0.13 0.11 Neutral D139F 1816 670.14 828.73 0.81 0.13 0.11 Down D139N 1810 1743.46 2795.27 0.62 0.33 0.38 Neutral D139W 1818 641.04 769.42 0.83 0.12 0.10 Neutral D139Y 1813 643.83 701.07 0.92 0.12 0.09 Down D139E 1805 4365.22 7664.89 0.57 0.48 1.01 Neutral 1140D 1824 447.31 470.26 0.95 0.08 0.06 Neutral 1140K 1827 470.80 510.28 0.92 0.08 0.07 Neutral 1140A 1841 521.91 583.80 0.89 0.09 0.08 Neutral 1140G 1835 514.54 519.88 0.99 0.09 0.07 Neutral 1140C 1829 552.10 550.46 1.00 0.10 0.07 Neutral 1140Y 1833 476.67 511.05 0.93 0.08 0.07 Down 1140V 1839 1483.60 2240.10 0.66 0.26 0.29 Neutral 1140W 1838 541.30 540.55 1.00 0.10 0.07 Neutral 1140F 1836 671.22 710.61 0.94 0.12 0.09 Neutral I140H 1826 568.54 584.67 0.97 0.10 0.08 Down 1140L 1840 4551.18 6862.42 0.66 0.80 0.90 Neutral 1140R 1828 479.35 467.38 1.03 0.08 0.06 Neutral 1140E 1825 480.00 481.92 1.00 0.08 0.06 Down 1140M 1837 1888.65 2695.29 0.70 0.33 0.35 Neutral I140T 1832 493.59 505.63 0.98 0.09 0.07 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 0 Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Down M141E 1844 2661.78 3381.08 0.79 0.64 0.66 Neutral M141I 1857 3206.64 3834.28 0.84 0.77 0.74 Neutral M141R 1847 3645.85 4050.91 0.90 0.88 0.79 Neutral M141T 1851 1916.97 2186.65 0.88 0.46 0.42 Neutral M141P 1861 957.33 1027.91 0.93 0.23 0.20 Neutral M141S 1853 2578.82 3190.11 0.81 0.62 0.62 Neutral M141C 1848 1162.41 1355.08 0.86 0.28 0.26 Down M141L 1859 3257.69 4218.46 0.77 0.79 0.82 Down M141A 1860 2798.52 3561.95 0.79 0.68 0.69 Down M141D 1843 1943.58 2586.12 0.75 0.47 0.50 Neutral M141W 1856 3860.87 4822.22 0.80 0.93 0.94 Neutral M141G 1854 1252.97 1525.59 0.82 0.30 0.30 Neutral M141H 1845 2221.73 2624.41 0.85 0.54 0.51 Neutral M141Y 1852 2117.90 2326.92 0.91 0.51 0.45 Neutral M141N 1849 3446.02 4175.18 0.83 0.83 0.81 Down 1142L 1878 4079.65 6338.98 0.64 0.72 0.83 Down 1142M 1875 2514.92 3872.66 0.65 0.44 0.51 Neutral 1142G 1873 590.45 573.21 1.03 0.10 0.07 Neutral I142K 1865 567.58 566.13 1.00 0.10 0.07 Down 1142A 1879 1102.77 1776.73 0.62 0.19 0.23 Neutral I142N 1868 544.78 582.84 0.93 0.10 0.08 Neutral 1142W 1876 614.88 660.20 0.93 0.11 0.09 Neutral 1142P 1880 517.98 553.16 0.94 0.09 0.07 Neutral I142Q 1869 561.05 579.03 0.97 0.10 0.08 Neutral 1142Y 1871 535.36 568.63 0.94 0.09 0.07 Down 1142V 1877 2412.99 3835.99 0.63 0.42 0.50 Neutral 1142T 1870 619.92 700.51 0.88 0.11 0.09 Neutral I142R 1866 592.22 631.35 0.94 0.10 0.08 Neutral 1142S 1872 560.11 608.47 0.92 0.10 0.08 Down 1142F 1874 988.49 1616.93 0.61 0.17 0.21 Neutral S143P 1899 681.44 714.91 0.95 0.13 0.10 Down S143C 1886 1242.25 1638.96 0.76 0.23 0.22 Neutral S143E 1882 679.14 698.14 0.97 0.13 0.09 Down S143G 1891 2178.31 3221.72 0.68 0.41 0.43 Down S143H 1883 1946.43 3055.74 0.64 0.37 0.41 Down S143R 1885 5284.60 7026.38 0.75 0.99 0.95 Down S143L 1897 1855.11 3143.09 0.59 0.35 0.42 Down S143Q 1888 4008.07 5922.69 0.68 0.75 0.80 Down S143N 1887 3447.12 4827.78 0.71 0.65 0.65 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral S143W 1894 1164.49 1414.47 0.82 0.22 0.19 Down S143A 1898 4862.16 6797.05 0.72 0.91 0.91 Down S143T 1889 3510.83 4873.23 0.72 0.66 0.66 Down S143Y 1890 2566.36 3755.42 0.68 0.48 0.51 Down S143M 1893 3680.60 6112.93 0.60 0.69 0.82 Neutral S1431 1895 6798.46 8447.06 0.80 1.28 1.14 Neutral F144K 1903 683.92 723.08 0.95 0.13 0.10 Neutral F144M 1912 727.58 785.61 0.93 0.14 0.11 Neutral F 144E 1901 684.55 697.38 0.98 0.13 0.09 Neutral F144S 1910 711.27 779.76 0.91 0.13 0.10 Neutral F144L 1916 668.14 725.88 0.92 0.13 0.10 Down F144W 1913 3272.56 4375.61 0.75 0.62 0.59 Neutral F144P 1918 658.07 729.61 0.90 0.12 0.10 Neutral F144R 1904 633.36 704.49 0.90 0.12 0.09 Neutral F144N 1906 648.28 686.56 0.94 0.12 0.09 Neutral F144C 1905 656.21 698.34 0.94 0.12 0.09 Neutral F 144G 1911 641.29 662.20 0.97 0.12 0.09 Neutral F144T 1908 704.60 804.24 0.88 0.13 0.11 Neutral F144Q 1907 679.28 759.34 0.89 0.13 0.10 Neutral F144H 1902 766.54 861.04 0.89 0.14 0.12 Neutral F 144V 1915 664.73 737.66 0.90 0.12 0.10 Down V 145A 1936 5042.62 7103.17 0.71 0.89 0.93 Down V145T 1927 3518.22 5408.09 0.65 0.62 0.71 Down V145L 1935 4048.83 6522.67 0.62 0.71 0.85 Down V145P 1937 2148.04 3271.70 0.66 0.38 0.43 Down V 145K 1922 4566.52 6542.14 0.70 0.80 0.85 Down V145N 1925 5756.42 8553.91 0.67 1.01 1.12 Down V145D 1919 3249.52 5915.18 0.55 0.57 0.77 Down V145H 1921 3868.79 6370.16 0.61 0.68 0.83 Down V 145R 1923 5093.69 7494.19 0.68 0.90 0.98 Down V145Q 1926 4550.79 6385.09 0.71 0.80 0.83 Down V145S 1929 5229.00 7486.54 0.70 0.92 0.98 Down V145G 1930 2139.70 3072.06 0.70 0.38 0.40 Down V145W 1933 1735.30 3046.73 0.57 0.31 0.40 Down V145C 1924 1652.16 3231.89 0.51 0.29 0.42 Down V145E 1.920 4086.60 6893.09 0.59 0.72 0.90 Down R146T 1945 4145.84 6737.53 0.62 0.78 0.91 Down R146L 1954 2149.16 3444.38 0.62 0.40 0.46 Down R146N 1943 4441.83 6346.03 0.70 0.83 0.85 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral R146H 1940 2791.26 3298.03 0.85 0.52 0.44 Down R146Q 1944 4232.35 6620.08 0.64 0.80 0.89 Down R146K 1941 5360.91 7104.88 0.75 1.01 0.96 Neutral R146C 1942 776.54 868.97 0.89 0.15 0.12 Neutral R146S 1947 8627.00 9288.66 0.93 1.62 1.25 Down R146D 1938 3803.07 5389.79 0.71 0.71 0.73 Down R146A 1955 4939.79 6859.12 0.72 0.93 0.92 Down R146Y 1946 3175.81 5447.89 0.58 0.60 0.73 Neutral R146P 1956 3019.88 2923.15 1.03 0.57 0.39 Down R146V 1953 3662.01 6193.78 0.59 0.69 0.83 Down R146E 1939 2538.71 3832.21 0.66 0.48 0.52 Down R146F 1949 1272.11 2074.69 0.61 0.24 0.28 Neutral G147R 1961 7744.82 8412.88 0.92 1.45 1.25 Neutral G147F 1968 7821.91 7899.45 0.99 1.47 1.18 Neutral G1471 1971 1451.75 1461.30 0.99 0.27 0.22 Down G147L 1973 1325.33 1787.45 0.74 0.25 0.27 Neutral G147A 1974 2288.45 2655.58 0.86 0.43 0.40 Down G147E 1958 1802.97 2340.36 0.77 0.34 0.35 Neutral G147H 1959 6234.09 7432.44 0.84 1.17 1.11 Down G147W 1970 5140.21 6807.71 0.76 0.96 1.01 Down G147T 1965 5531.13 7240.25 0.76 1.04 1.08 Neutral G147C 1962 6950.51 7385.23 0.94 1.30 1.10 Down G147S 1967 3071.28 3887.91 0.79 0.58 0.58 Neutral G147V 1972 4516.19 5576.27 0.81 0.85 0.83 Neutral G147Q 1964 6879.67 7686.98 0.89 1.29 1.14 Neutral G147M 1969 6059.54 7381.69 0.82 1.14 1.10 Up G147P 1975 494.94 392.93 1.26 0.07 0.05 Neutral D148R 1979 5874.44 7069.98 0.83 1.10 1.05 Down D 1481 1990 4934.66 6621.95 0.75 0.93 0.99 Neutral D148T 1983 5534.68 6527.74 0.85 1.04 0.97 Neutral D148G 1986 5545.91 6487.49 0.85 1.04 0.97 Neutral D148L 1992 1738.87 2136.70 0.81 0.33 0.32 Neutral D148V 1991 4521.62 5307.74 0.85 0.85 0.79 Neutral D148A 1993 7276.18 7955.06 0.91 1.36 1.18 Down D148W 1989 3622.09 4894.24 0.74 0.68 0.73 Neutral D148P 1994 7311.56 7404.67 0.99 1.37 1.10 Neutral D148S 1985 3190.82 3936.89 0.81 0.60 0.59 Down D148K 1978 2414.59 3115.25 0.78 0.45 0.46 Down D148E 1976 2457.68 3171.30 0.77 0.46 0.47 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral D148M 1988 928.12 1156.79 0.80 0.17 0.17 Neutral D148N 1981 5136.96 5810.99 0.88 0.96 0.87 Neutral D148C 1980 2617.98 3259.70 0.80 0.49 0.49 Neutral H149W 2008 578.88 610.12 0.95 0.10 0.08 Neutral H149A 2012 574.51 606.50 0.95 0.10 0.08 Neutral H149L 2011 562.23 585.57 0.96 0.10 0.08 Neutral H149C 1999 532.13 536.84 0.99 0.09 0.07 Neutral H149Q 2001 547.46 565.60 0.97 0.10 0.07 Neutral H149T 2002 545.99 567.99 0.96 0.10 0.07 Neutral H149Y 2003 553.52 575.93 0.96 0.10 0.08 Neutral H149P 2013 502.45 522.17 0.96 0.09 0.07 Neutral H149V 2010 515.00 521.68 0.99 0.09 0.07 Neutral H149R 1998 481.87 534.48 0.90 0.08 0.07 Neutral H149G 2005 492.47 525.75 0.94 0.09 0.07 Neutral H149E 1996 476.14 472.99 1.01 0.08 0.06 Neutral H149S 2004 481.76 508.54 0.95 0.08 0.07 Neutral H1491 2009 510.38 533.47 0.96 0.09 0.07 Neutral H149N 2000 542.00 555.29 0.98 0.10 0.07 Neutral R150S 50 4221.17 4687.08 0.90 0.58 0.66 Neutral R150E 42 9557.47 8282.03 1.15 1.31 1.17 Neutral R150G 51 10002.15 8470.68 1.18 1.37 1.19 Neutral R150M 53 8614.46 8306.99 1.04 1.18 1.17 Up R150P 59 2291.14 828.28 2.77 0.31 0.12 Neutral R150T 48 9808.17 8294.42 1.18 1.35 1.17 Neutral R150W 54 8373.53 7574.51 1.11 1.15 1.07 Neutral R150A 58 10175.13 8554.82 1.19 1.40 1.20 Neutral R150N 46 10191.05 8571.32 1.19 1.40 1.21 Neutral R150K 44 9471.29 8346.99 1.13 1.30 1.18 Neutral R150L 57 9751.98 8444.63 1.15 1.34 1.19 Neutral R150V 56 6869.28 6604.61 1.04 1.20 1.30 Neutral R150D 41 7230.41 6033.28 1.20 1.26 1.19 Down R1501 55 3120.05 4082.34 0.76 0.39 0.55 Neutral R150H 43 8281.04 8056.17 1.03 1.05 1.08 Neutral D 151 R 63 576.24 545.21 1.06 0.11 0.08 Neutral D151F 71 626.76 601.08 1.04 0.12 0.09 Neutral D151P 78 670.23 610.90 1.10 0.13 0.09 Neutral D151W 73 691.38 656.86 1.05 0.13 0.10 Neutral D151Q 66 634.58 619.91 1.02 0.12 0.09 Neutral D 151 L 76 638.24 627.06 1.02 0.12 0.09 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral D 151 S 69 612.74 579.48 1.06 0.11 0.09 Up D151G 70 1073.32 733.89 1.46 0.20 0.11 Neutral D151A 77 635.33 608.12 1.04 0.12 0.09 Neutral D151N 65 631.72 612.41 1.03 0.12 0.09 Neutral D151K 62 648.63 635.47 1.02 0.12 0.09 Neutral D151Y 68 744.90 724.43 1.03 0.14 0.11 Neutral D151V 75 586.23 585.19 1.00 0.11 0.09 Neutral D151T 67 589.61 587.04 1.00 0.11 0.09 Up D151M 72 2945.18 605.81 4.86 0.55 0.09 Neutral N152G 2024 9852.70 8326.15 1.18 1.35 1.17 Neutral N152C 2019 6322.44 7849.36 0.81 0.87 1.11 Neutral N152F 2025 9762.67 8643.34 1.13 1.34 1.22 Neutral N152L 2030 9176.14 8510.93 1.08 1.26 1.20 Neutral N152P 2032 7767.98 7907.66 0.98 1.07 1.11 Neutral N152R 2018 8348.81 7893.25 1.06 1.14 1.11 Down N152H 2016 3318.01 4257.74 0.78 0.46 0.60 Neutral N152T 2021 7155.46 7180.94 1.00 0.98 1.01 Neutral N152Y 2022 8343.23 7992.79 1.04 1.14 1.13 Neutral N152K 2017 7868.59 7956.82 0.99 1.08 1.12 Neutral N 152D 2014 10221.41 8616.74 1.19 1.40 1.21 Neutral N152W 2027 5717.25 7086.82 0.81 0.78 1.00 Neutral N1521 2028 10161.44 8648.89 1.17 1.39 1.22 Neutral N152A 2031 6669.94 5660.16 1.18 1.17 1.12 Down N152S 2023 4607.85 8096.31 0.57 0.58 1.08 Neutral S1531 549 2873.12 2619.74 1.10 0.39 0.37 Neutral S153R 539 4799.14 4905.35 0.98 0.66 0.69 Neutral S153K 538 1002.00 1199.78 0.84 0.14 0.17 Down S153C 540 1934.36 3181.56 0.61 0.27 0.45 Neutral S153G 545 6175.12 6148.70 1.00 0.85 0.87 Neutral S153H 537 9759.94 8837.02 1.10 1.34 1.24 Neutral S153L 551 1285.63 1575.63 0.82 0.18 0.22 Neutral S153V 550 8993.77 8047.48 1.12 1.23 1.13 Neutral S153T 543 10530.07 8798.72 1.20 1.44 1.24 Neutral S 153P 553 9442.29 8513.31 1.11 1.29 1.20 Neutral S 153A 552 644.02 569.42 1.13 0.09 0.08 Neutral S153F 546 10583.60 8979.56 1.18 1.45 1.26 Neutral S153D 535 8477.40 8662.71 0.98 1.16 1.22 Neutral S153Q 542 6654.12 7947.98 0.84 0.91 1.12 Neutral S153Y 544 10164.62 8758.66 1.16 1.39 1.23 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral P 154V 2049 1257.75 1273.72 0.99 0.24 0.19 Up P154W 2047 3838.51 2992.41 1.28 0.72 0.45 Neutral P154L 2050 5826.55 6782.07 0.86 1.09 1.01 Neutral P154C 2038 3097.69 3692.51 0.84 0.58 0.55 Neutral P154S 2043 7417.09 8143.14 0.91 1.39 1.21 Up P154K 2036 2407.68 1639.28 1.47 0.45 0.24 Neutral P1541 2048 7298.30 7549.63 0.97 1.37 1.12 Down P154A 2051 2043.76 2680.62 0.76 0.38 0.40 Neutral P154T 2041 1763.73 2075.38 0.85 0.33 0.31 Neutral P154H 2035 1072.51 1021.04 1.05 0.20 0.15 Neutral P154Y 2042 946.74 834.91 1.13 0.18 0.12 Neutral P154N 2039 1122.04 1229.36 0.91 0.21 0.18 Neutral P 154F 2045 845.38 757.86 1.12 0.16 0.11 Neutral P154R 2037 1975.77 1915.36 1.03 0.37 0.29 Neutral P154Q 2040 2228.56 2374.11 0.94 0.42 0.35 Neutral F155S 89 894.19 833.57 1.07 0.17 0.12 Neutral F155T 87 1137.71 1084.01 1.05 0.21 0.16 Neutral F155G 90 807.68 718.82 1.12 0.15 0.11 Neutral F155N 85 715.78 688.72 1.04 0.13 0.10 Neutral F155R 83 702.49 695.27 1.01 0.13 0.10 Neutral F155W 92 715.40 693.53 1.03 0.13 0.10 Up F155L 95 1322.13 864.19 1.53 0.25 0.13 Neutral F155Q 86 731.28 738.56 0.99 0.14 0.11 Neutral F155M 91 8252.43 8163.55 1.01 1.55 1.22 Neutral F155E 80 685.90 683.12 1.00 0.13 0.10 Up F155A 96 1250.93 760.12 1.65 0.23 0.11 Neutral F155P 97 666.89 658.85 1.01 0.13 0.10 Neutral F155V 94 681.25 679.13 1.00 0.13 0.10 Neutral F155H 81 696.34 683.06 1.02 0.13 0.10 Neutral F155Y 88 676.73 629.34 1.08 0.13 0.09 Up D156H 99 2722.09 2081.55 1.31 0.51 0.31 Up D156L 114 2548.30 1597.53 1.60 0.48 0.24 Neutral D156E 98 6300.50 6871.25 0.92 1.18 1.02 Up D 156A 115 2679.29 1734.45 1.54 0.50 0.26 Up D156W 111 1575.39 1268.36 1.24 0.30 0.19 Neutral D156C 102 2842.85 2704.37 1.05 0.53 0.40 Neutral D 156P 116 1002.13 998.80 1.00 0.19 0.15 Up D156V 113 1400.88 766.80 1.83 0.26 0.11 Up D 156K 100 1292.89 966.62 1.34 0.24 0.14 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 0 Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral D156S 107 969.70 837.57 1.16 0.18 0.12 Neutral D156G 108 794.14 709.60 1.12 0.15 0.11 Up D156T 105 2871.09 1843.03 1.56 0.54 0.27 Neutral D156Y 106 3406.50 3113.95 1.09 0.64 0.46 Up D156R 101 2431.23 1545.89 1.57 0.46 0.23 Up D 156M 110 817.96 502.82 1.63 0.12 0.07 Up G157K 2055 677.09 562.66 1.20 0.09 0.08 Neutral G157D 2052 603.28 513.64 1.17 0.08 0.07 Neutral G157F 2064 9535.19 8450.24 1.13 1.31 1.19 Up G157R 2056 704.56 540.98 1.30 0.10 0.08 Neutral G157H 2054 608.42 567.38 1.07 0.08 0.08 Up G157L 2069 582.39 476.09 1.22 0.08 0.07 Up G157N 2059 721.55 534.46 1.35 0.10 0.08 Up G157Y 2062 654.13 541.41 1.21 0.09 0.08 Up G157S 2063 924.62 596.70 1.55 0.13 0.08 Up G157T 2061 669.55 551.99 1.21 0.09 0.08 Up G157A 2070 861.29 552.54 1.56 0.12 0.08 Up G157Q 2060 655.49 522.72 1.25 0.09 0.07 Neutral G157P 2071 635.63 591.49 1.07 0.09 0.08 Neutral G157V 2068 654.45 573.19 1.14 0.09 0.08 Neutral G157M 2065 716.52 615.65 1.16 0.10 0.09 Neutral P158S 2082 7974.07 7118.62 1.12 1.09 1.00 Neutral P158Y 2081 7544.63 6885.81 1.10 1.03 0.97 Neutral P158R 2076 7142.54 6214.55 1.15 0.98 0.88 Up P158L 2089 9290.77 6775.04 1.37 1.27 0.95 Neutral P158V 2088 10642.99 8919.30 1.19 1.46 1.26 Up P158C 2077 6284.97 4792.49 1.31 0.86 0.67 Neutral P158A 2090 9579.29 8514.00 1.13 1.31 1.20 Up P158W 2086 5175.38 3078.22 1.68 0.71 0.43 Neutral P1581 2087 10312.96 8597.26 1.20 1.41 1.21 Up P158F 2084 6595.54 4090.71 1.61 0.90 0.58 Up P158Q 2079 10928.51 8709.20 1.25 1.50 1.23 Neutral P158T 2080 4204.23 3507.76 1.20 0.53 0.47 Neutral P158G 2083 6277.86 5496.27 1.14 0.79 0.73 Neutral P158K 2075 6860.82 6680.30 1.03 0.87 0.89 Neutral P158N 2078 3656.04 3874.48 0.94 0.46 0.52 Up P158D 2072 8959.02 7355.10 1.22 0.98 0.96 Neutral G159R 121 6441.49 5914.02 1.09 0.88 0.83 Neutral G159S 127 6594.46 6573.14 1.00 0.90 0.93 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 0 Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral G159Q 124 3996.96 4391.10 0.91 0.55 0.62 Neutral G159P 135 596.30 564.24 1.06 0.08 0.08 Up G159V 132 2453.98 732.46 3.35 0.34. 0.10 Neutral G159K 120 554.74 515.44 1.08 0.08 0.07 Neutral G159A 134 5157.14 4685.20 1.10 0.71 0.66 Up G159Y 126 1029.19 752.76 1.37 0.14 0.11 Neutral G159E 118 4327.74 4027.23 1.07 0.59 0.57 Up G159T 125 5059.91 1734.12 2.92 0.69 0.24 Up G159M 129 5905.06 4874.00 1.21 0.75 0.65 Neutral G1591 131 5725.99 5357.20 1.07 0.72 0.72 Neutral G159W 130 6787.40 6287.71 1.08 0.86 0.84 Neutral G159L 133 8231.62 7638.64 1.08 1.04 1.02 Neutral G159C 122 2897.77 3053.86 0.95 0.37 0.41 Down G160A 2108 2080.01 2823.12 0.74 0.60 0.58 Down G160H 2093 2001.10 3085.22 0.65 0.57 0.63 Down G160N 2097 3546.69 5339.11 0.66 1.02 1.09 Neutral G160W 2104 4334.72 3946.12 1.10 1.24 0.80 Down G160R 2095 2347.11 3791.36 0.62 0.67 0.77 Neutral G160P 2109 1047.77 929.25 1.13 0.30 0.19 Neutral G1601 2105 1794.48 1596.11 1.12 0.51 0.33 Down G160M 2103 2506.95 3576.91 0.70 0.72 0.73 Neutral G160C 2096 580.68 627.99 0.92 0.17 0.13 Down G160Q 2098 4740.98 6839.68 0.69 1.36 1.39 Neutral G160V 2106 3284.36 3030.37 1.08 0.94 0.62 Down G160S 2101 2991.02 4281.08 0.70 0.86 0.87 Neutral G160E 2092 3899.28 4071.63 0.96 1.12 0.83 Down G160L 2107 3396.11 4411.61 0.77 0.97 0.90 Neutral G160T 2099 3844.32 3943.21 0.97 1.10 0.80 Down N161 S 2119 1251.34 2417.50 0.52 0.36 0.49 Down N161C 2115 1591.15 2710.58 0.59 0.46 0.55 Down N161L 2126 4840.46 7275.68 0.67 1.39 1.48 Neutral N161R 2114 6437.08 7915.53 0.81 1.85 1.61 Down N161G 2120 3755.93 6728.88 0.56 1.08 1.37 Down N161W 2123 3135.58 3994.07 0.79 0.90 0.81 Down N161Y 2118 5507.52 7319.79 0.75 1.58 1.49 Down N161E 2111 5410.44 8192.46 0.66 1.55 1.67 Down N161P 2128 1231.02 1593.36 0.77 0.35 0.32 Neutral N161T 2117 7464.29 9082.12 0.82 2.14 1.85 Down N161H 2112 2727.71 5034.74 0.54 0.78 1.03 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral N1611 2124 8070.21 9914.56 0.81 2.31 2.02 Down N161V 2125 5238.40 7429.22 0.71 1.50 1.51 Down N161F 2121 3890.45 6624.80 0.59 1.12 1.35 Down N161Q 2116 4690.72 7412.73 0.63 1.35 1.51 Neutral L162A 2146 584.17 505.94 1.15 0.17 0.10 Neutral L162G 2140 582.48 602.57 0.97 0.17 0.12 Neutral L162C 2134 475.91 466.85 1.02 0.14 0.10 Neutral L162P 2147 514.26 519.71 0.99 0.15 0.11 Neutral L162R 2133 492.19 498.99 0.99 0.14 0.10 Down L1621 2144 2948.11 4018.68 0.73 0.85 0.82 Neutral L162S 2139 473.63 459.28 1.03 0.14 0.09 Neutral L162D 2129 512.72 487.18 1.05 0.15 0.10 Neutral L162M 2142 1013.31 1138.86 0.89 0.29 0.23 Neutral L162E 2130 563.63 631.85 0.89 0.16 0.13 Neutral L162T 2137 473.46 477.00 0.99 0.14 0.10 Neutral L162Y 2138 484.26 519.58 0.93 0.14 0.11 Neutral L162F 2141 484.37 469.30 1.03 0.14 0.10 Neutral L162W 2143 463.12 457.12 1.01 0.13 0.09 Neutral L162Q 2136 480.75 481.03 1.00 0.14 0.10 Neutral A163R 2152 562.68 563.06 1.00 0.16 0.11 Neutral A163G 2159 819.22 999.88 0.82 0.23 0.20 Neutral A163Y 2157 562.12 549.69 1.02 0.16 0.11 Neutral A163P 2166 557.10 559.72 1.00 0.16 0.11 Neutral A163S 2158 572.70 542.75 1.06 0.16 0.11 Neutral A163L 2165 532.98 539.88 0.99 0.15 0.11 Neutral A163C 2153 528.01 546.64 0.97 0.15 0.11 Neutral A163K 2151 510.99 502.63 1.02 0.15 0.10 Neutral A163V 2164 567.33 572.66 0.99 0.16 0.12 Down A163F 2160 931.85 1182.48 0.79 0.27 0.24 Neutral A163E 2149 560.80 539.21 1.04 0.16 0.11 Neutral A163T 2156 538.98 537.66 1.00 0.15 0.11 Neutral A163Q 2155 586.94 586.24 1.00 0.17 0.12 Neutral A1631 2163 554.29 579.47 0.96 0.16 0.12 Neutral A163N 2154 575.87 580.49 0.99 0.17 0.12 Neutral H164L 2183 547.21 565.25 0.97 0.16 0.12 Neutral H164M 2179 552.91 590.51 0.94 0.16 0.12 Neutral H164K 2169 575.53 589.33 0.98 0.17 0.12 Neutral H164P 2185 573.34 570.59 1.00 0.16 0.12 Neutral H164C 2171 551.45 576.69 0.96 0.16 0.12 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral H164R 2170 558.91 553.87 1.01 0.16 0.11 Neutral H164A 2184 549.93 598.96 0.92 0.16 0.12 Neutral H164V 2182 567.08 579.35 0.98 0.16 0.12 Down H164S 2176 4849.81 6939.34 0.70 1.39 1.41 Down H164N 2172 437.45 585.42 0.75 0.13 0.12 Neutral H164G 2177 545.54 547.89 1.00 0.16 0.11 Neutral H164F 2178 540.67 537.69 1.01 0.16 0.11 Neutral H164Y 2175 558.66 548.15 1.02 0.16 0.11 Neutral H164Q 2173 566.62 555.39 1.02 0.16 0.11 Neutral H164E 2168 569.92 612.16 0.93 0.16 0.12 Neutral A165W 2200 583.56 591.99 0.99 0.17 0.12 Neutral A165V 2202 560.38 564.19 0.99 0.16 0.11 Down A165G 2197 445.09 575.94 0.77 0.13 0.12 Neutral A165K 2189 537.18 537.57 1.00 0.15 0.11 Neutral A165L 2203 552.58 553.45 1.00 0.16 0.11 Neutral A165P 2204 535.50 554.41 0.97 0.15 0.11 Down A165Q 2193 983.84 1344.06 0.73 0.28 0.27 Neutral A165D 2186 534.17 577.13 0.93 0.15 0.12 Neutral A165H 2188 515.90 536.85 0.96 0.15 0.11 Neutral A165F 2198 493.42 496.39 0.99 0.14 0.10 Down A165S 2196 390.18 578.00 0.68 0.11 0.12 Neutral A165T 2194 506.15 502.78 1.01 0.15 0.10 Neutral A165R 2190 485.08 477.19 1.02 0.14 0.10 Neutral A165N 2192 509.08 499.01 1.02 0.15 0.10 Neutral A165M 2199 473.24 523.60 0.90 0.14 0.11 Neutral F166G 2216 623.89 586.56 1.06 0.11 0.08 Neutral F166S 2215 724.53 695.67 1.04 0.12 0.10 Neutral F166L 2221 760.25 829.02 0.92 0.13 0.12 Neutral F166V 2220 552.68 564.25 0.98 0.09 0.08 Neutral F166P 2223 530.80 562.94 0.94 0.09 0.08 Neutral F166N 2211 613.07 589.89 1.04 0.10 0.08 Neutral F166R 2209 534.62 543.15 0.98 0.09 0.08 Neutral F166A 2222 638.77 712.81 0.90 0.11 0.10 Neutral F166K 2208 598.42 615.59 0.97 0.10 0.09 Neutral F166H 2207 2770.43 2606.89 1.06 0.47 0.37 Neutral F166W 2218 8234.80 8549.89 0.96 1.40 1.20 Neutral F1661 2219 617.86 613.36 1.01 0.10 0.09 Neutral F166M 2217 537.05 571.21 0.94 0.09 0.08 Neutral F166C 2210 661.10 639.33 1.03 0.11 0.09 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral F166E 2206 616.99 582.48 1.06 0.10 0.08 Neutral Q167D 2224 4883.56 4579.11 1.07 0.83 0.64 Neutral Q167R 2228 7660.88 8025.72 0.95 1.30 1.12 Neutral Q 167A 2241 8466.37 8182.70 1.03 1.44 1.15 Neutral Q167S 2233 7915.08 8512.14 0.93 1.34 1.19 Neutral Q167F 2235 8209.07 8535.93 0.96 1.39 1.20 Down Q167Y 2232 5687.17 7642.43 0.74 0.96 1.07 Neutral Q167P 2242 7513.70 8011.11 0.94 1.27 1.12 Neutral Q167T 2231 7772.59 8173.09 0.95 1.32 1.15 Neutral Q167V 2239 7867.97 8191.44 0.96 1.33 1.15 Neutral Q167L 2240 7174.37 7937.04 0.90 1.22 1.11 Neutral Q167M 2236 8005.59 8974.74 0.89 1.36 1.26 Down Q167N 2230 3612.25 5004.93 0.72 0.61 0.70 Neutral Q167G 2234 6671.99 7782.93 0.86 1.13 1.09 Neutral Q167K 2227 6453.33 7646.48 0.84 1.09 1.07 Down Q167E 2225 5009.36 6388.75 0.78 0.85 0.90 Neutral P168N 2249 638.46 590.71 1.08 0.11 0.08 Neutral P168F 2255 673.09 638.53 1.05 0.11 0.09 Neutral P168R 2247 7038.51 7902.50 0.89 1.19 1.11 Neutral P 168W 2257 737.53 666.57 1.11 0.13 0.09 Neutral P168A 2261 833.88 736.90 1.13 0.14 0.10 Neutral P 168T 2251 646.42 645.28 1.00 0.11 0.09 Neutral P168V 2259 499.02 557.37 0.90 0.08 0.08 Neutral P 168G 2254 686.51 644.44 1.07 0.12 0.09 Neutral P168C 2248 568.42 598.90 0.95 0.10 0.08 Neutral P 168M 2256 734.84 652.57 1.13 0.12 0.09 Neutral P168H 2245 590.54 588.07 1.00 0.10 0.08 Neutral P168L 2260 715.20 706.06 1.01 0.12 0.10 Neutral P168S 2253 641.79 605.44 1.06 0.11 0.08 Neutral P168I 2258 560.15 568.90 0.98 0.09 0.08 Neutral P168D 2243 530.69 575.63 0.92 0.09 0.08 Neutral G169H 2264 791.08 828.63 0.95 0.13 0.12 Down G169A 2279 1556.29 2632.37 0.59 0.26 0.37 Neutral G169E 2263 789.82 829.24 0.95 0.13 0.12 Neutral G169C 2267 714.55 744.33 0.96 0.12 0.10 Neutral G169S 2272 1196.93 1427.18 0.84 0.20 0.20 Neutral G169L 2278 450.44 534.57 0.84 0.08 0.07 Neutral G169V 2277 703.56 675.20 1.04 0.12 0.09 Neutral G169T 2270 676.59 685.16 0.99 0.11 0.10 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral G169R 2266 1119.16 1166.00 0.96 0.19 0.16 Neutral G169W 2275 802.02 921.44 0.87 0.14 0.13 Neutral G169M 2274 962.20 1133.87 0.85 0.16 0.16 Neutral G1691 2276 671.79 677.10 0.99 0.11 0.09 Neutral G169P 2280 671.60 683.22 0.98 0.11 0.10 Neutral G169D 2262 714.59 766.96 0.93 0.12 0.11 Neutral G169Q 2269 977.05 901.01 1.08 0.17 0.13 Down P 170L 2298 5969.84 7995.99 0.75 1.01 1.12 Down P170R 2285 3566.07 5876.72 0.61 0.60 0.82 Down P1701 2296 5073.27 7150.78 0.71 0.86 1.00 Neutral P170T 2289 6734.46 8153.81 0.83 1.14 1.14 Down P170F 2293 2114.36 3365.04 0.63 0.36 0.47 Down P170Q 2288 4204.94 6162.63 0.68 0.71 0.86 Down P 170G 2292 5005.05 6924.03 0.72 0.85 0.97 Down P170S 2291 4526.99 6064.79 0.75 0.77 0.85 Down P 170H 2283 4569.14 6879.10 0.66 0.77 0.96 Down P170C 2286 931.84 2355.40 0.40 0.16 0.33 Down P170M 2294 3323.56 6318.16 0.53 0.56 0.89 Down P 170K 2284 4379.75 6206.45 0.71 0.74 0.87 Down P170W 2295 1794.33 2781.05 0.65 0.30 0.39 Neutral P170D 2281 1434.38 1462.91 0.98 0.25 0.29 Neutral P170A 2299 2733.72 2793.24 0.98 0.48 0.55 Down G171 S 564 2129.39 3316.87 0.64 0.36 0.46 Down G171M 566 2104.33 3308.36 0.64 0.36 0.46 Down G171N 560 4674.81 6965.17 0.67 0.79 0.98 Up G171P 572 1570.74 1204.39 1.30 0.27 0.17 Down G171R 558 1604.06 2486.74 0.65 0.27 0.35 Down G171Y 563 1519.56 2342.05 0.65 0.26 0.33 Down G171A 571 3517.89 5269.99 0.67 0.60 0.74 Down G171Q 561 2361.29 3915.33 0.60 0.40 0.55 Down G171H 556 1662.65 2616.63 0.64 0.28 0.37 Down G171L 570 1551.95 2516.17 0.62 0.26 0.35 Down G171W 567 1068.10 1663.46 0.64 0.18 0.23 Down G171C 559 1982.45 3409.68 0.58 0.34 0.48 Down G171K 557 1324.98 1867.15 0.71 0.22 0.26 Neutral G171E 555 1154.96 1199.65 0.96 0.20 0.24 Neutral G171D 554 791.81 690.33 1.15 0.14 0.14 Neutral 1172Y 2309 7427.25 7893.50 0.94 0.93 0.95 Neutral 1172T 2308 5861.67 6776.91 0.86 0.73 0.81 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral I172P 2318 6297.28 7073.49 0.89 0.79 0.85 Down I172A 2317 4666.76 6048.64 0.77 0.58 0.73 Neutral 11 72L 2316 9324.48 8876.38 1.05 1.17 1.07 Neutral I172Q 2307 6906.03 7743.66 0.89 0.87 0.93 Down 1172E 2301 3517.33 4567.20 0.77 0.44 0.55 Down 11 72C 2305 1784.43 2422.99 0.74 0.22 0.29 Neutral I172M 2313 9859.60 9096.03 1.08 1.24 1.09 Neutral I172D 2300 4276.25 4281.60 1.00 0.54 0.51 Neutral I172V 2315 9541.02 9174.91 1.04 1.20 1.10 Neutral I172R 2304 7010.86 7581.48 0.92 0.88 0.91 Neutral 11 72G 2311 2169.59 2350.53 0.92 0.27 0.28 Neutral I172W 2314 5870.25 7244.46 0.81 0.74 0.87 Neutral I172N 2306 5235.67 6253.19 0.84 0.66 0.75 Down G173C 2324 816.12 1115.07 0.73 0.10 0.13 Neutral G173L 2325 454.21 401.73 1.13 0.06 0.05 Neutral G173K 2322 741.76 685.79 1.08 0.09 0.08 Neutral G173W 2332 1278.44 1132.78 1.13 0.16 0.14 Neutral G173S 2329 865.76 793.10 1.09 0.11 0.10 Neutral G173A 2326 1041.22 1038.66 1.00 0.13 0.12 Neutral G173R 2323 973.70 877.71 1.11 0.12 0.11 Neutral G173N 2325 818.38 931.59 0.88 0.10 0.11 Neutral G173T 2327 481.41 485.39 0.99 0.06 0.06 Neutral G173D 2319 474.45 424.47 1.12 0.06 0.05 Neutral G173V 2324 505.39 476.04 1.06 0.06 0.06 Neutral G173F 2330 670.10 610.91 1.10 0.08 0.07 Neutral G173M 2331 1085.74 1324.87 0.82 0.14 0.16 Neutral G173Y 2328 1390.14 1296.93 1.07 0.17 0.16 Neutral G173P 2327 458.79 435.59 1.05 0.06 0.05 Neutral G174R 2342 452.76 437.41 1.04 0.06 0.05 Neutral G174A 2355 491.35 460.84 1.07 0.06 0.06 Neutral G174E 2339 489.49 459.57 1.07 0.06 0.06 Neutral G174F 2349 598.90 520.03 1.15 0.08 0.06 Neutral G174H 2340 577.19 518.90 1.11 0.07 0.06 Neutral G174T 2346 505.38 483.64 1.04 0.06 0.06 Neutral G174D 2338 476.79 454.13 1.05 0.06 0.05 Neutral G174S 2348 641.62 580.36 1.11 0.08 0.07 Neutral G174P 2356 525.07 505.41 1.04 0.07 0.06 Neutral G174W 2351 538.38 502.50 1.07 0.07 0.06 Neutral G174V 2353 504.50 425.17 1.19 0.06 0.05 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 0 Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral G174N 2344 506.54 460.95 1.10 0.06 0.06 Up G174Y 2347 722.10 525.97 1.37 0.09 0.06 Neutral G174M 2350 516.58 464.32 1.11 0.06 0.06 Neutral G174L 2354 474.83 436.08 1.09 0.06 0.05 Neutral D1751 2371 697.29 708.65 0.98 0.09 0.09 Neutral D175T 2364 601.82 560.11 1.07 0.08 0.07 Neutral D175N 2362 1495.98 1413.58 1.06 0.19 0.17 Neutral D175V 2372 694.28 652.82 1.06 0.09 0.08 Neutral D175S 2366 664.04 579.78 1.15 0.08 0.07 Neutral D175R 2360 593.04 505.98 1.17 0.07 0.06 Down D175G 2367 3147.62 4207.02 0.75 0.39 0.51 Up D175A 2374 633.65 519.61 1.22 0.08 0.06 Neutral D175F 2368 768.41 804.63 0.95 0.10 0.10 Neutral D175C 2361 535.75 498.44 1.07 0.07 0.06 Neutral D175Q 2363 702.74 633.64 1.11 0.09 0.08 Neutral D175Y 2365 574.71 539.79 1.06 0.07 0.06 Neutral D175L 2373 591.05 549.49 1.08 0.07 0.07 Up D175H 2358 830.09 564.37 1.47 0.10 0.07 Neutral D175P 2375 635.08 610.89 1.04 0.08 0.07 Up D175E 2357 959.14 495.19 1.94 0.10 0.07 Up A176F 148 10486.82 6516.31 1.61 1.31 0.78 Neutral A176Q 143 6410.52 6665.27 0.96 0.80 0.80 Neutral A176V 152 8890.53 8780.42 1.01 1.11 1.05 Neutral A176E 137 589.82 546.54 1.08 0.07 0.07 Neutral A176T 144 8471.98 8213.74 1.03 1.06 0.99 Neutral A176C 141 6777.92 5924.96 1.14 0.85 0.71 Neutral A176L 153 7190.01 6291.31 1.14 0.90 0.76 Neutral A176P 154 639.90 596.40 1.07 0.08 0.07 Neutral A176N 142 1351.92 1250.94 1.08 0.17 0.15 Neutral A176G 147 2185.25 2395.33 0.91 0.27 0.29 Down A176S 146 3003.29 3887.12 0.77 0.38 0.47 Neutral A176R 140 919.15 792.44 1.16 0.12 0.10 Neutral A176K 139 561.66 522.94 1.07 0.07 0.06 Neutral A176D 136 863.82 792.98 1.09 0.11 0.10 Neutral A176W 150 482.38 414.85 1.16 0.06 0.06 Neutral H177T 2383 600.03 570.23 1.05 0.08 0.07 Neutral H177P 2394 579.96 544.77 1.06 0.07 0.07 Neutral H177Q 2382 593.68 549.35 1.08 0.07 0.07 Neutral H177A 2393 536.01 523.32 1.02 0.07 0.06 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral H177S 2385 561.60 524.64 1.07 0.07 0.06 Neutral H177G 2386 559.31 519.85 1.08 0.07 0.06 Neutral H177W 2389 547.21 520.18 1.05 0.07 0.06 Neutral H177L 2392 486.50 433.60 1.12 0.06 0.05 Neutral H177V 2391 508.58 447.50 1.14 0.06 0.05 Neutral H1771 2390 489.45 455.90 1.07 0.06 0.05 Down H177R 2379 1913.95 2460.77 0.78 0.24 0.30 Neutral H 177N 2381 504.44 478.07 1.06 0.06 0.06 Neutral H177Y 2384 519.99 467.72 1.11 0.07 0.06 Neutral H177C 2380 521.67 489.93 1.06 0.07 0.06 Neutral H177D 2376 534.87 505.07 1.06 0.07 0.06 Neutral F178G 2406 451.96 391.96 1.15 0.05 0.05 Up F178C 2400 491.76 403.57 1.22 0.05 0.05 Neutral F178W 2408 488.21 441.35 1.11 0.05 0.05 Neutral F178R 2399 492.40 411.21 1.20 0.05 0.05 Neutral F178K 2398 490.87 494.09 0.99 0.05 0.06 Neutral F178S 2405 489.84 507.26 0.97 0.05 0.06 Neutral F178H 2397 525.63 500.02 1.05 0.06 0.06 Neutral F178P 2413 '441.78 397.05 1.11 0.05 0.05 Neutral F178V 2410 742.61 814.06 0.91 0.08 0.10 Neutral F178A 2412 421.25 367.26 1.15 0.05 0.04 Neutral F178Q 2402 409.62 360.29 1.14 0.04 0.04 Neutral F178Y 2404 861.20 830.80 1.04 0.09 0.10 Neutral F1781 2409 1118.23 1329.96 0.84 0.12 0.16 Neutral F178T 2403 560.54 487.01 1.15 0.10 0.10 Up F178L 2411 1788.95 1314.38 1.36 0.31 0.26 Neutral F178E 2396 524.72 515.62 1.02 0.06 0.07 Neutral D179P 173 526.54 527.98 1.00 0.06 0.06 Neutral D179L 171 444.31 410.22 1.08 0.05 0.05 Neutral D179E 155 520.82 438.27 1.19 0.06 0.05 Neutral D179G 165 470.21 426.64 1.10 0.05 0.05 Neutral D179S 164 461.51 421.09 1.10 0.05 0.05 Neutral D 179A 172 464.49 431.24 1.08 0.05 0.05 Neutral D179K 157 483.67 456.75 1.06 0.05 0.05 Neutral D 179T 162 451.18 419.76 1.07 0.05 0.05 Neutral D1791 169 425.91 372.56 1.14 0.05 0.04 Neutral D179R 158 473.21 450.10 1.05 0.05 0.05 Up D179N 160 2433.73 812.01 3.00 0.26 0.10 Neutral D179W 168 465.31 423.56 1.10 0.05 0.05 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 0 Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral D179Q 161 446.51 414.79 1.08 0.05 0.05 Up D179V 170 604.63 490.35 1.23 0.11 0.10 Up D179C 159 613.81 503.76 1.22 0.11 0.10 Neutral E180M 186 9630.23 8513.41 1.13 1.04 1.00 Neutral E180P 192 523.92 492.75 1.06 0.06 0.06 Neutral E180K 176 4017.43 3889.45 1.03 0.43 0.46 Up E180Y 182 6655.19 5379.42 1.24 0.72 0.63 Neutral E180Q 180 5146.93 4568.90 1.13 0.56 0.54 Neutral E180R 177 6932.51 6309.81 1.10 0.75 0.74 Neutral E180A 191 9562.37 8450.18 1.13 1.04 1.00 Up E180T 181 3718.16 2425.13 1.53 0.40 0.29 Neutral E1801 188 9126.95 7770.14 1.17 0.99 0.92 Up E18OF 185 7014.78 5382.78 1.30 0.76 0.63 Neutral E180C 178 2926.15 2569.75 1.14 0.32 0.30 Up E18OG 184 5952.65 4547.28 1.31 1.04 0.90 Up E180S 183 5217.80 3977.60 1.31 0.91 0.78 Up E18ON 179 6534.65 4843.84 1.35 1.14 0.96 Up E180D 174 7738.70 6277.22 1.23 1.35 1.24 Neutral D181S 202 9064.64 8368.97 1.08 0.98 0.99 Neutral D181Q 199 7875.57 7127.19 1.11 0.85 0.84 Neutral D 181 P 211 753.20 639.76 1.18 0.08 0.08 Up D181Y 201 1137.94 716.86 1.59 0.12 0.08 Up D 181 R 196 997.11 712.77 1.40 0.11 0.08 Up D 181 V 208 945.65 721.77 1.31 0.10 0.09 Up D181F 204 933.48 670.40 1.39 0.10 0.08 Neutral D181A 210 7936.89 7854.96 1.01 0.86 0.93 Neutral D181T 200 6867.00 6057.09 1.13 0.74 0.71 Up D181L 209 1727.20 1274.09 1.36 0.19 0.15 Neutral D181E 193 8647.28 8246.36 1.05 0.94 0.97 Up D181K 195 1087.36 696.83 1.56 0.12 0.08 Up D181M 205 3805.65 2986.75 1.27 0.41 0.35 Up D 181 C 197 549.29 447.40 1.23 0.10 0.09 Up D 181 G 203 2764.20 2056.56 1.34 0.48 0.41 Neutral E182C 216 601.45 561.21 1.07 0.07 0.07 Neutral E182P 230 606.01 574.24 1.06 0.07 0.07 Up E182S 221 967.49 642.27 1.51 0.10 0.08 Up E182T 219 2995.97 1779.42 1.68 0.32 0.21 Neutral E182R 215 661.10 622.75 1.06 0.07 0.07 Neutral E182D 212 2078.47 2140.28 0.97 0.23 0.25 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 0 Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral E182A 229 619.23 531.55 1.16 0.07 0.06 Neutral E182F 223 1484.85 1677.82 0.88 0.16 0.20 Neutral E182L 228 569.35 524.25 1.09 0.06 0.06 Neutral E1821 226 606.88 519.75 1.17 0.07 0.06 Neutral E182Y 220 593.61 561.88 1.06 0.06 0.07 Up E182Q 218 1393.28 804.84 1.73 0.15 0.09 Neutral E182W 225 556.78 536.32 1.04 0.06 0.06 Up E182M 224 649.73 524.43 1.24 0.11 0.10 Neutral E182G 222 604.92 543.78 1.11 0.11 0.11 Neutral R183P 2432 9143.00 8148.29 1.12 0.99 0.96 Neutral R183K 2417 9843.98 8685.25 1.13 1.07 1.02 Neutral R183W 2427 8144.07 7669.02 1.06 0.88 0.90 Neutral R183E 2415 9873.25 8403.44 1.17 1.07 0.99 Neutral R183A 2431 9386.14 8368.29 1.12 1.02 0.99 Down R183T 2421 4841.94 8385.09 0.58 0.52 0.99 Neutral R183L 2430 517.07 532.72 0.97 0.06 0.06 Neutral R183N 2419 10062.02 8456.13 1.19 1.09 1.00 Neutral R183H 2416 9434.01 8295.55 1.14 1.02 0.98 Neutral R183V 2429 9252.08 7954.42 1.16 1.00 0.94 Neutral R183C 2418 6603.93 6597.30 1.00 0.72 0.78 Neutral R183M 2426 9679.52 8250.27 1.17 1.05 0.97 Down R1831 2428 495.34 8009.63 0.06 0.05 0.94 Up R183G 2424 7326.36 6021.39 1.22 1.28 1.19 Up R183S 2423 7896.17 6240.74 1.27 1.38 1.23 Neutral W184G 2444 430.62 391.79 1.10 0.05 0.05 Neutral W184H 2435 440.24 428.35 1.03 0.05 0.05 Neutral W184L 2449 476.77 428.90 1.11 0.06 0.05 Neutral W184E 2434 463.88 438.97 1.06 0.05 0.05 Neutral W184P 2451 437.57 387.71 1.13 0.05 0.05 Neutral W184N 2439 467.91 468.52 1.00 0.06 0.06 Neutral W184A 2450 452.63 451.66 1.00 0.05 0.06 Neutral W 184T 2441 421.08 419.51 1.00 0.05 0.05 Neutral W184R 2437 457.42 390.02 1.17 0.05 0.05 Neutral W184Q 2440 450.92 448.33 1.01 0.05 0.05 Neutral W184V 2448 454.60 407.30 1.12 0.05 0.05 Neutral W184S 2443 486.70 485.16 1.00 0.06 0.06 Neutral W184M 2446 447.30 395.61 1.13 0.05 0.05 Neutral W1841 2447 478.17 503.24 0.95 0.06 0.06 Neutral W184F 2445 455.86 427.51 1.07 0.05 0.05 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Up T185R 235 1728.04 851.07 2.03 0.20 0.10 Up T185Y 239 937.75 540.66 1.73 0.11 0.07 Neutral T185W 244 577.54 501.10 1.15 0.07 0.06 Up T185H 233 1448.04 783.89 1.85 0.17 0.10 Up T185G 241 3922.30 1990.15 1.97 0.46 0.24 Neutral T185P 249 1773.27 1542.44 1.15 0.21 0.19 Neutral T185S 240 9554.77 8267.62 1.16 1.12 1.01 Up T185V 246 1648.14 - 897.66 1.84 0.19 0.11 Up T185Q 238 1594.81 583.93 2.73 0.19 0.07 Up T185N 237 790.61 546.44 1.45 0.09 0.07 Up T185C 236 1554.42 1248.58 1.24 0.18 0.15 Neutral T185L 247 483.25 463.52 1.04 0.06 0.06 Up T185A 248 1599.64 711.08 2.25 0.19 0.09 Up T185E 232 1324.02 703.76 1.88 0.16 0.09 Neutral T185D 231 485.86 418.67 1.16 0.06 0.06 Neutral N186G 2462 7592.31 6944.43 1.09 0.89 0.85 Neutral N186A 2469 7466.07 7519.13 0.99 0.88 0.92 Neutral N186T 2459 8897.05 8063.02 1.10 1.05 0.98 Neutral N186R 2456 3212.69 3085.21 1.04 0.38 0.38 Neutral N186L 2468 8097.42 7286.32 1.11 0.95 0.89 Neutral N186P 2470 2173.37 1948.86 1.12 0.26 0.24 Neutral N186S 2461 6854.56 6735.79 1.02 0.81 0.82 Neutral N186V 2467 6303.91 6575.96 0.96 0.74 0.80 Neutral N186Q 2458 4834.56 4621.18 1.05 0.57 0.56 Neutral N186H 2454 3390.53 3309.97 1.02 0.40 0.40 Neutral N186C 2457 3139.47 3113.35 1.01 0.37 0.38 Neutral N186E 2453 3801.36 3332.52 1.14 0.45 0.41 Neutral N186F 2463 3794.65 3316.48 1.14 0.45 0.40 Neutral N186Y 2460 6301.09 7570.59 0.83 0.74 0.92 Neutral N186D 2452 6853.09 6333.37 1.08 0.81 0.77 Up N187R 254 1042.36 709.74 1.47 0.12 0.09 Up N187M 262 1731.67 995.07 1.74 0.20 0.12 Neutral N187S 259 9538.59 8971.12 1.06 1.12 1.10 Neutral N187T 257 9856.38 8855.58 1.11 1.16 1.08 Neutral N187L 266 505.93 464.62 1.09 0.06 0.06 Neutral N187W 263 1694.86 1425.68 1.19 0.20 0.17 Up N187F 261 1240.41 731.98 1.69 0.15 0.09 Up N187K 253 2331.93 1140.19 2.05 0.27 0.14 Up N1871 264 1444.98 683.03 2.12 0.17 0.08 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Up N187A 267 4379.80 2616.49 1.67 0.52 0.32 Neutral N187P 268 644.27 572.98 1.12 0.08 0.07 Neutral N187D 250 9843.65 8801.57 1.12 1.16 1.07 Neutral N187G 260 535.06 514.10 1.04 0.07 0.07 Neutral N187C 255 1804.28 1860.67 0.97 0.23 0.25 Neutral N187H 252 1143.07 1071.67 1.07 0.14 0.14 Neutral F 188P 2489 10012.21 8943.91 1.12 1.18 1.09 Neutral F1881 2485 7342.21 6782.40 1.08 0.86 0.83 Neutral F188N 2477 10024.22 8961.63 1.12 1.18 1.09 Neutral F 188S 2481 9564.51 8841.98 1.08 1.13 1.08 Neutral F188Q 2478 9591.39 8664.63 1.11 1.13 1.06 Neutral F188K 2474 8347.12 7497.38 1.11 0.98 0.92 Neutral F188G 2482 9891.61 9065.43 1.09 1.16 1.11 Neutral F188W 2484 9389.97 8774.36 1.07 1.10 1.07 Neutral F188E 2472 10235.38 8984.46 1.14 1.20 1.10 Neutral F188H 2473 2065.12 1901.41 1.09 0.24 0.23 Neutral F188D 2471 10087.61 8889.75 1.13 1.19 1.09 Up F188A 2488 1502.70 1231.99 1.22 0.18 0.15 Neutral F188L 2487 8309.64 7501.30 1.11 0.98 0.92 Neutral F188R 2475 8182.64 7750.05 1.06 0.96 0.95 Up F188V 2486 7116.29 5860.00 1.21 1.24 1.16 Neutral R189L 2506 9236.08 8947.54 1.03 1.09 1.09 Neutral R189G 2500 10307.88 9096.35 1.13 1.21 1.11 Neutral R189K 2493 9365.15 9033.15 1.04 1.10 1.10 Neutral R189P 2508 3200.68 3533.96 0.91 0.38 0.43 Neutral R189E 2491 9552.57 8789.28 1.09 1.12 1.07 Neutral R189V 2505 9150.17 8088.39 1.13 1.08 0.99 Neutral R189D 2490 9506.16 8933.41 1.06 1.12 1.09 Neutral R189Y 2498 9893.14 8946.52 1.11 1.16 1.09 Neutral R189C 2494 5318.06 5457.78 0.97 0.63 0.67 Neutral R189A 2507 9718.09 8798.13 1.10 1.14 1.07 Neutral R189H 2492 1360.90 1350.33 1.01 0.16 0.16 Neutral R189W 2503 7657.12 7070.92 1.08 0.90 0.86 Neutral R189N 2495 7842.39 6675.36 1.17 1.37 1.32 Neutral R189T 2497 7610.10 6459.94 1.18 1.33 1.27 Neutral R189Q 2496 7465.37 6396.79 1.17 1.30 1.26 Down E190A 590 1510.06 2116.94 0.71 0.21 0.23 Neutral E190H 574 6276.13 7564.04 0.83 0.88 0:83 Down E190V 588 643.37 1658.11 0.39 0.09 0.18 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Up E190P 591 2420.68 1767.43 1.37 0.34 0.19 Neutral E190C 577 1827.25 2083.88 0.88 0.26 0.23 Up E190G 583 5313.99 4365.93 1.22 0.75 0.48 Down E190R 576 1185.26 1810.53 0.65 0.17 0.20 Down E1901 587 1880.80 2886.28 0.65 0.27 0.32 Down E190S 582 4542.61 5987.33 0.76 0.64 0.66 Down E190T 580 2293.47 4444.68 0.52 0.32 0.49 Up E190M 585 2557.21 1317.73 1.94 0.36 0.15 Neutral E190L 589 2542.38 2986.91 0.85 0.36 0.33 Down E190K 575 2960.37 4343.12 0.68 0.42 0.48 Up E190Y 581 7243.54 5742.33 1.26 1.27 1.13 Up E190D 573 7910.21 6468.78 1.22 1.38 1.28 Neutral Y191T 600 611.75 535.95 1.14 0.07 0.06 Neutral Y191H 594 2333.85 2191.64 1.06 0.28 0.24 Neutral Y191G 602 428.17 432.65 0.99 0.05 0.05 Neutral Y191L 608 379.02 357.82 1.06 0.05 0.04 Up Y191P 610 1359.30 1046.33 1.30 0.16 0.12 Neutral Y191Q 599 451.92 403.46 1.12 0.05 0.05 Neutral Y191K 595 464.62 406.52 1.14 0.06 0.05 Neutral Y191D 592 392.24 370.67 1.06 0.05 0.04 Neutral Y191A 609 452.13 418.53 1.08 0.05 0.05 Neutral Y191W 605 395.63 411.91 0.96 0.05 0.05 Neutral Y191S 601 530.80 447.13 1.19 0.06 0.05 Up Y191V 607 1553.58 1254.11 1.24 0.19 0.14 Neutral Y191E 593 395.04 407.49 0.97 0.05 0.05 Neutral Y191R 596 652.95 725.68 0.90 0.08 0.08 Neutral Y191C 597 530.42 463.90 1.14 0.06 0.05 Up N192R 615 640.72 482.61 1.33 0.09 0.05 Neutral N192L 627 591.92 571.56 1.04 0.08 0.06 Neutral N192Q 617 1089.41 1020.23 1.07 0.15 0.11 Neutral N192P 629 685.62 856.11 0.80 0.10 0.09 Up N192H 613 2274.24 1058.80 2.15 0.32 0.12 Up N192S 620 2043.65 1630.74 1.25 0.29 0.18 Neutral N192W 624 548.30 538.86 1.02 0.08 0.06 Up N192G 621 899.47 659.29 1.36 0.13 0.07 Up N192D 611 4213.33 2216.40 1.90 0.59 0.24 Neutral N192V 626 588.02 537.64 1.09 0.08 0.06 Neutral N192A 628 574.26 543.66 1.06 0.08 0.06 Neutral N192T 618 536.50 576.21 0.93 0.08 0.06 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral N192K 614 685.26 633.89 1.08 0.10 0.07 Up N192C 616 1310.46 987.31 1.33 0.18 0.11 Neutral N192M 623 547.98 537.29 1.02 0.08 0.06 Neutral L193P 2527 388.57 381.15 1.02 0.05 0.04 Neutral L193G 2520 437.84 478.44 0.92 0.05 0.05 Neutral L193F 2521 481.49 491.33 0.98 0.06 0.05 Neutral L193S 2519 448.35 449.03 1.00 0.05 0.05 Neutral L193W 2523 481.79 460.74 1.05 0.06 0.05 Neutral L193A 2526 510.96 468.83 1.09 0.06 0.05 Neutral L193R 2513 481.08 477.55 1.01 0.06 0.05 Neutral L193Q 2516 417.53 412.01 1.01 0.05 0.05 Neutral L193E 2510 401.70 409.23 0.98 0.05 0.05 Neutral L193K 2512 417.39 426.26 0.98 0.05 0.05 Neutral L193N 2515 432.35 434.95 0.99 0.05 0.05 Down L1931 2524 2767.03 3467.03 0.80 0.33 0.39 Neutral L193T 2517 679.48 638.88 1.06 0.08 0.07 Neutral L193D 2509 419.37 424.41 0.99 0.05 0.05 Neutral L193Y 2518 3022.00 2706.28 1.12 0.36 0.30 Neutral H194S 639 5518.27 6112.38 0.90 0.78 0.67 Neutral H194E 631 7667.53 8295.22 0.92 1.08 0.91 Neutral H194K 632 5130.62 6124.27 0.84 0.72 0.67 Neutral H194Q 636 6399.62 7113.56 0.90 0.90 0.78 Down H194V 645 1611.06 5696.43 0.28 0.23 0.63 Up H194T 637 3884.64 2598.12 1.50 0.55 0.29 Neutral H194L 646 5710.11 6872.56 0.83 0.80 0.76 Neutral H194Y 638 4922.31 5688.29 0.87 0.69 0.63 Down H194F 641 3787.65 5388.18 0.70 0.53 0.59 Neutral H194G 640 4636.22 5437.23 0.85 0.65 0.60 Down H1941 644 2901.13 3777.68 0.77 0.41 0.42 Down H 194W 643 5434.60 7448.23 0.73 0.77 0.82 Down H194M 642 2941.85 9057.43 0.32 0.41 1.00 Up H194A 647 4681.45 2746.90 1.70 0.66 0.30 Neutral H194P 648 5264.79 5058.19 1.04 0.74 0.56 Up R195C 273 4231.32 1853.20 2.28 0.60 0.20 Neutral R195F 280 687.70 720.42 0.95 0.10 0.08 Neutral R195W 282 5099.23 4524.84 1.13 0.72 0.50 Neutral R195T 276 1101.98 1175.85 0.94 0.16 0.13 Neutral R195L 285 5073.57 4520.73 1.12 0.72 0.50 Up R195G 279 5269.21 3025.93 1.74 0.74 0.33 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 0 Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Up R195Q 275 1958.69 1361.83 1.44 0.28 0.15 Down R195K 272 3839.86 7080.78 0.54 0.54 0.78 Neutral R195S 278 642.14 649.21 0.99 0.09 0.07 Up R195A 286 5605.90 3852.81 1.46 0.79 0.42 Up R195D 269 2724.53 1907.81 1.43 0.38 0.21 Neutral R195P 287 571.50 615.21 0.93 0.08 0.07 Neutral R195Y 277 763.31 794.42 0.96 0.11 0.09 Neutral R195E 270 7597.55 8468.35 0.90 1.07 0.93 Up R195V 284 1711.48 1037.62 1.65 0.24 0.11 Neutral V196T 2536 1040.90 1268.04 0.82 0.12 0.14 Neutral V196D 2528 443.04 446.39 0.99 0.05 0.05 Neutral V196G 2539 490.83 494.67 0.99 0.06 0.06 Neutral V196E 2529 488.55 489.74 1.00 0.06 0.05 Neutral V196A 2545 452.36 452.12 1.00 0.05 0.05 Up V196S 2538 1186.52 949.52 1.25 0.14 0.11 Neutral V196Q 2535 412.17 430.91 0.96 0.05 0.05 Neutral V196P 2546 576.83 620.88 0.93 0.07 0.07 Neutral V196R 2532 493.29 474.38 1.04 0.06 0.05 Neutral V196H 2530 465.64 479.66 0.97 0.06 0.05 Neutral V 196Y 2537 462.28 474.94 0.97 0.06 0.05 Neutral V1961 2543 1125.67 1229.87 0.92 0.13 0.14 Neutral V 196L 2544 464.80 491.01 0.95 0.06 0.05 Neutral V196K 2531 455.84 482.44 0.94 0.05 0.05 Neutral V196M 2541 479.36 518.00 0.93 0.06 0.06 Down A197G 2558 1238.39 2552.91 0.49 0.17 0.28 Up A197S 2557 3959.39 2633.91 1.50 0.56 0.29 Up A197L 2564 1013.13 809.32 1.25 0.14 0.09 Neutral A197P 2565 857.06 933.29 0.92 0.12 0.10 Down A197V 2563 2549.12 4355.70 0.59 0.36 0.48 Neutral A197Y 2556 650.21 722.49 0.90 0.09 0.08 Neutral A197Q 2554 658.64 652.52 1.01 0.09 0.07 Neutral A197R 2551 635.08 640.91 0.99 0.09 0.07 Down A197T 2555 1933.94 4482.59 0.43 0.27 0.49 Up A1971 2562 1440.69 1060.51 1.36 0.20 0.12 Neutral A197H 2549 604.11 638.63 0.95 0.09 0.07 Neutral A197E 2548 686.96 624.22 1.10 0.10 0.07 Down A197W 2561 1448.83 2588.64 0.56 0.20 0.29 Down A197N 2553 623.17 840.56 0.74 0.09 0.09 Up A197C 2552 4012.80 3140.52 1.28 0.70 0.62 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral A198T 296 761.19 700.22 1.09 0.11 0.08 Down A198K 291 490.20 1179.92 0.42 0.07 0.13 Up A198S 298 4061.28 3136.65 1.29 0.57 0.35 Neutral A198H 290 581.41 575.73 1.01 0.08 0.06 Neutral A198G 299 2610.82 2368.26 1.10 0.37 0.26 Down A198E 289 485.45 662.62 0.73 0.07 0.07 Neutral A198P 306 656.48 580.71 1.13 0.09 0.06 Up A198L 305 1339.94 726.74 1.84 0.19 0.08 Neutral A198R 292 570.33 565.56 1.01 0.08 0.06 Down A198V 304 3026.36 7305.85 0.41 0.43 0.80 Up A198M 301 1384.46 999.55 1.39 0.20 0.11 Neutral A198F 300 572.48 559.57 1.02 0.08 0.06 Neutral A198W 302 560.48 547.72 1.02 0.08 0.06 Down A198Y 297 486.57 612.28 0.79 0.07 0.07 Up A198D 288 633.49 474.50 1.34 0.09 0.05 Neutral H1991 2580 520.35 496.48 1.05 0.08 0.07 Neutral H199P 2584 437.57 404.21 1.08 0.07 0.05 Neutral H199G 2576 436.53 392.94 1.11 0.07 0.05 Neutral H199N 2571 420.26 375.18 1.12 0.07 0.05 Neutral H199S 2575 411.09 377.36 1.09 0.06 0.05 Neutral H199L 2582 531.61 530.53 1.00 0.08 0.07 Neutral H199M 2578 413.37 384.23 1.08 0.07 0.05 Neutral H199A 2583 391.56 381.36 1.03 0.06 0.05 Neutral H199C 2570 404.49 366.35 1.10 0.06 0.05 Neutral H199K 2568 402.34 383.95 1.05 0.06 0.05 Neutral H 199R 2569 422.19 387.94 1.09 0.07 0.05 Neutral H199V 2581 421.16 378.71 1.11 0.07 0.05 Neutral H199W 2579 377.01 345.02 1.09 0.06 0.05 Neutral H199T 2573 399.21 382.65 1.04 0.06 0.05 Neutral H199E 2567 399.49 385.83 1.04 0.06 0.05 Neutral E200P 2603 414.11 409.55 1.01 0.07 0.06 Neutral E200G 2595 440.94 402.85 1.09 0.07 0.05 Neutral E200A 2602 448.41 413.61 1.08 0.07 0.06 Neutral E200T 2592 461.19 418.51 1.10 0.07 0.06 Neutral E2001 2599 457.88 419.19 1.09 0.07 0.06 Neutral E200W 2598 418.40 403.05 1.04 0.07 0.05 Neutral E200R 2588 449.83 425.86 1.06 0.07 0.06 Neutral E200F 2596 446.49 417.58 1.07 0.07 0.06 Neutral E200M 2597 448.32 428.16 1.05 0.07 0.06 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral E200D 2585 428.91 401.64 1.07 0.07 0.05 Neutral E200V 2600 426.45 407.13 1.05 0.07 0.06 Neutral E2000 2589 413.11 384.79 1.07 0.07 0.05 Neutral E200S 2594 422.57 391.02 1.08 0.07 0.05 Neutral E200Y 2593 412.07 393.97 1.05 0.07 0.05 Neutral E200N 2590 430.94 412.07 1.05 0.07 0.06 Down L201 A 2621 754.66 957.77 0.79 0.12 0.13 Neutral L201R 2608 442.35 442.57 1.00 0.07 0.06 Neutral L201E 2605 464.22 443.89 1.05 0.07 0.06 Neutral L201P 2622 494.97 471.92 1.05 0.08 0.06 Neutral L201 G 2615 574.82 590.26 0.97 0.09 0.08 Down L201V 2620 3359.21 4623.67 0.73 0.53 0.62 Down L201T 2612 1509.22 2175.97 0.69 0.24 0.29 Up L2011 2619 2861.66 2231.87 1.28 0.45 0.30 Neutral L201 S 2614 859.79 964.65 0.89 0.14 0.13 Neutral L201 W 2618 1258.36 1335.56 0.94 0.20 0.18 Neutral L201 Q 2611 657.51 749.98 0.88 0.10 0.10 Neutral L201D 2604 486.09 471.81 1.03 0.08 0.06 Down L201M 2617 5637.84 7147.36 0.79 0.89 0.97 Neutral L201K 2607 484.89 467.23 1.04 0.08 0.06 Neutral L201N 2610 440.03 432.42 1.02 0.07 0.06 Neutral G202T 2631 556.53 546.05 1.02 0.09 0.07 Neutral G202Y 2632 533.64 530.73 1.01 0.08 0.07 Neutral G202E 2624 558.69 543.68 1.03 0.09 0.07 Neutral G202V 2638 569.22 572.58 0.99 0.09 0.08 Neutral G202S 2633 512.82 503.35 1.02 0.08 0.07 Neutral G202L 2639 513.71 508.34 1.01 0.08 0.07 Neutral G202I 2637 535.96 516.37 1.04 0.08 0.07 Neutral G202M 2635 507.94 500.04 1.02 0.08 0.07 Neutral G202H 2625 567.88 547.25 1.04 0.09 0.07 Neutral G202C 2628 508.19 499.05 1.02 0.08 0.07 Neutral G202R 2627 537.10 511.28 1.05 0.08 0.07 Neutral G202P 2641 544.39 535.24 1.02 0.09 0.07 Neutral G202A 2640 580.75 571.95 1.02 0.09 0.08 Neutral G202K 2626 531.07 520.45 1.02 0.08 0.07 Neutral G202D 2623 559.64 544.50 1.03 0.09 0.07 Down H203Y 2650 910.26 1218.02 0.75 0.14 0.16 Neutral H203E 2643 7284.23 7937.91 0.92 1.15 1.07 Neutral H203R 2645 545.70 545.36 1.00 0.09 0.07 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 0 Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral H203Q 2648 570.55 541.42 1.05 0.09 0.07 Neutral H203P 2660 547.00 527.67 1.04 0.09 0.07 Neutral H203G 2652 558.88 576.91 0.97 0.09 0.08 Neutral H203T 2649 534.16 535.33 1.00 0.08 0.07 Neutral H203D 2642 542.85 530.31 1.02 0.09 0.07 Down H203L 2658 1224.67 1746.14 0.70 0.19 0.24 Neutral H203N 2647 547.92 532.11 1.03 0.09 0.07 Neutral H203A 2659 513.18 515.49 1.00 0.08 0.07 Neutral H203S 2651 534.50 507.56 1.05 0.08 0.07 Neutral H203V 2657 565.64 554.43 1.02 0.09 0.07 Neutral H2031 2656 568.56 613.73 0.93 0.09 0.08 Neutral H203C 2646 504.41 522.69 0.97 0.08 0.07 Neutral S204R 2665 557.42 544.69 1.02 0.09 0.07 Neutral S204N 2667 733.30 754.34 0.97 0.12 0.10 Neutral S204A 2678 3654.83 3972.28 0.92 0.58 0.54 Down S204T 2669 1697.49 3586.11 0.47 0.27 0.48 Neutral S204Y 2670 550.01 538.07 1.02 0.09 0.07 Up S204V 2676 3063.02 1827.71 1.68 0.48 0.25 Neutral S204L 2677 501.10 594.44 0.84 0.08 0.08 Neutral S204H 2663 486.78 508.13 0.96 0.08 0.07 Neutral S204D 2661 507.05 489.81 1.04 0.08 0.07 Neutral S204Q 2668 530.67 472.92 1.12 0.08 0.06 Neutral S204G 2671 1483.41 1333.79 1.11 0.23 0.18 Neutral S204W 2674 487.01 504.11 0.97 0.08 0.07 Up S2041 2675 634.82 516.30 1.23 0.10 0.07 Neutral S204K 2664 484.92 471.83 1.03 0.08 0.06 Neutral S204P 2679 483.87 506.90 0.95 0.08 0.07 Neutral L205T 2688 1304.89 1099.25 1.19 0.13 0.12 Neutral L205D 2680 774.29 830.37 0.93 0.08 0.09 Neutral L205S 2690 686.11 601.35 1.14 0.07 0.07 Neutral L205G 2691 792.45 790.93 1.00 0.08 0.09 Neutral L205P 2698 592.15 673.32 0.88 0.06 0.07 Neutral L205E 2681 473.89 446.64 1.06 0.05 0.05 Down L205V 2696 5589.64 7308.12 0.76 0.57 0.80 Neutral L205M 2693 8334.85 8229.20 1.01 0.85 0.90 Neutral L205N 2686 1426.11 1322.80 1.08 0.15 0.15 Down L205C 2685 1903.14 2394.15 0.79 0.20 0.26 Down L2051. 2695 5644.28 7817.06 0.72 0.58 0.86 Neutral L205A 2697 1796.22 1704.85 1.05 0.18 0.19 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU. 25 0 Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral L205R 2684 508.62 575.22 0.88 0.05 0.06 Neutral L205W 2694 497.92 427.60 1.16 0.05 0.05 Neutral L205Q 2687 2191.83 2399.54 0.91 0.22 0.26 Neutral G2061 321 467.21 460.72 1.01 0.05 0.05 Neutral G206V 322 619.10 682.58 0.91 0.06 0.07 Up G206A 324 4554.61 2702.11 1.69 0.47 0.30 Neutral G206C 312 491.44 469.90 1.05 0.05 0.05 Up G206S 317 1226.37 919.66 1.33 0.13 0.10 Neutral G206P 325 503.21 497.87 1.01 0.05 0.05 Neutral G206L 323 499.74 469.53 1.06 0.05 0.05 Neutral G206D 307 490.08 451.61 1.09 0.05 0.05 Neutral G206M 319 478.55 451.47 1.06 0.05 0.05 Neutral G206R 311 677.07 831.95 0.81 0.07 0.09 Neutral G206Q 314 805.32 851.38 0.95 0.08 0.09 Neutral G206E 308 469.86 447.60 1.05 0.05 0.05 Neutral G206H 309 463.25 437.73 1.06 0.05 0.05 Neutral G206T 315 475.20 491.10 0.97 0.05 0.05 Neutral G206W 320 472.91 437.66 1.08 0.05 0.05 Up L207S 659 657.07 501.03 1.31 0.07 0.05 Neutral L207Y 658 1032.96 1142.52 0.90 0.11 0.13 Neutral L207A 666 6302.90 5614.64 1.12 0.65 0.62 Up L207R 653 3476.88 1332.44 2.61 0.36 0.15 Neutral L207P 667 528.87 508.95 1.04 0.05 0.06 Up L207Q 656 671.72 518.36 1.30 0.07 0.06 Neutral L207N 655 551.03 476.05 1.16 0.06 0.05 Up L207K 652 860.90 594.92 1.45 0.09 0.07 Neutral L207M 662 11903.05 12984.69 0.92 1.22 1.42 Neutral L207W 663 509.40 470.26 1.08 0.05 0.05 Neutral L207H 651 620.20 595.55 1.04 0.06 0.07 Neutral L207D 649 523.82 473.80 1.11 0.05 0.05 Neutral L207V 665 656.95 550.54 1.19 0.08 0.07 Neutral L2071 664 645.37 550.32 1.17 0.08 0.07 Up L207G 660 610.01 484.35 1.26 0.08 0.06 Neutral S208D 2699 10064.82 9325.26 1.08 1.03 1.02 Neutral S208V 2714 10469.49 9334.16 1.12 1.07 1.02 Neutral S208P 2717 9922.26 9236.91 1.07 1.02 1.01 Neutral S208G 2709 10452.64 9295.93 1.12 1.07 1.02 Neutral S208A 2716 10553.22 9517.15 1.11 1.08 1.04 Neutral S208K 2702 22659.58 19984.18 1.13 2.32 2.19 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 0 Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral S208N 2705 9993.85 9327.07 1.07 1.02 1.02 Neutral S208F 2710 8826.28 9040.21 0.98 0.91 0.99 Neutral S208Q 2706 10196.89 9183.58 1.11 1.05 1.01 Neutral S208W 2712 9229.04 9226.75 1.00 0.95 1.01 Neutral S208T 2707 9241.73 8912.77 1.04 0.95 0.98 Neutral S208E 2700 10198.81 9401.75 1.08 1.05 1.03 Down S208C 2704 10497.72 16287.64 0.64 1.08 1.79 Neutral S208R 2703 7639.06 6465.10 1.18 1.34 1.28 Up S208L 2715 7811.78 6354.14 1.23 1.37 1.25 Neutral H209T 2725 466.30 415.72 1.12 0.11 0.08 Neutral H209Y 2726 471.70 455.15 1.04 0.11 0.09 Neutral H209R 2721 489.49 463.09 1.06 0.12 0.09 Neutral H209Q 2724 513.42 476.96 1.08 0.12 0.09 Neutral H209A 2735 511.91 469.64 1.09 0.12 0.09 Neutral H209G 2728 495.58 466.25 1.06 0.12 0.09 Neutral H209N 2723 455.09 424.90 1.07 0.11 0.08 Neutral H209P 2736 526.85 480.73 1.10 0.13 0.09 Neutral H209W 2731 516.05 484.16 1.07 0.12 0.09 Neutral H209V 2733 499.35 465.99 1.07 0.12 0.09 Neutral H209D 2718 479.48 442.06 1.08 0.12 0.09 Neutral H209S 2727 490.77 438.98 1.12 0.12 0.09 Neutral H209F 2729 490.42 437.68 1.12 0.12 0.09 Neutral H209L 2734 491.46 441.89 1.11 0.12 0.09 Neutral H209C 2722 471.56 420.60 1.12 0.11 0.08 Neutral S21OC 331 634.06 565.38 1.12 0.15 0.11 Neutral S21OG 336 643.08 581.11 1.11 0.16 0.11 Up S2101 340 778.38 625.00 1.25 0.19 0.12 Neutral S21OR 330 644.74 565.67 1.14 0.16 0.11 Neutral S210L 342 737.60 623.25 1.18 0.18 0.12 Up S21OV 341 1190.35 856.63 1.39 0.29 0.17 Neutral S21OH 328 605.43 521.90 1.16 0.15 0.10 Neutral S21ON 332 615.29 556.38 1.11 0.15 0.11 Neutral S21OF 337 529.93 487.42 1.09 0.13 0.09 Neutral S210P 344 544.94 513.59 1.06 0.13 0.10 Neutral S21OW 339 527.32 486.97 1.08 0.13 0.09 Neutral S21OQ 333 593.74 548.93 1.08 0.14 0.11 Neutral S21OT 334 2977.61 3427.71 0.87 0.72 0.67 Neutral S210K 329 625.14 573.41 1.09 0.15 0.11 Neutral S21OA 343 1682.05 1546.97 1.09 0.25 0.21 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 0 Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral T211P 2755 3493.13 3774.82 0.93 0.84 0.73 Neutral T211R 2741 4636.24 5429.67 0.85 1.12 1.05 Neutral T211 K 2740 4457.25 5411.31 0.82 1.08 1.05 Neutral T21IG 2747 3443.93 3543.72 0.97 0.83 0.69 Down T211M 2749 3806.80 4871.37 0.78 0.92 0.95 Neutral T211N 2743 5924.95 6170.25 0.96 1.43 1.20 Neutral T211V 2752 5095.76 5335.63 0.96 1.23 1.04 Neutral T211H 2739 1885.69 1829.82 1.03 0.46 0.36 Neutral T211 Q 2744 4868.86 5772.70 0.84 1.18 1.12 Neutral T211 S 2746 4641.02 4565.80 1.02 1.12 0.89 Neutral T211A 2754 2696.88 2830.43 0.95 0.65 0.55 Neutral T211F 2748 1412.47 1277.53 1.11 0.34 0.25 Neutral T211D 2737 2442.24 2154.48 1.13 0.59 0.42 Neutral T211W 2750 1362.99 1207.40 1.13 0.33 0.23 Neutral T211L 2753 2376.23 2102.07 1.13 0.35 0.28 Neutral D212E 668 4877.68 4473.75 1.09 1.18 0.87 Neutral D212A 685 2710.82 2417.65 1.12 0.66 0.47 Neutral D212K 670 2296.16 2049.97 1.12 0.55 0.40 Neutral D212R 671 2273.87 2004.06 1.13 0.55 0.39 Neutral D212T 675 2923.39 2699.75 1.08 0.71 0.52 Neutral D212N 673 4575.59 5229.75 0.87 1.11 1.02 Up D212G 678 1011.62 657.28 1.54 0.24 0.13 Neutral D212S 677 5035.28 4894.92 1.03 1.22 0.95 Neutral D212P 686 3270.81 2918.36 1.12 0.79 0.57 Neutral D212Q 674 2823.54 2576.63 1.10 0.68 0.50 Neutral D212V 683 2000.60 1876.86 1.07 0.48 0.36 Neutral D212L 684 517.72 497.60 1.04 0.13 0.10 Neutral D212F 679 2378.07 2185.27 1.09 0.57 0.42 Neutral D212H 669 4696.49 4001.41 1.17 0.70 0.53 Neutral D212Y 676 5489.99 5319.27 1.03 0.49 0.55 Neutral I213Q 2763 9326.77 8702.80 1.07 0.96 0.95 Neutral I213T 2764 9396.39 8742.82 1.07 0.96 0.96 Neutral I213C 2761 9396.24 8859.11 1.06 0.96 0.97 Neutral I213P 2774 10248.90 9319.88 1.10 1.05 1.02 Neutral 1213H 2758 9826.58 9076.23 1.08 1.01 1.00 Neutral 1213A 2773 10044.30 9249.07 1.09 1.03 1.01 Neutral 1213V 2771 10260.18 9459.80 1.08 1.05 1.04 Neutral I213G 2767 21327.14 19706.88 1.08 2.19 2.16 Neutral 1213N 2762 8790.33 7995.03 1.10 0.90 0.88 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral I213L 2772 9974.73 9208.92 1.08 1.02 1.01 Neutral 1213S 2766 9599.72 9004.65 1.07 0.98 0.99 Neutral I213M 2769 9987.31 9083.77 1.10 1.02 1.00 Neutral 1213R 2760 9253.06 8997.34 1.03 0.95 0.99 Neutral I213K 2759 9682.80 9286.32 1.04 0.99 1.02 Neutral I213F 2768 9368.13 8940.38 1.05 0.96 0.98 Neutral 1213D 2756 7017.06 7368.43 0.95 0.77 0.97 Neutral 1213E 2757 8169.74 7234.77 1.13 0.90 0.95 Neutral G214L 2791 13 500.23 1313 5.46 1.03 1.38 1.44 Neutral G214Q 2782 9914.48 9182.63 1.08 1.02 1.01 Neutral G214S 2785 9503.68 9036.70 1.05 0.97 0.99 Neutral G214T 2783 9940.86 9214.25 1.08 1.02 1.01 Neutral G214V 2790 8185.36 7785.72 1.05 0.84 0.85 Neutral G2141 2789 6068.79 5773.01 1.05 0.62 0.63 Neutral G214R 2779 9720.43 9083.04 1.07 1.00 1.00 Neutral G214P 2793 8763.31 8875.24 0.99 0.90 0.97 Neutral G214E 2776 21602.30 19851.77 1.09 2.22 2.18 Neutral G214A 2792 10063.30 9154.93 1.10 1.03 1.00 Neutral G214D 2775 9967.49 9121.71 1.09 1.02 1.00 Neutral G214F 2786 9750.30 9157.75 1.06 1.00 1.00 Neutral G214Y 2784 9886.62 9025.45 1.10 1.01 0.99 Neutral G214M 2787 9472.77 8919.05 1.06 0.97 0.98 Neutral G214C 2780 6716.52 7097.60 0.95 0.69 0.78 Neutral A215L 2811 454.59 428.41 1.06 0.07 0.06 Neutral A215Q 2801 765.06 739.09 1.04 0.12 0.10 Neutral A215M 2807 672.22 624.41 1.08 0.10 0.09 Down A215G 2805 4240.44 6854.29 0.62 0.66 0.96 Neutral A215W 2808 377.79 348.04 1.09 0.06 0.05 Neutral A215S 2804 559.99 538.20 1.04 0.09 0.08 Neutral A215T 2802 664.02 711.35 0.93 0.10 0.10 Neutral A215V 2810 473.67 492.63 0.96 0.07 0.07 Neutral A215N 2800 4328.77 4488.89 0.96 0.67 0.63 Neutral A215P 2812 638.50 596.48 1.07 0.10 0.08 Neutral A215H 2796 3954.04 4447.65 0.89 0.61 0.62 Neutral A215K 2797 420.46 402.71 1.04 0.07 0.06 Neutral A215I 2809 413.93 386.28 1.07 0.06 0.05 Neutral A215R 2798 421.35 389.00 1.08 0.07 0.05 Neutral A215C 2799 437.44 425.03 1.03 0.07 0.06 Neutral A215D 2794 1031.48 913.25 1.13 0.11 0.12 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 0 Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral L216A 2830 808.93 759.54 1.07 0.13 0.12 Neutral L216C 2818 473.05 462.23 1.02 0.08 0.07 Neutral L216D 2813 497.61 457.15 1.09 0.08 0.07 Neutral L216E 2814 480.72 458.21 1.05 0.08 0.07 Neutral L216G 2824 473.61 452.00 1.05 0.08 0.07 Neutral L2161 2828 7525.06 8586.88 0.88 1.20 1.37 Neutral L216K 2816 478.52 460.66 1.04 0.08 0.07 Neutral L216M 2826 4641.29 5160.67 0.90 0.74 0.83 Neutral L216P 2831 466.46 475.96 0.98 0.07 0.08 Neutral L216Q 2820 693.10 638.62 1.09 0.11 0.10 Neutral L216R 2817 458.77 437.34 1.05 0.07 0.07 Neutral L216S 2823 454.85 441.50 1.03 0.07 0.07 Neutral L216T 2821 1484.74 1392.55 1.07 0.24 0.22 Down L216V 2829 5022.20 6281.17 0.80 0.80 1.01 Neutral L216W 2827 479.55 454.07 1.06 0.08 0.07 Neutral M217P 2850 458.79 440.59 1.04 0.07 0.06 Neutral M217Y 2841 459.96 427.87 1.07 0.07 0.06 Neutral M217T 2840 699.27 663.16 1.05 0.11 0.09 Down M217C 2837 5441.67 7486.86 0.73 0.85 1.05 Neutral M217S 2842 470.92 424.03 1.11 0.07 0.06 Neutral M217L 2848 443.33 403.49 1.10 0.07 0.06 Neutral M217N 2838 462.12 424.21 1.09 0.07 0.06 Neutral M217R 2836 454.58 442.20 1.03 0.07 0.06 Neutral M217Q 2839 449.94 427.47 1.05 0.07 0.06 Neutral M217K 2835 506.96 458.74 1.11 0.08 0.06 Neutral M217G 2843 746.17 728.78 1.02 0.12 0.10 Neutral M217A 2849 437.36 410.18 1.07 0.07 0.06 Neutral M217H 2834 442.18 398.29 1.11 0.07 0.06 Neutral M2171 2846 483.00 449.94 1.07 0.08 0.06 Neutral M217D 2832 503.49 491.20 1.03 0.04 0.05 Neutral Y218C 350 511.72 486.65 1.05 0.08 0.07 Down Y218F 356 4555.92 6084.93 0.75 0.71 0.85 Neutral Y218W 358 8521.86 9311.36 0.92 1.32 1.30 Neutral Y218L 361 834.41 743.23 1.12 0.13 0.10 Neutral Y218A 362 1935.94 1652.76 1.17 0.30 0.23 Neutral Y218P 363 503.58 469.06 1.07 0.08 0.07 Neutral Y218R 349 508.52 465.38 1.09 0.08 0.07 Neutral Y218N 351 704.77 640.35 1.10 0.11 0.09 Neutral Y218V 360 527.03 480.30 1.10 0.08 0.07 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral Y21-8Q 352 513.25 468.66 1.10 0.08 0.07 Up Y2181 359 698.50 542.67 1.29 0.11 0.08 Neutral Y218D 345 835.29 885.84 0.94 0.13 0.12 Up Y218S 354 3702.49 3099.73 1.19 0.58 0.43 Neutral Y218G 355 504.65 460.32 1.10 0.08 0.06 Neutral Y218E 346 511.24 471.64 1.08 0.08 0.07 Neutral P219L 2868 578.24 550.18 1.05 0.09 0.08 Neutral P219C 2856 622.59 613.51 1.01 0.10 0.09 Neutral P219V 2867 586.82 583.21 1.01 0.09 0.08 Neutral P219D 2851 819.59 881.94 0.93 0.13 0.12 Neutral P219F 2863 571.45 542.25 1.05 0.09 0.08 Neutral P219A 2869 1749.52 1799.14 0.97 0.27 0.25 Neutral P219T 2859 870.52 853.07 1.02 0.14 0.12 Neutral P219E 2852 895.73 858.50 1.04 0.14 0.12 Neutral P219Q 2858 601.64 557.23 1.08 0.09 0.08 Neutral P219R 2855 580.05 533.83 1.09 0.09 0.07 Neutral P219H 2853 595.81 592.49 1.01 0.09 0.08 Neutral P219G 2862 625.62 619.20 1.01 0.10 0.09 Neutral P219K 2854 647.47 633.20 1.02 0.10 0.09 Neutral P219S 2861 1549.48 1669.93 0.93 0.24 0.23 Neutral P219W 2865 929.41 912.72 1.02 0.14 0.13 Down S220R 2874 7949.20 10460.71 0.76 1.23 1.46 Neutral S220A 2887 9804.98 9347.41 1.05 1.52 1.31 Neutral S220Q 2878 9804.83 9328.79 1.05 1.52 1.30 Neutral S220T 2877 9371.43 9378.23 1.00 1.46 1.31 Down S220L 2886 1688.62 2607.71 0.65 0.26 0.36 Down S220K 2873 2607.58 3704.87 0.70 0.40 0.52 Neutral S220G 2880 9916.14 9356.60 1.06 1.54 1.31 Down S220H 2872 1496.17 1874.12 0.80 0.23 0.26 Neutral S220E 2871 3553.14 3992.18 0.89 0.55 0.56 Neutral S220M 2882 7913.94 8545.54 0.93 1.23 1.20 Neutral S220V 2885 10179.81 9414.03 1.08 1.58 1.32 Neutral S220P 2888 592.32 587.51 1.01 0.09 0.08 Down S2201 2884 6596.23 8678.69 0.76 1.02 1.21 Down S220F 2881 2458.37 3612.28 0.68 0.38 0.51 Neutral S220N 2876 10548.94 9399.76 1.12 1.64 1.31 Up Y221W 2902 1201.23 891.46 1.35 0.19 0.12 Neutral Y221 K 2892 595.72 575.31 1.04 0.09 0.08 Neutral Y221 Q 2896 592.45 568.96 1.04 0.09 0.08 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral Y221C 2894 583.88 558.96 1.04 0.09 0.08 Neutral Y221N 2895 607.96 599.09 1.01 0.09 0.08 Neutral Y221P 2907 575.23 546.02 1.05 0.09 0.08 Neutral Y221 V 2904 600.84 608.45 0.99 0.09 0.09 Neutral Y221A 2906 613.20 571.57 1.07 0.10 0.08 Neutral Y221 G 2899 558.30 544.78 1.02 0.09 0.08 Neutral Y221R 2893 508.18 483.59 1.05 0.08 0.07 Neutral Y221 S 2898 551.66 511.82 1.08 0.09 0.07 Up Y221M 2901 733.99 576.28 1.27 0.11 0.08 Neutral Y221 T 2897 552.92 554.37 1.00 0.09 0.08 Neutral Y221 L 2905 600.40 544.47 1.10 0.09 0.08 Neutral Y221E 2890 585.19 609.28 0.96 0.09 0.09 Down T222L 2924 1251.44 1749.83 0.72 0.21 0.25 Down T222Y 2916 3088.86 4344.09 0.71 0.52 0.61 Neutral T222R 2912 7857.83 8130.34 0.97 1.33 1.14 Neutral T222V 2923 6050.08 7520.37 0.80 1.03 1.06 Neutral T222P 2926 9566.57 8477.71 1.13 1.62 1.19 Neutral T222S 2917 8669.64 8464.76 1.02 1.47 1.19 Neutral T222A 2925 5927.34 6623.26 0.89 1.00 0.93 Down T222H 2910 4207.02 5413.49 0.78 0.71 0.76 Neutral T222G 2918 7265.81 7630.73 0.95 1.23 1.07 Neutral T222M 2920 4765.98 5354.04 0.89 0.81 0.75 Neutral T222F 2919 8084.32 8023.96 1.01 1.37 1.13 Neutral T222C 2913 1134.10 1047.66 1.08 0.19 0.15 Neutral T2221 2922 489.93 514.09 0.95 0.08 0.07 Neutral T222N 2914 8082.92 8215.81 0.98 1.37 1.15 Down T222W 2921 4390.84 5903.99 0.74 0.74 0.83 Neutral T222D 2908 4859.28 5584.93 0.87 0.53 0.73 Neutral F223L 380 2776.43 3305.29 0.84 0.47 0.46 Neutral F223T 372 7801.97 7792.62 1.00 1.32 1.09 Up F223C 369 3115.11 2488.91 1.25 0.53 0.35 Neutral F223R 368 5508.50 5094.99 1.08 0.93 0.71 Neutral F223N 370 7434.46 6650.94 1.12 1.26 0.93 Neutral F223P 382 8466.83 7678.71 1.10 1.43 1.08 Up F223E 365 7194.34 5884.03 1.22 1.22 0.83 Up F223G 375 3236.56 2599.04 1.25 0.55 0.36 Neutral F223Q 371 8100.68 7468.16 1.08 1.37 1.05 Up F223A 381 5226.86 3982.92 1.31 0.89 0.56 Up F223S 374 6006.80 4916.07 1.22 1.02 0.69 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 0 Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral F223Y 373 9072.25 8479.33 1.07 1.54 1.19 Neutral F223H 366 8573.59 8056.97 1.06 1.45 1.13 Neutral F223K 367 4021.97 3712.91 1.08 0.60 0.49 Neutral F223M 376 525.66 441.29 1.19 0.08 0.06 Neutral S224G 2937 5580.59 6030.81 0.93 0.89 0.97 Neutral S224T 2935 6189.79 7398.93 0.84 0.99 1.18 Neutral S224Q 2934 7258.89 8221.79 0.88 1.16 1.32 Neutral S224R 2931 4718.67 4984.94 0.95 0.76 0.80 Neutral S224P 2945 475.19 459.57 1.03 0.08 0.07 Neutral S2241 2941 5653.45 6319.33 0.89 0.90 1.01 Neutral S224V 2942 4074.45 5042.87 0.81 0.65 0.81 Down S224L 2943 4272.54 5590.35 0.76 0.68 0.89 Neutral S224C 2932 4057.16 4912.59 0.83 0.65 0.79 Neutral S224K 2930 7286.24 8122.32 0.90 1.17 1.30 Neutral S224D 2927 7201.97 8490.41 0.85 1.15 1.36 Neutral S224H 2929 5928.85 6787.33 0.87 0.95 1.09 Neutral S224M 2939 5967.51 6770.07 0.88 0.95 1.08 Neutral S224A 2944 469.39 427.21 1.10 0.08 0.07 Down S224W 2940 4323.69 5971.55 0.72 0.69 0.96 Neutral G225D 2946 4925.13 4615.89 1.07 0.83 0.65 Neutral G225R 2950 6317.32 6775.84 0.93 1.07 0.95 Neutral G225Q 2953 8693.50 8267.06 1.05 1.47 1.16 Neutral G225M 2958 3626.70 3585.88 1.01 0.61 0.50 Neutral G225P 2964 4775.00 4558.87 1.05 0.81 0.64 Neutral G225W 2959 6452.91 7515.31 0.86 1.09 1.05 Neutral G225S 2956 4811.54 4789.30 1.00 0.82 0.67 Neutral G225E 2947 9174.21 8356.85 1.10 1.55 1.17 Neutral G225V 2961 3525.03 3330.02 1.06 0.60 0.47 Neutral G225T 2954 7463.15 7841.71 0.95 1.26 1.10 Neutral G225K 2949 7135.01 7721.15 0.92 1.21 1.08 Neutral G225N 2952 5858.96 5807.35 1.01 0.99 0.81 Neutral G225C 2951 1631.86 1835.77 0.89 0.28 0.26 Neutral G225H 2948 8719.92 8448.61 1.03 1.48 1.19 Neutral G225A 2963 6048.29 5768.91 1.05 1.03 0.81 Neutral D226S 2974 8608.26 8605.77 1.00 1.46 1.21 Neutral D226W 2978 1817.34 2172.37 0.84 0.31 0.30 Down D226R 2968 5584.63 7070.57 0.79 0.95 0.99 Neutral D226A 2982 6987.67 7786.46 0.90 1.18 1.09 Neutral D226N 2970 6464.01 7314.30 0.88 1.10 1.03 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 0 Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral D226T 2972 3450.45 4219.45 0.82 0.58 0.59 Neutral D226E 2965 9308.62 8744.05 1.06 1.58 1.23 Neutral D226L 2981 3411.80 4254.22 0.80 0.58 0.60 Neutral D226P 2983 8574.77 8325.60 1.03 1.45 1.17 Neutral D226H 2966 4217.71 4180.90 1.01 0.71 0.59 Neutral D226G 2975 6320.31 7359.33 0.86 1.07 1.03 Neutral D2261 2979 7753.45 8016.92 0.97 1.31 1.12 Neutral D226M 2977 6501.53 7210.62 0.90 1.10 1.01 Neutral D226V 2980 3680.55 4504.86 0.82 0.62 0.63 Neutral D226C 2969 7227.15 7735.09 0.93 1.22 1.09 Neutral V227A 400 5109.18 5056.19 1.01 0.87 0.71 Up V227C 388 4040.96 3278.65 1.23 0.68 0.46 Up V227D 383 1190.09 731.34 1.63 0.20 0.10 Up V227E 384 5381.63 2605.20 2.07 0.91 0.37 Neutral V227K 386 580.24 550.24 1.05 0.10 0.08 Up V227L 399 4883.98 4000.68 1.22 0.83 0.56 Neutral V227P 401 3682.22 3644.94 1.01 0.62 0.51 Up V227S 393 3863.33 3131.47 1.23 0.65 0.44 Neutral V227T 391 9817.63 8523.33 1.15 1.66 1.20 Up V227W 397 1845.46 1374.06 1.34 0.31 0.19 Up V227Y 392 657.68 542.07 1.21 0.11 0.08 Neutral V227G 394 1040.74 883.01 1.18 0.15 0.12 Up V227H 385 689.20 504.65 1.37 0.10 0.07 Up V227Q 390 696.97 506.11 1.38 0.10 0.07 Neutral V227R 387 664.31 561.06 1.18 0.10 0.07 Neutral Q228A 419 9710.68 9175.62 1.06 4.50 3.13 Neutral Q228D 402 10931.89 9274.00 1.18 5.06 3.16 Neutral Q228E 403 9825.63 9396.31 1.05 4.55 3.20 Neutral Q228G 412 9400.23 9058.34 1.04 4.35 3.09 Neutral Q228H 404 9748.08 9288.74 1.05 4.51 3.17 Neutral Q228K 405 9999.23 9262.11 1.08 4.63 3.16 Neutral Q228L 418 9199.01 8900.02 1.03 4.26 3.03 Neutral Q228M 414 9510.07 8915.79 1.07 4.40 3.04 Neutral Q228N 408 8774.26 8679.09 1.01 4.06 2.96 Up Q228P 420 2862.74 1291.55 2.22 1.33 0.44 Neutral Q228R 406 7443.02 8091.71 0:92 3.45 2.76 Neutral Q228S 411 8188.30 8162.27 1.00 3.79 2.78 Neutral Q228T 409 4335.26 5179.47 0.84 2.01 1.77 Neutral Q228W 415 6169.39 6508.89 0.95 2.86 2.22 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral Q228Y 410 7426.87 7840.08 0.95 3.44 2.67 Neutral L229R 425 485.95 489.74 0.99 0.22 0.17 Up L229A 438 2627.78 2118.07 1.24 1.22 0.72 Up L229T 429 3780.54 1464.25 2.58 1.75 0.50 Neutral L229Q 428 5328.09 5303.89 1.00 2.47 1.81 Neutral L229P 439 4795.14 5009.73 0.96 2.22 1.71 Neutral L229E 422 737.30 657.34 1.12 0.34 0.22 Neutral L229W 435 577.28 520.84 1.11 0.27 0.18 Neutral L229M 434 3207.73 2829.20 1.13 1.49 0.96 Up L2291 436 1158.56 828.94 1.40 0.54 0.28 Neutral L229G 432 552.22 520.30 1.06 0.26 0.18 Up L229C 426 633.99 516.61 1.23 0.29 0.18 Neutral L229Y 430 549.90 504.60 1.09 0.25 0.17 Neutral L229D 421 498.06 485.50 1.03 0.23 0.17 Neutral L229H 423 551.54 501.77 1.10 0.26 0.17 Neutral L229V 437 6249.58 6487.57 0.96 2.89 2.21 Up A230L 704 3437.91 2154.62 1.60 1.59 0.73 Neutral A230G 698 6804.87 8304.63 0.82 3.15 2.83 Neutral A230W 701 4773.24 5118.69 0.93 2.21 1.74 Up A230P 705 699.78 568.62 1.23 0.32 0.19 Neutral A230D 687 7281.83 8033.59 0.91 3.37 2.74 Up A230R 691 2986.52 2304.10 1.30 1.38 0.79 Up A2301 702 4609.64 3490.44 1.32 2.13 1.19 Neutral A230S 697 9181.71 8982.15 1.02 4.25 3.06 Neutral A230C 692 5061.18 5781.86 0.88 2.34 1.97 Up A230V 703 5030.94 3433.18 1.47 2.33 1.17 Neutral A230T 695 8822.74 9169.52 0.96 4.08 3.13 Neutral A230Y 696 3327.47 2858.53 1.16 1.54 0.97 Neutral A230M 700 9543.01 9520.33 1.00 4.42 3.25 Neutral A230N 693 9217.40 9384.02 0.98 4.27 3.20 Up A230H 689 8514.47 6763.46 1.26 3.94 2.31 Neutral Q23 11 2998 4161.47 3993.24 1.04 1.93 1.36 Neutral Q231A 3001 6899.50 6650.48 1.04 3.19 2.27 Neutral Q231F 2995 4049.29 4120.56 0.98 1.87 1.40 Neutral Q231P 3002 613.73 591.34 1.04 0.28 0.20 Neutral Q231Y 2992 2460.04 2960.32 0.83 1.14 1.01 Down Q231R 2988 366.16 1013.08 0.36 0.17 0.35 Up Q231 L 3000 3744.09 2834.26 1.32 1.73 0.97 Neutral Q231D 2984 7507.92 7957.26 0.94 3.48 2.71 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral Q231 G 2994 5743.70 6012.88 0.96 2.66 2.05 Neutral Q231 V 2999 6114.28 6172.88 0.99 2.83 2.10 Neutral Q231 W 2997 4910.80 4767.26 1.03 2.27 1.62 Neutral Q231 S 2993 6593.10 7180.32 0.92 3.05 2.45 Neutral Q231H 2986 4961.12 5622.05 0.88 2.30 1.92 Up Q231 C 2989 970.74 697.37 1.39 0.45 0.24 Down Q231M 2996 3314.86 4166.20 0.80 1.53 1.42 Neutral D232H 3004 6046.51 7174.55 0.84 2.80 2.45 Down D232G 3013 5492.29 7079.04 0.78 2.54 2.41 Neutral D232R 3006 5077.01 5692.86 0.89 2.35 1.94 Neutral D232P 3021 7665.95 8291.54 0.92 3.55 2.83 Neutral D232Y 3011 3001.62 3628.15 0.83 1.39 1.24 Neutral D232N 3008 825.42 739.97 1.12 0.38 0.25 Up D232S 3012 14389.74 5104.26 2.82 6.66 1.74 Neutral D232F 3014 3599.26 3719.64 0.97 1.67 1.27 Neutral D232V 3018 7938.31 9176.75 0.87 3.68 3.13 Neutral D232K 3005 4844.31 5829.58 0.83 2.24 1.99 Neutral D232W 3016 8404.13 9037.60 0.93 3.89 3.08 Neutral D232Q 3009 7550.58 8008.46 0.94 3.50 2.73 Neutral D232E 3003 9294.39 9251.91 1.00 4.30 3.15 Neutral D232T 3010 9434.20 9583.53 0.98 4.37 3.27 Up D232L 3019 7603.68 4213.70 1.80 3.52 1.44 Neutral D233Q 446 653.34 640.95 1.02 0.30 0.22 Neutral D233P 458 629.51 626.42 1.00 0.29 0.21 Neutral D233S 449 637.89 623.07 1.02 0.30 0.21 Neutral D233T 447 621.24 615.06 1.01 0.29 0.21 Neutral D233A 457 650.58 634.46 1.03 0.30 0.22 Neutral D233W 453 644.19 649.94 0.99 0.30 0.22 Neutral D233G 450 657.96 666.27 0.99 0.30 0.23 Up D233R 443 715.14 467.03 1.53 0.33 0.16 Up D233E 440 2881.17 1918.57 1.50 1.33 0.65 Neutral D233N 445 580.50 572.32 1.01 0.27 0.20 Neutral D233V 455 609.36 603.42 1.01 0.28 0.21 Neutral D233M 452 581.45 593.79 0.98 0.27 0.20 Neutral D233L 456 584.42 597.47 0.98 0.27 0.20 Neutral D233K 442 608.53 615.71 0.99 0.28 0.21 Neutral D2331 454 682.66 661.78 1.03 0.32 0.23 Up 1234A 476 1458.10 1018.50 1.43 0.31 0.18 Up 1234T 467 1451.51 1188.67 1.22 0.31 0.21 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 0 Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Down I234V 474 3474.82 5245.94 0.66 0.73 0.91 Up I234W 473 743.35 570.02 1.30 0.16 0.10 Up 1234E 460 1301.06 840.09 1.55 0.27 0.15 Neutral 1234G 470 498.38 467.78 1.07 0.10 0.08 Down I234L 475 2584.47 3312.61 0.78 0.54 0.57 Up I234H 461 684.95 503.63 1.36 0.14 0.09 Down I234M 472 3478.87 4732.62 0.74 0.73 0.82 Up I234N 465 633.30 513.69 1.23 0.13 0.09 Neutral I234Y 468 749.28 930.94 0.80 0.16 0.16 Neutral 1234P 477 470.41 431.33 1.09 0.10 0.07 Neutral I234D 459 428.28 397.06 1.08 0.09 0.07 Up 1234Q 466 1095.18 837.53 1.31 0.23 0.15 Up 1234C 464 702.09 483.22 1.45 0.15 0.08 Neutral D235H 3023 5217.44 6443.75 0.81 1.10 1.12 Neutral D235G 3032 5966.03 6875.44 0.87 1.26 1.19 Down D235A 3039 5874.20 9191.04 0.64 1.24 1.59 Neutral D235P 3040 488.90 464.91 1.05 0.10 0.08 Neutral D235L 3038 6353.97 6868.10 0.93 1.34 1.19 Down D235V 3037 4167.59 6418.00 0.65 0.88 1.11 Neutral D235E 3022 8377.14 8154.10 1.03 1.76 1.41 Neutral D235R 3025 7249.34 7013.16 1.03 1.53 1.22 Neutral D235Q 3028 6969.55 7752.26 0.90 1.47 1.34 Neutral D235T 3029 6608.45 7282.18 0.91 1.39 1.26 Down D235C 3026 3805.25 5237.38 0.73 0.80 0.91 Down D235S 3031 3798.36 6310.00 0.60 0.80 1.09 Neutral D235N 3027 6427.98 6780.43 0.95 1.35 1.18 Neutral D235Y 3030 3539.06 3728.70 0.95 0.75 0.65 Neutral D235I 3036 5390.78 5499.20 0.98 1.14 0.95 Neutral G236M 3053 8157.95 7452.06 1.09 1.72 1.29 Neutral G236R 3045 8890.85 8115.23 1.10 1.87 1.41 Neutral G236D 3041 3820.99 4576.94 0.83 0.80 0.79 Neutral G236S 3051 9887.69 8558.48 1.16 2.08 1.48 Down G236T 3049 6244.13 7949.24 0.79 1.32 1.38 Neutral G236C 3046 8441.80 7993.25 1.06 1.78 1.39 Neutral G236K 3044 9473.18 8370.29 1.13 2.00 1.45 Neutral G236E 3042 7240.97 7573.43 0.96 1.53 1.31 Up G236P 3059 969.12 668.23 1.45 0.20 0.12 Neutral G2361 3055 5356.96 5189.19 1.03 1.13 0.90 Down G236Y 3050 4511.53 5725.61 0.79 0.95 0.99 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 0 Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral G236L 3057 8099.87 7699.72 1.05 1.71 1.34 Down G236V 3056 4448.72 6422.58 0.69 0.94 1.11 Neutral G236N 3047 8477.40 8088.17 1.05 1.79 1.40 Neutral G236F 3052 5761.86 5560.83 1.04 1.21 0.96 Neutral I237S 3070 587.31 536.19 1.10 0.12 0.09 Up 1237L 3076 2880.14 2240.61 1.29 0.61 0.39 Neutral 1237R 3064 572.70 548.66 1.04 0.12 0.10 Neutral 1237Q 3067 552.21 543.69 1.02 0.12 0.09 Neutral 1237K 3063 571.56 531.05 1.08 0.12 0.09 Neutral I237D 3060 567.39 512.64 1.11 0.12 0.09 Down 1237A 3077 1512.93 2138.58 0.71 0.32 0.37 Neutral 1237T 3068 572.40 524.74 1.09 0.12 0.09 Neutral I237E 3061 555.97 535.94 1.04 0.12 0.09 Neutral 1237C 3065 565.11 532.36 1.06 0.12 0.09 Neutral 1237G 3071 620.23 586.38 1.06 0.13 0.10 Neutral 1237P 3078 554.04 497.24 1.11 0.12 0.09 Neutral 1237Y 3069 688.92 602.65 1.14 0.15 0.10 Down I237W 3074 4188.38 5663.94 0.74 0.62 0.75 Neutral I237N 3066 5368.49 6271.59 0.86 0.80 0.83 Down Q238G 3089 1382.45 2524.64 0.55 0.29 0.44 Down Q238H 3081 3150.20 5045.01 0.62 0.66 0.88 Down Q238S 3088 3298.60 4524.89 0.73 0.69 0.78 Down Q238Y 3087 2078.90 2953.44 0.70 0.44 0.51 Down Q238F 3090 1342.33 1916.87 0.70 0.28 0.33 Down Q238E 3080 4075.95 5719.51 0.71 0.86 0.99 Down Q238L 3095 3030.44 4771.52 0.64 0.64 0.83 Neutral Q238W 3092 3649.81 4317.00 0.85 0.77 0.75 Neutral Q238P 3097 568.68 548.50 1.04 0.12 0.10 Down Q238R 3083 4199.78 5952.76 0.71 0.88 1.03 Down Q238C 3084 3179.60 4072.46 0.78 0.67 0.71 Neutral Q238N 3085 3119.13 3894.89 0.80 0.66 0.68 Down Q2381 3093 3863.21 5191.15 0.74 0.81 0.90 Neutral Q238T 3086 7425.48 7998.67 0.93 1.56 1.39 Down Q238K 3082 4717.87 5952.01 0.79 0.99 1.03 Neutral A239S 3108 7235.02 7630.43 0.95 1.52 1.32 Down A239Q 3105 4817.25 8226.13 0.59 1.01 1.43 Down A239T 3106 1232.13 2351.52 0.52 0.26 0.41 Neutral A239P 3116 606.39 564.14 1.07 0.13 0.10 Neutral A239V 3114 6075.94 6919.38 0.88 1.28 1.20 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral A239L 3115 7174.28 7878.58 0.91 1.51 1.37 Neutral A239Y 3107 5570.87 6668.58 0.84 1.17 1.16 Neutral A239I 3113 6821.36 7628.60 0.89 1.44 1.32 Neutral A239C 3103 4986.74 5916.10 0.84 1.05 1.03 Neutral A239G 3109 6430.98 7617.20 0.84 1.35 1.32 Down A239W 3112 2215.28 4554.04 0.49 0.47 0.79 Neutral A239F 3110 719.92 750.33 0.96 0.15 0.13 Neutral A239K 3101 8365.39 8161.53 1.02 1.76 1.42 Neutral A239H 3100 6013.93 6892.53 0.87 1.27 1.20 Neutral A239R 3102 8860.20 8322.26 1.06 1.87 1.44 Neutral A239D 3098 9256.74 8197.40 1.13 1.02 1.08 Up I240G 489 550.59 455.20 1.21 0.09 0.06 Neutral I240Q 485 1050.40 921.68 1.14 0.16 0.12 Down I240P 496 2259.38 3251.71 0.69 0.35 0.42 Down I240R 482 2771.00 3465.26 0.80 0.43 0.44 Up 1240S 488 2033.91 1204.66 1.69 0.32 0.15 Neutral I240K 481 5557.21 6183.54 0.90 0.87 0.79 Down I240V 493 4682.76 6307.59 0.74 0.73 0.81 Neutral I240D 478 480.83 456.39 1.05 0.08 0.06 Neutral I240A 495 2099.13 1776.41 1.18 0.33 0.23 Up 1240C 483 970.78 650.04 1.49 0.15 0.08 Neutral 1240L 494 8303.04 8506.66 0.98 1.30 1.09 Down I240F 490 1345.29 2090.14 0.64 0.21 0.27 Up I240Y 487 1910.61 1482.53 1.29 0.30 0.19 Neutral 1240M 491 8056.10 7463.56 1.08 1.26 0.95 Neutral I240T 486 2147.14 1862.29 1.15 0.34 0.24 Neutral Y241 V 3132 568.18 567.15 1.00 0.09 0.07 Neutral Y241A 3134 514.00 498.25 1.03 0.08 0.06 Neutral Y241 G 3127 484.83 493.78 0.98 0.08 0.06 Neutral Y241H 3119 555.41 547.86 1.01 0.09 0.07 Neutral Y241R 3121 479.35 491.61 0.98 0.08 0.06 Neutral Y241P 3135 542.62 468.74 1.16 0.09 0.06 Neutral Y241 Q 3124 494.42 468.65 1.05 0.08 0.06 Neutral Y241L 3133 486.82 484.95 1.00 0.08 0.06 Neutral Y241 T 3125 574.08 548.16 1.05 0.09 0.07 Neutral Y241 S 3126 512.62 498.70 1.03 0.08 0.06 Neutral Y241W 3130 592.83 556.32 1.07 0.09 0.07 Neutral Y241N 3123 438.44 443.51 0.99 0.07 0.06 Neutral Y241M 3129 488.24 448.13 1.09 0.08 0.06 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral Y2411 3131 469.78 446.31 1.05 0.07 0.06 Neutral Y241D 3117 454.99 443.57 1.03 0.07 0.06 Neutral G242A 3153 1948.43 1965.86 0.99 0.31 0.25 Neutral G242F 3147 2367.13 2861.31 0.83 0.37 0.37 Down G242L 3152 4261.36 6043.02 0.71 0.67 0.77 Neutral G242N 3142 1712.51 1893.88 0.90 0.27 0.24 Neutral G242P 3154 2683.19 3311.87 0.81 0.42 0.42 Down G242W 3149 1200.76 1522.34 0.79 0.19 0.19 Neutral G242T 3144 1845.15 1926.23 0.96 0.29 0.25 Neutral G242R 3140 1425.79 1462.84 0.97 0.22 0.19 Neutral G242V 3151 1864.42 2075.51 0.90 0.29 0.27 Down G242S 3146 3463.26 4491.54 0.77 0.54 0.57 Down G2421 3150 881.04 2441.87 0.36 0.14 0.31 Neutral G242Y 3145 895.61 928.34 0.96 0.14 0.12 Neutral G242H 3138 1038.60 1063.68 0.98 0.16 0.14 Neutral G242E 3137 1039.40 1200.19 0.87 0.16 0.15 Neutral G242K 3139 1259.85 1404.80 0.90 0.20 0.18 Down R243P 3173 3936.04 7438.61 0.53 0.62 0.95 Neutral R243K 3158 8397.44 8514.77 0.99 1.32 1.09 Neutral R243T 3162 7451.28 7306.32 1.02 1.17 0.93 Neutral R243L 3171 6953.44 7458.28 0.93 1.09 0.95 Neutral R243A 3172 8253.02 8378.15 0.99 1.29 1.07 Neutral R243H 3157 6757.06 7710.25 0.88 1.06 0.99 Neutral R243Q 3161 7563.55 8367.33 0.90 1.19 1.07 Neutral R243S 3164 7872.26 8367.98 0.94 1.23 1.07 Down R2431 3169 4421.12 8337.68 0.53 0.69 1.07 Neutral R243C 3159 6128.24 6907.63 0.89 0.96 0.88 Neutral R243N 3160 7064.71 7808.36 0.90 1.11 1.00 Neutral R243Y 3163 6415.10 7427.20 0.86 1.01 0.95 Neutral R243G 3165 9279.36 8697.39 1.07 1.46 1.11 Neutral R243D 3155 5769.78 6318.28 0.91 0.90 0.81 Neutral R243V 3170 6349.88 7531.41 0.84 1.00 0.96 Neutral S244P 3192 7394.47 7844.16 0.94 1.16 1.00 Down S244L 3190 3480.19 7154.31 0.49 0.55 0.91 Neutral S244W 3187 10346.96 9035.98 1.15 1.62 1.15 Neutral S244M 3186 728.14 748.02 0.97 0.11 0.10 Neutral S244V 3189 6842.04 7456.02 0.92 1.07 0.95 Neutral S244Q 3181 9318.66 8746.49 1.07 1.46 1.12 Neutral S244D 3174 6915.01 7609.44 0.91 1.08 0.97 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 0 Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral S244E 3175 8814.39 8156.16 1.08 1.38 1.04 Neutral S244T 3182 7442.34 8205.48 0.91 1.17 1.05 Down S244H 3176 5019.42 8528.78 0.59 0.79 1.09 Neutral S244G 3184 888.96 801.21 1.11 0.14 0.10 Neutral S244A 3191 9174.68 8474.43 1.08 1.44 1.08 Neutral S244F 3185 962.91 1017.49 0.95 0.15 0.13 Neutral S244Y 3183 6333.20 6595.86 0.96 0.99 0.84 Neutral S244R 3178 10483.23 9488.64 1.10 0.93 0.99 Neutral Q245P 3211 8046.62 8690.91 0.93 1.26 1.11 Neutral Q2451 3207 7611.43 8270.47 0.92 1.19 1.06 Down Q245F 3204 3940.03 8048.83 0.49 0.62 1.03 Neutral Q245V 3208 7785.27 8186.90 0.95 1.22 1.05 Up Q245M 3205 494.18 323.62 1.53 0.08 0.04 Neutral Q245T 3200 8684.29 8676.53 1.00 1.36 1.11 Neutral Q245E 3194 10044.47 8646.78 1.16 1.58 1.10 Neutral Q245S 3202 8700.39 8695.56 1.00 1.36 1.11 Neutral Q245R 3197 8323.06 8629.37 0.96 1.31 1.10 Neutral Q245G 3203, 8495.47 8561.87 0.99 1.33 1.09 Neutral Q245H 3195 8236.63 8640.32 0.95 1.29 1.10 Neutral Q245L 3209 6762.99 6774.37 1.00 1.06 0.87 Neutral Q245K 3196 347.86 290.28 1.20 0.05 0.04 Neutral Q245W 3206 7517.93 8157.63 0.92 1.18 1.04 Neutral Q245C 3198 7377.19 7707.00 0.96 1.16 0.98 Down N246W 3225 3998.57 5256.41 0.76 0.55 0.68 Neutral N246R 3216 6324.43 7263.78 0.87 0.87 0.93 Neutral N246A 3229 7162.60 7821.64 0.92 0.98 1.00 Neutral N246F 3223 5961.78 6704.16 0.89 0.82 0.86 Neutral N246G 3222 7132.52 7954.86 0.90 0.98 1.02 Neutral N246P 3230 5753.82 6382.30 0.90 0.79 0.82 Neutral N246V 327 7113.82 7563.12 0.94 0.98 0.97 Neutral N246Q 3218 8249.22 7962.93 1.04 1.13 1.02 Neutral N246Y 3220 6460.04 7091.47 0.91 0.89 0.91 Neutral N246C 3217 3668.07 4131.97 0.89 0.50 0.53 Neutral N2461 3226 6761.84 6684.68 1.01 0.93 0.86 Neutral N246L 3228 7470.87 7558.25 0.99 1.03 0.97 Neutral N246S 3221 7681.59 7872.41 0.98 1.05 1.01 Neutral N246T 3219 7476.51 7504.31 1.00 1.03 0.96 Neutral N246K 3215 8008.77 7820.31 1.02 1.10 1.00 Neutral N246D 3212 7062.38 7827.99 0.90 0.78 1.03 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral P247A 3249 8242.00 7947.96 1.04 1.13 1.02 Neutral P247D 3231 6640.01 7179.97 0.92 0.91 0.92 Neutral P247E 3232 8181.45 7231.43 1.13 1.12 0.93 Neutral P247F 3243 8964.42 7929.76 1.13 1.23 1.02 Neutral P247G 3242 7256.65 7455.20 0.97 1.00 0.96 Neutral P247H 3233 8093.84 7667.72 1.06 1.11 0.99 Neutral P2471 3246 7375.24 7729.05 0.95 1.01 0.99 Neutral P247K 3234 8454.74 7912.16 1.07 1.16 1.02 Neutral P247L 3248 8316.29 8009.70 1.04 1.14 1.03 Neutral P247N 3237 8142.72 8006.73 1.02 1.12 1.03 Neutral P247Q 3238 8231.43 7739.72 1.06 1.13 0.99 Neutral P247R 3235 7029.19 7443.10 0.94 0.96 0.96 Neutral P247S 3241 8040.91 7895.89 1.02 1.10 1.01 Neutral P247T 3239 7243.03 7527.94 0.96 0.99 0.97 Neutral P247V 3247 7907.19 7717.20 1.02 1.08 0.99 Neutral V248W 3264 6631.29 6916.87 0.96 0.91 0.89 Neutral V248L 3266 8767.88 8252.54 1.06 1.20 1.06 Neutral V248Q 3257 6709.44 6735.33 1.00 0.92 0.87 Neutral V248M 3263 7437.73 7338.43 1.01 1.02 0.94 Neutral V248Y 3259 6509.63 6927.69 0.94 0.89 0.89 Neutral V248G 3261 6438.97 6744.48 0.95 0.88 0.87 Neutral V248C 3255 3692.16 3816.99 0.97 0.51 0.49 Neutral V248R 3254 7253.81 7153.37 1.01 1.00 0.92 Neutral V248A 3267 8420.73 7739.03 1.09 1.16 0.99 Neutral V248H 3252 8578.28 7867.88 1.09 1.18 1.01 Neutral V2481 3265 8473.10 8209.35 1.03 1.16 1.05 Neutral V248T 3258 8100.54 7751.03 1.05 1.11 1.00 Neutral V248K 3253 7147.53 7653.87 0.93 0.98 0.98 Neutral V248S 3260 6899.65 6729.67 1.03 0.95 0.86 Neutral V248F 3262 6736.68 6651.01 1.01 0.92 0.85 Neutral V248E 3251 9210.34 8235.44 1.12 1.01 1.08 Neutral Q249T 3276 6909.47 7370.27 0.94 0.95 0.95 Neutral Q249W 3282 10145.55 8691.89 1.17 1.39 1.12 Neutral Q249R 373 7102.73 7103.74 1.00 0.97 0.91 Down Q249E 3270 3987.22 7583.88 0.53 0.55 0.97 Neutral Q249A 3286 8992.77 8414.65 1.07 1.23 1.08 Neutral Q249P 3287 8376.56 8108.11 1.03 1.15 1.04 Neutral Q249C 3274 5978.93 5496.03 1.09 0.82 0.71 Neutral Q249G 3279 7612.71 7662.25 0.99 1.04 0.98 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral Q249N 3275 7180.54 7257.66 0.99 0.99 0.93 Neutral Q249K 3272 7772.72 7296.54 1.07 1.07 0.94 Neutral Q249I 3283 7262.56 7159.06 1.01 1.00 0.92 Neutral Q249Y 3277 6047.16 6053.08 1.00 0.83 0.78 Neutral Q249V 3284 8717.93 8059.04 1.08 1.20 1.04 Neutral Q249L 3285 6532.65 6824.78 0.96 0.90 0.88 Neutral Q249H 3271 8441.70 7557.69 1.12 1.16 0.97 Neutral P250L 3305 9455.47 8580.12 1.10 1.30 1.10 Neutral P250S 3298 7684.90 7513.77 1.02 1.05 0.97 Neutral P250R 3292 7701.81 7566.23 1.02 1.06 0.97 Neutral P250Y 3297 7886.68 7534.22 1.05 1.08 0.97 Neutral P250M 3301 8416.52 8221.73 1.02 1.15 1.06 Neutral P250F 3300 8150.35 7703.24 1.06 1.12 0.99 Neutral P250A 3306 8963.20 8460.94 1.06 1.23 1.09 Neutral P250K 3291 7830.18 7732.04 1.01 1.07 0.99 Neutral P250G 3299 7623.88 7834.34 0.97 1.05 1.01 Neutral P250N 3294 7600.44 7961.88 0.95 1.04 1.02 Down P250T 3296 1147.37 1489.99 0.77 0.16 0.19 Neutral P250W 3302 7431.76 7755.84 0.96 1.02 1.00 Neutral P250D 3288 7767.77 7525.09 1.03 1.07 0.97 Neutral P250V 3304 7355.32 7719.82 0.95 1.01 0.99 Neutral P250Q 3295 7797.52 8203.80 0.95 1.07 1.05 Down I251A 3324 4953.41 8984.79 0.55 0.48 0.96 Neutral 1251Q 3314 10910.92 9221.40 1.18 1.07 0.98 Neutral 1251G 3 318 11041.83 9640.57 1.15 1.08 1.03 Neutral 1251L 3323 11028.53 9408.72 1.17 1.08 1.00 Neutral 1251K 3 310 11050.61 9421.73 1.17 1.08 1.01 Neutral I251R 3311 10950.25 9220.62 1.19 1.07 0.98 Neutral I251E 3308 10262.05 9115.62 1.13 1.00 0.97 Neutral 1251D 3307 10582.82 9557.71 1.11 1.04 1.02 Neutral 1251T 3315 10884.22 9485.20 1.15 1.06 1.01 Neutral I251 C 3312 10348.04 9428.04 1.10 1.01 1.01 Neutral 1251Y 3 316 10319.00 9450.22 1.09 1.01 1.01 Neutral 1251P 3325 10762.38 9410.57 1.14 1.05 1.00 Neutral I251S 3317 8445.88 7160.96 1.18 1.07 0.96 Neutral I251W 3321 7305.95 6974.26 1.05 0.92 0.93 Neutral 1251V 3322 8343.83 7350.61 1.14 0.91 0.98 Neutral G252F 3337 7921.80 7529.24 1.05 1.09 0.97 Neutral G252W 3339 6989.36 7313.18 0.96 0.96 0.94 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 C/ Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral G252A 3343 8567.46 8300.90 1.03 1.18 1.07 Neutral G252R 3330 7756.55 7447.08 1.04 1.06 0.96 Neutral G252L 3342 8684.63 8094.21 1.07 1.19 1.04 Neutral G252E 3327 7651.86 7211.52 1.06 1.05 0.93 Neutral G252D 3326 7977.50 7049.47 1.13 1.09 0.91 Neutral G252K 3329 9685.27 8502.04 1.14 1.33 1.09 Neutral G252S 3336 7596.71 6986.94 1.09 1.04 0.90 Neutral G252T 3334 7242.98 7147.95 1.01 0.99 0.92 Neutral G252P 3344 8175.79 8226.12 0.99 1.12 1.06 Neutral G252H 3328 8030.53 7802.24 1.03 1.10 1.00 Neutral G252C 3331 5540.29 5421.44 1.02 0.76 0.70 Neutral G252V 3341 7910.50 7997.71 0.99 1.09 1.03 Neutral G2521 3340 7702.75 7964.05 0.97 1.06 1.02 Neutral P253C 3350 7906.13 8213.73 0.96 0.99 1.04 Neutral P253G 3356 9640.00 8446.66 1.14 1.20 1.07 Neutral P253Q 3352 9482.36 8631.24 1.10 1.18 1.09 Neutral P2531 3360 6906.18 7721.21 0.89 0.86 0.97 Neutral P253L 3362 8851.11 8489.29 1.04 1.10 1.07 Neutral P253R 3349 9020.78 8580.86 1.05 1.12 1.08 Neutral P253A 3363 8697.23 8410.29 1.03 1.08 1.06 Neutral P253E 3346 9074.45 8476.99 1.07 1.13 1.07 Neutral P253Y 3354 7935.28 8171.53 0.97 0.99 1.03 Neutral P253W 3359 6635.85 7293.26 0.91 0.83 0.92 Neutral P253M 3358 6895.66 7648.23 0.90 0.86 0.96 Neutral P253V 3361 7058.87 7756.04 0.91 0.88 0.98 Neutral P253T 3353 6728.25 7541.00 0.89 0.84 0.95 Neutral P253K 3348 6929.49 7400.65 0.94 0.86 0.93 Neutral P253N 3351 7354.73 7533.05 0.98 0.92 0.95 Neutral Q254R 3368 9454.92 8474.29 1.12 1.18 1.07 Neutral Q254G 3374 3549.45 3806.63 0.93 0.44 0.48 Neutral Q254W 3377 3389.45 3326.38 1.02 0.42 0.42 Neutral Q254T 3371 7491.28 7853.86 0.95 0.93 0.99 Neutral Q254A 3381 7226.25 7451.70 0.97 0.90 0.94 Neutral Q254F 3375 6263.95 6007.53 1.04 0.78 0.76 Neutral Q254D 3364 9098.08 8154.92 1.12 1.13 1.03 Neutral Q254P 3382 6827.99 7340.40 0.93 0.85 0.93 Neutral Q254L 3380 7602.15 7940.64 0.96 0.95 1.00 Neutral Q254C 3369 9284.18 8479.77 1.09 1.16 1.07 Neutral Q254Y 3372 8847.02 7831.28 1.13 1.10 0.99 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 0 Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral Q2541 3378 9340.36 8662.75 1.08 1.16 1.09 Neutral Q254E 3365 9466.76 8516.08 1.11 1.18 1.07 Neutral Q254V 3379 9803.92 8575.31 1.14 1.22 1.08 Neutral Q254S 3373 7768.13 8801.19 0.88 1.15 1.17 Neutral T2551 3397 9880.58 8415.65 1.17 1.23 1.06 Neutral T255Q 3390 9537.20 8410.86 1.13 1.19 1.06 Neutral T255P 3401 7468.08 7296.37 1.02 0.93 0.92 Neutral T255R 3387 5740.42 4974.50 1.15 0.72 0.63 Neutral T255C 3388 2626.79 2503.21 1.05 0.33 0.32 Neutral T255N 3389 5128.08 4479.75 1.14 0.64 0.57 Neutral T255S 3392 7334.60 6905.71 1.06 0.91 0.87 Neutral T255V 3398 5463.42 5187.78 1.05 0.68 0.65 Neutral T255E 3384 7691.31 7194.23 1.07 0.96 0.91 Neutral T255G 3393 8166.77 7682.14 1.06 1.02 0.97 Neutral T255K 3386 6636.15 5647.18 1.18 0.83 0.71 Neutral T255A 3400 4436.98 4322.98 1.03 0.55 0.55 Neutral T255F 3394 3562.89 3107.64 1.15 0.44 0.39 Neutral T255L 3399 4904.06 4266.71 1.15 0.61 0.54 Neutral T255H 3385 8243.01 7352.60 1.12 1.22 0.98 Up P256S 3412 10876.81 9018.60 1.21 1.36 1.14 Up P256V 3418 10408.68 8594.11 1.21 1.30 1.08 Neutral P256F 3414 6020.49 5181.94 1.16 0.75 0.65 Neutral P256Y 3411 10270.90 8699.77 1.18 1.28 1.10 Neutral P2561 3417 9089.54 7980.23 1.14 1.13 1.01 Neutral P256A 3420 9426.67 8868.67 1.06 1.18 1.12 Neutral P256L 3419 8342.08 7217.69 1.16 1.04 0.91 Neutral P256G 3413 4631.84 4679.24 0.99 0.58 0.59 Neutral P256N 3408 4406.75 3946.90 1.12 0.55 0.50 Neutral P256R 3406 4975.17 4155.27 1.20 0.62 0.52 Neutral P256Q 3409 6177.77 5546.92 1.11 0.77 0.70 Neutral P256E 3403 9266.75 8366.07 1.11 1.16 1.06 Neutral P256K 3405 5919.72 5928.31 1.00 0.74 0.75 Neutral P256M 3415 8787.02 8554.52 1.03 1.10 1.08 Neutral P256C 3407 4674.45 4633.67 1.01 0.69 0.62 Neutral K257C 3425 4327.83 4267.45 1.01 0.54 0.54 Neutral K257M 3433 5985.85 5236.20 1.14 0.75 0.66 Neutral K257V 3436 7316.42 7115.65 1.03 0.91 0.90 Neutral K257A 3438 9355.23 8528.52 1.10 1.17 1.08 Neutral K257E 3422 10237.19 9141.73 1.12 1.28 1.15 Table 9. Results of Initial Screen for Temperature Sensitive Mutants Temp. hMMP-1 SEQ ID Avg. Avg. Ratio Res. Res.
Phenotype mutation NO RFU RFU 25 0 Act. Act.
25 C 37 C 37 C Mut/wt Mut/wt Neutral K257S 3430 9952.97 8464.79 1.18 1.24 1.07 Neutral K257L 3437 10053.73 8711.61 1.15 1.25 1.10 Neutral K2571 3435 8609.80 7806.76 1.10 1.07 0.98 Neutral K257G 3431 8280.79 7718.36 1.07 1.03 0.97 Neutral K257N 3426 8528.22 7707.49 1.11 1.06 0.97 Neutral K257F 3432 7720.51 6633.90 1.16 0.96 0.84 Neutral K257W 3434 7039.69 7120.56 0.99 0.88 0.90 Neutral K257R 3424 9688.77 9114.18 1.06 1.21 1.15 Neutral K257P 3439 8039.60 7464.88 1.08 1.19 0.99 Neutral K257T 3428 9346.88 8849.42 1.06 1.39 1.18 Neutral A258Q 3447 7000.31 6977.33 1.00 0.87 0.88 Neutral A258Y 3449 6636.02 5998.83 1.11 0.83 0.76 Neutral A258W 3454 9438.05 8527.86 1.11 1.18 1.08 Neutral A258G 3451 7204.05 7778.97 0.93 0.90 0.98 Neutral A258L 3457 1222.62 1226.40 1.00 0.15 0.15 Neutral A258F 3452 9548.91 8531.04 1.12 1.19 1.08 Neutral A258M 3453 8161.79 8061.20 1.01 1.02 1.02 Neutral A258N 3446 7808.83 6968.56 1.12 0.97 0.88 Neutral A258V 3456 8395.80 8391.43 1.00 1.05 1.06 Neutral A258T 3448 8674.71 7958.00 1.09 1.08 1.00 Neutral A2581 3455 8452.43 7509.34 1.13 1.05 0.95 Up A258D 3440 7741.51 6346.88 1.22 0.97 0.80 Neutral A258R 3444 9008.56 7908.51 1.14 1.12 1.00 Neutral A258E 3441 10198.40 8709.16 1.17 1.27 1.10 Neutral A258P 3458 10414.06 9178.82 1.13 1.55 1.22 The 199 hMMP-1 putative hit mutants were rescreened, using the same assay, and 104 primary hits were confirmed (see Table 11, below). hMMP-1 mutants that were active at 25 C and had at least a 16 % decrease in activity at 37 C
(e.g., the ratio of the activities at 25 C or 37 C (25 C/37 C) is greater than or equal to 1.2) were deemed to be confirmed primary temperature sensitive hits.
Table 10, below, lists the hMMP-1 mutation, the average RFU at 25 C and 37 C, and the ratio of the activities (25 C/37 C). The Table also lists the temperature phenotype: DOWN, indicates the ratio (25 C/37 C) of the activity of the mutant is decreased compared to the ratio (25 C/37 C) of the activity of the wildtype, i.e.

decreased greater than 16 % the activity of the wildtype; NEUTRAL, indicates the ratio (25 C/37 C) of the activity of the mutant is similar to the ratio (25 C/37 C) of the activity of wildtype, i.e. within 16 % of the activity of the wildtype;
and UP, indicates the ratio (25 C/37 C) of the activity of the mutant is increased compared to the ratio (25 C/37 C) of the activity of the wildtype, i.e. increased more than 16 %
the activity of the wildtype.
Table 10, below, also lists the residual activities at 25 C and 37 C, as compared to wild type hMMP-1. The residual activity is the ratio of the hMMP-1 mutant activity versus the wildtype hMMP-1 activity at the indicated temperature, either 25 C or 37 C. A ratio of less than one indicates that a given mutant has less activity than the wildtype at the indicated temperature and a ratio of greater than one indicates that the mutant has more activity than the wildtype. Several of the hMMP-1 primary hit mutants exhibited activities that were comparable to or greater than wildtype hMMP-1 at 25 C. All of the hMMP-1 confirmed as primary hits exhibited decreated activities at 37 C, thereby reconfirming their decreased activity at elevated temperatures.
Table 10. Results of Initial Screen for Temper ture Sensitive hMMP-1 mutants Temp. hMMP-1 SEQ Avg. Avg. Ratio Res. Res. Act.
Phenotype mutation ID NO RFU RFU 25 C/ Act. Mut/wt C 37 C 37 C Mut/wt 37 C

Neutral T84F 847 6312.72 6453.46 0.98 1.10 1.27 Neutral E85F 866 6092.47 6362.37 0.96 1.06 1.26 Up L95K 6 1333.28 1191.46 1.12 0.15 0.14 Down L951 18 1707.98 2294.02 0.74 0.30 0.45 Down R98D 1083 2905.96 3867.31 0.75 0.33 0.47 Down 199Q 1109 3318.21 4623.91 0.72 0.37 0.56 Down E100V 512 3980.72 5009.20 0.79 1.26 1.01 Neutral E100R 500 7410.11 7964.52 0.93 0.83 0.96 Neutral E100S 506 3768.09 4664.58 0.81 0.42 0.56 Neutral E100T 504 6985.28 7478.12 0.93 0.79 0.90 Neutral E100F 508 6709.27 7436.60 0.90 0.75 0.90 Neutral E1001 511 8824.19 8458.79 1.04 0.99 1.02 Neutral E100N 502 8809.68 8215.63 1.07 0.99 0.99 Neutral T103Y 524 1181.09 1423.76 0.83 0.37 0.29 Neutral P104A 1177 8861.30 8360.82 1.06 1.00 1.01 Up P104M 1172 6709.44 7118.65 0.94 0.88 0.75 Up D105A 39 2674.16 1227.06 2.18 0.65 0.24 Up D105F 33 2009.56 1221.58 1.65 0.49 0.24 Table 10. Results of Initial Screen for Temper ture Sensitive hMMP-1 mutants Temp. hMMP-1 SEQ Avg. Avg. Ratio Res. Res. Act.
Phenotype mutation ID NO RFU RFU 25 C/ Act. Mut/wt 25 C 37 C 37 C Mut/wt 37 C

Up D105G 32 2407.89 1686.68 1.43 0.58 0.34 Up D1051 36 1732.38 1105.99 1.57 0.42 0.22 U D105L 38 1563.61 859.56 1.82 0.38 0.17 Up D105N 27 3766.72 1475.08 2.55 0.91 0.29 Up D105R 25 3892.02 2016.90 1.93 0.94 0.40 Up D105S 31 3646.49 2727.22 1.34 0.88 0.54 U D105T 29 2513.64 1729.46 1.45 0.61 0.34 Up D105W 35 2565.93 1855.05 1.38 0.62 0.37 Neutral D105E 22 4000.92 3366.64 1.19 0.59 0.45 Neutral L106C 1183 2995.56 3678.33 0.81 0.34 0.44 Neutral L106S 1188 2730.64 2899.36 0.94 0.31 0.35 Neutral A109H 1237 7206.01 7536.96 0.96 0.81 0.91 Neutral D1.1OA 1271 4179.59 5112.44 0.82 0.47 0.62 Neutral V111R 1277 2401.69 2925.16 0.82 0.27 0.35 Neutral D112S 1301 7203.69 7600.93 0.95 0.81 0.92 Neutral A118T 1414 745.83 665.63 1.12 0.13 0.13 Down S123V 1516 3220.29 4504.25 0.71 0.41 0.60 Neutral N124D 1520 6218.73 6620.92 0.94 0.92 0.88 Neutral T126S 1567 7114.42 6856.69 1.04 1.06 0.91 Up G147P 1975 494.94 392.93 1.26 0.07 0.05 Up R150P 59 2291.14 828.28 2.77 0.31 0.12 Neutral R150V 56 6869.28 6604.61 1.04 1.20 1.30 Neutral R150D 41 7230.41 6033.28 1.20 1.26 1.19 Down R1501 55 3120.05 4082.34 0.76 0.39 0.55 Neutral R150H 43 8281.04 8056.17 1.03 1.05 1.08 Up D151G 70 1073.32 733.89 1.46 0.20 0.11 Neutral N152A 2031 6669.94 5660.16 1.18 1.17 1.12 Down N152S 2023 4607.85 8096.31 0.57 0.58 1.08 Neutral S153T 543 10530.07 8798.72 1.20 1.44 1.24 Up F155L 95 1322.13 864.19 1.53 0.25 0.13 Up F155A 96 1250.93 760.12 1.65 0.23 0.11 Up D156H 99 2722.09 2081.55 1.31 0.51 0.31 Up D156L 114 2548.30 1597.53 1.60 0.48 0.24 Up D156A 115 2679.29 1734.45 1.54 0.50 0.26 Up D156W 111 1575.39 1268.36 1.24 0.30 0.19 Up D156V 113 1400.88 766.80 1.83 0.26 0.11 Up D156K 100 1292.89 966.62 1.34 0.24 0.14 U D156T 105 2871.09 1843.03 1.56 0.54 0.27 Up D156R 101 2431.23 1545.89 1.57 0.46 0.23 U D156M 110 817.96 502.82 1.63 0.12 0.07 Neutral P158T 2080 4204.23 3507.76 1.20 0.53 0.47 Neutral P158G 2083 6277.86 5496.27 1.14 0.79 0.73 Neutral P158K 2075 6860.82 6680.30 1.03 0.87 0.89 Table 10. Results of Initial Screen for Temper ture Sensitive hMMP-1 mutants Temp. hMMP-1 SEQ Avg. Avg. Ratio Res. Res. Act.
Phenotype mutation ID NO RFU RFU 25 C/ Act. Mut/wt 25 C 37 C 37 C Mut/wt 37 C

Neutral P158N 2078 3656.04 3874.48 0.94 0.46 0.52 Up G159V 132 2453.98 732.46 3.35 0.34 0.10 L J2 125 5059.91 1734.12 2.92 0.69 0.24 Up G159M 129 5905.06 4874.00 1.21 0.75 0.65 Neutral G1591 131 5725.99 5357.20 1.07 0.72 0.72 Neutral G159W 130 6787.40 6287.71 1.08 0.86 0.84 Neutral G159L 133 8231.62 7638.64 1.08 1.04 1.02 Neutral G159C 122 2897.77 3053.86 0.95 0.37 0.41 Neutral P170D 2281 1434.38 1462.91 0.98 0.25 0.29 Neutral P170A 2299 2733.72 2793.24 0.98 0.48 0.55 Up G171P 572 1570.74 1204.39 1.30 0.27 0.17 Neutral G171E 555 1154.96 1199.65 0.96 0.20 0.24 Neutral G171D 554 791.81 690.33 1.15 0.14 0.14 U A176F 148 10486.82 6516.31 1.61 1.31 0.78 Neutral A176W 150 482.38 414.85 1.16 0.06 0.06 Neutral F178T 2403 560.54 487.01 1.15 0.10 0.10 U F178L 2411 1788.95 1314.38 1.36 0.31 0.26 Up D179N 160 2433.73 812.01 3.00 0.26 0.10 U D179V 170 604.63 490.35 1.23 0.11 0.10 Up D179C 159 613.81 503.76 1.22 0.11 0.10 U El 80Y 182 6655.19 5379.42 1.24 0.72 0.63 Neutral E18OR 177 6932.51 6309.81 1.10 0.75 0.74 Up El 80T 181 3718.16 2425.13 1.53 0.40 0.29 U E180F 185 7014.78 5382.78 1.30 0.76 0.63 Up E18OG 184 5952.65 4547.28 1.31 1.04 0.90 Up E180S 183 5217.80 3977.60 1.31 0.91 0.78 Up E18ON 179 6534.65 4843.84 1.35 1.14 0.96 U El 80D 174 7738.70 6277.22 1.23 1.35 1.24 Neutral D181T 200 6867.00 6057.09 1.13 0.74 0.71 Up D181L 209 1727.20 1274.09 1.36 0.19 0.15 U D181K 195 1087.36 696.83 1.56 0.12 0.08 Up D 181 C 197 549.29 447.40 1.23 0.10 0.09 Up D181G 203 2764.20 2056.56 1.34 0.48 0.41 Up E182T 219 2995.97 1779.42 1.68 0.32 0.21 Up E182Q 218 1393.28 804.84 1.73 0.15 0.09 Up E182M 224 649.73 524.43 1.24 0.11 0.10 Neutral E182G 222 604.92 543.78 1.11 0.11 0.11 U R183G 2424 7326.36 6021.39 1.22 1.28 1.19 Up R183S 2423 7896.17 6240.74 1.27 1.38 1.23 Up T185R 235 1728.04 851.07 2.03 0.20 0.10 Up T185Y 239 937.75 540.66 1.73 0.11 0.07 Up T185H 233 1448.04 783.89 1.85 0.17 0.10 Up T185G 241 3922.30 1990.15 1.97 0.46 0.24 Table 10. Results of Initial Screen for Temper ture Sensitive hMMP-1 mutants Temp. hMMP-1 SEQ Avg. Avg. Ratio Res. Res. Act.
Phenotype mutation ID NO RFU RFU 25 C/ Act. Mut/wt 25 C 37 C 37 C Mut/wt 37 C

Up T185V 246 1648.14 897.66 1.84 0.19 0.11 Up T185Q 238 1594.81 583.93 2.73 0.19 0.07 Up T185A 248 1599.64 711.08 2.25 0.19 0.09 Up T185E 232 1324.02 703.76 1.88 0.16 0.09 Neutral T185D 231 485.86 418.67 1.16 0.06 0.06 Up N187R 254 1042.36 709.74 1.47 0.12 0.09 Up N187M 262 1731.67 995.07 1.74 0.20 0.12 Neutral N187W 263 1694.86 1425.68 1.19 0.20 0.17 Up N187F 261 1240.41 731.98 1.69 0.15 0.09 U N187K 253 2331.93 1140.19 2.05 0.27 0.14 Up N1871 264 1444.98 683.03 2.12 0.17 0.08 Up N187A 267 4379.80 2616.49 1.67 0.52 0.32 Neutral N187G 260 535.06 514.10 1.04 0.07 0.07 Neutral N187C 255 1804.28 1860.67 0.97 0.23 0.25 Neutral N187H 252 1143.07 1071.67 1.07 0.14 0.14 Up F188V 2486 7116.29 5860.00 1.21 1.24 1.16 Neutral R189N 2495 7842.39 6675.36 1.17 1.37 1.32 Neutral R189T 2497 7610.10 6459.94 1.18 1.33 1.27 Neutral R189Q 2496 7465.37 6396.79 1.17 1.30 1.26 Up E190G 583 5313.99 4365.93 1.22 0.75 0.48 U E190Y 581 7243.54 5742.33 1.26 1.27 1.13 Up E190D 573 7910.21 6468.78 1.22 1.38 1.28 Up Y191V 607 1553.58 1254.11 1.24 0.19 0.14 U N192H 613 2274.24 1058.80 2.15 0.32 0.12 Up N192S 620 2043.65 1630.74 1.25 0.29 0.18 U N192D 611 4213.33 2216.40 1.90 0.59 0.24 Up N192C 616 1310.46 987.31 1.33 0.18 0.11 Neutral H194P 648 5264.79 5058.19 1.04 0.74 0.56 Up R195C 273 4231.32 1853.20 2.28 0.60 0.20 Neutral R195W 282 5099.23 4524.84 1.13 0.72 0.50 Neutral R195L 285 5073.57 4520.73 1.12 0.72 0.50 Up R195G 279 5269.21 3025.93 1.74 0.74 0.33 Up R195Q 275 1958.69 1361.83 1.44 0.28 0.15 Up R195A 286 5605.90 3852.81 1.46 0.79 0.42 Up R195D 269 2724.53 1907.81 1.43 0.38 0.21 Up R195V 284 1711.48 1037.62 1.65 0.24 0.11 Up A197C 2552 4012.80 3140.52 1.28 0.70 0.62 Neutral A198G 299 2610.82 2368.26 1.10 0.37 0.26 Up A198L 305 1339.94 726.74 1.84 0.19 0.08 U A198M 301 1384.46 999.55 1.39 0.20 0.11 Up G206A 324 4554.61 2702.11 1.69 0.47 0.30 Up G206S 317 1226.37 919.66 1.33 0.13 0.10 Up L207R 653 3476.88 1332.44 2.61 0.36 0.15 Table 10. Results of Initial Screen for Temper ture Sensitive hMMP-1 mutants Temp. hMMP-1 SEQ Avg. Avg. Ratio Res. Res. Act.
Phenotype mutation ID NO RFU RFU 25 C/ Act. Mut/wt 25 C 37 C 37 C Mut/wt 37 C

Neutral L207V 665 656.95 550.54 1.19 0.08 0.07 Neutral L2071 664 645.37 550.32 1.17 0.08 0.07 U L207G 660 610.01 484.35 1.26 0.08 0.06 Neutral S208R 2703 7639.06 6465.10 1.18 1.34 1.28 Up S208L 2715 7811.78 6354.14 1.23 1.37 1.25 Up S210V 341 1190.35 856.63 1.39 0.29 0.17 Neutral S210A 343 1682.05 1546.97 1.09 0.25 0.21 Neutral T211L 2753 2376.23 2102.07 1.13 0.35 0.28 Up D212G 678 1011.62 657.28 1.54 0.24 0.13 Neutral D212H 669 4696.49 4001.41 1.17 0.70 0.53 U Y218S 354 3702.49 3099.73 1.19 0.58 0.43 Up F223C 369 3115.11 2488.91 1.25 0.53 0.35 Up F223E 365 7194.34 5884.03 1.22 1.22 0.83 U F223G 375 3236.56 2599.04 1.25 0.55 0.36 Up F223A 381 5226.86 3982.92 1.31 0.89 0.56 Up F223S 374 6006.80 4916.07 1.22 1.02 0.69 Neutral F223K 367 4021.97 3712.91 1.08 0.60 0.49 Neutral F223M 376 525.66 441.29 1.19 0.08 0.06 U V227C 388 4040.96 3278.65 1.23 0.68 0.46 Up V227D 383 1190.09 731.34 1.63 0.20 0.10 U V227E 384 5381.63 X2605.20 2.07 0.91 0.37 Up V227L 399 4883.98 4000.68 1.22 0.83 0.56 Up V227S 393 3863.33 3131.47 1.23 0.65 0.44 Up V227W 397 1845.46 1374.06 1.34 0.31 0.19 Neutral V227G 394 1040.74 883.01 1.18 0.15 0.12 Up V227H 385 689.20 504.65 1.37 0.10 0.07 Up V227Q 390 696.97 506.11 1.38 0.10 0.07 Neutral V227R 387 664.31 561.06 1.18 0.10 0.07 Up Q228P 420 2862.74 1291.55 2.22 1.33 0.44 Up L229A 438 2627.78 2118.07 1.24 1.22 0.72 U L229T 429 3780.54 1464.25 2.58 1.75 0.50 Up L2291 436 1158.56 828.94 1.40 0.54 0.28 Up A230V 703 5030.94 3433.18 1.47 2.33 1.17 Up D233E 440 2881.17 1918.57 1.50 1.33 0.65 Up 1234A 476 1458.10 1018.50 1.43 0.31 0.18 Up 1234T 467 1451.51 1188.67 1.22 0.31 0.21 Up 1234E 460 1301.06 840.09 1.55 0.27 0.15 U 1234Q 466 1095.18 837.53 1.31 0.23 0.15 Up 1237L 475 2880.14 2240.61 1.29 0.61 0.39 Down 1237W 3074 4188.38 5663.94 0.74 0.62 0.75 Neutral 1237N 3066 5368.49 6271.59 0.86 0.80 0.83 Up 1240S 488 2033.91 1204.66 1.69 0.32 0.15 Neutral 1240A 495 2099.13 1776.41 1.18 0.33 0.23 Table 10. Results of Initial Screen for Temper ture Sensitive hMMP-1 mutants Temp. hMMP-1 SEQ Avg. Avg. Ratio Res. Res. Act.
Phenotype mutation m NO RFU RFU 25 C/ Act. Mut/wt 25 C 37 C 37 C Mut/wt 37 C

Up 1240C 483 970.78 650.04 1.49 0.15 0.08 Neutral 1251S 3317 8445.88 7160.96 1.18 1.07 0.96 Neutral I251 W 3321 7305.95 6974.26 1.05 0.92 0.93 Neutral Q254S 3373 7768.13 8801.19 0.88 1.15 1.17 Neutral T255H 3385 8243.01 7352.60 1.12 1.22 0.98 Neutral P256C 3407 4674.45 4633.67 1.01 0.69 0.62 Neutral K257P 3439 8039.60 7464.88 1.08 1.19 0.99 Neutral K257T 3428 9346.88 8849.42 1.06 1.39 1.18 Neutral A258P 3458 10414.06 9178.82 1.13 1.55 1.22 TABLE 11: Reconfirmed HITs Temperature hMMP-1 SEQ ID
Phenotype mutation NO
Up L95K 6 Down E100V 512 Neutral T103Y 524 Up D105A 39 Up D105F 33 Up D105G 32 Up D1051 36 Up D105L 38 Up D105R 25 Up D105S 31 Up D105W 35 Up R150P 59 Up D151G 70 Neutral S 153T 543 Up F155L 95 Up F155A 96 Up D156H 99 Up D156L 114 Up D156W 111 Up D156V 113 Up D156K 100 Up D156T 105 Up D156R 101 Up G159V 132 Up G159T 125 Up D179N 160 U El 80Y 182 Neutral E18OR 177 Up E180T 181 Up E1 80F 185 Neutral D 181 T 200 Up D181L 209 Up D181K 195 Up E182Q 218 Up T185Y 239 Up T185H 233 Up T185G 241 Up T185V 246 Up T185A 248 Up N187R 254 Up N187M 262 Neutral N187W 263 Up N187F 261 Up N187K 253 Up N1 87I 264 Up N187A 267 Up E190G 583 Up Y191V 607 Up N192H 613 Up N192S 620 Up N192C 616 Neutral H194P 648 Neutral R195W 282 Neutral R195L 285 Up R195G 279 Up R195A 286 Up R195D 269 Up R195V 284 Neutral A198G 299 Up A198L 305 Up A198M 301 Up G206A 324 Up G206S 317 Up L207R 653 Up D212G 678 Up Y218S 354 Up F223C 369 Up F223E 365 Up F223A 381 Up F223S 374 Up V227D 383 Up V227E 384 Up V227W 397 Up Q228P 420 Up L229T 429 Up L2291 436 Up D233E 440 Up 1234A 476 Up 1234E 460 Up 1234Q 466 Up 1237L 475 Up 1240S 488 Neutral 1240A 495 Up 1240C 483 B. 14-mL protein expression In this example, the hMMP-1 mutants that were identified as temperature sensitive primary hits in Example 2 were expressed in 14 ml culture tubes and their enzymatic activity was measured at 25 C, 34 C and 37 C for 1 hour, 2 hours or overnight in order to verify the desired phenotype of decreased activity at elevated temperatures. Protein was expressed and purified as in Example 1 with the exception that the expression was performed in 14 ml tubes rather than a 96-well plate.
Four (4) l of each hMMP-1 mutant supernatant was transferred to a 96-well microplate. Supernatants were activated with APMA as described in Example 2A
above, except that the solution was incubated at the reaction temperature of 25 C, 34 C, or 37 C for 2 hours. As above, following activation, 100 gl of TCNB
containing 10 gM Mca-K-P-L-G-L-Dpa-A-R-NH2 fluorescent substrate was added to each tube at the indicated reaction temperature (25 C, 34 C or 37 C) for one hour.
Wildtype hMMP-1 was used as a positive control and supernatant from cells transformed with the vector was used as a negative control. Fluorescence was detected by measuring fluorescence in a fluorescent plate reader at 320 nm exitation/405 nm emission.
Relative fluorescence units (RFU) were determined. Duplicate reactions were performed for each sample, reaction temperature, and positive and negative control.
The data is shown in Table 12A (1 hour incubation); Table 12B (2 hour incubations) and Table 12C (overnight incubation), below. Mutants that were active at 25 C but demonstrated at least a 33% decreased activity at 34 C or 37 C
(i.e. had a ratio of activity at 25 C and 34 C or a ratio of activity of 25 C and 37 C equal to or greater than 1.5 under any of the time point conditions tested were identified as temperature sensitive hits. Tables 12A-12C, below, list the hMMP-1 mutation, the RFU at 25 C, 34 C and 37 C, and the ratio of the activities (at both 25 and 25 C/37 C) of 64 hMMP-1 mutants whose decreased enzymatic activity at elevated temperatures were confirmed. Some of the hMMP-1 mutants, were noticeably more active at 25 C than at an elevated temperature. For example, hMMP-1 mutant D179N (SEQ ID NO:160) was 87.5% more active at 25 C than 37 C after an overnight incubation (see e.g. Table 12C). Additionally, although expression levels, and therefore overall RFU values, varied in different experiments, the ratios of the activities remained the same. For example, mutant D156T was tested twice (see Table 12C below) and although each test gave different data RFU
values the ratio of the values were similar and consistently within the 1.5 ratio parameter.
Table 12A. Temperature Sensitive hMMP-1 Mutants, 1 hour incubation hMMP-1 SEQ ID RFU RFU RFU Ratio Ratio mutation NO 25 C 34 C 37 C 25 C/ 25 C/

L95K 6 2677.64 553.00 572.70 4.84 4.68 D105A 39 3496.48 697.79 1119.92 5.01 3.12 D105F 33 1749.85 554.69 685.49 3.15 2.55 D105G 32 7450.35 2196.32 3514.50 3.39 2.12 D1051 36 4720.96 638.42 943.44 7.39 5.00 D105L 38 2636.80 490.04 552.90 5.38 4.77 D105N 27 7487.95 776.33 1513.73 9.65 4.95 D105R 25 1732.70 641.23 736.92 2.70 2.35 D105S 31 8637.40 3782.36 6510.05 2.28 1.33 D105W 35 4263.51 1321.69 2422.77 3.23 1.76 D105T 29 2666.45 770.72 1685.33 3.46 1.58 R150P 59 7568.19 1678.59 2010.33 4.51 3.76 D151G 70 973.47 517.98 595.63 1.88 1.63 F155A 96 1800.92 592.07 596.31 3.04 3.02 D156K 100 8718.91 1733.90 1839.60 5.03 4.74 D156T 105 8034.06 2216.02 2255.25 3.63 3.56 D156L 114 1825.01 528.43 619.10 3.45 2.95 D156A 115 1495.21 450.17 496.04 3.32 3.01 D156W 111 1006.97 463.48 493.84 2.17 2.04 D156V 113 1140.60 484.30 504.38 2.36 2.26 D156T 105 2796.00 581.90 743.53 4.80 3.76 D156H 99 3489.60 578.59 711.59 6.03 4.90 D156R 101 4983.67 678.23 734.95 7.35 6.78 G159V 132 3416.77 705.80 739.87 4.84 4.62 G159T 125 4081.99 1732.63 1865.15 2.36 2.19 A176F 148 967.31 539.31 517.16 1.79 1.87 D179N 160 4105.85 492.00 513.37 8.35 8.00 E180Y 182 8803.90 3904.31 5268.18 2.25 1.67 E180T 181 5957.38 1155.89 1430.72 5.15 4.16 E18OF 185 7484.41 2677.89 3141.69 2.79 2.38 D181L 209 1629.22 559.04 549.09 2.91 2.97 D181K 195 844.40 570.98 569.44 1.48 1.48 E182T 219 2244.96 653.93 668.01 3.43 3.36 E182Q 218 1066.68 583.87 582.84 1.83 1.83 T185R 235 1599.19 867.00 872.66 1.84 1.83 T185H 233 3616.30 1601.20 1842.01 2.26 1.96 T185Q 238 4365.21 1512.02 1899.46 2.89 2.30 T185A 248 1374.00 567.04 608.05 2.42 2.26 T185E 232 2145.28 1263.20 1399.76 1.70 1.53 N187R 254 1659.90 955.75 1054.91 1.74 1.57 N187M 262 2842.50 1343.95 1464.36 2.12 1.94 N187F 261 1846.10 716.62 786.07 2.58 2.35 N187K 253 2428.31 1703.73 1914.84 1.43 1.27 N1871 264 2455.44 717.51 773.59 3.42 3.17 R195V 284 3121.02 1947.80 2132.94 1.60 1.46 A198L 305 4547.61 1570.19 2061.87 2.90 2.21 A198M 301 1948.92 1101.86 1535.22 1.77 1.27 G206A 324 667.50 543.90 540.79 1.23 1.23 G206S 317 608.46 427.44 412.07 1.42 1.48 S210V 341 1952.12 961.54 1791.55 2.03 1.09 Y218S 354 1674.47 1531.03 1573.00 1.09 1.06 F223E 365 5837.16 2747.99 4955.08 2.12 1.18 V227C 388 1138.96 684.05 722.68 1.67 1.58 V227E 384 5892.76 653.81 803.12 9.01 7.34 V227W 397 716.50 607.92 646.75 1.18 1.11 Q228P 420 676.11 488.99 495.88 1.38 1.36 L229T 429 768.59 492.66 491.49 1.56 1.56 L229I 436 1470.04 753.87 1231.17 1.95 1.19 D233E 440 1195.07 959.25 1056.45 1.25 1.13 I234A 476 1402.15 1014.61 1127.63 1.38 1.24 I234T 467 857.79 644.52 712.49 1.33 1.20 I234E 460 2281.82 591.10 762.52 3.86 2.99 I240S 488 2678.36 776.88 1314.40 3.45 2.04 I240C 483 1540.91 474.82 666.63 3.25 2.31 Table 12B. Temperature Sensitive hMMP-1 Mutants, 2 hours incubation hMMP-1 SEQ ID RFU RFU RFU Ratio Ratio mutation NO 25 C 34 C 37 C 25 C/ 25 C/

L95K 6 4650.42 748.29 746.89 6.21 6.23 D105A 39 5669.31 824.07 1336.14 6.88 4.24 D105F 33 2980.00 623.89 818.63 4.78 3.64 D105G 32 8821.81 2759.24 4313.40 3.20 2.05 D1051 36 6832.34 780.32 1110.07 8.76 6.15 D105L 38 4206.38 534.24 607.46 7.87 6.92 D105N 27 8920.05 918.13 1727.44 9.72 5.16 D105R 25 2821.20 722.46 813.68 3.90 3.47 D105S 31 9355.63 4607.18 7274.97 2.03 1.29 D105W 35 6663.80 1690.93 3081.59 3.94 2.16 D105T 29 4457.16 974.63 2220.03 4.57 2.01 R150P 59 8750.30 2315.11 2497.86 3.78 3.50 D151G 70 1264.62 589.27 616.51 2.15 2.05 F155A 96 2824.01 779.72 746.59 3.62 3.78 D156K 100 8576.47 2210.63 2310.30 3.88 3.71 D156T 105 8727.27 2679.17 2752.35 3.26 3.17 D156L 114 2916.24 576.84 688.08 5.06 4.24 D156A 115 2299.63 533.68 554.21 4.31 4.15 D156W 111 1502.86 539.74 575.12 2.78 2.61 D156V 113 1593.06 534.71 542.36 2.98 2.94 D156T 105 4469.68 690.87 848.14 6.47 5.27 D156H 99 5387.79 698.77 819.82 7.71 6.57 D156R 101 7020.81 793.83 872.40 8.84 8.05 G159V 132 4673.44 856.78 838.46 5.45 5.57 G159T 125 6704.95 2294.40 2347.74 2.92 2.86 A176F 148 1609.85 654.43 618.72 2.46 2.60 D179N 160 5660.69 644.51 656.31 8.78 8.63 E180Y 182 8557.09 4979.24 6079.36 1.72 1.41 E180T 181 7870.99 1532.35 1794.15 5.14 4.39 E180F 185 8508.13 3597.75 3975.22 2.36 2.14 D181L 209 2710.97 619.39 611.92 4.38 4.43 D181K 195 1130.63 625.01 608.68 1.81 1.86 E182T 219 3702.08 791.23 826.28 4.68 4.48 E182Q 218 1331.50 639.84 623.11 2.08 2.14 T185R 235 2637.31 1187.63 1183.37 2.22 2.23 T185H 233 5593.77 2278.26 2534.15 2.46 2.21 T185Q 238 7006.87 2250.58 2642.74 3.11 2.65 T185A 248 2474.96 663.82 707.09 3.73 3.50 T185E 232 3948.43 2088.15 2091.32 1.89 1.89 N187R 254 3006.08 1352.97 1421.87 2.22 2.11 N187M 262 4934.44 1811.35 1893.07 2.72 2.61 N187F 261 3227.96 877.21 931.04 3.68 3.47 N187K 253 4182.49 2425.34 2652.79 1.72 1.58 N187I 264 4218.55 849.11 887.80 4.97 4.75 R195V 284 4847.81 2724.92 2984.10 1.78 1.62 A198L 305 6756.76 2056.50 2642.76 3.29 2.56 A198M 301 3777.50 1708.61 2155.58 2.21 1.75 G206A 324 872.27 603.01 586.57 1.45 1.49 G206S 317 932.69 492.65 463.60 1.89 2.01 S210V 341 3349.95 1249.47 2314.86 2.68 1.45 Y218S 354 2878.50 2373.98 2350.27 1.21 1.22 F223E 365 8318.70 3685.68 6209.93 2.26 1.34 V227C 388 1998.67 950.01 992.19 2.10 2.01 V227E 384 7904.54 839.00 1015.12 9.42 7.79 V227W 397 996.55 729.20 787.87 1.37 1.26 Q228P 420 1082.56 607.78 586.63 1.78 1.85 L229T 429 1221.05 580.15 564.49 2.10 2.16 L229I 436 2790.27 1050.86 1803.44 2.66 1.55 D233E 440 2195.02 1393.95 1454.71 1.57 1.51 I234A 476 2375.42 1473.70 1594.08 1.61 1.49 I234T 467 1199.18 713.83 796.81 1.68 1.50 I234E 460 3920.02 705.86 923.57 5.55 4.24 I240S 488 3867.71 973.97 1575.05 3.97 2.46 I240C 483 2688.75 561.91 853.66 4.78 3.15 Table 12C. Temperature Sensitive hMMP-1 Mutants, Overnight incubation hMMP-1 SEQ ID RFU RFU RFU Ratio Ratio mutation NO 25 C 34 C 37 C 25 C/ 25 C/

L95K 6 7744.34 1803.12 1677.96 4.29 4.62 D105A 39 8466.62 1302.84 1931.17 6.50 4.38 D105F 33 6725.59 938.60 1173.23 7.17 5.73 D105G 32 8940.06 3560.75 5390.32 2.51 1.66 D1051 36 8394.32 1614.57 1958.96 5.20 4.29 D105L 38 6546.78 957.95 1070.51 6.83 6.12 D105N 27 9119.04 1459.16 2347.74 6.25 3.88 D105R 25 5775.25 1407.06 1499.57 4.10 3.85 D105S 31 9300.85 5584.70 8234.95 1.67 1.13 D105W 35 8617.36 2851.22 4593.06 3.02 1.88 D105T 29 7910.47 1899.25 3292.01 4.17 2.40 R150P 59 9011.11 3533.16 3559.66 2.55 2.53 D151G 70 1956.65 959.80 1097.68 2.04 1.78 F155A 96 4891.89 2016.76 1843.31 2.43 2.65 D156K 100 8696.27 3968.92 3858.90 2.19 2.25 D156T 105 8972.20 3971.43 3854.84 2.26 2.33 D156L 114 5254.55 972.64 1232.94 5.40 4.26 D156A 115 3585.37 1098.25 1110.73 3.26 3.23 D156W 111 2570.24 1091.27 1206.22 2.36 2.13 D156V 113 2208.99 954.21 997.64 2.31 2.21 D156T 105 7229.28 1256.02 1540.11 5.76 4.69 D156H 99 7587.19 1451.49 1763.27 5.23 4.30 D156R 101 8622.23 1735.02 1846.71 4.97 4.67 G159V 132 6555.27 1821.53 1683.20 3.60 3.89 G159T 125 9105.95 321Ø57 3160.07 2.84 2.88 A176F 148 4191.69 1414.21 1336.32 2.96 3.14 D179N 160 7317.57 1504.84 1485.28 4.86 4.93 E180Y 182 9281.77 6080.89 6894.61 1.53 1.35 E180T 181 8475.04 2585.89 2809.15 3.28 3.02 E180F 185 9360.74 5183.25 5335.15 1.81 1.75 D181L 209 4534.34 1078.98 1000.80 4.20 4.53 D181K 195 1869.47 946.27 928.55 1.98 2.01 E182T 219 6752.25 1483.52 1496.55 4.55 4.51 E182Q 218 2212.75 1065.07 1035.24 2.08 2.14 T185R 235 6281.97 2425.71 2300.61 2.59 2.73 T185H 233 8531.85 3164.69 3515.59 2.70 2.43 T185Q 238 9044.23 3639.00 4012.93 2.49 2.25 T185A 248 6156.97 1110.68 1059.61 5.54 5.81 T185E 232 8479.18 3868.06 3892.33 2.19 2.18 N187R 254 7593.11 2415.63 2370.01 3.14 3.20 N187M 262 8605.76 2769.52 2720.28 3.11 3.16 N187F 261 7352.85 1612.23 1704.23 4.56 4.31 N187K 253 8667.36 3458.94 3709.62 2.51 2.34 N187I 264 8306.40 1459.25 1465.77 5.69 5.67 R195V 284 8634.05 4648.03 4960.91 1.86 1.74 A198L 305 8795.36 3469.36 4181.78 2.54 2.10 A198M 301 8352.73 3215.69 3637.79 2.60 2.30 G206A 324 2492.53 1038.14 974.96 2.40 2.56 G206S 317 2845.84 908.82 808.42 3.13 3.52 S210V 341 7104.17 2441.96 3939.90 2.91 1.80 Y218S 354 7740.61 4057.37 4093.29 1.91 1.89 F223E 365 9650.44 4849.58 7645.34 1.99 1.26 V227C 388 5833.84 2207.20 2432.82 2.64 2.40 V227E 384 8630.90 2283.07 2152.81 3.78 4.01 V227W 397 3070.92 1370.13 1456.45 2.24 2.11 Q228P 420 3673.33 1162.95 1081.32 3.16 3.40 L229T 429 3543.75 1103.34 1030.05 3.21 3.44 L229I 436 7333.92 1832.18 3268.93 4.00 2.24 D233E 440 6694.93 2570.71 2661.43 2.60 2.52 I234A 476 6250.56 3890.90 4043.80 1.61 1.55 I234T 467 3507.08 1099.58 1228.23 3.19 2.86 I234E 460 7541.73 1365.08 1901.96 5.52 3.97 I240S 488 4376.99 2108.15 2592.19 2.08 1.69 I240C 483 6170.51 1174.96 2223.23 5.25 2.78 Table 13 below depicts the residual activity (the ratio of hMMP-1 mutant RFU/wt hMMP-1 RFU) of the hMMP-1 mutants following overnight incubation with the fluorescent peptide. The activity of mutants at 25 C, 34 C, or 37 C
were compared to the activity of wildtype hMMP-1 at the respective temperatures. At 25 C, five hMMP-1 mutants (El 80F, El 80Y, D156T, D156K, RI 50P) were more active than wildtype hMMP-1 as indicated by a residual activity >1. At elevated temperatures, all of the hMMP-1 mutants exhibited an overall decrease in activity when compared to wildtype hMMP-1 at the same temperature, thus confirming the phenotype of the hMMP-1 mutants as temperature sensitive mutants.

Table 13. Residual Activity of hMMP-1 Temperature Sensitive Mutants, Overnight Incubation hMMP-1 SEQ ID Residual Residual Residual mutation NO Activity Activity Activity L95K 6 0.80 0.20 0.20 D105A 39 0.93 0.15 0.22 Table 13. Residual Activity of hMMP-1 Temperature Sensitive Mutants, Overnight Incubation hMMP-1 SEQ ID Residual Residual Residual mutation NO Activity Activity Activity D105F 33 0.74 0.11 0.13 D105G 32 0.99 0.42 0.60 D1051 36 0.93 0.19 0.22 D105L 38 0.72 0.11 0.12 D105N 27 1.01 0.17 0.26 D105R 25 0.64 0.16 0.17 D105S 31 1.03 0.65 0.92 D105W 35 0.95 0.33 0.51 D105T 29 0.87 0.22 0.37 R150P 59 0.99 0.41 0.44 D151G 70 0.22 0.11 0.12 F155A 96 0.51 0.22 0.22 D156K 100 0.97 0.46 0.46 D156T 105 1.00 0.46 0.46 D156L 114 0.58 0.11 0.14 D156A 115 0.40 0.13 0.12 D156W 111 0.28 0.13 0.14 D156V 113 0.24 0.11 0.11 D156T 105 0.80 0.15 0.17 D156H 99 0.84 0.17 0.20 D156R 101 0.95 0.20 0.21 G159V 132 0.73 0.21 0.20 G159T 125 1.00 0.37 0.39 A176F 148 0.43 0.16 0.16 D179N 160 0.81 0.17 0.18 E180Y 182 1.02 0.70 0.85 E180T 181 0.93 0.30 0.35 E180F 185 1.03 0.60 0.66 D181L 209 0.50 0.12 0.12 D181K 195 0.21 0.11 0.11 E182T 219 0.74 0.17 0.18 E182Q 218 0.24 0.12 0.13 T185R 235 0.69 0.28 0.28 T185H 233 0.94 0.37 0.43 T185Q 238 1.00 0.42 0.49 T185A 248 0.68 0.13 0.13 T185E 232 0.93 0.45 0.48 N187R 254 0.84 0.28 0.29 N187M 262 0.95 0.32 0.33 Table 13. Residual Activity of hMMP-1 Temperature Sensitive Mutants, Overnight Incubation hMMP-1 SEQ ID Residual Residual Residual mutation NO Activity Activity Activity N187F 261 0.81 0.19 0.21 N187K 253 0.95 0.40 0.46 N1871 264 0.92 0.17 0.18 R195V 284 0.96 0.54 0.59 A198L 305 0.98 0.40 0.49 A198M 301 0.87 0.36 0.42 G206A 324 0.27 0.12 0.12 G206S 317 0.31 0.10 0.10 S210V 341 0.78 0.29 0.44 Y218S 354 0.85 0.47 0.50 F223E 365 1.07 0.57 0.86 V227C 388 0.64 0.26 0.27 V227E 384 0.95 0.27 0.24 V227W 397 0.34 0.16 0.16 Q228P 420 0.38 0.13 0.13 L229T 429 0.37 0.12 0.12 L229I 436 0.76 0.20 0.38 D233E 440 0.69 0.28 0.31 I234A 476 0.69 0.45 0.45 I234T 467 0.39 0.13 0.14 I234E 460 0.83 0.16 0.21 I240S 488 0.48 0.25 0.29 1240C 483 0.68 0.14 0.25 C. hMMP-1 Top Mutant Hits Fourteen (14) positions were identified as top hit positions: 95, 105, 150, 156, 159, 179, 180, 182, 185, 187, 198, 227, 234 and 240. Twenty three (23) hMMP-1 mutants at 14 positions were selected as top hits based on two criteria, including: 1) the ratio of the activities (25 C to 37 C and 25 C to 34 C); and 2) the activity (in RFUs). All of the mutants listed in Table 14 below had an activity greater than 2000 and a ratio of 25 C to 37 C greater than 2. The eleven hits identified with a ** are the hits that ranked high for both the ratio or activities and the activity level, and were used to develop a combinatorial library as described in Example 3.

Table 14: Top Hits L95K** D1051 D105N** D105L
D105A D105G R150P** D156R
D156H D156K** D156T** G159V**
G159T D179N** E180T** E180F
E182T T185Q N1871 A198L**
V227E** 1234E 1240S**

Example 3 Combinatorial hMMP-1 Variant Libraryanapec 1. Generation In this example, a combinatorial hMMP-1 variant library was generated from the mutants selected in Example 2C and shown in Table 14 with a double asterix (**).
Mutants at positions 182, 185 and 187 were excluded in the generation of the combinatorial library because of the importance of these positions for hMMP-1 catalytic activity. The library was generated to contain every possible combination of amino acid variants for each of the selected mutants. Table 15 depicts all mutant combinations theoretically contained in the library. The theoretical diversity of the library is 1536 mutants, which includes wild type, the 11 single mutants and all possible combinations of the mutants. The positions indicated are with respect to positions corresponding to amino acid residues of hMMP-1 set forth in SEQ ID
NO:2.
Each row and column indicates one polypeptide containing the noted mutations.
For example, 156K 179N 227E, refers to a polypeptide containing three amino acid replacements at positions corresponding to positions set forth in SEQ ID NO:2:
D by K at position 156, D by N at position 179 and V by E at position 227. The library was generated and expressed as described in Example 1.

The constructed library (designated CPS library) contained a total of 1238 mutants, including the wildtype and 9 individual hits. The distribution of the number of mutations in the library was determined. The constructed and screened library contained 81 % of the maximal diversity.
Table 15. Combinatorial Library Mutants '95K 105N 179N 156T 179N 227E 240S 150P 156K 159V 227E

95, 105N 156K 179N 180T 95K 105N 150P 156T 180T

DEMANDE OU BREVET VOLUMINEUX

LA PRRSENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS

THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME

NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:

NOTE POUR LE TOME / VOLUME NOTE:

Claims (81)

1. A modified matrix metalloprotease-1 (MMP-1), comprising an amino acid replacement in the sequence of amino acid residues of an MMP-1 polypeptide or a catalytically active fragment thereof, wherein:
the amino acid replacement confers to the MMP-1 or the catalytically active fragment thereof, a ratio of enzymatic activity at a permissive temperature compared to at a nonpermissive temperature of at least 1.5, wherein:
the permissive temperature is 25°C;
the non-permissive temperature is 37 °C; and if the modified MMP-1 is a catalytically active fragment thereof, the active fragment exhibits the ratio of enzymatic activity.

2. The modified MMP-1 of claim 1, wherein the unmodified polypeptide comprises the sequence of amino acids set forth in SEQ ID NO:1, or is an allelic or species variant thereof, a zymogen, a mature form, or a catalytically active fragment that contains the modification.

3. The modified MMP-1 polypeptide of claim 2, wherein the unmodified MMP-1 polypeptide comprises the sequence of amino acids set forth in SEQ ID
NO:2, or is an allelic and species variant thereof, a mature form, or a catalytically active fragment thereof that contains the modification.

4. The modified MMP-1 polypeptide of claim 2 or claim 3, wherein the catalytically active fragment comprises the catalytic domain or a catalytically active portion of the catalytic domain.

5. A modified MMP-1 of any of claims 1-4 that has lower activity at the nonpermissive temperature than the MMP-1 that does not include the modification has at the nonpermissive temperature.

6. A modified MMP-1 polypeptide of claim 5, wherein its activity at the nonpermissive temperature is less than 90%, 80%, 70%, 60%, 50%, 40%, 30%, 25%, 20%,15%,10%,5%, 3%, 1% or less of the activity of the unmodified MMP-1.

7. The modified MMP-1 polypeptide of any of claims 1-6, wherein the modified MMP-1 polypeptide exhibits at least 1.6, 1.7, 1.8, 1.9, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 20.0, 30, 40, 50, 60, 70, 80, 90, 100 fold or more increased enzymatic activity at a permissive temperature compared to a nonpermissive temperature.

8. The modified MMP-1 polypeptide of any of claims 1-7 that contains only the catalytic domain of an MMP-1 or a catalytically active portion thereof, wherein the catalytic domain contains at least one of the amino acid replacements that confers the ratio of enzymatic activity.

9. A fusion protein, comprising the modified MMP-1 polypeptide of claim 8 with a second but different polypeptide that is not an MMP-1.

10. The modified MMP-1 polypeptide of any of claims 1-9 wherein:
the amino acid replacement is at a position corresponding to any one or more of positions 84, 85, 95, 98, 99, 100, 103, 104, 105, 106, 109, 110, 111, 112, 118, 123, 124, 126, 147, 150, 151, 152, 153, 155, 156, 158, 159, 170, 171, 176, 178, 179, 180, 181, 182, 183, 185, 187, 188, 189, 190, 191, 192, 194, 195, 197, 198, 206, 207, 208, 210, 211, 212, 218, 223, 227, 228, 229, 230, 233, 234, 237, 240, 251, 254, 255, 256, 257 and 258 in an MMP-1 polypeptide comprising the sequence of amino acids set forth in SEQ ID
NO:2.

11. A modified MMP-1 polypeptide, comprising an amino acid replacement selected from among T84F, E85F, L95K, L95I, R98D, 199Q, E100V, E100R, E100S, E100T, E100F, E100I, E100N, T103Y, P104A, P104M, D105A, D105F, D105G, D105I, D105L, D105N, D105R, D105S, D105T, D105W, D105E, L106C, L106S, A109H, D110A, V111R, D112S, A118T, S123V, N124D, T126S, G147P, R150P, R150V, R150D, R1501, R150H, D151G, N152A, N152S, S153T, F155L, F155A, D156H, D156L, D156A, D156W, D156V, D156K, D156T, D156R, D156M, P158T, P158G, P158K, P158N, G159V, G159T, G159M, G159I, G159W, G159L, G159C, P170D, P170A, G171P, G171E, G171D, A176F, A176W, F178T, F178L, D179N, D179V, D179C, E180Y, E180R, E180T, E180F, E180G, E180S, E180N, E180D, D181T, D181L, D181K, D181C, D181G, E182T, E182Q, E182M, E182G, E183G, R183S, T185R, T185Y, T185H, T185G, T185V, T185Q, T185A, T185E, T18513, N187R, N187M, N187W, N187F, N187K, N187I, N187A, N187G, N187C, N187H, F188V, R189N, R189Q, E190G, E190Y, E190D, Y191V, N192H, N192S, N192D, N192C, H194P, R195C, R195W, R195L, R195G, R195Q, R195A, R19513, R195V, A197V, A197C, A198G, A198L, A198M, G206A, G206S, L207R, L207V, L207I, L207G, S208R, S208L, S210V, S210A, T211L, D212G, D212H, Y218S, F223C, F223E, F223G, F223A, F223S, F223K, F223M, V227C, V227D, V227E, V227L, V227S, V227W, V227G, V227H, V227Q, V227R, Q228P, L229A, L229T, L229I, A230V, D233E, I234A, I234T, I234E, I234Q, I237L, I237W, I237N, I240S, I240A, I240C, I251S, I251W, Q254S, T255H, P256C, K257P, K257T and A258P.

12. The modified MMP-1 polypeptide of any of claims 1-10 wherein:
the amino acid replacement is at a position corresponding to any one or more of positions 95, 105, 150, 151, 155, 156, 159, 176, 179, 180, 181, 182, 185, 187, 195, 198, 206, 210, 212, 218, 223, 227, 228, 229, 230, 233, 234, and 240 in an MMP-1 polypeptide having a sequence of amino acids set forth in SEQ ID NO:2; and the amino acid replacement confers to the MMP-1, allelic or species variant thereof or an active fragment thereof, a ratio of enzymatic activity at a permissive temperature compared to at a nonpermissive temperature of at least 1.5.

13. The modified MMP-1 polypeptide of claim 12, wherein the amino acid replacement is selected from among L95K, D105A, D105F, D105G, D1051, D105L, D105N, D105R, D105S, D105T, D105W, R150P, D151G, F155A, D156K, D156T, D156L, D156A, D156W, D156V, D156H, D156R, G159V, G159T, A176F, D179N, E180Y, E180T, E180F, D181L, D181K, E182T, E182Q, T18511, T185H, T185Q, T185A, T185E, N187R, N187M, N187F, N187K, N1871, R195V, A198L, A198M, G206A, G206S, S210V, Y218S, F223E, V227C, V227E, V227W, Q228P, L229T, L229I, D233E, I234A, I234T, I234E, I240S, and I240C.

14. The modified MMP-1 polypeptide of any of claims 1-13, wherein the polypeptide retains the activity of the unmodified MMP-1 at the permissive temperature.

15. The modified MMP-1 polypeptide of claim 14, wherein the polypeptide retains at least or about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%,140%,150% or more activity.

16. The modified MMP-1 polypeptide of any of claims 1-15, wherein:
the amino acid replacement is at a position corresponding to any one or more of positions 95, 105, 150, 156, 159, 179, 180, 182, 185, 187, 195, 198, 212, 223, 227, 234, and 240 in an MMP-1 polypeptide having a sequence of amino acids set forth in SEQ ID
NO:2; and the modified MMP-1 polypeptide retains at least or about 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 140%, 150% or more of the activity at 25 °C
compared to MMP-1 not containing the modification at 25 °C.

17. The modified MMP-1 polypeptide of claim 16, wherein the amino acid replacement in an MMP-1 polypeptide selected from among L95K, D105A, D105G, D1051, D105L, D105N, D105S, D105W, D105T, R150P, D156K, D156T, D156V, D156H, D156R, G159V, G159T, D179N, E180Y, E180T, E180F, E182T, T185H, T185Q, T185E, N187M, N187K, N1871, R195V, A198L, F223E, V227E, I234E and I240S.

18. The modified MMP-1 polypeptide of any of claims 1-17, wherein the activity of the polypeptide, following exposure to the nonpermissive temperature, is reversible upon exposure to the permissive temperature.

19. The modified MMP-1 polypeptide of claim 18, wherein upon exposure to the nonpermissive temperature and return to the permissive temperature the polypeptide exhibits at or about 120%, 125%, 130%, 140%, 150%, 160%, 170%, 180%, 200% or more of the activity compared to at the nonpermissive temperature.

20. The modified MMP-1 polypeptide of claim 18 or claim 19, wherein the amino acid replacement is selected from among D105A, D105F, D105G, D105S, D105T, R150P, G159T, E180Y, E180T, E180F, T185H, T185Q, T185A, T185E, N187R, N187M, N187K, R195V, A198L, A198M, S210V, Y218S, F223E, V227W, L229I and I240C.

21. The modified MMP-1 polypeptide of any of claims 1-20, wherein the activity of the polypeptide is irreversibly inactive upon exposure to the nonpermissive temperature.

22. The modified MMP-1 polypeptide of claim 21, wherein upon exposure to the nonpermissive temperature and return to the permissive temperature the polypeptide exhibits at or about 50%, 60%, 70%, 80%, 90%, 100%, 105%, 110%, 115%, or 120%
of the activity at the non-permissive temperature.

23. The modified MMP-1 polypeptide of claim 21 or claim 22, wherein the amino acid replacement is selected from among L95K, D105I, D105L, D105N, D105R, D105W, D151G, F155A, D156K, D156T, D156L, D156A, D156W, D156V, D156H, D156R, G159V, A176F, D179N, D181L, D181K, E182T, E182Q, T185R, N187F, N187I, G206A, G206S, V227C, V227E, Q228E, L229T, D233E, I234A, I234T, I234E
and 1240S.

24. The modified MMP-1 polypeptide of any of claims 1-23 that has a sequence of amino acids set forth in any of SEQ ID NOS: 6, 25, 27, 29, 31, 32, 33, 35, 36, 38, 39, 59, 70, 95, 96, 99, 100, 101, 105, 111, 113-115, 125, 132, 148, 160, 181, 182, 185, 195, 209, 218, 219, 232, 233, 235, 238, 248, 253, 254, 261, 262, 264, 284, 301, 305, 317, 324, 341, 354, 365, 384, 388, 397, 420, 429, 436, 440, 460, 467, 476, 483 and 488.

25. A modified MMP-1 polypeptide that has a sequence of amino acids set forth in any of SEQ ID NOS: 3-705, 779-3458, 3507-3531 and 3541-3546.

26. The modified MMP-1 polypeptide of any of claims 1-23, wherein the polypeptide contains 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more amino acid replacement(s).

27. The modified MMP-1 polypeptide of claim 26, wherein the polypeptide comprises two or more amino acid replacement(s) and the replacements are at a position corresponding to any two or more of positions 95, 105, 150, 156, 159, 179, 180, 182, 185, 187, 198, 227, 234 and 240 in an MMP-1 polypeptide having a sequence of amino acids set forth in SEQ ID NO:2.

28. The modified MMP-1 polypeptide of claim 27, wherein the two or more modifications are selected from among L95K, D105N, R150P, D156K, D156T, G159V, D179N, E180T, A198L, V227E, and 1240S.

29. The modified MMP-1 polypeptide of claim 28, wherein the modified MMP-1 polypeptide is selected from among a polypeptide having amino acid replacements D156K/G159V/D179N; R150P/V227E; D156T/V227E; G159V/A198L;
D105N/A198L; D179N/V227E; A198L/V227E; E180T/V227E; D179N/A198L;
D156K/D179N; D105N/R150P/D156K/G159V/D179N/E180T; D105N/R150P/E180T;
G159V/I240S; D156T/D179N/I240S; D156T/G159V; R150P/E180T; D156T/D179N;
D179N/I240S; L95K/D156T/D179N; G159V/D179N; L95K/D105N/E180T;
R150P/D156T/A198L; L95K/D105N/R150P/D156T/G159V/A198L/V227E/I240S;
L95K/R150P; and D105N/E180T.

30. The modified MMP-1 polypeptide of any of claims 1-29, further comprising at least one amino acid replacement(s) that confers increased activity compared to the MMP-1 polypeptide not containing the amino acid replacement(s).

31. The modified MMP-1 polypeptide of claim 30, wherein the amino acid replacement(s) is at a position corresponding to any one or more of positions 81, 84, 85, 86, 87, 89, 104, 105, 106, 107, 108, 109, 124, 131, 133, 134, 135, 143, 146, 147, 150, 152, 153, 154, 157, 158, 160, 161, 164, 166, 167, 180, 183, 189, 190, 207, 208, 211, 213, 214, 216, 218, 220, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 235, 236, 238, 239, 244, 249, 254, 256, 257 and 258 in an MMP-1 polypeptide comprising the sequence of amino acids set forth in SEQ ID NO:2.

32. The modified MMP-1 polypeptide of claim 31, wherein the amino acid replacement is selected from among F81L, F81A, F81G, F81Q, F81R, F81H, T84H, T84L, T84D, T84R, T84G, T84A, E85S, E85V, G86S, N87P, N87R, N87G, N87Q, R89A, R89T, R89G, R89K, P104E, P104D, P104Q, D105V, L106V, P107T, P107S, P107A, R108E, R108A, R108K, R108S, A109S, A109R, A109G, A109M, A109V, N124G, T131D, K132R, V133T, V133L, S134E, S134D, E135M, S143I, R146S, G147R, G147F, R150E, R150G, R150M, T150T, R150A, R150N, R150K, R150L, R150V, R150D, N152G, N152F, N152L, N152I, S153T, S153P, S153F, S153D, S153Y, P154S, P154I, G157F, P158V, P158I, G160Q, N161L, N161R, N161Y, N161E, N161T, N161I, N161V, N161F, N161Q, H164S, F166W, Q167R, Q167A, Q167S, Q167F, Q167P, Q167T, Q167V, Q167M, E180D, R183S, R189N, R189T, R189Q, E190D, L207M, S208K, S208R, S208L, T211N, I213G, G214L, G214E, L216I, Y218W, S220R, S220A, S220Q, S220T, S220G, S220M, S220V, S220N, T222R, T222P, T222S, T222F, T222N, F223Y, F223H, S224Q, S224K, S224D, G225Q, G225E, G225H, D226S, D226E, D226P, D226I, V227T, Q228A, Q228D, Q228E, Q228G, Q228H, Q228K, Q228L, Q228M, Q228N, Q228R, Q228S, Q228T, Q228W, Q228Y, L229Q, L229P, L229V, A230G, A230W, A230D, A230I, A230S, A230C, A230V, A230T, A230M, A230N, A230H, Q231I, Q231A, Q231F, Q231D, Q231G, Q231V, Q231W, Q231S, Q231H, Q231M, D232H, D232G, D232R, D232P, D232Y, D232S, D232F, D232V, D232K, D232W, D232Q, D232E, D232T, D232L, D235G, D235A, D235L, D235E, D235R, D235Q, D235T, D235N, G236M, G236R, G236S, G236T, G236C, G236K, G236E, G236L, G236N, Q238T, A239S, A239V, A239L, A2391, A239G, A239K, A239H, A239R, S244W, S244Q, Q249W, Q254S, P256S, K257E, K257R, and A258P.

33. The modified MMP-1 polypeptide of claim 32, wherein the modified MMP-1 polypeptide is selected from a polypeptide having amino acid replacements S208K/G159V; S208K/D179N; S208K/V227E; G214E/G159V; G214E/D179N; and I213G/D179N.

34. The modified MMP-1 polypeptide of any of claims 1-33 that is a zymogen.

35. The modified MMP-1 polypeptide of any of claims 1-33 that is a mature enzyme.

36. The modified MMP-1 polypeptide of any of claims 1-33 that contains only the catalytically active domain or a catalytically active portion of the catalytic domain.

37. The modified MMP-1 polypeptide of any of claims 1-33 that lacks all or a portion of a proline rich linker and/or a hemopexin domain.

38. The modified MMP-1 polypeptide of any of claims 1-37, comprising one or more additional modifications.

39. The modified MMP-1 polypeptide of claim 38, wherein the one or more additional modifications confer increased stability, increased half-life, altered substrate specificity and/or increased resistance to inhibitors.

40. The modified MMP-1 polypeptide of any of claims 1-39 that is glycosylated or PEGylated.

41. The modified MMP-1 polypeptide of any of claims 1-40 that is a fusion protein.

42. The modified MMP-1 polypeptide of claim 41 that is fused to an Fc domain.

43. A nucleic acid molecule, comprising a sequence of nucleotides encoding a modified MMP-1 polypeptide of any of claims 1-39.

44. A vector, comprising the nucleic acid molecule of claim 43.

45. The vector of claim 44, wherein the vector is a prokaryotic vector, viral vector or a eukaryotic vector.

46. The vector of claim 45, wherein the vector is a mammalian vector or a yeast vector.

47. The vector of claim 45, wherein the vector is selected from among an adenovirus, an adeno-associated virus, a retrovirus, a herpes virus, a lentivirus, a poxvirus, a cytomegalovirus and Pichia.

48. A cell, comprising the vector of any of claims 44-47.

49. The cell of claim 48 that is a prokaryotic cell or a mammalian cell.

50. The cell of claim 48 or claim 49, wherein the cell expresses the modified MMP-1 polypeptide.

51. A pharmaceutical composition, comprising a modified MMP-1 polypeptide of any of claims 1-42.

52. A method of treating a disease or condition of the extracellular matrix (ECM), comprising administering to the ECM a modified MMP-1 polypeptide of any of claims 1-42 or a pharmaceutical composition of claim 51, wherein:
the permissive temperature is below the normal temperature of the ECM; and the MMP-1 is administered at or below the permissive temperature.

53. The method of claim 52, wherein the MMP-1 is provided in a composition that is at or below the permissive temperature.

54. The method of claim 52 or 53, wherein the MMP-1 is mixed with a composition that is at or below the permissive temperature immediately before administration.

55. The method of any of claims 52-54, wherein, prior to administration, the ECM is cooled to below the physiological temperature of the body.

56. The method of any of claims 52-55, wherein following administration, the ECM is maintained below the physiological temperature of the body for a predetermined time.

57. The method of any of claims 52-56, wherein the MMP-1 is a zymogen and is processed before administration.

58. The method of claim 57, wherein the MMP-1 is processed by a processing agent.

59. The method of claim 58, wherein the processing agent is selected from among plasmin, plasma kallikrein, trypsin-1, trypsin-2, neutrophil elastase, cathepsin G, tryptase, chymase, proteinase-3, proteinase-3, furin, urinary plasminogen activator (uPA), an active MMP, 4-aminophenylmercuric acetate (AMPA), HgCl2, N-ethylmaleimide, sodium dodecyl sulfate (SDS), chaotropic agents, oxidized glutathione, reactive oxygen, Au(I) salts, acidic pH and heat.

60. The method of claim 59, wherein the active MMP is selected from among an MMP-1, MMP-2, MMP-3, MMP-7, MMP-10, MMP-26 and MT1-MMP.

61. The method of claim 58 or claim 59, wherein the processing agent is AMPA.

62. The method of any of claims 59-61, wherein the processing agent is purified away from the modified MMP-1 polypeptide before administration.

63. The method of any of claims 52-62, wherein the modified MMP-1 polypeptide is administered at a therapeutically effective amount to treat the disease or condition.

64. The method of any of claims 52-63, wherein administration is selected from among subcutaneous, intramuscular, intralesional, intradermal, topical, transdermal, intravenous, oral and rectal.

65. The method of any of claims 52-64, wherein administration is sub-epidermal administration.

66. The method of any of claims 52-65, wherein administration is subcutaneous administration.

67. The method of any of claims 52-66, further comprising administering a pharmacologic agent selected from among other biologics, small molecule compounds, dispersing agents, anesthetics and vasoconstrictors or combinations thereof.

68. The method of claim 67, wherein the dispersing agent is a hyaluronan-degrading enzyme.

69. The method of claim 68, wherein the hyaluronan degrading enzyme is a hyaluronidase.

70. The method of claim 67, wherein the anesthetic is lidocaine.

71. The method of claim 67, wherein the vasoconstrictor is an alpha adrenergic receptor agonist.

72. The method of claim 71, wherein the alpha adrenergic receptor agonist is selected from among levonordefrin, epinephrine and norepinephrine.

73. The method of any of claims 67-72, wherein the other pharmacologic agent(s) is administered simultaneously, sequentially or intermittently from the MMP-1.

74. The method of any of claims 67-72; wherein the other agent(s) is administered prior to administration of the MMP-1.

75. The method of any of claims 52-74, wherein the disease or condition of the ECM is a collagen-mediated disease or condition.

76. The method of claim 75, wherein the collagen-mediated disease or condition is selected from among cellulite, Dupuytren's disease, Peyronie's disease, Ledderhose fibrosis, stiff joints, existing scars, scleroderma, lymphedema and collagenous colitis.

77. The method of claim 76, wherein the collagen-mediated disease or condition is stiff joints that is frozen shoulder.

78. The method of claim 76, wherein the collagen-mediated disease or condition is existing scars that is selected from among surgical adhesions, keloids, hypertrophic scars and depressed scars.

79. The method of any of claims 52-74, wherein the ECM-mediated disease or condition is herniated protruding discs.

80. Use of a modified MMP-1 polypeptide of any of claims 1-42 or a pharmaceutical composition of claim 51 for formulation of a medicament for treatment of a disease or condition of the extracellular matrix (ECM).

81. A pharmaceutical composition for use for treating a disease or condition of the extracellular matrix (ECM),wherein the composition comprises a modified polypeptide of any of claims 1-42.